

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number  
**WO 01/16318 A2**

(51) International Patent Classification <sup>7</sup> :	C12N 15/12, C07K 14/47, 14/705, G01N 33/53, C12N 15/62, C07K 16/18	PCT/US00/04414	22 February 2000 (22.02.2000)	US
(21) International Application Number:	PCT/US00/23328	PCT/US00/05601	1 March 2000 (01.03.2000)	US
(22) International Filing Date:	24 August 2000 (24.08.2000)	60/187,202	3 March 2000 (03.03.2000)	US
(25) Filing Language:	English	60/191,007	21 March 2000 (21.03.2000)	US
(26) Publication Language:	English	PCT/US00/08439	30 March 2000 (30.03.2000)	US
(30) Priority Data:	PCT/US99/20111	60/199,397	25 April 2000 (25.04.2000)	US
	PCT/US99/21090	PCT/US00/14042	22 May 2000 (22.05.2000)	US
		60/209,832	5 June 2000 (05.06.2000)	US
(71) Applicant (for all designated States except US):	GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).			
(72) Inventors; and				
(75) Inventors/Applicants (for US only):	EATON, Dan, L. [US/US]; 75 Knight Drive, San Rafael, CA 94901 (US). FILVAROFF, Ellen [US/US]; 538 18th Avenue, San Francisco, CA 94121 (US). GERRITSEN, Mary, E. [CA/US]; 541 Parrott Drive, San Mateo, CA 94402 (US). GODDARD, Audrey [CA/US]; 110 Congo Street, San Francisco, CA 94131 (US). GODOWSKI, Paul, J. [US/US]; 2627 Easton Drive, Burlingame, CA 94010 (US). GRIMALDI, Christopher, J. [US/US]; 1434 36th			

[Continued on next page]

(54) Title: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME

<subunit 1 of 1, 266 aa, 1 stop  
<MW: 29766, pI: 8.39, NX (S/T): 0  
MWWFQQGLSFLPSALVIWTSAAFIFSYITAVTLHHIDPALPYISDTGTVAPEKCLFGAMLNIA  
AVLCIATIYVRYKQVHALSPEENVIIKLNKAGLVLGILSCLGLSIVANFQKTLFAAHVSGAV  
LTFGMGSLYMFVQTILSYQMOPKIHGKQVFWRLLLVIWCGVSALSMLTCSVLSHSGNFGTDL  
EQKLHWNPEDKGYVLHMITTAAEWSMSFSFFGFFLTYIRDFQKISLRVEANLHGLTLYDTAPC  
PINNERTRLLSRDI

**Important features:**

**Type II transmembrane domain:**

amino acids 13-33

**Other Transmembrane domains:**

amino acids 54-73, 94-113, 160-180, 122-141

**N-myristoylation sites.**

amino acids 57-63, 95-101, 99-105, 124-130, 183-189

**WO 01/16318 A2**

(57) Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.



Avenue, San Francisco, CA 94122 (US). GURNEY, Austin, L. [US/US]; 1 Debbie Lane, Belmont, CA 94002 (US). WATANABE, Colin, K. [US/US]; 128 Corliss Drive, Moraga, CA 94556 (US). WOOD, William, I. [US/US]; 35 Southdown Court, Hillsborough, CA 94010 (US).

(74) Agents: KRESNAK, Mark, T. et al.; Genentech, Inc., MS49, 1 DNA Way, South San Francisco, CA 94080-4990 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- *Without international search report and to be republished upon receipt of that report.*
- *With (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description.*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE  
SAME**

**FIELD OF THE INVENTION**

The present invention relates generally to the identification and isolation of novel DNA and to the  
5 recombinant production of novel polypeptides.

**BACKGROUND OF THE INVENTION**

Extracellular proteins play important roles in, among other things, the formation, differentiation and  
10 maintenance of multicellular organisms. The fate of many individual cells, e.g., proliferation, migration,  
differentiation, or interaction with other cells, is typically governed by information received from other cells  
and/or the immediate environment. This information is often transmitted by secreted polypeptides (for instance,  
mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and hormones) which  
are, in turn, received and interpreted by diverse cell receptors or membrane-bound proteins. These secreted  
15 polypeptides or signaling molecules normally pass through the cellular secretory pathway to reach their site of  
action in the extracellular environment.

Secreted proteins have various industrial applications, including as pharmaceuticals, diagnostics,  
biosensors and bioreactors. Most protein drugs available at present, such as thrombolytic agents, interferons,  
interleukins, erythropoietins, colony stimulating factors, and various other cytokines, are secretory proteins.  
Their receptors, which are membrane proteins, also have potential as therapeutic or diagnostic agents. Efforts  
20 are being undertaken by both industry and academia to identify new, native secreted proteins. Many efforts are  
focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel  
secreted proteins. Examples of screening methods and techniques are described in the literature [see, for  
example, Klein et al., *Proc. Natl. Acad. Sci.* 93:7108-7113 (1996); U.S. Patent No. 5,536,637].

Membrane-bound proteins and receptors can play important roles in, among other things, the formation,  
25 differentiation and maintenance of multicellular organisms. The fate of many individual cells, e.g., proliferation,  
migration, differentiation, or interaction with other cells, is typically governed by information received from  
other cells and/or the immediate environment. This information is often transmitted by secreted polypeptides  
(for instance, mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and  
hormones) which are, in turn, received and interpreted by diverse cell receptors or membrane-bound proteins.  
30 Such membrane-bound proteins and cell receptors include, but are not limited to, cytokine receptors, receptor  
kinases, receptor phosphatases, receptors involved in cell-cell interactions, and cellular adhesin molecules like  
selectins and integrins. For instance, transduction of signals that regulate cell growth and differentiation is  
regulated in part by phosphorylation of various cellular proteins. Protein tyrosine kinases, enzymes that catalyze  
that process, can also act as growth factor receptors. Examples include fibroblast growth factor receptor and

nerve growth factor receptor.

Membrane-bound proteins and receptor molecules have various industrial applications, including as pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance, can be employed as therapeutic agents to block receptor-ligand interactions. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction.

- 5        Efforts are being undertaken by both industry and academia to identify new, native receptor or membrane-bound proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel receptor or membrane-bound proteins.

#### SUMMARY OF THE INVENTION

- 10       In one embodiment, the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a PRO polypeptide.

In one aspect, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule encoding a PRO polypeptide having a full-length amino acid sequence as disclosed herein, an amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane protein, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of the full-length amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a).

In other aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94%

nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule comprising the coding sequence of a full-length PRO polypeptide cDNA as disclosed herein, the coding sequence of a PRO polypeptide lacking the signal peptide as disclosed herein, 5 the coding sequence of an extracellular domain of a transmembrane PRO polypeptide, with or without the signal peptide, as disclosed herein or the coding sequence of any other specifically defined fragment of the full-length amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a).

In a further aspect, the invention concerns an isolated nucleic acid molecule comprising a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid 10 sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% 15 nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively 20 at least about 99% nucleic acid sequence identity to (a) a DNA molecule that encodes the same mature polypeptide encoded by any of the human protein cDNAs deposited with the ATCC as disclosed herein, or (b) the complement of the DNA molecule of (a).

Another aspect the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated, or is complementary to such encoding nucleotide sequence, wherein the transmembrane domain(s) 25 of such polypeptide are disclosed herein. Therefore, soluble extracellular domains of the herein described PRO polypeptides are contemplated.

Another embodiment is directed to fragments of a PRO polypeptide coding sequence, or the complement thereof, that may find use as, for example, hybridization probes, for encoding fragments of a PRO polypeptide 30 that may optionally encode a polypeptide comprising a binding site for an anti-PRO antibody or as antisense oligonucleotide probes. Such nucleic acid fragments are usually at least about 20 nucleotides in length, alternatively at least about 30 nucleotides in length, alternatively at least about 40 nucleotides in length, alternatively at least about 50 nucleotides in length, alternatively at least about 60 nucleotides in length, alternatively at least about 70 nucleotides in length, alternatively at least about 80 nucleotides in length, 35 alternatively at least about 90 nucleotides in length, alternatively at least about 100 nucleotides in length, alternatively at least about 110 nucleotides in length, alternatively at least about 120 nucleotides in length, alternatively at least about 130 nucleotides in length, alternatively at least about 140 nucleotides in length,

alternatively at least about 150 nucleotides in length, alternatively at least about 160 nucleotides in length, alternatively at least about 170 nucleotides in length, alternatively at least about 180 nucleotides in length, alternatively at least about 190 nucleotides in length, alternatively at least about 200 nucleotides in length, alternatively at least about 250 nucleotides in length, alternatively at least about 300 nucleotides in length, alternatively at least about 350 nucleotides in length, alternatively at least about 400 nucleotides in length, 5 alternatively at least about 450 nucleotides in length, alternatively at least about 500 nucleotides in length, alternatively at least about 600 nucleotides in length, alternatively at least about 700 nucleotides in length, alternatively at least about 800 nucleotides in length, alternatively at least about 900 nucleotides in length and alternatively at least about 1000 nucleotides in length, wherein in this context the term "about" means the referenced nucleotide sequence length plus or minus 10% of that referenced length. It is noted that novel 10 fragments of a PRO polypeptide-encoding nucleotide sequence may be determined in a routine manner by aligning the PRO polypeptide-encoding nucleotide sequence with other known nucleotide sequences using any of a number of well known sequence alignment programs and determining which PRO polypeptide-encoding nucleotide sequence fragment(s) are novel. All of such PRO polypeptide-encoding nucleotide sequences are contemplated herein. Also contemplated are the PRO polypeptide fragments encoded by these nucleotide 15 molecule fragments, preferably those PRO polypeptide fragments that comprise a binding site for an anti-PRO antibody.

In another embodiment, the invention provides isolated PRO polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.

In a certain aspect, the invention concerns an isolated PRO polypeptide, comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81% amino acid sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid 20 sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91% amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% 25 amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to a PRO polypeptide having a full-length amino acid sequence as disclosed herein, an amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane protein, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of the full-length amino acid sequence as disclosed herein.

30 In a further aspect, the invention concerns an isolated PRO polypeptide comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81% amino acid sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least about 83%

amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91% amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to an amino acid sequence encoded by any of the human protein cDNAs deposited with the ATCC as disclosed herein.

In a specific aspect, the invention provides an isolated PRO polypeptide without the N-terminal signal sequence and/or the initiating methionine and is encoded by a nucleotide sequence that encodes such an amino acid sequence as hereinbefore described. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO polypeptide and recovering the PRO polypeptide from the cell culture.

Another aspect the invention provides an isolated PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO polypeptide and recovering the PRO polypeptide from the cell culture.

In yet another embodiment, the invention concerns agonists and antagonists of a native PRO polypeptide as defined herein. In a particular embodiment, the agonist or antagonist is an anti-PRO antibody or a small molecule.

In a further embodiment, the invention concerns a method of identifying agonists or antagonists to a PRO polypeptide which comprise contacting the PRO polypeptide with a candidate molecule and monitoring a biological activity mediated by said PRO polypeptide. Preferably, the PRO polypeptide is a native PRO polypeptide.

In a still further embodiment, the invention concerns a composition of matter comprising a PRO polypeptide, or an agonist or antagonist of a PRO polypeptide as herein described, or an anti-PRO antibody, in combination with a carrier. Optionally, the carrier is a pharmaceutically acceptable carrier.

Another embodiment of the present invention is directed to the use of a PRO polypeptide, or an agonist or antagonist thereof as hereinbefore described, or an anti-PRO antibody, for the preparation of a medicament useful in the treatment of a condition which is responsive to the PRO polypeptide, an agonist or antagonist thereof or an anti-PRO antibody.

In other embodiments of the present invention, the invention provides vectors comprising DNA encoding any of the herein described polypeptides. Host cell comprising any such vector are also provided. By

way of example, the host cells may be CHO cells, *E. coli*, or yeast. A process for producing any of the herein described polypeptides is further provided and comprises culturing host cells under conditions suitable for expression of the desired polypeptide and recovering the desired polypeptide from the cell culture.

In other embodiments, the invention provides chimeric molecules comprising any of the herein described polypeptides fused to a heterologous polypeptide or amino acid sequence. Example of such chimeric molecules 5 comprise any of the herein described polypeptides fused to an epitope tag sequence or a Fc region of an immunoglobulin.

In another embodiment, the invention provides an antibody which binds, preferably specifically, to any of the above or below described polypeptides. Optionally, the antibody is a monoclonal antibody, humanized antibody, antibody fragment or single-chain antibody.

10 In yet other embodiments, the invention provides oligonucleotide probes useful for isolating genomic and cDNA nucleotide sequences or as antisense probes, wherein those probes may be derived from any of the above or below described nucleotide sequences.

15 In yet other embodiments, the present invention is directed to methods of using the PRO polypeptides of the present invention for a variety of uses based upon the functional biological assay data presented in the Examples below.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a nucleotide sequence (SEQ ID NO:1) of a native sequence PRO180 cDNA, wherein SEQ ID NO:1 is a clone designated herein as "DNA26843-1389".

20 Figure 2 shows the amino acid sequence (SEQ ID NO:2) derived from the coding sequence of SEQ ID NO:1 shown in Figure 1.

Figure 3 shows a nucleotide sequence (SEQ ID NO:3) of a native sequence PRO218 cDNA, wherein SEQ ID NO:3 is a clone designated herein as "DNA30867-1335".

25 Figure 4 shows the amino acid sequence (SEQ ID NO:4) derived from the coding sequence of SEQ ID NO:3 shown in Figure 3.

Figure 5 shows a nucleotide sequence (SEQ ID NO:5) of a native sequence PRO263 cDNA, wherein SEQ ID NO:5 is a clone designated herein as "DNA34431-1177".

Figure 6 shows the amino acid sequence (SEQ ID NO:6) derived from the coding sequence of SEQ ID NO:5 shown in Figure 5.

30 Figure 7 shows a nucleotide sequence (SEQ ID NO:7) of a native sequence PRO295 cDNA, wherein SEQ ID NO:7 is a clone designated herein as "DNA38268-1188".

Figure 8 shows the amino acid sequence (SEQ ID NO:8) derived from the coding sequence of SEQ ID NO:7 shown in Figure 7.

35 Figure 9 shows a nucleotide sequence (SEQ ID NO:9) of a native sequence PRO874 cDNA, wherein SEQ ID NO:9 is a clone designated herein as "DNA40621-1440".

Figure 10 shows the amino acid sequence (SEQ ID NO:10) derived from the coding sequence of SEQ ID NO:9 shown in Figure 9.

Figure 11 shows a nucleotide sequence (SEQ ID NO:11) of a native sequence PRO300 cDNA, wherein SEQ ID NO:11 is a clone designated herein as "DNA40625-1189".

Figure 12 shows the amino acid sequence (SEQ ID NO:12) derived from the coding sequence of SEQ ID NO:11 shown in Figure 11.

5 Figure 13 shows a nucleotide sequence (SEQ ID NO:13) of a native sequence PRO1864 cDNA, wherein SEQ ID NO:13 is a clone designated herein as "DNA45409-2511".

Figure 14 shows the amino acid sequence (SEQ ID NO:14) derived from the coding sequence of SEQ ID NO:13 shown in Figure 13.

Figure 15 shows a nucleotide sequence (SEQ ID NO:15) of a native sequence PRO1282 cDNA, wherein SEQ ID NO:15 is a clone designated herein as "DNA45495-1550".

10 Figure 16 shows the amino acid sequence (SEQ ID NO:16) derived from the coding sequence of SEQ ID NO:15 shown in Figure 15.

Figure 17 shows a nucleotide sequence (SEQ ID NO:17) of a native sequence PRO1063 cDNA, wherein SEQ ID NO:17 is a clone designated herein as "DNA49820-1427".

15 Figure 18 shows the amino acid sequence (SEQ ID NO:18) derived from the coding sequence of SEQ ID NO:17 shown in Figure 17.

Figure 19 shows a nucleotide sequence (SEQ ID NO:19) of a native sequence PRO1773 cDNA, wherein SEQ ID NO:19 is a clone designated herein as "DNA56406-1704".

Figure 20 shows the amino acid sequence (SEQ ID NO:20) derived from the coding sequence of SEQ ID NO:19 shown in Figure 19.

20 Figure 21 shows a nucleotide sequence (SEQ ID NO:21) of a native sequence PRO1013 cDNA, wherein SEQ ID NO:21 is a clone designated herein as "DNA56410-1414".

Figure 22 shows the amino acid sequence (SEQ ID NO:22) derived from the coding sequence of SEQ ID NO:21 shown in Figure 21.

25 Figure 23 shows a nucleotide sequence (SEQ ID NO:23) of a native sequence PRO937 cDNA, wherein SEQ ID NO:23 is a clone designated herein as "DNA56436-1448".

Figure 24 shows the amino acid sequence (SEQ ID NO:24) derived from the coding sequence of SEQ ID NO:23 shown in Figure 23.

Figure 25 shows a nucleotide sequence (SEQ ID NO:25) of a native sequence PRO842 cDNA, wherein SEQ ID NO:25 is a clone designated herein as "DNA56855-1447".

30 Figure 26 shows the amino acid sequence (SEQ ID NO:26) derived from the coding sequence of SEQ ID NO:25 shown in Figure 25.

Figure 27 shows a nucleotide sequence (SEQ ID NO:27) of a native sequence PRO1180 cDNA, wherein SEQ ID NO:27 is a clone designated herein as "DNA56860-1510".

35 Figure 28 shows the amino acid sequence (SEQ ID NO:28) derived from the coding sequence of SEQ ID NO:27 shown in Figure 27.

Figure 29 shows a nucleotide sequence (SEQ ID NO:29) of a native sequence PRO831 cDNA, wherein SEQ ID NO:29 is a clone designated herein as "DNA56862-1343".

Figure 30 shows the amino acid sequence (SEQ ID NO:30) derived from the coding sequence of SEQ ID NO:29 shown in Figure 29.

Figure 31 shows a nucleotide sequence (SEQ ID NO:31) of a native sequence PRO1115 cDNA, wherein SEQ ID NO:31 is a clone designated herein as "DNA56868-1478".

5 Figure 32 shows the amino acid sequence (SEQ ID NO:32) derived from the coding sequence of SEQ ID NO:31 shown in Figure 31.

Figure 33 shows a nucleotide sequence (SEQ ID NO:33) of a native sequence PRO1277 cDNA, wherein SEQ ID NO:33 is a clone designated herein as "DNA56869-1545".

Figure 34 shows the amino acid sequence (SEQ ID NO:34) derived from the coding sequence of SEQ ID NO:33 shown in Figure 33.

10 Figure 35 shows a nucleotide sequence (SEQ ID NO:35) of a native sequence PRO1074 cDNA, wherein SEQ ID NO:35 is a clone designated herein as "DNA57704-1452".

Figure 36 shows the amino acid sequence (SEQ ID NO:36) derived from the coding sequence of SEQ ID NO:35 shown in Figure 35.

15 Figure 37 shows a nucleotide sequence (SEQ ID NO:37) of a native sequence PRO1344 cDNA, wherein SEQ ID NO:37 is a clone designated herein as "DNA58723-1588".

Figure 38 shows the amino acid sequence (SEQ ID NO:38) derived from the coding sequence of SEQ ID NO:37 shown in Figure 37.

Figure 39 shows a nucleotide sequence (SEQ ID NO:39) of a native sequence PRO1136 cDNA, wherein SEQ ID NO:39 is a clone designated herein as "DNA57827-1493".

20 Figure 40 shows the amino acid sequence (SEQ ID NO:40) derived from the coding sequence of SEQ ID NO:39 shown in Figure 39.

Figure 41 shows a nucleotide sequence (SEQ ID NO:41) of a native sequence PRO1109 cDNA, wherein SEQ ID NO:41 is a clone designated herein as "DNA58737-1473".

25 Figure 42 shows the amino acid sequence (SEQ ID NO:42) derived from the coding sequence of SEQ ID NO:41 shown in Figure 41.

Figure 43 shows a nucleotide sequence (SEQ ID NO:43) of a native sequence PRO1003 cDNA, wherein SEQ ID NO:43 is a clone designated herein as "DNA58846-1409".

Figure 44 shows the amino acid sequence (SEQ ID NO:44) derived from the coding sequence of SEQ ID NO:43 shown in Figure 43.

30 Figure 45 shows a nucleotide sequence (SEQ ID NO:45) of a native sequence PRO1138 cDNA, wherein SEQ ID NO:45 is a clone designated herein as "DNA58850-1495".

Figure 46 shows the amino acid sequence (SEQ ID NO:46) derived from the coding sequence of SEQ ID NO:45 shown in Figure 45.

35 Figure 47 shows a nucleotide sequence (SEQ ID NO:47) of a native sequence PRO994 cDNA, wherein SEQ ID NO:47 is a clone designated herein as "DNA58855-1422".

Figure 48 shows the amino acid sequence (SEQ ID NO:48) derived from the coding sequence of SEQ ID NO:47 shown in Figure 47.

Figure 49 shows a nucleotide sequence (SEQ ID NO:49) of a native sequence PRO1069 cDNA, wherein SEQ ID NO:49 is a clone designated herein as "DNA59211-1450".

Figure 50 shows the amino acid sequence (SEQ ID NO:50) derived from the coding sequence of SEQ ID NO:49 shown in Figure 49.

5 Figure 51 shows a nucleotide sequence (SEQ ID NO:51) of a native sequence PRO1411 cDNA, wherein SEQ ID NO:51 is a clone designated herein as "DNA59212-1627".

Figure 52 shows the amino acid sequence (SEQ ID NO:52) derived from the coding sequence of SEQ ID NO:51 shown in Figure 51.

Figure 53 shows a nucleotide sequence (SEQ ID NO:53) of a native sequence PRO1129 cDNA, wherein SEQ ID NO:53 is a clone designated herein as "DNA59213-1487".

10 Figure 54 shows the amino acid sequence (SEQ ID NO:54) derived from the coding sequence of SEQ ID NO:53 shown in Figure 53.

Figure 55 shows a nucleotide sequence (SEQ ID NO:55) of a native sequence PRO1027 cDNA, wherein SEQ ID NO:55 is a clone designated herein as "DNA59605-1418".

15 Figure 56 shows the amino acid sequence (SEQ ID NO:56) derived from the coding sequence of SEQ ID NO:55 shown in Figure 55.

Figure 57 shows a nucleotide sequence (SEQ ID NO:57) of a native sequence PRO1106 cDNA, wherein SEQ ID NO:57 is a clone designated herein as "DNA59609-1470".

Figure 58 shows the amino acid sequence (SEQ ID NO:58) derived from the coding sequence of SEQ ID NO:57 shown in Figure 57.

20 Figure 59 shows a nucleotide sequence (SEQ ID NO:59) of a native sequence PRO1291 cDNA, wherein SEQ ID NO:59 is a clone designated herein as "DNA59610-1556".

Figure 60 shows the amino acid sequence (SEQ ID NO:60) derived from the coding sequence of SEQ ID NO:59 shown in Figure 59.

25 Figure 61 shows a nucleotide sequence (SEQ ID NO:61) of a native sequence PRO3573 cDNA, wherein SEQ ID NO:61 is a clone designated herein as "DNA59837-2545".

Figure 62 shows the amino acid sequence (SEQ ID NO:62) derived from the coding sequence of SEQ ID NO:61 shown in Figure 61.

Figure 63 shows a nucleotide sequence (SEQ ID NO:63) of a native sequence PRO3566 cDNA, wherein SEQ ID NO:63 is a clone designated herein as "DNA59844-2542".

30 Figure 64 shows the amino acid sequence (SEQ ID NO:64) derived from the coding sequence of SEQ ID NO:63 shown in Figure 63.

Figure 65 shows a nucleotide sequence (SEQ ID NO:65) of a native sequence PRO1098 cDNA, wherein SEQ ID NO:65 is a clone designated herein as "DNA59854-1459".

35 Figure 66 shows the amino acid sequence (SEQ ID NO:66) derived from the coding sequence of SEQ ID NO:65 shown in Figure 65.

Figure 67 shows a nucleotide sequence (SEQ ID NO:67) of a native sequence PRO1158 cDNA, wherein SEQ ID NO:67 is a clone designated herein as "DNA60625-1507".

Figure 68 shows the amino acid sequence (SEQ ID NO:68) derived from the coding sequence of SEQ ID NO:67 shown in Figure 67.

Figure 69 shows a nucleotide sequence (SEQ ID NO:69) of a native sequence PRO1124 cDNA, wherein SEQ ID NO:69 is a clone designated herein as "DNA60629-1481".

5 Figure 70 shows the amino acid sequence (SEQ ID NO:70) derived from the coding sequence of SEQ ID NO:69 shown in Figure 69.

Figure 71 shows a nucleotide sequence (SEQ ID NO:71) of a native sequence PRO1287 cDNA, wherein SEQ ID NO:71 is a clone designated herein as "DNA61755-1554".

Figure 72 shows the amino acid sequence (SEQ ID NO:72) derived from the coding sequence of SEQ ID NO:71 shown in Figure 71.

10 Figure 73 shows a nucleotide sequence (SEQ ID NO:73) of a native sequence PRO1335 cDNA, wherein SEQ ID NO:73 is a clone designated herein as "DNA62812-1594".

Figure 74 shows the amino acid sequence (SEQ ID NO:74) derived from the coding sequence of SEQ ID NO:73 shown in Figure 73.

15 Figure 75 shows a nucleotide sequence (SEQ ID NO:75) of a native sequence PRO1315 cDNA, wherein SEQ ID NO:75 is a clone designated herein as "DNA62815-1576".

Figure 76 shows the amino acid sequence (SEQ ID NO:76) derived from the coding sequence of SEQ ID NO:75 shown in Figure 75.

Figure 77 shows a nucleotide sequence (SEQ ID NO:77) of a native sequence PRO1357 cDNA, wherein SEQ ID NO:77 is a clone designated herein as "DNA64881-1602".

20 Figure 78 shows the amino acid sequence (SEQ ID NO:78) derived from the coding sequence of SEQ ID NO:77 shown in Figure 77.

Figure 79 shows a nucleotide sequence (SEQ ID NO:79) of a native sequence PRO1356 cDNA, wherein SEQ ID NO:79 is a clone designated herein as "DNA64886-1601".

25 Figure 80 shows the amino acid sequence (SEQ ID NO:80) derived from the coding sequence of SEQ ID NO:79 shown in Figure 79.

Figure 81 shows a nucleotide sequence (SEQ ID NO:81) of a native sequence PRO1557 cDNA, wherein SEQ ID NO:81 is a clone designated herein as "DNA64902-1667".

Figure 82 shows the amino acid sequence (SEQ ID NO:82) derived from the coding sequence of SEQ ID NO:81 shown in Figure 81.

30 Figure 83 shows a nucleotide sequence (SEQ ID NO:83) of a native sequence PRO1347 cDNA, wherein SEQ ID NO:83 is a clone designated herein as "DNA64950-1590".

Figure 84 shows the amino acid sequence (SEQ ID NO:84) derived from the coding sequence of SEQ ID NO:83 shown in Figure 83.

35 Figure 85 shows a nucleotide sequence (SEQ ID NO:85) of a native sequence PRO1302 cDNA, wherein SEQ ID NO:85 is a clone designated herein as "DNA65403-1565".

Figure 86 shows the amino acid sequence (SEQ ID NO:86) derived from the coding sequence of SEQ ID NO:85 shown in Figure 85.

Figure 87 shows a nucleotide sequence (SEQ ID NO:87) of a native sequence PRO1270 cDNA, wherein SEQ ID NO:87 is a clone designated herein as "DNA66308-1537".

Figure 88 shows the amino acid sequence (SEQ ID NO:88) derived from the coding sequence of SEQ ID NO:87 shown in Figure 87.

5 Figure 89 shows a nucleotide sequence (SEQ ID NO:89) of a native sequence PRO1268 cDNA, wherein SEQ ID NO:89 is a clone designated herein as "DNA66519-1535".

Figure 90 shows the amino acid sequence (SEQ ID NO:90) derived from the coding sequence of SEQ ID NO:89 shown in Figure 89.

Figure 91 shows a nucleotide sequence (SEQ ID NO:91) of a native sequence PRO1327 cDNA, wherein SEQ ID NO:91 is a clone designated herein as "DNA66521-1583".

10 Figure 92 shows the amino acid sequence (SEQ ID NO:92) derived from the coding sequence of SEQ ID NO:91 shown in Figure 91.

Figure 93 shows a nucleotide sequence (SEQ ID NO:93) of a native sequence PRO1328 cDNA, wherein SEQ ID NO:93 is a clone designated herein as "DNA66658-1584".

15 Figure 94 shows the amino acid sequence (SEQ ID NO:94) derived from the coding sequence of SEQ ID NO:93 shown in Figure 93.

Figure 95 shows a nucleotide sequence (SEQ ID NO:95) of a native sequence PRO1329 cDNA, wherein SEQ ID NO:95 is a clone designated herein as "DNA66660-1585".

Figure 96 shows the amino acid sequence (SEQ ID NO:96) derived from the coding sequence of SEQ ID NO:95 shown in Figure 95.

20 Figure 97 shows a nucleotide sequence (SEQ ID NO:97) of a native sequence PRO1340 cDNA, wherein SEQ ID NO:97 is a clone designated herein as "DNA66663-1598".

Figure 98 shows the amino acid sequence (SEQ ID NO:98) derived from the coding sequence of SEQ ID NO:97 shown in Figure 97.

25 Figure 99 shows a nucleotide sequence (SEQ ID NO:99) of a native sequence PRO1342 cDNA, wherein SEQ ID NO:99 is a clone designated herein as "DNA66674-1599".

Figure 100 shows the amino acid sequence (SEQ ID NO:100) derived from the coding sequence of SEQ ID NO:99 shown in Figure 99.

Figure 101 shows a nucleotide sequence (SEQ ID NO:101) of a native sequence PRO3579 cDNA, wherein SEQ ID NO:101 is a clone designated herein as "DNA68862-2546".

30 Figure 102 shows the amino acid sequence (SEQ ID NO:102) derived from the coding sequence of SEQ ID NO:101 shown in Figure 101.

Figure 103 shows a nucleotide sequence (SEQ ID NO:103) of a native sequence PRO1472 cDNA, wherein SEQ ID NO:103 is a clone designated herein as "DNA68866-1644".

35 Figure 104 shows the amino acid sequence (SEQ ID NO:104) derived from the coding sequence of SEQ ID NO:103 shown in Figure 103.

Figure 105 shows a nucleotide sequence (SEQ ID NO:105) of a native sequence PRO1461 cDNA, wherein SEQ ID NO:105 is a clone designated herein as "DNA68871-1638".

WO 01/16318

Figure 106 shows the amino acid sequence (SEQ ID NO:106) derived from the coding sequence of SEQ ID NO:105 shown in Figure 105.

Figure 107 shows a nucleotide sequence (SEQ ID NO:107) of a native sequence PRO1568 cDNA, wherein SEQ ID NO:107 is a clone designated herein as "DNA68880-1676".

Figure 108 shows the amino acid sequence (SEQ ID NO:108) derived from the coding sequence of SEQ 5 ID NO:107 shown in Figure 107.

Figure 109 shows a nucleotide sequence (SEQ ID NO:109) of a native sequence PRO1753 cDNA, wherein SEQ ID NO:109 is a clone designated herein as "DNA68883-1691".

Figure 110 shows the amino acid sequence (SEQ ID NO:110) derived from the coding sequence of SEQ ID NO:109 shown in Figure 109.

10 Figure 111 shows a nucleotide sequence (SEQ ID NO:111) of a native sequence PRO1570 cDNA, wherein SEQ ID NO:111 is a clone designated herein as "DNA68885-1678".

Figure 112 shows the amino acid sequence (SEQ ID NO:112) derived from the coding sequence of SEQ ID NO:111 shown in Figure 111.

15 Figure 113 shows a nucleotide sequence (SEQ ID NO:113) of a native sequence PRO1446 cDNA, wherein SEQ ID NO:113 is a clone designated herein as "DNA71277-1636".

Figure 114 shows the amino acid sequence (SEQ ID NO:114) derived from the coding sequence of SEQ ID NO:113 shown in Figure 113.

Figure 115 shows a nucleotide sequence (SEQ ID NO:115) of a native sequence PRO1565 cDNA, wherein SEQ ID NO:115 is a clone designated herein as "DNA73727-1673".

20 Figure 116 shows the amino acid sequence (SEQ ID NO:116) derived from the coding sequence of SEQ ID NO:115 shown in Figure 115.

Figure 117 shows a nucleotide sequence (SEQ ID NO:117) of a native sequence PRO1572 cDNA, wherein SEQ ID NO:117 is a clone designated herein as "DNA73734-1680".

25 Figure 118 shows the amino acid sequence (SEQ ID NO:118) derived from the coding sequence of SEQ ID NO:117 shown in Figure 117.

Figure 119 shows a nucleotide sequence (SEQ ID NO:119) of a native sequence PRO1573 cDNA, wherein SEQ ID NO:119 is a clone designated herein as "DNA73735-1681".

Figure 120 shows the amino acid sequence (SEQ ID NO:120) derived from the coding sequence of SEQ ID NO:119 shown in Figure 119.

30 Figure 121 shows a nucleotide sequence (SEQ ID NO:121) of a native sequence PRO1550 cDNA, wherein SEQ ID NO:121 is a clone designated herein as "DNA76393-1664".

Figure 122 shows the amino acid sequence (SEQ ID NO:122) derived from the coding sequence of SEQ ID NO:121 shown in Figure 121.

35 Figure 123 shows a nucleotide sequence (SEQ ID NO:123) of a native sequence PRO1693 cDNA, wherein SEQ ID NO:123 is a clone designated herein as "DNA77301-1708".

Figure 124 shows the amino acid sequence (SEQ ID NO:124) derived from the coding sequence of SEQ ID NO:123 shown in Figure 123.

WO 01/16318

Figure 125 shows a nucleotide sequence (SEQ ID NO:125) of a native sequence PRO1566 cDNA, wherein SEQ ID NO:125 is a clone designated herein as "DNA77568-1626".

Figure 126 shows the amino acid sequence (SEQ ID NO:126) derived from the coding sequence of SEQ ID NO:125 shown in Figure 125.

5 Figure 127 shows a nucleotide sequence (SEQ ID NO:127) of a native sequence PRO1774 cDNA, wherein SEQ ID NO:127 is a clone designated herein as "DNA77626-1705".

Figure 128 shows the amino acid sequence (SEQ ID NO:128) derived from the coding sequence of SEQ ID NO:127 shown in Figure 127.

10 Figure 129 shows a nucleotide sequence (SEQ ID NO:129) of a native sequence PRO1928 cDNA, wherein SEQ ID NO:129 is a clone designated herein as "DNA81754-2532".

Figure 130 shows the amino acid sequence (SEQ ID NO:130) derived from the coding sequence of SEQ ID NO:129 shown in Figure 129.

15 Figure 131 shows a nucleotide sequence (SEQ ID NO:131) of a native sequence PRO1865 cDNA, wherein SEQ ID NO:131 is a clone designated herein as "DNA81757-2512".

Figure 132 shows the amino acid sequence (SEQ ID NO:132) derived from the coding sequence of SEQ ID NO:131 shown in Figure 131.

20 Figure 133 shows a nucleotide sequence (SEQ ID NO:133) of a native sequence PRO1925 cDNA, wherein SEQ ID NO:133 is a clone designated herein as "DNA82302-2529".

Figure 134 shows the amino acid sequence (SEQ ID NO:134) derived from the coding sequence of SEQ ID NO:133 shown in Figure 133.

25 Figure 135 shows a nucleotide sequence (SEQ ID NO:135) of a native sequence PRO1926 cDNA, wherein SEQ ID NO:135 is a clone designated herein as "DNA82340-2530".

Figure 136 shows the amino acid sequence (SEQ ID NO:136) derived from the coding sequence of SEQ ID NO:135 shown in Figure 135.

30 Figure 137 shows a nucleotide sequence (SEQ ID NO:137) of a native sequence PRO1801 cDNA, wherein SEQ ID NO:137 is a clone designated herein as "DNA83500-2506".

Figure 138 shows the amino acid sequence (SEQ ID NO:138) derived from the coding sequence of SEQ ID NO:137 shown in Figure 137.

35 Figure 139 shows a nucleotide sequence (SEQ ID NO:139) of a native sequence PRO4405 cDNA, wherein SEQ ID NO:139 is a clone designated herein as "DNA84920-2614".

Figure 140 shows the amino acid sequence (SEQ ID NO:140) derived from the coding sequence of SEQ ID NO:139 shown in Figure 139.

40 Figure 141 shows a nucleotide sequence (SEQ ID NO:141) of a native sequence PRO3435 cDNA, wherein SEQ ID NO:141 is a clone designated herein as "DNA85066-2534".

Figure 142 shows the amino acid sequence (SEQ ID NO:142) derived from the coding sequence of SEQ ID NO:141 shown in Figure 141.

45 Figure 143 shows a nucleotide sequence (SEQ ID NO:143) of a native sequence PRO3543 cDNA, wherein SEQ ID NO:143 is a clone designated herein as "DNA86571-2551".

Figure 144 shows the amino acid sequence (SEQ ID NO:144) derived from the coding sequence of SEQ ID NO:143 shown in Figure 143.

Figure 145 shows a nucleotide sequence (SEQ ID NO:145) of a native sequence PRO3443 cDNA, wherein SEQ ID NO:145 is a clone designated herein as "DNA87991-2540".

5 Figure 146 shows the amino acid sequence (SEQ ID NO:146) derived from the coding sequence of SEQ ID NO:145 shown in Figure 145.

Figure 147 shows a nucleotide sequence (SEQ ID NO:147) of a native sequence PRO3442 cDNA, wherein SEQ ID NO:147 is a clone designated herein as "DNA92238-2539".

Figure 148 shows the amino acid sequence (SEQ ID NO:148) derived from the coding sequence of SEQ ID NO:147 shown in Figure 147.

10 Figure 149 shows a nucleotide sequence (SEQ ID NO:149) of a native sequence PRO5990 cDNA, wherein SEQ ID NO:149 is a clone designated herein as "DNA96042-2682".

Figure 150 shows the amino acid sequence (SEQ ID NO:150) derived from the coding sequence of SEQ ID NO:149 shown in Figure 149.

15 Figure 151 shows a nucleotide sequence (SEQ ID NO:151) of a native sequence PRO4342 cDNA, wherein SEQ ID NO:151 is a clone designated herein as "DNA96787-2534".

Figure 152 shows the amino acid sequence (SEQ ID NO:152) derived from the coding sequence of SEQ ID NO:151 shown in Figure 151.

Figure 153 shows a nucleotide sequence (SEQ ID NO:153) of a native sequence PRO10096 cDNA, wherein SEQ ID NO:153 is a clone designated herein as "DNA125185-2806".

20 Figure 154 shows the amino acid sequence (SEQ ID NO:154) derived from the coding sequence of SEQ ID NO:153 shown in Figure 153.

Figure 155 shows a nucleotide sequence (SEQ ID NO:155) of a native sequence PRO10272 cDNA, wherein SEQ ID NO:155 is a clone designated herein as "DNA147531-2821".

25 Figure 156 shows the amino acid sequence (SEQ ID NO:156) derived from the coding sequence of SEQ ID NO:155 shown in Figure 155.

Figure 157 shows a nucleotide sequence (SEQ ID NO:157) of a native sequence PRO5801 cDNA, wherein SEQ ID NO:157 is a clone designated herein as "DNA115291-2681".

Figure 158 shows the amino acid sequence (SEQ ID NO:158) derived from the coding sequence of SEQ ID NO:157 shown in Figure 157.

30 Figure 159 shows a nucleotide sequence (SEQ ID NO:159) of a native sequence PRO20110 cDNA, wherein SEQ ID NO:159 is a clone designated herein as "DNA166819".

Figure 160 shows the amino acid sequence (SEQ ID NO:160) derived from the coding sequence of SEQ ID NO:159 shown in Figure 159.

35 Figure 161 shows a nucleotide sequence (SEQ ID NO:161) of a native sequence PRO20040 cDNA, wherein SEQ ID NO:161 is a clone designated herein as "DNA164625-2890".

Figure 162 shows the amino acid sequence (SEQ ID NO:162) derived from the coding sequence of SEQ ID NO:161 shown in Figure 161.

Figure 163 shows a nucleotide sequence (SEQ ID NO:163) of a native sequence PRO20233 cDNA, wherein SEQ ID NO:163 is a clone designated herein as "DNA165608".

Figure 164 shows the amino acid sequence (SEQ ID NO:164) derived from the coding sequence of SEQ ID NO:163 shown in Figure 163.

5 Figure 165 shows a nucleotide sequence (SEQ ID NO:165) of a native sequence PRO19670 cDNA, wherein SEQ ID NO:165 is a clone designated herein as "DNA131639-2874".

Figure 166 shows the amino acid sequence (SEQ ID NO:166) derived from the coding sequence of SEQ ID NO:165 shown in Figure 165.

Figure 167 shows a nucleotide sequence (SEQ ID NO:167) of a native sequence PRO1890 cDNA, wherein SEQ ID NO:167 is a clone designated herein as "DNA79230-2525".

10 10 Figure 168 shows the amino acid sequence (SEQ ID NO:168) derived from the coding sequence of SEQ ID NO:167 shown in Figure 167.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

##### I. Definitions

15 The terms "PRO polypeptide" and "PRO" as used herein and when immediately followed by a numerical designation refer to various polypeptides, wherein the complete designation (i.e., PRO/number) refers to specific polypeptide sequences as described herein. The terms "PRO/number polypeptide" and "PRO/number" wherein the term "number" is provided as an actual numerical designation as used herein encompass native sequence polypeptides and polypeptide variants (which are further defined herein). The PRO polypeptides described herein may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods. The term "PRO polypeptide" refers to each individual PRO/number polypeptide disclosed herein. All disclosures in this specification which refer to the "PRO polypeptide" refer to each of the polypeptides individually as well as jointly. For example, descriptions of the preparation of, purification of, derivation of, formation of antibodies to or against, administration of, compositions containing, treatment of a disease with, etc., pertain to each polypeptide of the invention individually. The term "PRO polypeptide" also includes variants of the PRO/number polypeptides disclosed herein.

A "native sequence PRO polypeptide" comprises a polypeptide having the same amino acid sequence as the corresponding PRO polypeptide derived from nature. Such native sequence PRO polypeptides can be 30 isolated from nature or can be produced by recombinant or synthetic means. The term "native sequence PRO polypeptide" specifically encompasses naturally-occurring truncated or secreted forms of the specific PRO polypeptide (e.g., an extracellular domain sequence), naturally-occurring variant forms (e.g., alternatively spliced forms) and naturally-occurring allelic variants of the polypeptide. In various embodiments of the invention, the native sequence PRO polypeptides disclosed herein are mature or full-length native sequence 35 polypeptides comprising the full-length amino acids sequences shown in the accompanying figures. Start and stop codons are shown in bold font and underlined in the figures. However, while the PRO polypeptide disclosed in the accompanying figures are shown to begin with methionine residues designated herein as amino

acid position 1 in the figures, it is conceivable and possible that other methionine residues located either upstream or downstream from the amino acid position 1 in the figures may be employed as the starting amino acid residue for the PRO polypeptides.

The PRO polypeptide "extracellular domain" or "ECD" refers to a form of the PRO polypeptide which is essentially free of the transmembrane and cytoplasmic domains. Ordinarily, a PRO polypeptide ECD will have less than 1% of such transmembrane and/or cytoplasmic domains and preferably, will have less than 0.5% of such domains. It will be understood that any transmembrane domains identified for the PRO polypeptides of the present invention are identified pursuant to criteria routinely employed in the art for identifying that type of hydrophobic domain. The exact boundaries of a transmembrane domain may vary but most likely by no more than about 5 amino acids at either end of the domain as initially identified herein. Optionally, therefore, an extracellular domain of a PRO polypeptide may contain from about 5 or fewer amino acids on either side of the transmembrane domain/extracellular domain boundary as identified in the Examples or specification and such polypeptides, with or without the associated signal peptide, and nucleic acid encoding them, are contemplated by the present invention.

The approximate location of the "signal peptides" of the various PRO polypeptides disclosed herein are shown in the present specification and/or the accompanying figures. It is noted, however, that the C-terminal boundary of a signal peptide may vary, but most likely by no more than about 5 amino acids on either side of the signal peptide C-terminal boundary as initially identified herein, wherein the C-terminal boundary of the signal peptide may be identified pursuant to criteria routinely employed in the art for identifying that type of amino acid sequence element (e.g., Nielsen et al., Prot. Eng. 10:1-6 (1997) and von Heinje et al., Nucl. Acids. Res. 14:4683-4690 (1986)). Moreover, it is also recognized that, in some cases, cleavage of a signal sequence from a secreted polypeptide is not entirely uniform, resulting in more than one secreted species. These mature polypeptides, where the signal peptide is cleaved within no more than about 5 amino acids on either side of the C-terminal boundary of the signal peptide as identified herein, and the polynucleotides encoding them, are contemplated by the present invention.

"PRO polypeptide variant" means an active PRO polypeptide as defined above or below having at least about 80% amino acid sequence identity with a full-length native sequence PRO polypeptide sequence as disclosed herein, a PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein. Such PRO polypeptide variants include, for instance, PRO polypeptides wherein one or more amino acid residues are added, or deleted, at the N- or C-terminus of the full-length native amino acid sequence. Ordinarily, a PRO polypeptide variant will have at least about 80% amino acid sequence identity, alternatively at least about 81% amino acid sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90% amino acid

sequence identity, alternatively at least about 91 % amino acid sequence identity, alternatively at least about 92 % amino acid sequence identity, alternatively at least about 93 % amino acid sequence identity, alternatively at least about 94 % amino acid sequence identity, alternatively at least about 95 % amino acid sequence identity, alternatively at least about 96 % amino acid sequence identity, alternatively at least about 97 % amino acid sequence identity, alternatively at least about 98 % amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to a full-length native sequence PRO polypeptide sequence as disclosed herein, a PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of a full-length PRO polypeptide sequence as disclosed herein. Ordinarily, PRO variant polypeptides are at least about 10 amino acids in length, alternatively at least about 20 amino acids in length, alternatively at least about 30 amino acids in length, alternatively at least about 40 amino acids in length, alternatively at least about 50 amino acids in length, alternatively at least about 60 amino acids in length, alternatively at least about 70 amino acids in length, alternatively at least about 80 amino acids in length, alternatively at least about 90 amino acids in length, alternatively at least about 100 amino acids in length, alternatively at least about 150 amino acids in length, alternatively at least about 200 amino acids in length, alternatively at least about 300 amino acids in length, or more.

"Percent (%) amino acid sequence identity" with respect to the PRO polypeptide sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific PRO polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 below has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1 below. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

## 100 times the fraction X/Y

where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. As examples of % amino acid sequence identity calculations using this method, Tables 2 and 3 demonstrate how to calculate the % amino acid sequence identity of the amino acid sequence designated "Comparison Protein" to the amino acid sequence designated "PRO", wherein "PRO" represents the amino acid sequence of a hypothetical PRO polypeptide of interest, "Comparison Protein" represents the amino acid sequence of a polypeptide against which the "PRO" polypeptide of interest is being compared, and "X", "Y" and "Z" each represent different hypothetical amino acid residues.

Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program. However, % amino acid sequence identity values may also be obtained as described below by using the WU-BLAST-2 computer program (Altschul et al., Methods in Enzymology 266:460-480 (1996)). Most of the WU-BLAST-2 search parameters are set to the default values. Those not set to default values, i.e., the adjustable parameters, are set with the following values: overlap span = 1, overlap fraction = 0.125, word threshold (T) = 11, and scoring matrix = BLOSUM62. When WU-BLAST-2 is employed, a % amino acid sequence identity value is determined by dividing (a) the number of matching identical amino acid residues between the amino acid sequence of the PRO polypeptide of interest having a sequence derived from the native PRO polypeptide and the comparison amino acid sequence of interest (i.e., the sequence against which the PRO polypeptide of interest is being compared which may be a PRO variant polypeptide) as determined by WU-BLAST-2 by (b) the total number of amino acid residues of the PRO polypeptide of interest. For example, in the statement "a polypeptide comprising an the amino acid sequence A which has or having at least 80% amino acid sequence identity to the amino acid sequence B", the amino acid sequence A is the comparison amino acid sequence of interest and the amino acid sequence B is the amino acid sequence of the PRO polypeptide of interest.

Percent amino acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)). The NCBI-BLAST2 sequence comparison program may be downloaded from <http://www.ncbi.nlm.nih.gov> or otherwise obtained from the National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several search parameters, wherein all of those search parameters are set to default values including, for example, unmask = yes, strand = all, expected occurrences = 10, minimum low complexity length = 15/5, multi-pass e-value = 0.01, constant for multi-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.

In situations where NCBI-BLAST2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

100 times the fraction X/Y

where X is the number of amino acid residues scored as identical matches by the sequence alignment program NCBI-BLAST2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino 5 acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A.

"PRO variant polynucleotide" or "PRO variant nucleic acid sequence" means a nucleic acid molecule which encodes an active PRO polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with a nucleotide acid sequence encoding a full-length native sequence PRO polypeptide 10 sequence as disclosed herein, a full-length native sequence PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein. Ordinarily, a PRO variant polynucleotide will have at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid 15 sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% 20 nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity with a nucleic 25 acid sequence encoding a full-length native sequence PRO polypeptide sequence as disclosed herein, a full-length native sequence PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal sequence, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein. Variants do not encompass the native nucleotide sequence.

30       Ordinarily, PRO variant polynucleotides are at least about 30 nucleotides in length, alternatively at least about 60 nucleotides in length, alternatively at least about 90 nucleotides in length, alternatively at least about 120 nucleotides in length, alternatively at least about 150 nucleotides in length, alternatively at least about 180 nucleotides in length, alternatively at least about 210 nucleotides in length, alternatively at least about 240 nucleotides in length, alternatively at least about 270 nucleotides in length, alternatively at least about 300 35 nucleotides in length, alternatively at least about 450 nucleotides in length, alternatively at least about 600 nucleotides in length, alternatively at least about 900 nucleotides in length, or more.

"Percent (%) nucleic acid sequence identity" with respect to PRO-encoding nucleic acid sequences identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in the PRO nucleic acid sequence of interest, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, 5 using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. For purposes herein, however, % nucleic acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 below has been filed with user documentation in the U.S. 10 Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1 below. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

15 In situations where ALIGN-2 is employed for nucleic acid sequence comparisons, the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain % nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:

20 100 times the fraction W/Z

where W is the number of nucleotides scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence 25 D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C. As examples of % nucleic acid sequence identity calculations, Tables 4 and 5, demonstrate how to calculate the % nucleic acid sequence identity of the nucleic acid sequence designated "Comparison DNA" to the nucleic acid sequence designated "PRO-DNA", wherein "PRO-DNA" represents a hypothetical PRO-encoding nucleic acid sequence of interest, "Comparison DNA" represents the nucleotide sequence of a nucleic acid molecule 30 against which the "PRO-DNA" nucleic acid molecule of interest is being compared, and "N", "L" and "V" each represent different hypothetical nucleotides.

Unless specifically stated otherwise, all % nucleic acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program. However, % nucleic acid sequence identity values may also be obtained as described below by using the WU-BLAST-2 35 computer program (Altschul et al., Methods in Enzymology 266:460-480 (1996)). Most of the WU-BLAST-2 search parameters are set to the default values. Those not set to default values, i.e., the adjustable parameters, are set with the following values: overlap span = 1, overlap fraction = 0.125, word threshold (T) = 11, and

scoring matrix = BLOSUM62. When WU-BLAST-2 is employed, a % nucleic acid sequence identity value is determined by dividing (a) the number of matching identical nucleotides between the nucleic acid sequence of the PRO polypeptide-encoding nucleic acid molecule of interest having a sequence derived from the native sequence PRO polypeptide-encoding nucleic acid and the comparison nucleic acid molecule of interest (i.e., the sequence against which the PRO polypeptide-encoding nucleic acid molecule of interest is being compared which 5 may be a variant PRO polynucleotide) as determined by WU-BLAST-2 by (b) the total number of nucleotides of the PRO polypeptide-encoding nucleic acid molecule of interest. For example, in the statement "an isolated nucleic acid molecule comprising a nucleic acid sequence A which has or having at least 80% nucleic acid sequence identity to the nucleic acid sequence B", the nucleic acid sequence A is the comparison nucleic acid molecule of interest and the nucleic acid sequence B is the nucleic acid sequence of the PRO polypeptide-encoding nucleic acid molecule of interest.

10 Percent nucleic acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., *Nucleic Acids Res.* 25:3389-3402 (1997)). The NCBI-BLAST2 sequence comparison program may be downloaded from <http://www.ncbi.nlm.nih.gov> or otherwise obtained from the National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several search parameters, wherein all of those 15 search parameters are set to default values including, for example, unmask = yes, strand = all, expected occurrences = 10, minimum low complexity length = 15/5, multi-pass e-value = 0.01, constant for multi-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.

In situations where NCBI-BLAST2 is employed for sequence comparisons, the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can 20 alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain % nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:

$$100 \text{ times the fraction } W/Z$$

25 where W is the number of nucleotides scored as identical matches by the sequence alignment program NCBI-BLAST2 in that program's alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C.

30 In other embodiments, PRO variant polynucleotides are nucleic acid molecules that encode an active PRO polypeptide and which are capable of hybridizing, preferably under stringent hybridization and wash conditions, to nucleotide sequences encoding a full-length PRO polypeptide as disclosed herein. PRO variant polypeptides may be those that are encoded by a PRO variant polynucleotide.

35 "Isolated," when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous

solutes. In preferred embodiments, the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes polypeptide *in situ* within recombinant cells, since at least one component of the PRO polypeptide natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.

- 5 An "isolated" PRO polypeptide-encoding nucleic acid or other polypeptide-encoding nucleic acid is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the polypeptide-encoding nucleic acid. An isolated polypeptide-encoding nucleic acid molecule is other than in the form or setting in which it is found in nature.
- 10 Isolated polypeptide-encoding nucleic acid molecules therefore are distinguished from the specific polypeptide-encoding nucleic acid molecule as it exists in natural cells. However, an isolated polypeptide-encoding nucleic acid molecule includes polypeptide-encoding nucleic acid molecules contained in cells that ordinarily express the polypeptide where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.
- 15 The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

20 Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

25 The term "antibody" is used in the broadest sense and specifically covers, for example, single anti-PRO monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies), anti-PRO antibody compositions with polyepitopic specificity, single chain anti-PRO antibodies, and fragments of anti-PRO antibodies (see below). The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts.

30 "Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when

complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).

"Stringent conditions" or "high stringency conditions", as defined herein, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

"Moderately stringent conditions" may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent than those described above. An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

The term "epitope tagged" when used herein refers to a chimeric polypeptide comprising a PRO polypeptide fused to a "tag polypeptide". The tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused. The tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes. Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues).

As used herein, the term "immunoadhesin" designates antibody-like molecules which combine the binding specificity of a heterologous protein (an "adhesin") with the effector functions of immunoglobulin constant domains. Structurally, the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is "heterologous"), and an immunoglobulin constant domain sequence. The adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand. The immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any

immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD or IgM.

"Active" or "activity" for the purposes herein refers to form(s) of a PRO polypeptide which retain a biological and/or an immunological activity of native or naturally-occurring PRO, wherein "biological" activity refers to a biological function (either inhibitory or stimulatory) caused by a native or naturally-occurring PRO other than the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring PRO and an "immunological" activity refers to the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring PRO.

The term "antagonist" is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a native PRO polypeptide disclosed herein. In a similar manner, the term "agonist" is used in the broadest sense and includes any molecule that mimics a biological activity of a native PRO polypeptide disclosed herein. Suitable agonist or antagonist molecules specifically include agonist or antagonist antibodies or antibody fragments, fragments or amino acid sequence variants of native PRO polypeptides, peptides, antisense oligonucleotides, small organic molecules, etc. Methods for identifying agonists or antagonists of a PRO polypeptide may comprise contacting a PRO polypeptide with a candidate agonist or antagonist molecule and measuring a detectable change in one or more biological activities normally associated with the PRO polypeptide.

"Treatment" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.

"Chronic" administration refers to administration of the agent(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time. "Intermittent" administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature.

"Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc. Preferably, the mammal is human.

Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order.

"Carriers" as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution. Examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-

forming counterions such as sodium; and/or nonionic surfactants such as TWEEN™, polyethylene glycol (PEG), and PLURONICS™.

"Antibody fragments" comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')<sub>2</sub>, and Fv fragments; diabodies; linear antibodies (Zapata et al., *Protein Eng.* 8(10): 1057-1062 [1995]); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment, a designation reflecting the ability to crystallize readily. Pepsin treatment yields an F(ab')<sub>2</sub> fragment that has two antigen-combining sites and is still capable of cross-linking antigen.

"Fv" is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the V<sub>H</sub>-V<sub>L</sub> dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab fragments differ from Fab' fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')<sub>2</sub> antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

The "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains.

Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2.

"Single-chain Fv" or "sFv" antibody fragments comprise the V<sub>H</sub> and V<sub>L</sub> domains of antibody, wherein these domains are present in a single polypeptide chain. Preferably, the Fv polypeptide further comprises a polypeptide linker between the V<sub>H</sub> and V<sub>L</sub> domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv, see Pluckthun in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenberg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).

The term "diabodies" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (V<sub>H</sub>) connected to a light-chain variable domain (V<sub>L</sub>) in the same polypeptide chain (V<sub>H</sub>-V<sub>L</sub>). By using a linker that is too short to allow pairing between the two domains

on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).

An "isolated" antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.

An antibody that "specifically binds to" or is "specific for" a particular polypeptide or an epitope on a particular polypeptide is one that binds to that particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope.

The word "label" when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody. The label may be detectable by itself (e.g. radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.

By "solid phase" is meant a non-aqueous matrix to which the antibody of the present invention can adhere. Examples of solid phases encompassed herein include those formed partially or entirely of glass (e.g., controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones. In certain embodiments, depending on the context, the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g., an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275,149.

A "liposome" is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug (such as a PRO polypeptide or antibody thereto) to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.

A "small molecule" is defined herein to have a molecular weight below about 500 Daltons.

Table 1

```

/*
*
* C-C increased from 12 to 15
* Z is average of EQ
* B is average of ND
* match with stop is _M; stop-stop = 0; J (joker) match = 0
*/
#define _M -8 /* value of a match with a stop */

10 int _day[26][26] = {
/* A B C D E F G H I J K L M N O P Q R S T U V W X Y Z */
/* A */ { 2, 0,-2, 0, 0,-4, 1,-1,-1, 0,-1,-2,-1, 0,_M, 1, 0,-2, 1, 1, 0, 0,-6, 0,-3, 0},
/* B */ { 0, 3,-4, 3, 2,-5, 0, 1,-2, 0, 0,-3,-2, 2,_M,-1, 1, 0, 0, 0, 0,-2,-5, 0,-3, 1},
/* C */ {-2,-4,15,-5,-5,-4,-3,-3,-2, 0,-5,-6,-5,-4,_M,-3,-5,-4, 0,-2, 0,-2,-8, 0, 0,-5},
15 /* D */ { 0, 3,-5, 4, 3,-6, 1, 1,-2, 0, 0,-4,-3, 2,_M,-1, 2,-1, 0, 0, 0,-2,-7, 0,-4, 2},
/* E */ { 0, 2,-5, 3, 4,-5, 0, 1,-2, 0, 0,-3,-2, 1,_M,-1, 2,-1, 0, 0, 0,-2,-7, 0,-4, 3},
/* F */ {-4,-5,-4,-6,-5, 9,-5,-2, 1, 0,-5, 2, 0,-4,_M,-5,-5,-4,-3,-3, 0,-1, 0, 0, 7,-5},
/* G */ { 1, 0,-3, 1, 0,-5, 5,-2,-3, 0,-2,-4,-3, 0,_M,-1,-1,-3, 1, 0, 0,-1,-7, 0,-5, 0},
/* H */ {-1, 1,-3, 1, 1,-2,-2, 6,-2, 0, 0,-2,-2, 2,_M, 0, 3, 2,-1,-1, 0,-2,-3, 0, 0, 2},
/* I */ {-1,-2,-2,-2,-2, 1,-3,-2, 5, 0,-2, 2, 2,-2,_M,-2,-2,-2,-1, 0, 0, 4,-5, 0,-1,-2},
/* J */ { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,_M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0},
/* K */ {-1, 0,-5, 0, 0,-5,-2, 0,-2, 0, 5,-3, 0, 1,_M,-1, 1, 3, 0, 0, 0,-2,-3, 0,-4, 0},
/* L */ {-2,-3,-6,-4,-3, 2,-4,-2, 2, 0,-3, 6, 4,-3,_M,-3,-2,-3,-1, 0, 2,-2, 0,-1,-2},
/* M */ {-1,-2,-5,-3,-2, 0,-3,-2, 2, 0, 0, 4, 6,-2,_M,-2,-1, 0,-2,-1, 0, 2,-4, 0,-2,-1},
25 /* N */ { 0, 2,-4, 2, 1,-4, 0, 2,-2, 0, 1,-3,-2, 2,_M,-1, 1, 0, 1, 0, 0,-2,-4, 0,-2, 1},
/* O */ { _M, _M },
/* P */ { 1,-1,-3,-1,-1,-5,-1, 0,-2, 0,-1,-3,-2,-1,_M, 6, 0, 0, 1, 0, 0,-1,-6, 0,-5, 0},
/* Q */ { 0, 1,-5, 2, 2,-5,-1, 3,-2, 0, 1,-2,-1, 1,_M, 0, 4, 1,-1,-1, 0,-2,-5, 0,-4, 3},
/* R */ {-2, 0,-4,-1,-1,-4,-3, 2,-2, 0, 3,-3, 0, 0,_M, 0, 1, 6, 0,-1, 0,-2, 2, 0,-4, 0},
30 /* S */ { 1, 0, 0, 0, 0,-3, 1,-1,-1, 0, 0,-3,-2, 1,_M, 1,-1, 0, 2, 1, 0,-1,-2, 0,-3, 0},
/* T */ { 1, 0,-2, 0, 0,-3, 0,-1, 0, 0, 0,-1,-1, 0,_M, 0,-1,-1, 1, 3, 0, 0,-5, 0,-3, 0},
/* U */ { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,_M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0},
/* V */ { 0,-2,-2,-2,-2,-1,-1,-2, 4, 0,-2, 2, 2,-2,_M,-1,-2,-2,-1, 0, 0, 4,-6, 0,-2,-2},
/* W */ {-6,-5,-8,-7,-7, 0,-7,-3,-5, 0,-3,-2,-4,-4,_M,-6,-5, 2,-2,-5, 0,-6,17, 0, 0,-6},
35 /* X */ { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,_M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0},
/* Y */ {-3,-3, 0,-4,-4, 7,-5, 0,-1, 0,-4,-1,-2,-2,_M,-5,-4,-4,-3,-3, 0,-2, 0, 0,10,-4},
/* Z */ { 0, 1,-5, 2, 3,-5, 0, 2,-2, 0, 0,-2,-1, 1,_M, 0, 3, 0, 0, 0, 0,-2,-6, 0,-4, 4}
};

40

```

45

50

55

Table 1 (cont?)

```

/*
 */
#include <stdio.h>
#include <ctype.h>

5      #define MAXJMP    16    /* max jumps in a diag */
#define MAXGAP    24    /* don't continue to penalize gaps larger than this */
#define J MPS    1024   /* max jmps in an path */
#define MX     4     /* save if there's at least MX-1 bases since last jmp */

10     #define DMAT     3     /* value of matching bases */
#define DMIS     0     /* penalty for mismatched bases */
#define DINSO    8     /* penalty for a gap */
#define DINS1    1     /* penalty per base */
15     #define PINSO    8     /* penalty for a gap */
#define PINS1    4     /* penalty per residue */

20     struct jmp {
        short      n[MAXJMP];    /* size of jmp (neg for delay) */
        unsigned short x[MAXJMP]; /* base no. of jmp in seq x */
                                /* limits seq to 2^16 -1 */
    };

25     struct diag {
        int       score;        /* score at last jmp */
        long      offset;       /* offset of prev block */
        short      ijmp;        /* current jmp index */
        struct jmp  jp;         /* list of jmps */
    };

30     struct path {
        int      spc;          /* number of leading spaces */
        short    n[J MPS]; /* size of jmp (gap) */
        int      x[J MPS]; /* loc of jmp (last elem before gap) */
    };

35     char      *ofile;        /* output file name */
char      *namex[2];    /* seq names: getseqs() */
char      *prog;          /* prog name for err msgs */
char      *seqx[2];        /* seqs: getseqs() */
40     int       dmax;          /* best diag: nw() */
int       dmax0;          /* final diag */
int       dna;             /* set if dna: main() */
int       endgaps;        /* set if penalizing end gaps */
int       gapx, gapy;    /* total gaps in seqs */
45     int       len0, len1;    /* seq lens */
int       ngapx, ngapy;  /* total size of gaps */
int       smax;            /* max score: nw() */
int       *xbm;             /* bitmap for matching */
long      offset;          /* current offset in jmp file */
50     struct diag  *dx;        /* holds diagonals */
struct path   pp[2];    /* holds path for seqs */

55     char      *calloc(), *malloc(), *index(), *strcpy();
char      *getseq(), *g_malloc();

```

**Table 1 (cont')**

```

/* Needleman-Wunsch alignment program
 *
 * usage: progs file1 file2
 * where file1 and file2 are two dna or two protein sequences.
5  * The sequences can be in upper- or lower-case and may contain ambiguity
 * Any lines beginning with ';' or '>' or '<' are ignored
 * Max file length is 65535 (limited by unsigned short x in the jmp struct)
 * A sequence with 1/3 or more of its elements ACGTU is assumed to be DNA
 * Output is in the file "align.out"
 *
10 * The program may create a tmp file in /tmp to hold info about traceback.
 * Original version developed under BSD 4.3 on a vax 8650
 */
#include "nw.h"
15 #include "day.h"

static _dbval[26] = {
    1,14,2,13,0,0,4,11,0,0,12,0,3,15,0,0,0,5,6,8,8,7,9,0,10,0
};
20 static _pbval[26] = {
    1, 2|(1<<('D'-'A'))|(1<<('N'-'A')), 4, 8, 16, 32, 64,
    128, 256, 0xFFFFFFFF, 1<<10, 1<<11, 1<<12, 1<<13, 1<<14,
25 1<<15, 1<<16, 1<<17, 1<<18, 1<<19, 1<<20, 1<<21, 1<<22,
    1<<23, 1<<24, 1<<25|(1<<('E'-'A'))|(1<<('Q'-'A'))
};

main(ac, av)
30 {
    int ac;
    char *av[ ];
{
    prog = av[0];
    if (ac != 3) {
        fprintf(stderr, "usage: %s file1 file2\n", prog);
35    fprintf(stderr, "where file1 and file2 are two dna or two protein sequences.\n");
        fprintf(stderr, "The sequences can be in upper- or lower-case\n");
        fprintf(stderr, "Any lines beginning with ';' or '<' are ignored\n");
        fprintf(stderr, "Output is in the file \"align.out\"\n");
        exit(1);
40    }
    namex[0] = av[1];
    namex[1] = av[2];
    seqx[0] = getseq(namex[0], &len0);
    seqx[1] = getseq(namex[1], &len1);
45    xbm = (dna)? _dbval : _pbval;

    endgaps = 0; /* 1 to penalize endgaps */
    ofile = "align.out"; /* output file */

50    nw(); /* fill in the matrix, get the possible jmps */
    readjmps(); /* get the actual jmps */
    print(); /* print stats, alignment */

    cleanup(0); /* unlink any tmp files */
55 }

```

Table 1 (cont')

```

/* do the alignment, return best score: main()
 * dna: values in Fitch and Smith, PNAS, 80, 1382-1386, 1983
 * pro: PAM 250 values
 * When scores are equal, we prefer mismatches to any gap, prefer
 5   * a new gap to extending an ongoing gap, and prefer a gap in seqx
 * to a gap in seq y.
 */
nw()
{
10    char      *px, *py;          /* seqs and ptrs */
    int       *ndely, *dely;     /* keep track of dely */
    int       ndlx, delx;       /* keep track of delx */
    int       *tmp;             /* for swapping row0, row1 */
    int       mis;              /* score for each type */
15    int       ins0, ins1;       /* insertion penalties */
    register id;              /* diagonal index */
    register ij;              /* jmp index */
    register *col0, *coll;     /* score for curr, last row */
    register xx, yy;           /* index into seqs */
20
dx = (struct diag *)g_calloc("to get diags", len0+len1+1, sizeof(struct diag));

ndely = (int *)g_calloc("to get ndely", len1+1, sizeof(int));
dely = (int *)g_calloc("to get dely", len1+1, sizeof(int));
25  col0 = (int *)g_calloc("to get col0", len1+1, sizeof(int));
    col1 = (int *)g_calloc("to get col1", len1+1, sizeof(int));
    ins0 = (dna)? DINS0 : PINS0;
    ins1 = (dna)? DINS1 : PINS1;

30  smax = -10000;
if (endgaps) {
    for (col0[0] = dely[0] = -ins0, yy = 1; yy <= len1; yy++) {
        col0[yy] = dely[yy] = col0[yy-1] - ins1;
        ndely[yy] = yy;
35    }
    col0[0] = 0;           /* Waterman Bull Math Biol 84 */
}
else
    for (yy = 1; yy <= len1; yy++)
        dely[yy] = -ins0;
40

/* fill in match matrix
 */
45  for (px = seqx[0], xx = 1; xx <= len0; px++, xx++) {
    /* initialize first entry in col
     */
    if (endgaps) {
        if (xx == 1)
            col1[0] = delx = -(ins0+ins1);
50    else
            col1[0] = delx = col0[0] - ins1;
        ndlx = xx;
    }
    else {
55        col1[0] = 0;
        delx = -ins0;
        ndlx = 0;
    }
}
60

```

Table 1 (cont')

...nw

```

for (py = seqx[1], yy = 1; yy <= len1; py++, yy++) {
    mis = col0[yy-1];
    if (dna)
        mis += (xbm[*px-'A']&xbm[*py-'A'])? DMAT : DMIS;
    else
        mis += _day[*px-'A'][*py-'A'];

    /* update penalty for del in x seq;
     * favor new del over ongong del
     * ignore MAXGAP if weighting endgaps
     */
    if (endgaps || ndely[yy] < MAXGAP) {
        if (col0[yy] - ins0 >= dely[yy]) {
            dely[yy] = col0[yy] - (ins0+ins1);
            ndely[yy] = 1;
        } else {
            dely[yy] -= ins1;
            ndely[yy]++;
        }
    } else {
        if (col0[yy] - (ins0+ins1) >= dely[yy]) {
            dely[yy] = col0[yy] - (ins0+ins1);
            ndely[yy] = 1;
        } else
            ndely[yy]++;
    }

    /* update penalty for del in y seq;
     * favor new del over ongong del
     */
    if (endgaps || ndelx < MAXGAP) {
        if (col1[yy-1] - ins0 >= delx) {
            delx = col1[yy-1] - (ins0+ins1);
            ndelx = 1;
        } else {
            delx -= ins1;
            ndelx++;
        }
    } else {
        if (col1[yy-1] - (ins0+ins1) >= delx) {
            delx = col1[yy-1] - (ins0+ins1);
            ndelx = 1;
        } else
            ndelx++;
    }

    /* pick the maximum score; we're favoring
     * mis over any del and delx over dely
     */
}

```

55

60

Table 1 (cont')

...nw

```

id = xx - yy + len1 - 1;
if (mis >= delx && mis >= dely[yy])
    col1[yy] = mis;
5   else if (delx >= dely[yy]) {
        col1[yy] = delx;
        ij = dx[id].ijmp;
        if (dx[id].jp.n[0] && (!dna || (ndelx >= MAXJMP
        && xx > dx[id].jp.x[ij]+MX) || mis > dx[id].score+DINS0)) {
            dx[id].ijmp++;
            if (++ij >= MAXJMP) {
                writejmps(id);
                ij = dx[id].ijmp = 0;
                dx[id].offset = offset;
                offset += sizeof(struct jmp) + sizeof(offset);
            }
        }
        dx[id].jp.n[ij] = ndelx;
        dx[id].jp.x[ij] = xx;
        dx[id].score = delx;
20   }
    else {
        col1[yy] = dely[yy];
        ij = dx[id].ijmp;
        if (dx[id].jp.n[0] && (!dna || (ndely[yy] >= MAXJMP
        && xx > dx[id].jp.x[ij]+MX) || mis > dx[id].score+DINS0)) {
            dx[id].ijmp++;
            if (++ij >= MAXJMP) {
                writejmps(id);
                ij = dx[id].ijmp = 0;
                dx[id].offset = offset;
                offset += sizeof(struct jmp) + sizeof(offset);
            }
        }
        dx[id].jp.n[ij] = -ndely[yy];
        dx[id].jp.x[ij] = xx;
        dx[id].score = dely[yy];
    }
40   if (xx == len0 && yy < len1) {
        /* last col
        */
        if (endgaps)
            col1[yy] -= ins0+ins1*(len1-yy);
        if (col1[yy] > smax) {
            smax = col1[yy];
            dmax = id;
        }
    }
50   if (endgaps && xx < len0)
        col1[yy-1] -= ins0+ins1*(len0-xx);
        if (col1[yy-1] > smax) {
            smax = col1[yy-1];
            dmax = id;
        }
55   }
        tmp = col0; col0 = col1; col1 = tmp;
    }
        (void) free((char *)ndely);
        (void) free((char *)dely);
        (void) free((char *)col0);
        (void) free((char *)col1);
60   }

```

**Table 1 (cont')**

```

/*
 *
 * print() -- only routine visible outside this module
 *
5   * static:
 * getmat() -- trace back best path, count matches: print()
 * pr_align() -- print alignment of described in array pf []: print()
 * dumpblock() -- dump a block of lines with numbers, stars: pr_align()
 * nums() -- put out a number line: dumpblock()
10  * putline() -- put out a line (name, [num], seq, [num]): dumpblock()
 * stars() - put a line of stars: dumpblock()
 * stripname() -- strip any path and prefix from a seqname
 */

15 #include "nw.h"

#define SPC      3
#define P_LINE   256 /* maximum output line */
#define P_SPC    3 /* space between name or num and seq */

20 extern _day[26][26];
int olen;           /* set output line length */
FILE *fx;           /* output file */

25 print()
{
    int lx, ly, firstgap, lastgap; /* overlap */

    if ((fx = fopen(ofile, "w")) == 0) {
        fprintf(stderr, "%s: can't write %s\n", prog, ofile);
        cleanup(1);
    }
    fprintf(fx, "< first sequence: %s (length = %d)\n", namex[0], len0);
    fprintf(fx, "< second sequence: %s (length = %d)\n", namex[1], len1);
35   olen = 60;
    lx = len0;
    ly = len1;
    firstgap = lastgap = 0;
    if (dmax < len1 - 1) { /* leading gap in x */
40      pp[0].spc = firstgap = len1 - dmax - 1;
      ly -= pp[0].spc;
    }
    else if (dmax > len1 - 1) { /* leading gap in y */
45      pp[1].spc = firstgap = dmax - (len1 - 1);
      lx -= pp[1].spc;
    }
    if (dmax0 < len0 - 1) { /* trailing gap in x */
50      lastgap = len0 - dmax0 - 1;
      lx -= lastgap;
    }
    else if (dmax0 > len0 - 1) { /* trailing gap in y */
55      lastgap = dmax0 - (len0 - 1);
      ly -= lastgap;
    }
    getmat(lx, ly, firstgap, lastgap);
    pr_align();
}

60

```

Table 1 (cont')

```

/*
 * trace back the best path, count matches
 */
static
5    getmat(lx, ly, firstgap, lastgap)           getmat
      int     lx, ly;                      /* "core" (minus endgaps) */
      int     firstgap, lastgap;          /* leading/trailing overlap */
{
10   int         nm, i0, i1, siz0, siz1;
      char        outx[32];
      double       pct;
      register    n0, n1;
      register char *p0, *p1;

15   /* get total matches, score
 */
      i0 = i1 = siz0 = siz1 = 0;
      p0 = seqx[0] + pp[1].spc;
      p1 = seqx[1] + pp[0].spc;
20   n0 = pp[1].spc + 1;
      n1 = pp[0].spc + 1;

      nm = 0;
25   while (*p0 && *p1) {
        if (siz0) {
          p1++;
          n1++;
          siz0--;
        }
30   else if (siz1) {
          p0++;
          n0++;
          siz1--;
        }
35   else {
          if (xbm[*p0-'A']&xhm[*p1-'A'])
            nm++;
          if (n0++ == pp[0].n[i0])
            siz0 = pp[0].n[i0++];
40   if (n1++ == pp[1].n[i1])
            siz1 = pp[1].n[i1++];
          p0++;
          p1++;
        }
45   }

/* pct homology:
 * if penalizing endgaps, base is the shorter seq
 * else, knock off overhangs and take shorter core
 */
50   if (endgaps)
      lx = (len0 < len1)? len0 : len1;
    else
      lx = (lx < ly)? lx : ly;
55   pct = 100.*(double)nm/(double)lx;
   fprintf(fx, "\n");
   fprintf(fx, "< %d match%s in an overlap of %d: %.2f percent similarity\n",
          nm, (nm == 1)? "" : "es", lx, pct);

```

Table 1 (cont')

```

fprintf(fx, "<gaps in first sequence: %d", gapx); ...getmat
5   if (gapx) {
        (void) sprintf(outx, " (%d %s%s)", ngapx, (dna)? "base": "residue", (ngapx == 1)? ":" : "s");
        fprintf(fx, "%s", outx);

fprintf(fx, ", gaps in second sequence: %d", gapy);
10  if (gapy) {
        (void) sprintf(outx, " (%d %s%s)", ngapy, (dna)? "base": "residue", (ngapy == 1)? ":" : "s");
        fprintf(fx, "%s", outx);
    }
15  if (dma)
        fprintf(fx,
            "\n<score: %d (match = %d, mismatch = %d, gap penalty = %d + %d per base)\n",
            smax, DMAT, DMIS, DINS0, DINS1);
    else
        fprintf(fx,
            "\n<score: %d (Dayhoff PAM 250 matrix, gap penalty = %d + %d per residue)\n",
            smax, PINS0, PINS1);
if (endgaps)
    fprintf(fx,
        "<endgaps penalized. left endgap: %d %s%s, right endgap: %d %s%s\n",
        firstgap, (dma)? "base": "residue", (firstgap == 1)? ":" : "s",
        lastgap, (dma)? "base": "residue", (lastgap == 1)? ":" : "s");
else
    fprintf(fx, "<endgaps not penalized\n");
30
}
35
static nm; /* matches in core -- for checking */
static lmax; /* lengths of stripped file names */
static ij[2]; /* jmp index for a path */
static nc[2]; /* number at start of current line */
static ni[2]; /* current elem number -- for gapping */
static siz[2];
40 static char *ps[2]; /* ptr to current element */
static char *po[2]; /* ptr to next output char slot */
static char out[2][P_LINE]; /* output line */
static char star[P_LINE]; /* set by stars() */

/*
* print alignment of described in struct path pp [ ]
*/
45 static pr_align()
{
    int nn; /* char count */
    int more;
50    register i;

    for (i = 0, lmax = 0; i < 2; i++) {
        nn = stripname(namex[i]);
        if (nn > lmax)
            lmax = nn;

        nc[i] = 1;
        ni[i] = 1;
        siz[i] = ij[i] = 0;
        ps[i] = seqx[i];
        po[i] = out[i];
    }
55
60
}
pr_align

```

**Table 1 (cont')**

```

for (nn = nm = 0, more = 1; more; ) {
    for (i = more = 0; i < 2; i++) {
        /*
         * do we have more of this sequence?
         */
        if (!*ps[i])
            continue;
    }
    more++;

    if (pp[i].spc) { /* leading space */
        *po[i]++ = ' ';
        pp[i].spc--;
    }
    else if (siz[i]) { /* in a gap */
        *po[i]++ = '-';
        siz[i]--;
    }
    else { /* we're putting a seq element
             */
        *po[i] = *ps[i];
        if (islower(*ps[i]))
            *ps[i] = toupper(*ps[i]);
        po[i]++;
        ps[i]++;
    }

    /*
     * are we at next gap for this seq?
     */
    if (ni[i] == pp[i].x[ij[i]]) {
        /*
         * we need to merge all gaps
         * at this location
         */
        siz[i] = pp[i].n[ij[i]++];
        while (ni[i] == pp[i].x[ij[i]])
            siz[i] += pp[i].n[ij[i]++];
    }
    ni[i]++;
}

if (++nn == olen || !more && nn) {
    dumpblock();
    for (i = 0; i < 2; i++)
        po[i] = out[i];
    nn = 0;
}
}

/*
 * dump a block of lines, including numbers, stars: pr_align()
 */
static
dumpblock()
{
    register i;
    for (i = 0; i < 2; i++)
        *po[i]-- = '\0';
}

```

...pr\_align

dumpblock

**Table 1 (cont')**

```

...dumpblock

5   (void) putc('\n', fx);
    for (i = 0; i < 2; i++) {
        if (*out[i] && (*out[i] != ' ' || *(po[i]) != ' '))
            if (i == 0)
                nums(i);
            if (i == 0 && *out[1])
                stars();
10   putline(i);
        if (i == 0 && *out[1])
            fprintf(fx, star);
        if (i == 1)
            nums(i);
15   }
}
}

20 /*
 * put out a number line: dumpblock()
 */
static
nums(ix)                                numbs
25 {                                         int      ix;      /* index in out[] holding seq line */
    char      nline[P_LINE];
    register  i, j;
    register char  *pn, *px, *py;

30   for (pn = nline, i = 0; i < lmax + P_SPC; i++, pn++)
        *pn = ' ';
    for (i = nc[ix], py = out[ix]; *py; py++, pn++) {
        if (*py == ' ' || *py == '-')
            *pn = ' ';
        else {
            if (i%10 == 0 || (i == 1 && nc[ix] != 1)) {
                j = (i < 0)? -i : i;
                for (px = pn; j /= 10, px--)
                    *px = j%10 + '0';
                if (i < 0)
                    *px = '-';
            }
            else
                *pn = ' ';
45   i++;
        }
    }
    *pn = '\0';
    nc[ix] = i;
50   for (pn = nline; *pn; pn++)
        (void) putc(*pn, fx);
    (void) putc('\n', fx);
}

55 /*
 * put out a line (name, [num], seq, [num]): dumpblock()
 */
static
putline(ix)                                putline
60   int      ix;                                {

```

**Table 1 (cont')**

```

...putline
      int          i;
      register char *px;
  5   for (px = namex[ix], i = 0; *px && *px != ':'; px++, i++)
          (void) putc(*px, fx);
      for (; i < lmax+P_SPC; i++)
          (void) putc(' ', fx);
 10  /* these count from 1:
      * ni[] is current element (from 1)
      * nc[] is number at start of current line
      */
 15  for (px = out[ix]; *px; px++)
          (void) putc(*px&0x7F, fx);
      (void) putc('\n', fx);
  }                                     stars
 20  /*
      * put a line of stars (seqs always in out[0], out[1]): dumpblock()
      */
 25  static
stars() {
  {                                     stars
      int          i;
      register char *p0, *p1, cx, *px;
 30  if (!*out[0] || (*out[0] == ' ' && *(po[0]) == ' ') ||
      !*out[1] || (*out[1] == ' ' && *(po[1]) == ' '))
          return;
      px = star;
      for (i = lmax+P_SPC; i; i--)
          *px++ = ' ';
 35  for (p0 = out[0], p1 = out[1]; *p0 && *p1; p0++, p1++) {
          if (isalpha(*p0) && isalpha(*p1)) {
 40          if (xbm[*p0-'A']&xbm[*p1-'A']) {
              cx = '*';
              nm++;
          }
          else if (!dma && _day[*p0-'A'][*p1-'A'] > 0)
              cx = '.';
          else
              cx = ' ';
      }
      else
          cx = ' ';
 50  *px++ = cx;
      *px++ = '\n';
      *px = '\0';
 55  }
}

```

Table 1 (cont')

```

/*
 * strip path or prefix from pn, return len: pr_align()
 */
static
5    stripname(pn)
      char   *pn;    /* file name (may be path) */
{
      register char   *px, *py;

10   py = 0;
      for (px = pn; *px; px++)
          if (*px == '/')
              py = px + 1;
15   if (py)
          (void) strcpy(pn, py);
      return(strlen(pn));
}
20

25

30

35

40

45

50

55

60

```

Table 1 (cont')

```

/*
 * cleanup() -- cleanup any tmp file
 * getseq() -- read in seq, set dna, len, maxlen
 * g_calloc() -- calloc() with error checkin
 5   * readjmps() -- get the good jmps, from tmp file if necessary
 * writejmps() -- write a filled array of jmps to a tmp file: nw()
 */
#include "nw.h"
#include <sys/file.h>
10
char  *jname = "/tmp/homgXXXXXX";           /* tmp file for jmps */
FILE  *fj;

15
int   cleanup();                         /* cleanup tmp file */
long  lseek();

/*
 * remove any tmp file if we blow
 */
20
cleanup(i)
    int   i;
{
    if (fj)
        (void) unlink(jname);
25
    exit(i);
}

/*
 * read, return ptr to seq, set dna, len, maxlen
30
 * skip lines starting with ';', '<', or '>'
 * seq in upper or lower case
 */
char  *
getseq(file, len)
35
    char  *file;    /* file name */
    int   *len;     /* seq len */
{
    char  line[1024], *pseq;
    register char  *px, *py;
40
    int   natgc, tlen;
    FILE  *fp;

    if ((fp = fopen(file, "r")) == 0) {
        fprintf(stderr, "%s: can't read %s\n", prog, file);
45
        exit(1);
    }
    tlen = natgc = 0;
    while (fgets(line, 1024, fp)) {
        if (*line == ';' || *line == '<' || *line == '>')
50
            continue;
        for (px = line; *px != '\n'; px++)
            if (isupper(*px) || islower(*px))
                tlen++;
    }
55
    if ((pseq = malloc((unsigned)(tlen+6))) == 0) {
        fprintf(stderr, "%s: malloc() failed to get %d bytes for %s\n", prog, tlen+6, file);
        exit(1);
    }
    pseq[0] = pseq[1] = pseq[2] = pseq[3] = '\0';
60

```

**Table 1 (cont')**

```

...getseq

5      py = pseq + 4;
*len = tlen;
rewind(fp);

10     while (fgets(line, 1024, fp)) {
        if (*line == ';' || *line == '<' || *line == '>')
            continue;
        for (px = line; *px != '\n'; px++) {
            if (isupper(*px))
                *py++ = *px;
            else if (islower(*px))
                *py++ = toupper(*px);
            if (index("ATGCU", *(py-1)))
                natgc++;
        }
        *py++ = '\0';
15     *py = '\0';
(void) fclose(fp);
dna = natgc > (tlen/3);
return(pseq+4);
}

25     char *
g_malloc(msg, nx, sz)
{
    char *msg; /* program. calling routine */
    int nx, sz; /* number and size of elements */
30
35     char *px, *calloc();
if ((px = calloc((unsigned)nx, (unsigned)sz)) == 0) {
    if (*msg) {
        fprintf(stderr, "%s: g_malloc() failed %s (n=%d, sz=%d)\n", prog, msg, nx, sz);
        exit(1);
    }
}
return(px);
}

40
/*
 * get final jmps from dx[] or tmp file, set pp[], reset dmax: main()
 */
readjmps()
45 {
    int fd = -1;
    int siz, i0, i1;
    register i, j, xx;

50     if (fj) {
        (void) fclose(fj);
        if ((fd = open(jname, O_RDONLY, 0)) < 0) {
            fprintf(stderr, "%s: can't open() %s\n", prog, jname);
            cleanup(1);
55     }
}
for (i = i0 = i1 = 0, dmax0 = dmax, xx = len0; ; i++) {
    while (1) {
        for (j = dx[dmax].ijmp; j >= 0 && dx[dmax].jp.x[j] >= xx; j--)
60
;
```

Table 1 (cont?)

...readjmps

```

if (j < 0 && dx[dmax].offset && fj) {
    (void) lseek(fd, dx[dmax].offset, 0);
    (void) read(fd, (char *)&dx[dmax].jp, sizeof(struct jmp));
    (void) read(fd, (char *)&dx[dmax].offset, sizeof(dx[dmax].offset));
    dx[dmax].ijmp = MAXJMP-1;
}
else
    break;
}
if (i >= JMPS) {
    fprintf(stderr, "%s: too many gaps in alignment\n", prog);
    cleanup(1);
}
if (j >= 0) {
    siz = dx[dmax].jp.n[j];
    xx = dx[dmax].jp.x[j];
    dmax += siz;
    if (siz < 0) { /* gap in second seq */
        pp[1].n[i1] = -siz;
        xx += siz;
        /* id = xx - yy + len1 - 1
         */
        pp[1].x[i1] = xx - dmax + len1 - 1;
        gapy++;
        ngapy -= siz;
    /* ignore MAXGAP when doing endgaps */
        siz = (-siz < MAXGAP || endgaps)? -siz : MAXGAP;
        i1++;
    }
    else if (siz > 0) { /* gap in first seq */
        pp[0].n[i0] = siz;
        pp[0].x[i0] = xx;
        gapx++;
        ngapx += siz;
    /* ignore MAXGAP when doing endgaps */
        siz = (siz < MAXGAP || endgaps)? siz : MAXGAP;
        i0++;
    }
}
else
    break;
}
/* reverse the order of jmps
 */
for (j = 0, i0--; j < i0; j++, i0--) {
    i = pp[0].n[j]; pp[0].n[j] = pp[0].n[i0]; pp[0].n[i0] = i;
    i = pp[0].x[j]; pp[0].x[j] = pp[0].x[i0]; pp[0].x[i0] = i;
}
for (j = 0, i1--; j < i1; j++, i1--) {
    i = pp[1].n[j]; pp[1].n[j] = pp[1].n[i1]; pp[1].n[i1] = i;
    i = pp[1].x[j]; pp[1].x[j] = pp[1].x[i1]; pp[1].x[i1] = i;
}
if (fd >= 0)
    (void) close(fd);
if (fj) {
    (void) unlink(jname);
    fj = 0;
    offset = 0;
}
}

```

Table 1 (cont')

```

/*
 * write a filled jmp struct offset of the prev one (if any): nw()
 */
5   writejmps(ix)
     int      ix;
{
     char    *mktemp();

10  if (!fj) {
        if (mktemp(jname) < 0) {
            fprintf(stderr, "%s: can't mktemp() %s\n", prog, jname);
            cleanup(1);
        }
15  if ((fj = fopen(jname, "w")) == 0) {
            fprintf(stderr, "%s: can't write %s\n", prog, jname);
            exit(1);
        }
20  (void) fwrite((char *)&dx[ix].jp, sizeof(struct jmp), 1, fj);
     (void) fwrite((char *)&dx[ix].offset, sizeof(dx[ix].offset), 1, fj);
}

25

30

35

40

45

50

55

60

```

Table 2

PRO	XXXXXXXXXXXXXXXXXX	(Length = 15 amino acids)
Comparison Protein	XXXXXYYYYYYYY	(Length = 12 amino acids)

5 % amino acid sequence identity =

(the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide) =

10 5 divided by 15 = 33.3%

Table 3

PRO	XXXXXXXXXX	(Length = 10 amino acids)
Comparison Protein	XXXXXYYYYYYYZZYZ	(Length = 15 amino acids)

5 % amino acid sequence identity =

(the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide) =

10 5 divided by 10 = 50%

Table 4

PRO-DNA	NNNNNNNNNNNNNN	(Length = 14 nucleotides)
Comparison DNA	NNNNNNNNNNNNNN	(Length = 16 nucleotides)

5 % nucleic acid sequence identity =

(the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number of nucleotides of the PRO-DNA nucleic acid sequence) =

10 6 divided by 14 = 42.9%

Table 5

PRO-DNA	NNNNNNNNNNNN	(Length = 12 nucleotides)
Comparison DNA	NNNNLLLVV	(Length = 9 nucleotides)

5 % nucleic acid sequence identity =

(the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number of nucleotides of the PRO-DNA nucleic acid sequence) =

10 4 divided by 12 = 33.3%

II. Compositions and Methods of the InventionA. Full-Length PRO Polypeptides

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO polypeptides. In particular, cDNAs encoding various PRO polypeptides have been identified and isolated, as disclosed in further detail in the Examples below. It is noted 5 that proteins produced in separate expression rounds may be given different PRO numbers but the UNQ number is unique for any given DNA and the encoded protein, and will not be changed. However, for sake of simplicity, in the present specification the protein encoded by the full length native nucleic acid molecules disclosed herein as well as all further native homologues and variants included in the foregoing definition of PRO, will be referred to as "PRO/number", regardless of their origin or mode of preparation.

10 As disclosed in the Examples below, various cDNA clones have been deposited with the ATCC. The actual nucleotide sequences of those clones can readily be determined by the skilled artisan by sequencing of the deposited clone using routine methods in the art. The predicted amino acid sequence can be determined from the nucleotide sequence using routine skill. For the PRO polypeptides and encoding nucleic acids described herein, Applicants have identified what is believed to be the reading frame best identifiable with the sequence 15 information available at the time.

B. PRO Polypeptide Variants

In addition to the full-length native sequence PRO polypeptides described herein, it is contemplated that 20 PRO variants can be prepared. PRO variants can be prepared by introducing appropriate nucleotide changes into the PRO DNA, and/or by synthesis of the desired PRO polypeptide. Those skilled in the art will appreciate that amino acid changes may alter post-translational processes of the PRO, such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics.

Variations in the native full-length sequence PRO or in various domains of the PRO described herein, 25 can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934. Variations may be a substitution, deletion or insertion of one or more codons encoding the PRO that results in a change in the amino acid sequence of the PRO as compared with the native sequence PRO. Optionally the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of the PRO. Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the desired activity may 30 be found by comparing the sequence of the PRO with that of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine, i.e., conservative amino acid replacements. Insertions or deletions may optionally be in the range of about 1 to 5 amino acids. The variation 35 allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence.

PRO polypeptide fragments are provided herein. Such fragments may be truncated at the N-terminus or C-terminus, or may lack internal residues, for example, when compared with a full length native protein. Certain fragments lack amino acid residues that are not essential for a desired biological activity of the PRO polypeptide.

PRO fragments may be prepared by any of a number of conventional techniques. Desired peptide 5 fragments may be chemically synthesized. An alternative approach involves generating PRO fragments by enzymatic digestion, e.g., by treating the protein with an enzyme known to cleave proteins at sites defined by particular amino acid residues, or by digesting the DNA with suitable restriction enzymes and isolating the desired fragment. Yet another suitable technique involves isolating and amplifying a DNA fragment encoding 10 a desired polypeptide fragment, by polymerase chain reaction (PCR). Oligonucleotides that define the desired termini of the DNA fragment are employed at the 5' and 3' primers in the PCR. Preferably, PRO polypeptide fragments share at least one biological and/or immunological activity with the native PRO polypeptide disclosed herein.

In particular embodiments, conservative substitutions of interest are shown in Table 6 under the heading 15 of preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes, denominated exemplary substitutions in Table 6, or as further described below in reference to amino acid classes, are introduced and the products screened.

Table 6

	<u>Original Residue</u>	<u>Exemplary Substitutions</u>	<u>Preferred Substitutions</u>
5	Ala (A)	val; leu; ile	val
	Arg (R)	lys; gln; asn	lys
	Asn (N)	gln; his; lys; arg	gln
	Asp (D)	glu	glu
	Cys (C)	ser	ser
10	Gln (Q)	asn	asn
	Glu (E)	asp	asp
	Gly (G)	pro; ala	ala
	His (H)	asn; gln; lys; arg	arg
	Ile (I)	leu; val; met; ala; phe; norleucine	leu
15	Leu (L)	norleucine; ile; val; met; ala; phe	ile
	Lys (K)	arg; gln; asn	arg
	Met (M)	leu; phe; ile	leu
20	Phe (F)	leu; val; ile; ala; tyr	leu
	Pro (P)	ala	ala
	Ser (S)	thr	thr
	Thr (T)	ser	ser
	Trp (W)	tyr; phe	tyr
25	Tyr (Y)	trp; phe; thr; ser	phe
	Val (V)	ile; leu; met; phe; ala; norleucine	leu

Substantial modifications in function or immunological identity of the PRO polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophilic: cys, ser, thr;
- (3) acidic: asp, glu;
- (4) basic: asn, gln, his, lys, arg;
- (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the remaining (non-conserved) sites.

The variations can be made using methods known in the art such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis [Carter et al., *Nucl. Acids Res.*, 13:4331 (1986); Zoller et al., *Nucl. Acids Res.*, 10:6487 (1987)], cassette mutagenesis [Wells et al., *Gene*, 34:315 (1985)], restriction selection mutagenesis [Wells et al., *Philos. Trans. R. Soc. London SerA*,

317:415 (1986)] or other known techniques can be performed on the cloned DNA to produce the PRO variant DNA.

Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid  
5 among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant [Cunningham and Wells, Science, 244: 1081-1085 (1989)]. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions [Creighton, The Proteins, (W.H. Freeman & Co., N.Y.); Chothia, J. Mol. Biol., 150:1 (1976)]. If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used.  
10

### C. Modifications of PRO

Covalent modifications of PRO are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a PRO polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues of the PRO.  
15 Derivatization with bifunctional agents is useful, for instance, for crosslinking PRO to a water-insoluble support matrix or surface for use in the method for purifying anti-PRO antibodies, and vice-versa. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimidate.  
20

Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the  $\alpha$ -amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, 25 pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the PRO polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence PRO (either by removing the underlying glycosylation site or by deleting the glycosylation  
30 by chemical and/or enzymatic means), and/or adding one or more glycosylation sites that are not present in the native sequence PRO. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present.

Addition of glycosylation sites to the PRO polypeptide may be accomplished by altering the amino acid sequence. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence PRO (for O-linked glycosylation sites). The PRO amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the PRO polypeptide at preselected bases such that codons are generated that will translate into the  
35

desired amino acids.

Another means of increasing the number of carbohydrate moieties on the PRO polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

5 Removal of carbohydrate moieties present on the PRO polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety 10 of endo- and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of PRO comprises linking the PRO polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

15 The PRO of the present invention may also be modified in a way to form a chimeric molecule comprising PRO fused to another, heterologous polypeptide or amino acid sequence.

In one embodiment, such a chimeric molecule comprises a fusion of the PRO with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino- or carboxyl- terminus of the PRO. The presence of such epitope-tagged forms of the PRO can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the PRO to 20 be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field et al., Mol. Cell. Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and Cellular Biology, 5:3610-3616 (1985)]; and the 25 Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp et al., BioTechnology, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)]; an  $\alpha$ -tubulin epitope peptide [Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)].

30 In an alternative embodiment, the chimeric molecule may comprise a fusion of the PRO with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule (also referred to as an "immunoadhesin"), such a fusion could be to the Fc region of an IgG molecule. The Ig fusions preferably include the substitution of a soluble (transmembrane domain deleted or inactivated) form of a PRO polypeptide in place of at least one variable region within an Ig molecule. In a particularly preferred 35 embodiment, the immunoglobulin fusion includes the hinge, CH2 and CH3, or the hinge, CH1, CH2 and CH3 regions of an IgG1 molecule. For the production of immunoglobulin fusions see also US Patent No. 5,428,130 issued June 27, 1995.

D. Preparation of PRO

The description below relates primarily to production of PRO by culturing cells transformed or transfected with a vector containing PRO nucleic acid. It is, of course, contemplated that alternative methods, which are well known in the art, may be employed to prepare PRO. For instance, the PRO sequence, or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques [see, e.g., Stewart 5 et al., Solid-Phase Peptide Synthesis, W.H. Freeman Co., San Francisco, CA (1969); Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1963)]. *In vitro* protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions. Various portions of the PRO may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length 10 PRO.

1. Isolation of DNA Encoding PRO

DNA encoding PRO may be obtained from a cDNA library prepared from tissue believed to possess the PRO mRNA and to express it at a detectable level. Accordingly, human PRO DNA can be conveniently 15 obtained from a cDNA library prepared from human tissue, such as described in the Examples. The PRO-encoding gene may also be obtained from a genomic library or by known synthetic procedures (e.g., automated nucleic acid synthesis).

Libraries can be screened with probes (such as antibodies to the PRO or oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA 20 or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989). An alternative means to isolate the gene encoding PRO is to use PCR methodology [Sambrook et al., supra; Dieffenbach et al., PCR Primer: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1995)].

The Examples below describe techniques for screening a cDNA library. The oligonucleotide sequences 25 selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened. Methods of labeling are well known in the art, and include the use of radiolabels like  $^{32}\text{P}$ -labeled ATP, biotinylation or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook et al., supra.

Sequences identified in such library screening methods can be compared and aligned to other known 30 sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined using methods known in the art and as described herein.

Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic 35 libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook et al., supra, to detect precursors and processing intermediates of mRNA that may not have been reverse-transcribed into cDNA.

## 2. Selection and Transformation of Host Cells

Host cells are transfected or transformed with expression or cloning vectors described herein for PRO production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1991) and Sambrook et al., supra.

Methods of eukaryotic cell transfection and prokaryotic cell transformation are known to the ordinarily skilled artisan, for example,  $\text{CaCl}_2$ ,  $\text{CaPO}_4$ , liposome-mediated and electroporation. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook et al., supra, or electroporation is generally used for prokaryotes. Infection with *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw et al., Gene, 23:315 (1983) and WO 89/05859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology, 52:456-457 (1978) can be employed. General aspects of mammalian cell host system transfections have been described in U.S. Patent No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen et al., J. Bact., 130:946 (1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76:3829 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, e.g., polybrene, polyornithine, may also be used. For various techniques for transforming mammalian cells, see Keown et al., Methods in Enzymology, 185:527-537 (1990) and Mansour et al., Nature, 336:348-352 (1988).

Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells. Suitable prokaryotes include but are not limited to eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as *E. coli*. Various *E. coli* strains are publicly available, such as *E. coli* K12 strain MM294 (ATCC 31,446); *E. coli* X1776 (ATCC 31,537); *E. coli* strain W3110 (ATCC 27,325) and K5 772 (ATCC 53,635). Other suitable prokaryotic host cells include Enterobacteriaceae such as *Escherichia*, e.g., *E. coli*, *Enterobacter*, *Erwinia*, *Klebsiella*, *Proteus*, *Salmonella*, e.g., *Salmonella typhimurium*, *Serratia*, e.g., *Serratia marcescans*, and *Shigella*, as well as *Bacilli* such as *B. subtilis* and *B. licheniformis* (e.g., *B. licheniformis* 41P disclosed in DD 266,710 published 12 April 1989), *Pseudomonas* such as *P. aeruginosa*, and *Streptomyces*. These examples are illustrative rather than limiting. Strain W3110 is one particularly preferred host or parent host because it is a common host strain for recombinant DNA product fermentations. Preferably, the host cell secretes minimal amounts of proteolytic enzymes. For example, strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with examples of such hosts including *E. coli* W3110 strain 1A2, which has the complete genotype *tonA*; *E. coli* W3110 strain 9E4, which has the complete genotype *tonA ptr3*; *E. coli* W3110 strain 27C7 (ATCC 55,244), which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT kanr*; *E. coli* W3110 strain 37D6, which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT rbs7*.

*ilvG kan'*; *E. coli* W3110 strain 40B4, which is strain 37D6 with a non-kanamycin resistant *degP* deletion mutation; and an *E. coli* strain having mutant periplasmic protease disclosed in U.S. Patent No. 4,946,783 issued 7 August 1990. Alternatively, *in vitro* methods of cloning, e.g., PCR or other nucleic acid polymerase reactions, are suitable.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning 5 or expression hosts for PRO-encoding vectors. *Saccharomyces cerevisiae* is a commonly used lower eukaryotic host microorganism. Others include *Schizosaccharomyces pombe* (Beach and Nurse, *Nature*, 290: 140 [1981]; EP 139,383 published 2 May 1985); *Kluyveromyces* hosts (U.S. Patent No. 4,943,529; Fleer et al., *Bio/Technology*, 9:968-975 (1991)) such as, e.g., *K. lactis* (MW98-8C, CBS683, CBS4574; Louvencourt et al., *J. Bacteriol.*, 154(2):737-742 [1983]), *K. fragilis* (ATCC 12,424), *K. bulgaricus* (ATCC 16,045), *K. wickeramii* (ATCC 24,178), *K. waltii* (ATCC 56,500), *K. drosophilae* (ATCC 36,906; Van den Berg et al., *Bio/Technology*, 8:135 (1990)), *K. thermotolerans*, and *K. marxianus*; *yarrowia* (EP 402,226); *Pichia pastoris* (EP 183,070; Sreekrishna et al., *J. Basic Microbiol.*, 28:265-278 [1988]); *Candida*; *Trichoderma reesiae* (EP 244,234); *Neurospora crassa* (Case et al., *Proc. Natl. Acad. Sci. USA*, 76:5259-5263 [1979]); *Schwanniomyces* such as *Schwanniomyces occidentalis* (EP 394,538 published 31 October 1990); and filamentous fungi such as, 10 e.g., *Neurospora*, *Penicillium*, *Tolypocladium* (WO 91/00357 published 10 January 1991), and *Aspergillus* hosts such as *A. nidulans* (Ballance et al., *Biochem. Biophys. Res. Commun.*, 112:284-289 [1983]; Tilburn et al., *Gene*, 26:205-221 [1983]; Yelton et al., *Proc. Natl. Acad. Sci. USA*, 81: 1470-1474 [1984]) and *A. niger* (Kelly and Hynes, *EMBO J.*, 4:475-479 [1985]). Methylotropic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of *Hansenula*, *Candida*, 15 *Kloeckera*, *Pichia*, *Saccharomyces*, *Torulopsis*, and *Rhodotorula*. A list of specific species that are exemplary of this class of yeasts may be found in C. Anthony, *The Biochemistry of Methylotrophs*, 269 (1982).

Suitable host cells for the expression of glycosylated PRO are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as *Drosophila S2* and *Spodoptera Sf9*, as well as plant 20 cells. Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., *J. Gen Virol.*, 36:59 (1977)); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, *Proc. Natl. Acad. Sci. USA*, 77:4216 (1980)); mouse sertoli cells (TM4, Mather, *Biol. Reprod.*, 23:243-251 (1980)); human lung 25 cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT 060562, ATCC CCL51). The selection of the appropriate host cell is deemed to be within the skill in the art.

### 3. Selection and Use of a Replicable Vector

The nucleic acid (e.g., cDNA or genomic DNA) encoding PRO may be inserted into a replicable vector 30 for cloning (amplification of the DNA) or for expression. Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art. Vector components generally

include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques which are known to the skilled artisan.

The PRO may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the PRO-encoding DNA that is inserted into the vector. The signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, e.g., the yeast invertase leader, alpha factor leader (including *Saccharomyces* and *Kluyveromyces*  $\alpha$ -factor leaders, the latter described in U.S. Patent No. 5,010,182), or acid phosphatase leader, the *C. albicans* glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990. In mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.

Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the  $2\mu$  plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells.

Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*.

An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the PRO-encoding nucleic acid, such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al., *Proc. Natl. Acad. Sci. USA*, 77:4216 (1980). A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7 [Stinchcomb et al., *Nature*, 282:39 (1979); Kingsman et al., *Gene*, 7:141 (1979); Tschemper et al., *Gene*, 10:157 (1980)]. The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 [Jones, *Genetics*, 85:12 (1977)].

Expression and cloning vectors usually contain a promoter operably linked to the PRO-encoding nucleic acid sequence to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the  $\beta$ -lactamase and lactose promoter systems [Chang et al., *Nature*, 275:615 (1978); Goeddel et al., *Nature*, 281:544 (1979)], alkaline phosphatase, a tryptophan (*trp*) promoter system [Goeddel, *Nucleic Acids Res.*, 8:4057 (1980); EP 36,776], and hybrid

promoters such as the tac promoter [deBoer et al., *Proc. Natl. Acad. Sci. USA*, 80:21-25 (1983)]. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding PRO.

Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman et al., *J. Biol. Chem.*, 255:2073 (1980)] or other glycolytic enzymes [Hess et al., *J. Adv. Enzyme Reg.*, 7:149 (1968); Holland, *Biochemistry*, 17:4900 (1978)], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytchrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.

PRO transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems.

Transcription of a DNA encoding the PRO by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin,  $\alpha$ -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the PRO coding sequence, but is preferably located at a site 5' from the promoter.

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding PRO.

Still other methods, vectors, and host cells suitable for adaptation to the synthesis of PRO in recombinant vertebrate cell culture are described in Gething et al., *Nature*, 293:620-625 (1981); Mantei et al., *Nature*, 281:40-46 (1979); EP 117,060; and EP 117,058.

4. Detecting Gene Amplification/Expression

Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA [Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)], dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed 5 that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological methods, such as 10 immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence PRO polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to PRO DNA and encoding a specific 15 antibody epitope.

5. Purification of Polypeptide

Forms of PRO may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g. Triton-X 100) or by enzymatic 20 cleavage. Cells employed in expression of PRO can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents.

It may be desired to purify PRO from recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as 25 DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the PRO. Various methods of protein purification may be employed and such methods are known in the art and described for example in Deutscher, Methods in Enzymology, 182 (1990); Scopes, Protein Purification: Principles and Practice, Springer-Verlag, New York (1982). The purification 30 step(s) selected will depend, for example, on the nature of the production process used and the particular PRO produced.

E. Uses for PRO

Nucleotide sequences (or their complement) encoding PRO have various applications in the art of 35 molecular biology, including uses as hybridization probes, in chromosome and gene mapping and in the generation of anti-sense RNA and DNA. PRO nucleic acid will also be useful for the preparation of PRO polypeptides by the recombinant techniques described herein.

The full-length native sequence PRO gene, or portions thereof, may be used as hybridization probes for a cDNA library to isolate the full-length PRO cDNA or to isolate still other cDNAs (for instance, those encoding naturally-occurring variants of PRO or PRO from other species) which have a desired sequence identity to the native PRO sequence disclosed herein. Optionally, the length of the probes will be about 20 to about 50 bases. The hybridization probes may be derived from at least partially novel regions of the full length native nucleotide sequence wherein those regions may be determined without undue experimentation or from genomic sequences including promoters, enhancer elements and introns of native sequence PRO. By way of example, a screening method will comprise isolating the coding region of the PRO gene using the known DNA sequence to synthesize a selected probe of about 40 bases. Hybridization probes may be labeled by a variety of labels, including radionucleotides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems. Labeled probes having a sequence complementary to that of the PRO gene of the present invention can be used to screen libraries of human cDNA, genomic DNA or mRNA to determine which members of such libraries the probe hybridizes to. Hybridization techniques are described in further detail in the Examples below.

Any EST sequences disclosed in the present application may similarly be employed as probes, using the methods disclosed herein.

Other useful fragments of the PRO nucleic acids include antisense or sense oligonucleotides comprising a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target PRO mRNA (sense) or PRO DNA (antisense) sequences. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment of the coding region of PRO DNA. Such a fragment generally comprises at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, for example, Stein and Cohen (*Cancer Res.* 48:2659, 1988) and van der Krol et al. (*BioTechniques* 6:958, 1988).

Binding of antisense or sense oligonucleotides to target nucleic acid sequences results in the formation of duplexes that block transcription or translation of the target sequence by one of several means, including enhanced degradation of the duplexes, premature termination of transcription or translation, or by other means. The antisense oligonucleotides thus may be used to block expression of PRO proteins. Antisense or sense oligonucleotides further comprise oligonucleotides having modified sugar-phosphodiester backbones (or other sugar linkages, such as those described in WO 91/06629) and wherein such sugar linkages are resistant to endogenous nucleases. Such oligonucleotides with resistant sugar linkages are stable *in vivo* (i.e., capable of resisting enzymatic degradation) but retain sequence specificity to be able to bind to target nucleotide sequences.

Other examples of sense or antisense oligonucleotides include those oligonucleotides which are covalently linked to organic moieties, such as those described in WO 90/10048, and other moieties that increases affinity of the oligonucleotide for a target nucleic acid sequence, such as poly-(L-lysine). Further still, intercalating agents, such as ellipticine, and alkylating agents or metal complexes may be attached to sense or antisense oligonucleotides to modify binding specificities of the antisense or sense oligonucleotide for the target nucleotide sequence.

Antisense or sense oligonucleotides may be introduced into a cell containing the target nucleic acid sequence by any gene transfer method, including, for example, CaPO<sub>4</sub>-mediated DNA transfection, electroporation, or by using gene transfer vectors such as Epstein-Barr virus. In a preferred procedure, an antisense or sense oligonucleotide is inserted into a suitable retroviral vector. A cell containing the target nucleic acid sequence is contacted with the recombinant retroviral vector, either *in vivo* or *ex vivo*. Suitable retroviral vectors include, but are not limited to, those derived from the murine retrovirus M-MuLV, N2 (a retrovirus derived from M-MuLV), or the double copy vectors designated DCTSA, DCT5B and DCT5C (see WO 90/13641).

Sense or antisense oligonucleotides also may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell.

Alternatively, a sense or an antisense oligonucleotide may be introduced into a cell containing the target nucleic acid sequence by formation of an oligonucleotide-lipid complex, as described in WO 90/10448. The sense or antisense oligonucleotide-lipid complex is preferably dissociated within the cell by an endogenous lipase.

Antisense or sense RNA or DNA molecules are generally at least about 5 bases in length, about 10 bases in length, about 15 bases in length, about 20 bases in length, about 25 bases in length, about 30 bases in length, about 35 bases in length, about 40 bases in length, about 45 bases in length, about 50 bases in length, about 55 bases in length, about 60 bases in length, about 65 bases in length, about 70 bases in length, about 75 bases in length, about 80 bases in length, about 85 bases in length, about 90 bases in length, about 95 bases in length, about 100 bases in length, or more.

The probes may also be employed in PCR techniques to generate a pool of sequences for identification of closely related PRO coding sequences.

Nucleotide sequences encoding a PRO can also be used to construct hybridization probes for mapping the gene which encodes that PRO and for the genetic analysis of individuals with genetic disorders. The nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosome using known techniques, such as *in situ* hybridization, linkage analysis against known chromosomal markers, and hybridization screening with libraries.

When the coding sequences for PRO encode a protein which binds to another protein (example, where the PRO is a receptor), the PRO can be used in assays to identify the other proteins or molecules involved in the binding interaction. By such methods, inhibitors of the receptor/ligand binding interaction can be identified. Proteins involved in such binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction. Also, the receptor PRO can be used to isolate correlative ligand(s). Screening assays can be designed to find lead compounds that mimic the biological activity of a native PRO or a receptor for PRO. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates. Small

molecules contemplated include synthetic organic or inorganic compounds. The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays and cell based assays, which are well characterized in the art.

Nucleic acids which encode PRO or its modified forms can also be used to generate either transgenic animals or "knock out" animals which, in turn, are useful in the development and screening of therapeutically useful reagents. A transgenic animal (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an embryonic stage. A transgene is a DNA which is integrated into the genome of a cell from which a transgenic animal develops. In one embodiment, cDNA encoding PRO can be used to clone genomic DNA encoding PRO in accordance with established techniques and the genomic sequences used to generate transgenic animals that contain cells which express DNA encoding PRO. Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009. Typically, particular cells would be targeted for PRO transgene incorporation with tissue-specific enhancers. Transgenic animals that include a copy of a transgene encoding PRO introduced into the germ line of the animal at an embryonic stage can be used to examine the effect of increased expression of DNA encoding PRO. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. In accordance with this facet of the invention, an animal is treated with the reagent and a reduced incidence of the pathological condition, compared to untreated animals bearing the transgene, would indicate a potential therapeutic intervention for the pathological condition.

Alternatively, non-human homologues of PRO can be used to construct a PRO "knock out" animal which has a defective or altered gene encoding PRO as a result of homologous recombination between the endogenous gene encoding PRO and altered genomic DNA encoding PRO introduced into an embryonic stem cell of the animal. For example, cDNA encoding PRO can be used to clone genomic DNA encoding PRO in accordance with established techniques. A portion of the genomic DNA encoding PRO can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector [see e.g., Thomas and Capecchi, *Cell*, 51:503 (1987) for a description of homologous recombination vectors]. The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected [see e.g., Li et al., *Cell*, 69:915 (1992)]. The selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras [see e.g., Bradley, in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152]. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knockout animals can be characterized for instance, for their ability to defend against certain pathological conditions and for their development of pathological conditions due to absence of

the PRO polypeptide.

Nucleic acid encoding the PRO polypeptides may also be used in gene therapy. In gene therapy applications, genes are introduced into cells in order to achieve *in vivo* synthesis of a therapeutically effective genetic product, for example for replacement of a defective gene. "Gene therapy" includes both conventional gene therapy where a lasting effect is achieved by a single treatment, and the administration of gene therapeutic agents, which involves the one time or repeated administration of a therapeutically effective DNA or mRNA. Antisense RNAs and DNAs can be used as therapeutic agents for blocking the expression of certain genes *in vivo*. It has already been shown that short antisense oligonucleotides can be imported into cells where they act as inhibitors, despite their low intracellular concentrations caused by their restricted uptake by the cell membrane. (Zamecnik *et al.*, Proc. Natl. Acad. Sci. USA 83:4143-4146 [1986]). The oligonucleotides can be modified to enhance their uptake, e.g. by substituting their negatively charged phosphodiester groups by uncharged groups.

There are a variety of techniques available for introducing nucleic acids into viable cells. The techniques vary depending upon whether the nucleic acid is transferred into cultured cells *in vitro*, or *in vivo* in the cells of the intended host. Techniques suitable for the transfer of nucleic acid into mammalian cells *in vitro* include the use of liposomes, electroporation, microinjection, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. The currently preferred *in vivo* gene transfer techniques include transfection with viral (typically retroviral) vectors and viral coat protein-liposome mediated transfection (Dzau *et al.*, Trends in Biotechnology 11, 205-210 [1993]). In some situations it is desirable to provide the nucleic acid source with an agent that targets the target cells, such as an antibody specific for a cell surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc. Where liposomes are employed, proteins which bind to a cell surface membrane protein associated with endocytosis may be used for targeting and/or to facilitate uptake, e.g. capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half-life. The technique of receptor-mediated endocytosis is described, for example, by Wu *et al.*, J. Biol. Chem. 262, 4429-4432 (1987); and Wagner *et al.*, Proc. Natl. Acad. Sci. USA 87, 3410-3414 (1990). For review of gene marking and gene therapy protocols see Anderson *et al.*, Science 256, 808-813 (1992).

The PRO polypeptides described herein may also be employed as molecular weight markers for protein electrophoresis purposes and the isolated nucleic acid sequences may be used for recombinantly expressing those markers.

The nucleic acid molecules encoding the PRO polypeptides or fragments thereof described herein are useful for chromosome identification. In this regard, there exists an ongoing need to identify new chromosome markers, since relatively few chromosome marking reagents, based upon actual sequence data are presently available. Each PRO nucleic acid molecule of the present invention can be used as a chromosome marker.

The PRO polypeptides and nucleic acid molecules of the present invention may also be used diagnostically for tissue typing, wherein the PRO polypeptides of the present invention may be differentially expressed in one tissue as compared to another, preferably in a diseased tissue as compared to a normal tissue of the same tissue type. PRO nucleic acid molecules will find use for generating probes for PCR, Northern

analysis, Southern analysis and Western analysis.

The PRO polypeptides described herein may also be employed as therapeutic agents. The PRO polypeptides of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the PRO product hereof is combined in admixture with a pharmaceutically acceptable carrier vehicle. Therapeutic formulations are prepared for storage by mixing the active ingredient having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN™, PLURONICS™ or PEG.

15 The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution.

Therapeutic compositions herein generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

20 The route of administration is in accord with known methods, e.g. injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial or intralesional routes, topical administration, or by sustained release systems.

25 Dosages and desired drug concentrations of pharmaceutical compositions of the present invention may vary depending on the particular use envisioned. The determination of the appropriate dosage or route of administration is well within the skill of an ordinary physician. Animal experiments provide reliable guidance for the determination of effective doses for human therapy. Interspecies scaling of effective doses can be performed following the principles laid down by Mordini, J. and Chappell, W. "The use of interspecies scaling in toxicokinetics" In Toxicokinetics and New Drug Development, Yacobi et al., Eds., Pergamon Press, New York 1989, pp. 42-96.

30 When *in vivo* administration of a PRO polypeptide or agonist or antagonist thereof is employed, normal dosage amounts may vary from about 10 ng/kg to up to 100 mg/kg of mammal body weight or more per day, preferably about 1 µg/kg/day to 10 mg/kg/day, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature; see, for example, U.S. Pat. Nos. 4,657,760; 5,206,344; or 5,225,212. It is anticipated that different formulations will be effective for different treatment compounds and different disorders, that administration targeting one organ or tissue, for example, may necessitate delivery in a manner different from that to another organ or tissue.

35 Where sustained-release administration of a PRO polypeptide is desired in a formulation with release characteristics suitable for the treatment of any disease or disorder requiring administration of the PRO

polypeptide, microencapsulation of the PRO polypeptide is contemplated. Microencapsulation of recombinant proteins for sustained release has been successfully performed with human growth hormone (rhGH), interferon-(rhIFN- ), interleukin-2, and MN rgp120. Johnson et al., Nat. Med., 2:795-799 (1996); Yasuda, Biomed. Ther., 27:1221-1223 (1993); Hora et al., Bio/Technology, 8:755-758 (1990); Cleland, "Design and Production of Single Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems," in Vaccine Design: The Subunit and Adjuvant Approach, Powell and Newman, eds, (Plenum Press: New York, 1995), pp. 439-462; WO 97/03692, WO 96/40072, WO 96/07399; and U.S. Pat. No. 5,654,010.

The sustained-release formulations of these proteins were developed using poly-lactic-glycolic acid (PLGA) polymer due to its biocompatibility and wide range of biodegradable properties. The degradation products of PLGA, lactic and glycolic acids, can be cleared quickly within the human body. Moreover, the degradability of this polymer can be adjusted from months to years depending on its molecular weight and composition. Lewis, "Controlled release of bioactive agents from lactide/glycolide polymer," in: M. Chasin and R. Langer (Eds.), Biodegradable Polymers as Drug Delivery Systems (Marcel Dekker: New York, 1990), pp. 1-41.

This invention encompasses methods of screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). Screening assays for antagonist drug candidates are designed to identify compounds that bind or complex with the PRO polypeptides encoded by the genes identified herein, or otherwise interfere with the interaction of the encoded polypeptides with other cellular proteins. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates.

The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays, and cell-based assays, which are well characterized in the art.

All assays for antagonists are common in that they call for contacting the drug candidate with a PRO polypeptide encoded by a nucleic acid identified herein under conditions and for a time sufficient to allow these two components to interact.

In binding assays, the interaction is binding and the complex formed can be isolated or detected in the reaction mixture. In a particular embodiment, the PRO polypeptide encoded by the gene identified herein or the drug candidate is immobilized on a solid phase, e.g., on a microtiter plate, by covalent or non-covalent attachments. Non-covalent attachment generally is accomplished by coating the solid surface with a solution of the PRO polypeptide and drying. Alternatively, an immobilized antibody, e.g., a monoclonal antibody, specific for the PRO polypeptide to be immobilized can be used to anchor it to a solid surface. The assay is performed by adding the non-immobilized component, which may be labeled by a detectable label, to the immobilized component, e.g., the coated surface containing the anchored component. When the reaction is complete, the non-reacted components are removed, e.g., by washing, and complexes anchored on the solid surface are detected. When the originally non-immobilized component carries a detectable label, the detection of label immobilized on the surface indicates that complexing occurred. Where the originally non-immobilized component does not carry a label, complexing can be detected, for example, by using a labeled antibody specifically binding the immobilized complex.

If the candidate compound interacts with but does not bind to a particular PRO polypeptide encoded by a gene identified herein, its interaction with that polypeptide can be assayed by methods well known for detecting protein-protein interactions. Such assays include traditional approaches, such as, e.g., cross-linking, co-immunoprecipitation, and co-purification through gradients or chromatographic columns. In addition, protein-protein interactions can be monitored by using a yeast-based genetic system described by Fields and co-workers (Fields and Song, Nature (London), 340:245-246 (1989); Chien et al., Proc. Natl. Acad. Sci. USA, 88:9578-9582 (1991)) as disclosed by Chevray and Nathans, Proc. Natl. Acad. Sci. USA, 89: 5789-5793 (1991). Many transcriptional activators, such as yeast GAL4, consist of two physically discrete modular domains, one acting as the DNA-binding domain, the other one functioning as the transcription-activation domain. The yeast expression system described in the foregoing publications (generally referred to as the "two-hybrid system") takes advantage of this property, and employs two hybrid proteins, one in which the target protein is fused to the DNA-binding domain of GAL4, and another, in which candidate activating proteins are fused to the activation domain. The expression of a GAL1-lacZ reporter gene under control of a GAL4-activated promoter depends on reconstitution of GAL4 activity via protein-protein interaction. Colonies containing interacting polypeptides are detected with a chromogenic substrate for β-galactosidase. A complete kit (MATCHMAKER™) for identifying protein-protein interactions between two specific proteins using the two-hybrid technique is commercially available from Clontech. This system can also be extended to map protein domains involved in specific protein interactions as well as to pinpoint amino acid residues that are crucial for these interactions.

Compounds that interfere with the interaction of a gene encoding a PRO polypeptide identified herein and other intra- or extracellular components can be tested as follows: usually a reaction mixture is prepared containing the product of the gene and the intra- or extracellular component under conditions and for a time allowing for the interaction and binding of the two products. To test the ability of a candidate compound to inhibit binding, the reaction is run in the absence and in the presence of the test compound. In addition, a placebo may be added to a third reaction mixture, to serve as positive control. The binding (complex formation) between the test compound and the intra- or extracellular component present in the mixture is monitored as described hereinabove. The formation of a complex in the control reaction(s) but not in the reaction mixture containing the test compound indicates that the test compound interferes with the interaction of the test compound and its reaction partner.

To assay for antagonists, the PRO polypeptide may be added to a cell along with the compound to be screened for a particular activity and the ability of the compound to inhibit the activity of interest in the presence of the PRO polypeptide indicates that the compound is an antagonist to the PRO polypeptide. Alternatively, antagonists may be detected by combining the PRO polypeptide and a potential antagonist with membrane-bound PRO polypeptide receptors or recombinant receptors under appropriate conditions for a competitive inhibition assay. The PRO polypeptide can be labeled, such as by radioactivity, such that the number of PRO polypeptide molecules bound to the receptor can be used to determine the effectiveness of the potential antagonist. The gene encoding the receptor can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting. Coligan et al., Current Protocols in Immun., 1(2): Chapter 5 (1991).

Preferably, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the PRO polypeptide and a cDNA library created from this RNA is divided into pools and used to transfet COS cells or other cells that are not responsive to the PRO polypeptide. Transfected cells that are grown on glass slides are exposed to labeled PRO polypeptide. The PRO polypeptide can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase. Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an interactive sub-pooling and re-screening process, eventually yielding a single clone that encodes the putative receptor.

As an alternative approach for receptor identification, labeled PRO polypeptide can be photoaffinity-linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE and exposed to X-ray film. The labeled complex containing the receptor can be excised, resolved into peptide fragments, and subjected to protein micro-sequencing. The amino acid sequence obtained from micro- sequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the gene encoding the putative receptor.

In another assay for antagonists, mammalian cells or a membrane preparation expressing the receptor would be incubated with labeled PRO polypeptide in the presence of the candidate compound. The ability of the compound to enhance or block this interaction could then be measured.

More specific examples of potential antagonists include an oligonucleotide that binds to the fusions of immunoglobulin with PRO polypeptide, and, in particular, antibodies including, without limitation, poly- and monoclonal antibodies and antibody fragments, single-chain antibodies, anti-idiotypic antibodies, and chimeric or humanized versions of such antibodies or fragments, as well as human antibodies and antibody fragments. Alternatively, a potential antagonist may be a closely related protein, for example, a mutated form of the PRO polypeptide that recognizes the receptor but imparts no effect, thereby competitively inhibiting the action of the PRO polypeptide.

Another potential PRO polypeptide antagonist is an antisense RNA or DNA construct prepared using antisense technology, where, e.g., an antisense RNA or DNA molecule acts to block directly the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the polynucleotide sequence, which encodes the mature PRO polypeptides herein, is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et al., *Nucl. Acids Res.*, 6:3073 (1979); Cooney et al., *Science*, 241: 456 (1988); Dervan et al., *Science*, 251:1360 (1991)), thereby preventing transcription and the production of the PRO polypeptide. The antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into the PRO polypeptide (antisense - Okano, *Neurochem.*, 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression (CRC Press: Boca Raton, FL, 1988). The oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be expressed *in vivo* to inhibit production of the PRO

polypeptide. When antisense DNA is used, oligodeoxyribonucleotides derived from the translation-initiation site, e.g., between about -10 and +10 positions of the target gene nucleotide sequence, are preferred.

Potential antagonists include small molecules that bind to the active site, the receptor binding site, or growth factor or other relevant binding site of the PRO polypeptide, thereby blocking the normal biological activity of the PRO polypeptide. Examples of small molecules include, but are not limited to, small peptides or peptide-like molecules, preferably soluble peptides, and synthetic non-peptidyl organic or inorganic compounds.

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization to the complementary target RNA, followed by endonucleolytic cleavage. Specific ribozyme cleavage sites within a potential RNA target can be identified by known techniques. For further details see, e.g., Rossi, *Current Biology*, 4:469-471 (1994), and PCT publication No. WO 97/33551 (published September 18, 1997).

Nucleic acid molecules in triple-helix formation used to inhibit transcription should be single-stranded and composed of deoxynucleotides. The base composition of these oligonucleotides is designed such that it promotes triple-helix formation via Hoogsteen base-pairing rules, which generally require sizeable stretches of purines or pyrimidines on one strand of a duplex. For further details see, e.g., PCT publication No. WO 97/33551, *supra*.

These small molecules can be identified by any one or more of the screening assays discussed hereinabove and/or by any other screening techniques well known for those skilled in the art.

Diagnostic and therapeutic uses of the herein disclosed molecules may also be based upon the positive functional assay hits disclosed and described below.

#### F. Anti-PRO Antibodies

The present invention further provides anti-PRO antibodies. Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies.

25

##### 1. Polyclonal Antibodies

The anti-PRO antibodies may comprise polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include the PRO polypeptide or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

2. Monoclonal Antibodies

The anti-PRO antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized *in vitro*.

5 The immunizing agent will typically include the PRO polypeptide or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a  
10 hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or  
15 survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More  
20 preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63].

25 The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against PRO. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the  
30 Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980).

After the desired hybridoma cells are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods [Goding, supra]. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown *in vivo* as ascites in a mammal.

35 The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences [U.S. Patent No. 4,816,567; Morrison et al., *supra*] or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

The antibodies may be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking.

*In vitro* methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art.

### 3. Human and Humanized Antibodies

The anti-PRO antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones

et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(1):86-95 (1991)]. Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology 10, 779-783 (1992); Lonberg et al., Nature 368 856-859 (1994); Morrison, Nature 368, 812-13 (1994); Fishwild et al., Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14, 826 (1996); Lonberg and Huszar, Intern. Rev. Immunol. 13 65-93 (1995).

The antibodies may also be affinity matured using known selection and/or mutagenesis methods as described above. Preferred affinity matured antibodies have an affinity which is five times, more preferably 10 times, even more preferably 20 or 30 times greater than the starting antibody (generally murine, humanized or human) from which the matured antibody is prepared.

30

#### 4. Bispecific Antibodies

35 Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for the PRO, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain

pairs, where the two heavy chains have different specificities [Milstein and Cuello, *Nature*, **305**:537-539 (1983)]. Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., *EMBO J.*, **10**:3655-3659 (1991).

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH<sub>2</sub>, and CH<sub>3</sub> regions. It is preferred to have the first heavy-chain constant region (CH<sub>1</sub>) containing the site necessary for light-chain binding present in 10 at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., *Methods in Enzymology*, **121**:210 (1986).

According to another approach described in WO 96/27011, the interface between a pair of antibody 15 molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH<sub>3</sub> region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large 20 amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab')<sub>2</sub> 25 bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared can be prepared using chemical linkage. Brennan et al., *Science* **229**:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')<sub>2</sub> fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB 30 derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Fab' fragments may be directly recovered from *E. coli* and chemically coupled to form bispecific antibodies. Shalaby et al., *J. Exp. Med.* **175**:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab')<sub>2</sub> molecule. Each Fab' fragment was separately secreted from *E. coli* and subjected 35 to directed chemical coupling *in vitro* to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

Various technique for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelnik *et al.*, J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers.

5 This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger *et al.*, Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain ( $V_H$ ) connected to a light-chain variable domain ( $V_L$ ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the  $V_H$  and  $V_L$  domains of one fragment are forced to pair with

10 the complementary  $V_L$  and  $V_H$  domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber *et al.*, J. Immunol. 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt *et al.*, J. Immunol. 147:60 (1991).

15 Exemplary bispecific antibodies may bind to two different epitopes on a given PRO polypeptide herein. Alternatively, an anti-PRO polypeptide arm may be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (Fc $\gamma$ R), such as Fc $\gamma$ RI (CD64), Fc $\gamma$ RII (CD32) and Fc $\gamma$ RIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular PRO polypeptide. Bispecific antibodies may also be used to localize

20 cytotoxic agents to cells which express a particular PRO polypeptide. These antibodies possess a PRO-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the PRO polypeptide and further binds tissue factor (TF).

25        5.        Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells [U.S. Patent No. 4,676,980], and for treatment of HIV infection [WO 91/00360; WO 92/200373; EP 03089]. It is contemplated that the antibodies may be prepared *in vitro* using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptopbutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

35        6.        Effector Function Engineering

It may be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, *e.g.*, the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) may be

introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron *et al.*, J. Exp Med., **176**: 1191-1195 (1992) and Shope, J. Immunol., **148**: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff *et al.* Cancer Research, **53**: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson *et al.*, Anti-Cancer Drug Design, **3**: 219-230 (1989).

#### 7. Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (*e.g.*, an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (*i.e.*, a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, *Aleurites fordii* proteins, dianthin proteins, *Phytolaca americana* proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the trichothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include <sup>212</sup>Bi, <sup>131</sup>I, <sup>131</sup>In, <sup>90</sup>Y, and <sup>186</sup>Re.

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-disfluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta *et al.*, Science, **238**: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

In another embodiment, the antibody may be conjugated to a "receptor" (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (*e.g.*, avidin) that is conjugated to a cytotoxic agent (*e.g.*, a radionucleotide).

#### 8. Immunoliposomes

The antibodies disclosed herein may also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein *et al.*, Proc. Natl. Acad. Sci. USA, **82**: 3688 (1985); Hwang *et al.*, Proc. Natl. Acad. Sci. USA, **77**: 4030 (1980); and U.S. Pat. Nos.

4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.

Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter.

- 5 Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin *et al.*, J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon *et al.*, J. National Cancer Inst., 81(19): 1484 (1989).

10 9. Pharmaceutical Compositions of Antibodies

Antibodies specifically binding a PRO polypeptide identified herein, as well as other molecules identified by the screening assays disclosed hereinbefore, can be administered for the treatment of various disorders in the form of pharmaceutical compositions.

If the PRO polypeptide is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, lipofections or liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, *e.g.*, Marasco *et al.*, Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993). The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition may comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, supra.

The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, *e.g.*, films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and  $\gamma$  ethyl-L-glutamate, non-degradable ethylene-vinyl

acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

10

#### G. Uses for anti-PRO Antibodies

The anti-PRO antibodies of the invention have various utilities. For example, anti-PRO antibodies may be used in diagnostic assays for PRO, *e.g.*, detecting its expression (and in some cases, differential expression) in specific cells, tissues, or serum. Various diagnostic assay techniques known in the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in either heterogeneous or homogeneous phases [Zola, Monoclonal Antibodies: A Manual of Techniques, CRC Press, Inc. (1987) pp. 147-158]. The antibodies used in the diagnostic assays can be labeled with a detectable moiety. The detectable moiety should be capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ , or  $^{125}\text{I}$ , a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase. Any method known in the art for conjugating the antibody to the detectable moiety may be employed, including those methods described by Hunter et al., Nature, 144:945 (1962); David et al., Biochemistry, 13:1014 (1974); Pain et al., J. Immunol. Meth., 40:219 (1981); and Nygren, J. Histochem. and Cytochem., 30:407 (1982).

25 Anti-PRO antibodies also are useful for the affinity purification of PRO from recombinant cell culture or natural sources. In this process, the antibodies against PRO are immobilized on a suitable support, such as Sephadex resin or filter paper, using methods well known in the art. The immobilized antibody then is contacted with a sample containing the PRO to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the PRO, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent that will release the PRO from the antibody.

30 The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

35 All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.

EXAMPLES

Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, Manassas, VA.

5

EXAMPLE 1: Extracellular Domain Homology Screening to Identify Novel Polypeptides and cDNA Encoding Therefor

The extracellular domain (ECD) sequences (including the secretion signal sequence, if any) from about 950 known secreted proteins from the Swiss-Prot public database were used to search EST databases. The EST 10 databases included public databases (e.g., Dayhoff, GenBank), and proprietary databases (e.g. LIFESEQ™, Incyte Pharmaceuticals, Palo Alto, CA). The search was performed using the computer program BLAST or BLAST-2 (Altschul et al., *Methods in Enzymology* 266:460-480 (1996)) as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequences. Those comparisons with a BLAST score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into consensus DNA 15 sequences with the program "phrap" (Phil Green, University of Washington, Seattle, WA).

Using this extracellular domain homology screen, consensus DNA sequences were assembled relative to the other identified EST sequences using phrap. In addition, the consensus DNA sequences obtained were often (but not always) extended using repeated cycles of BLAST or BLAST-2 and phrap to extend the consensus sequence as far as possible using the sources of EST sequences discussed above.

20 Based upon the consensus sequences obtained as described above, oligonucleotides were then synthesized and used to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for a PRO polypeptide. Forward and reverse PCR primers generally range from 20 to 30 nucleotides and are often designed to give a PCR product of about 100-1000 bp in length. The probe sequences are typically 40-55 bp in length. In some cases, additional 25 oligonucleotides are synthesized when the consensus sequence is greater than about 1-1.5kbp. In order to screen several libraries for a full-length clone, DNA from the libraries was screened by PCR amplification, as per Ausubel et al., *Current Protocols in Molecular Biology*, with the PCR primer pair. A positive library was then used to isolate clones encoding the gene of interest using the probe oligonucleotide and one of the primer pairs.

30 The cDNA libraries used to isolate the cDNA clones were constructed by standard methods using commercially available reagents such as those from Invitrogen, San Diego, CA. The cDNA was primed with oligo dT containing a NotI site, linked with blunt to Sall hemikinased adaptors, cleaved with NotI, sized appropriately by gel electrophoresis, and cloned in a defined orientation into a suitable cloning vector (such as pRK5B or pRK5D; pRK5B is a precursor of pRK5D that does not contain the SfiI site; see, Holmes et al., *Science*, 253:1278-1280 (1991)) in the unique XhoI and NotI sites.

35

EXAMPLE 2: Isolation of cDNA clones by Amylase Screening1. Preparation of oligo dT primed cDNA library

mRNA was isolated from a human tissue of interest using reagents and protocols from Invitrogen, San Diego, CA (Fast Track 2). This RNA was used to generate an oligo dT primed cDNA library in the vector pRK5D using reagents and protocols from Life Technologies, Gaithersburg, MD (Super Script Plasmid System).

5 In this procedure, the double stranded cDNA was sized to greater than 1000 bp and the Sall/NotI linker cDNA was cloned into Xhol/NotI cleaved vector. pRK5D is a cloning vector that has an sp6 transcription initiation site followed by an SfiI restriction enzyme site preceding the Xhol/NotI cDNA cloning sites.

2. Preparation of random primed cDNA library

10 A secondary cDNA library was generated in order to preferentially represent the 5' ends of the primary cDNA clones. Sp6 RNA was generated from the primary library (described above), and this RNA was used to generate a random primed cDNA library in the vector pSST-AMY.0 using reagents and protocols from Life Technologies (Super Script Plasmid System, referenced above). In this procedure the double stranded cDNA was sized to 500-1000 bp, linker with blunt to NotI adaptors, cleaved with SfiI, and cloned into SfiI/NotI 15 cleaved vector. pSST-AMY.0 is a cloning vector that has a yeast alcohol dehydrogenase promoter preceding the cDNA cloning sites and the mouse amylase sequence (the mature sequence without the secretion signal) followed by the yeast alcohol dehydrogenase terminator, after the cloning sites. Thus, cDNAs cloned into this vector that are fused in frame with amylase sequence will lead to the secretion of amylase from appropriately transfected yeast colonies.

20

3. Transformation and Detection

25 DNA from the library described in paragraph 2 above was chilled on ice to which was added electrocompetent DH10B bacteria (Life Technologies, 20 ml). The bacteria and vector mixture was then electroporated as recommended by the manufacturer. Subsequently, SOC media (Life Technologies, 1 ml) was added and the mixture was incubated at 37°C for 30 minutes. The transformants were then plated onto 20 standard 150 mm LB plates containing ampicillin and incubated for 16 hours (37°C). Positive colonies were scraped off the plates and the DNA was isolated from the bacterial pellet using standard protocols, e.g. CsCl-gradient. The purified DNA was then carried on to the yeast protocols below.

The yeast methods were divided into three categories: (1) Transformation of yeast with the 30 plasmid/cDNA combined vector; (2) Detection and isolation of yeast clones secreting amylase; and (3) PCR amplification of the insert directly from the yeast colony and purification of the DNA for sequencing and further analysis.

35 The yeast strain used was HD56-5A (ATCC-90785). This strain has the following genotype: MAT alpha, ura3-52, leu2-3, leu2-112, his3-11, his3-15, MAL<sup>+</sup>, SUC<sup>+</sup>, GAL<sup>+</sup>. Preferably, yeast mutants can be employed that have deficient post-translational pathways. Such mutants may have translocation deficient alleles in sec71, sec72, sec62, with truncated sec71 being most preferred. Alternatively, antagonists (including antisense nucleotides and/or ligands) which interfere with the normal operation of these genes, other proteins

implicated in this post translation pathway (e.g., SEC61p, SEC72p, SEC62p, SEC63p, TDJ1p or SSA1p-4p) or the complex formation of these proteins may also be preferably employed in combination with the amylase-expressing yeast.

Transformation was performed based on the protocol outlined by Gietz et al., *Nucl. Acid. Res.*, 20:1425 (1992). Transformed cells were then inoculated from agar into YEPD complex media broth (100 ml) and grown overnight at 30°C. The YEPD broth was prepared as described in Kaiser et al., *Methods in Yeast Genetics*, Cold Spring Harbor Press, Cold Spring Harbor, NY, p. 207 (1994). The overnight culture was then diluted to about  $2 \times 10^6$  cells/ml (approx. OD<sub>600</sub>=0.1) into fresh YEPD broth (500 ml) and regrown to  $1 \times 10^7$  cells/ml (approx. OD<sub>600</sub>=0.4-0.5).

The cells were then harvested and prepared for transformation by transfer into GS3 rotor bottles in a Sorval GS3 rotor at 5,000 rpm for 5 minutes, the supernatant discarded, and then resuspended into sterile water, and centrifuged again in 50 ml falcon tubes at 3,500 rpm in a Beckman GS-6KR centrifuge. The supernatant was discarded and the cells were subsequently washed with LiAc/TE (10 ml, 10 mM Tris-HCl, 1 mM EDTA pH 7.5, 100 mM Li<sub>2</sub>OOCCH<sub>3</sub>), and resuspended into LiAc/TE (2.5 ml).

Transformation took place by mixing the prepared cells (100 µl) with freshly denatured single stranded salmon testes DNA (Lofstrand Labs, Gaithersburg, MD) and transforming DNA (1 µg, vol. < 10 µl) in microfuge tubes. The mixture was mixed briefly by vortexing, then 40% PEG/TE (600 µl, 40% polyethylene glycol-4000, 10 mM Tris-HCl, 1 mM EDTA, 100 mM Li<sub>2</sub>OOCCH<sub>3</sub>, pH 7.5) was added. This mixture was gently mixed and incubated at 30°C while agitating for 30 minutes. The cells were then heat shocked at 42°C for 15 minutes, and the reaction vessel centrifuged in a microfuge at 12,000 rpm for 5-10 seconds, decanted and resuspended into TE (500 µl, 10 mM Tris-HCl, 1 mM EDTA pH 7.5) followed by recentrifugation. The cells were then diluted into TE (1 ml) and aliquots (200 µl) were spread onto the selective media previously prepared in 150 mm growth plates (VWR).

Alternatively, instead of multiple small reactions, the transformation was performed using a single, large scale reaction, wherein reagent amounts were scaled up accordingly.

The selective media used was a synthetic complete dextrose agar lacking uracil (SCD-Ura) prepared as described in Kaiser et al., *Methods in Yeast Genetics*, Cold Spring Harbor Press, Cold Spring Harbor, NY, p. 208-210 (1994). Transformants were grown at 30°C for 2-3 days.

The detection of colonies secreting amylase was performed by including red starch in the selective growth media. Starch was coupled to the red dye (Reactive Red-120, Sigma) as per the procedure described by Biely et al., *Anal. Biochem.*, 172:176-179 (1988). The coupled starch was incorporated into the SCD-Ura agar plates at a final concentration of 0.15% (w/v), and was buffered with potassium phosphate to a pH of 7.0 (50-100 mM final concentration).

The positive colonies were picked and streaked across fresh selective media (onto 150 mm plates) in order to obtain well isolated and identifiable single colonies. Well isolated single colonies positive for amylase secretion were detected by direct incorporation of red starch into buffered SCD-Ura agar. Positive colonies were determined by their ability to break down starch resulting in a clear halo around the positive colony visualized directly.

4. Isolation of DNA by PCR Amplification

When a positive colony was isolated, a portion of it was picked by a toothpick and diluted into sterile water (30 µl) in a 96 well plate. At this time, the positive colonies were either frozen and stored for subsequent analysis or immediately amplified. An aliquot of cells (5 µl) was used as a template for the PCR reaction in a 25 µl volume containing: 0.5 µl Klentaq (Clontech, Palo Alto, CA); 4.0 µl 10 mM dNTP's (Perkin Elmer-Cetus); 2.5 µl Kentaq buffer (Clontech); 0.25 µl forward oligo 1; 0.25 µl reverse oligo 2; 12.5 µl distilled water.

5 The sequence of the forward oligonucleotide 1 was:

5'-TGTAAAACGACGCCAGTTAAATAGACCTGCAATTATTAATCT-3' (SEQ ID NO:169)

The sequence of reverse oligonucleotide 2 was:

5'-CAGGAAACAGCTATGACCACCTGCACACCTGCAAATCCATT-3' (SEQ ID NO:170)

10 PCR was then performed as follows:

a.		Denature	92°C, 5 minutes
b.	3 cycles of:	Denature	92°C, 30 seconds
		Anneal	59°C, 30 seconds
		Extend	72°C, 60 seconds
c.	3 cycles of:	Denature	92°C, 30 seconds
		Anneal	57°C, 30 seconds
		Extend	72°C, 60 seconds
d.	25 cycles of:	Denature	92°C, 30 seconds
		Anneal	55°C, 30 seconds
		Extend	72°C, 60 seconds
25	e.	Hold	4°C

The underlined regions of the oligonucleotides annealed to the ADH promoter region and the amylase region, respectively, and amplified a 307 bp region from vector pSST-AMY.0 when no insert was present. Typically, the first 18 nucleotides of the 5' end of these oligonucleotides contained annealing sites for the 30 sequencing primers. Thus, the total product of the PCR reaction from an empty vector was 343 bp. However, signal sequence-fused cDNA resulted in considerably longer nucleotide sequences.

Following the PCR, an aliquot of the reaction (5 µl) was examined by agarose gel electrophoresis in a 1% agarose gel using a Tris-Borate-EDTA (TBE) buffering system as described by Sambrook et al., supra. Clones resulting in a single strong PCR product larger than 400 bp were further analyzed by DNA sequencing 35 after purification with a 96 Qiaquick PCR clean-up column (Qiagen Inc., Chatsworth, CA).

EXAMPLE 3: Isolation of cDNA Clones Using Signal Algorithm Analysis

Various polypeptide-encoding nucleic acid sequences were identified by applying a proprietary signal sequence finding algorithm developed by Genentech, Inc. (South San Francisco, CA) upon ESTs as well as 40 clustered and assembled EST fragments from public (e.g., GenBank) and/or private (LIFESEQ®, Incyte Pharmaceuticals, Inc., Palo Alto, CA) databases. The signal sequence algorithm computes a secretion signal score based on the character of the DNA nucleotides surrounding the first and optionally the second methionine

codon(s) (ATG) at the 5'-end of the sequence or sequence fragment under consideration. The nucleotides following the first ATG must code for at least 35 unambiguous amino acids without any stop codons. If the first ATG has the required amino acids, the second is not examined. If neither meets the requirement, the candidate sequence is not scored. In order to determine whether the EST sequence contains an authentic signal sequence, the DNA and corresponding amino acid sequences surrounding the ATG codon are scored using a set of seven sensors (evaluation parameters) known to be associated with secretion signals. Use of this algorithm resulted in the identification of numerous polypeptide-encoding nucleic acid sequences.

EXAMPLE 4: Isolation of cDNA Clones Encoding Human PRO Polypeptides

Using the techniques described in Examples 1 to 3 above, numerous full-length cDNA clones were identified as encoding PRO polypeptides as disclosed herein. These cDNAs were then deposited under the terms of the Budapest Treaty with the American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209, USA (ATCC) as shown in Table 7 below.

Table 7

	<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
15	DNA26843-1389	203099	August 4, 1998
	DNA30867-1335	209807	April 28, 1998
	DNA34431-1177	209399	October 17, 1997
	DNA38268-1188	209421	October 28, 1997
20	DNA40621-1440	209922	June 2, 1998
	DNA40625-1189	209788	April 21, 1998
	DNA45409-2511	203579	January 12, 1999
	DNA45495-1550	203156	August 25, 1998
	DNA49820-1427	209932	June 2, 1998
25	DNA56406-1704	203478	November 17, 1998
	DNA56410-1414	209923	June 2, 1998
	DNA56436-1448	209902	May 27, 1998
	DNA56855-1447	203004	June 23, 1998
	DNA56860-1510	209952	June 9, 1998
30	DNA56862-1343	203174	September 1, 1998
	DNA56868-1478	203024	June 23, 1998
	DNA56869-1545	203161	August 25, 1998
	DNA57704-1452	209953	June 9, 1998
	DNA58723-1588	203133	August 18, 1998
35	DNA57827-1493	203045	July 1, 1998
	DNA58737-1473	203136	August 18, 1998
	DNA58846-1409	209957	June 9, 1998
	DNA58850-1495	209956	June 9, 1998
	DNA58855-1422	203018	June 23, 1998
40	DNA59211-1450	209960	June 9, 1998
	DNA59212-1627	203245	September 9, 1998
	DNA59213-1487	209959	June 9, 1998
	DNA59605-1418	203005	June 23, 1998
	DNA59609-1470	209963	June 9, 1998
45	DNA59610-1556	209990	June 16, 1998
	DNA59837-2545	203658	February 9, 1999
	DNA59844-2542	203650	February 9, 1999
	DNA59854-1459	209974	June 16, 1998

Table 7 (cont')

	DNA60625-1507	209975	June 16, 1998
	DNA60629-1481	209979	June 16, 1998
	DNA61755-1554	203112	August 11, 1998
5	DNA62812-1594	203248	September 9, 1998
	DNA62815-1576	203247	September 9, 1998
	DNA64881-1602	203240	September 9, 1998
	DNA64886-1601	203241	September 9, 1998
	DNA64902-1667	203317	October 6, 1998
10	DNA64950-1590	203224	September 15, 1998
	DNA65403-1565	203230	September 15, 1998
	DNA66308-1537	203159	August 25, 1998
	DNA66519-1535	203236	September 15, 1998
15	DNA66521-1583	203225	September 15, 1998
	DNA66658-1584	203229	September 15, 1998
	DNA66660-1585	203279	September 22, 1998
	DNA66663-1598	203268	September 22, 1998
	DNA66674-1599	203281	September 22, 1998
20	DNA68862-2546	203652	February 9, 1999
	DNA68866-1644	203283	September 22, 1998
	DNA68871-1638	203280	September 22, 1998
	DNA68880-1676	203319	October 6, 1998
	DNA68883-1691	203535	December 15, 1998
25	DNA68885-1678	203311	October 6, 1998
	DNA71277-1636	203285	September 22, 1998
	DNA73727-1673	203459	November 3, 1998
	DNA73734-1680	203363	October 20, 1998
	DNA73735-1681	203356	October 20, 1998
30	DNA76393-1664	203323	October 6, 1998
	DNA77301-1708	203407	October 27, 1998
	DNA77568-1626	203134	August 18, 1998
	DNA77626-1705	203536	December 15, 1998
	DNA81754-2532	203542	December 15, 1998
35	DNA81757-2512	203543	December 15, 1998
	DNA82302-2529	203534	December 15, 1998
	DNA82340-2530	203547	December 22, 1998
	DNA83500-2506	203391	October 29, 1998
	DNA84920-2614	203966	April 27, 1999
40	DNA85066-2534	203588	January 12, 1999
	DNA86571-2551	203660	February 9, 1999
	DNA87991-2540	203656	February 9, 1999
	DNA92238-2539	203602	January 20, 1999
	DNA96042-2682	PTA-382	July 20, 1999
45	DNA96787-2534	203589	January 12, 1999
	DNA125185-2806	PTA-1031	December 7, 1999
	DNA147531-2821	PTA-1185	January 11, 2000
	DNA115291-2681	PTA-202	June 8, 1999
	DNA164625-28890	PTA-1535	March 21, 2000
	DNA131639-2874	PTA-1784	April 25, 2000
50	DNA79230-2525	203549	December 22, 1998

These deposits were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture of the deposit for 30 years from the date of deposit. The

deposits will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the culture of the deposit to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35  
5 USC § 122 and the Commissioner's rules pursuant thereto (including 37 CFR § 1.14 with particular reference to 886 OG 638).

The assignee of the present application has agreed that if a culture of the materials on deposit should die or be lost or destroyed when cultivated under suitable conditions, the materials will be promptly replaced on notification with another of the same. Availability of the deposited material is not to be construed as a license  
10 to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

**EXAMPLE 5: Use of PRO as a hybridization probe**

The following method describes use of a nucleotide sequence encoding PRO as a hybridization probe.  
15 DNA comprising the coding sequence of full-length or mature PRO as disclosed herein is employed as a probe to screen for homologous DNAs (such as those encoding naturally-occurring variants of PRO) in human tissue cDNA libraries or human tissue genomic libraries.

Hybridization and washing of filters containing either library DNAs is performed under the following high stringency conditions. Hybridization of radiolabeled PRO-derived probe to the filters is performed in a  
20 solution of 50% formamide, 5x SSC, 0.1% SDS, 0.1% sodium pyrophosphate, 50 mM sodium phosphate, pH 6.8, 2x Denhardt's solution, and 10% dextran sulfate at 42°C for 20 hours. Washing of the filters is performed in an aqueous solution of 0.1x SSC and 0.1% SDS at 42°C.

DNAs having a desired sequence identity with the DNA encoding full-length native sequence PRO can then be identified using standard techniques known in the art.  
25

**EXAMPLE 6: Expression of PRO in *E. coli***

This example illustrates preparation of an unglycosylated form of PRO by recombinant expression in *E. coli*.

The DNA sequence encoding PRO is initially amplified using selected PCR primers. The primers  
30 should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector. A variety of expression vectors may be employed. An example of a suitable vector is pBR322 (derived from *E. coli*; see Bolivar et al., *Gene*, 2:95 (1977)) which contains genes for ampicillin and tetracycline resistance. The vector is digested with restriction enzyme and dephosphorylated. The PCR amplified sequences are then ligated into the vector. The vector will preferably include sequences which encode  
35 for an antibiotic resistance gene, a trp promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase cleavage site), the PRO coding region, lambda transcriptional terminator, and an argU gene.

The ligation mixture is then used to transform a selected *E. coli* strain using the methods described in Sambrook et al., *supra*. Transformants are identified by their ability to grow on LB plates and antibiotic resistant colonies are then selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing.

Selected clones can be grown overnight in liquid culture medium such as LB broth supplemented with antibiotics. The overnight culture may subsequently be used to inoculate a larger scale culture. The cells are then grown to a desired optical density, during which the expression promoter is turned on.

After culturing the cells for several more hours, the cells can be harvested by centrifugation. The cell pellet obtained by the centrifugation can be solubilized using various agents known in the art, and the solubilized PRO protein can then be purified using a metal chelating column under conditions that allow tight binding of the protein.

PRO may be expressed in *E. coli* in a poly-His tagged form, using the following procedure. The DNA encoding PRO is initially amplified using selected PCR primers. The primers will contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector, and other useful sequences providing for efficient and reliable translation initiation, rapid purification on a metal chelation column, and proteolytic removal with enterokinase. The PCR-amplified, poly-His tagged sequences are then ligated into an expression vector, which is used to transform an *E. coli* host based on strain 52 (W3110 fuhA(tonA) lon galE rpoHts(htpRts) clpP(lacIq)). Transformants are first grown in LB containing 50 mg/ml carbenicillin at 30°C with shaking until an O.D.600 of 3-5 is reached. Cultures are then diluted 50-100 fold into CRAP media (prepared by mixing 3.57 g (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.71 g sodium citrate•2H<sub>2</sub>O, 1.07 g KCl, 5.36 g Difco yeast extract, 5.36 g Sheffield hycase SF in 500 mL water, as well as 110 mM MPOS, pH 7.3, 0.55% (w/v) glucose and 7 mM MgSO<sub>4</sub>) and grown for approximately 20-30 hours at 30°C with shaking. Samples are removed to verify expression by SDS-PAGE analysis, and the bulk culture is centrifuged to pellet the cells. Cell pellets are frozen until purification and refolding.

*E. coli* paste from 0.5 to 1 L fermentations (6-10 g pellets) is resuspended in 10 volumes (w/v) in 7 M guanidine, 20 mM Tris, pH 8 buffer. Solid sodium sulfite and sodium tetrathionate is added to make final concentrations of 0.1M and 0.02 M, respectively, and the solution is stirred overnight at 4°C. This step results in a denatured protein with all cysteine residues blocked by sulfitolization. The solution is centrifuged at 40,000 rpm in a Beckman Ultracentrifuge for 30 min. The supernatant is diluted with 3-5 volumes of metal chelate column buffer (6 M guanidine, 20 mM Tris, pH 7.4) and filtered through 0.22 micron filters to clarify. The clarified extract is loaded onto a 5 ml Qiagen Ni-NTA metal chelate column equilibrated in the metal chelate column buffer. The column is washed with additional buffer containing 50 mM imidazole (Calbiochem, Utrol grade), pH 7.4. The protein is eluted with buffer containing 250 mM imidazole. Fractions containing the desired protein are pooled and stored at 4°C. Protein concentration is estimated by its absorbance at 280 nm using the calculated extinction coefficient based on its amino acid sequence.

The proteins are refolded by diluting the sample slowly into freshly prepared refolding buffer consisting of: 20 mM Tris, pH 8.6, 0.3 M NaCl, 2.5 M urea, 5 mM cysteine, 20 mM glycine and 1 mM EDTA. Refolding volumes are chosen so that the final protein concentration is between 50 to 100 micrograms/ml. The

refolding solution is stirred gently at 4°C for 12-36 hours. The refolding reaction is quenched by the addition of TFA to a final concentration of 0.4% (pH of approximately 3). Before further purification of the protein, the solution is filtered through a 0.22 micron filter and acetonitrile is added to 2-10% final concentration. The refolded protein is chromatographed on a Poros R1/H reversed phase column using a mobile buffer of 0.1% TFA with elution with a gradient of acetonitrile from 10 to 80%. Aliquots of fractions with A280 absorbance  
5 are analyzed on SDS polyacrylamide gels and fractions containing homogeneous refolded protein are pooled. Generally, the properly refolded species of most proteins are eluted at the lowest concentrations of acetonitrile since those species are the most compact with their hydrophobic interiors shielded from interaction with the reversed phase resin. Aggregated species are usually eluted at higher acetonitrile concentrations. In addition to resolving misfolded forms of proteins from the desired form, the reversed phase step also removes endotoxin  
10 from the samples.

Fractions containing the desired folded PRO polypeptide are pooled and the acetonitrile removed using a gentle stream of nitrogen directed at the solution. Proteins are formulated into 20 mM Hepes, pH 6.8 with 0.14 M sodium chloride and 4% mannitol by dialysis or by gel filtration using G25 Superfine (Pharmacia) resins equilibrated in the formulation buffer and sterile filtered.  
15

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

**EXAMPLE 7: Expression of PRO in mammalian cells**

This example illustrates preparation of a potentially glycosylated form of PRO by recombinant expression in mammalian cells.  
20 The vector, pRK5 (see EP 307,247, published March 15, 1989), is employed as the expression vector. Optionally, the PRO DNA is ligated into pRK5 with selected restriction enzymes to allow insertion of the PRO DNA using ligation methods such as described in Sambrook et al., *supra*. The resulting vector is called pRK5-PRO.

In one embodiment, the selected host cells may be 293 cells. Human 293 cells (ATCC CCL 1573) are  
25 grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components and/or antibiotics. About 10 µg pRK5-PRO DNA is mixed with about 1 µg DNA encoding the VA RNA gene [Thimmappaya et al., *Cell*, 31:543 (1982)] and dissolved in 500 µl of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M CaCl<sub>2</sub>. To this mixture is added, dropwise, 500 µl of 50 mM HEPES (pH 7.35), 280 mM NaCl, 1.5 mM NaPO<sub>4</sub>, and a precipitate is allowed to form for 10 minutes at 25°C. The  
30 precipitate is suspended and added to the 293 cells and allowed to settle for about four hours at 37°C. The culture medium is aspirated off and 2 ml of 20% glycerol in PBS is added for 30 seconds. The 293 cells are then washed with serum free medium, fresh medium is added and the cells are incubated for about 5 days.

Approximately 24 hours after the transfections, the culture medium is removed and replaced with culture medium (alone) or culture medium containing 200 µCi/ml <sup>35</sup>S-cysteine and 200 µCi/ml <sup>35</sup>S-methionine. After  
35 a 12 hour incubation, the conditioned medium is collected, concentrated on a spin filter, and loaded onto a 15% SDS gel. The processed gel may be dried and exposed to film for a selected period of time to reveal the presence of PRO polypeptide. The cultures containing transfected cells may undergo further incubation (in

serum free medium) and the medium is tested in selected bioassays.

- In an alternative technique, PRO may be introduced into 293 cells transiently using the dextran sulfate method described by Sompanyrac et al., Proc. Natl. Acad. Sci., 78:7575 (1981). 293 cells are grown to maximal density in a spinner flask and 700 µg pRK5-PRO DNA is added. The cells are first concentrated from the spinner flask by centrifugation and washed with PBS. The DNA-dextran precipitate is incubated on the cell pellet for four hours. The cells are treated with 20% glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, 5 µg/ml bovine insulin and 0.1 µg/ml bovine transferrin. After about four days, the conditioned media is centrifuged and filtered to remove cells and debris. The sample containing expressed PRO can then be concentrated and purified by any selected method, such as dialysis and/or column chromatography.
- 10 In another embodiment, PRO can be expressed in CHO cells. The pRK5-PRO can be transfected into CHO cells using known reagents such as CaPO<sub>4</sub> or DEAE-dextran. As described above, the cell cultures can be incubated, and the medium replaced with culture medium (alone) or medium containing a radiolabel such as <sup>35</sup>S-methionine. After determining the presence of PRO polypeptide, the culture medium may be replaced with serum free medium. Preferably, the cultures are incubated for about 6 days, and then the conditioned medium 15 is harvested. The medium containing the expressed PRO can then be concentrated and purified by any selected method.

Epitope-tagged PRO may also be expressed in host CHO cells. The PRO may be subcloned out of the pRK5 vector. The subclone insert can undergo PCR to fuse in frame with a selected epitope tag such as a poly-his tag into a Baculovirus expression vector. The poly-his tagged PRO insert can then be subcloned into a SV40 driven vector containing a selection marker such as DHFR for selection of stable clones. Finally, the CHO cells 20 can be transfected (as described above) with the SV40 driven vector. Labeling may be performed, as described above, to verify expression. The culture medium containing the expressed poly-His tagged PRO can then be concentrated and purified by any selected method, such as by Ni<sup>2+</sup>-chelate affinity chromatography.

PRO may also be expressed in CHO and/or COS cells by a transient expression procedure or in CHO 25 cells by another stable expression procedure.

Stable expression in CHO cells is performed using the following procedure. The proteins are expressed as an IgG construct (immunoadhesin), in which the coding sequences for the soluble forms (e.g. extracellular domains) of the respective proteins are fused to an IgG1 constant region sequence containing the hinge, CH2 and CH2 domains and/or is a poly-His tagged form.

30 Following PCR amplification, the respective DNAs are subcloned in a CHO expression vector using standard techniques as described in Ausubel et al., Current Protocols of Molecular Biology, Unit 3.16, John Wiley and Sons (1997). CHO expression vectors are constructed to have compatible restriction sites 5' and 3' of the DNA of interest to allow the convenient shuttling of cDNA's. The vector used expression in CHO cells is as described in Lucas et al., Nucl. Acids Res. 24:9 (1774-1779 (1996), and uses the SV40 early 35 promoter/enhancer to drive expression of the cDNA of interest and dihydrofolate reductase (DHFR). DHFR expression permits selection for stable maintenance of the plasmid following transfection.

Twelve micrograms of the desired plasmid DNA is introduced into approximately 10 million CHO cells using commercially available transfection reagents Superfect® (Qiagen), Dospel® or Fugene® (Boehringer Mannheim). The cells are grown as described in Lucas et al., *supra*. Approximately  $3 \times 10^7$  cells are frozen in an ampule for further growth and production as described below.

The ampules containing the plasmid DNA are thawed by placement into water bath and mixed by vortexing. The contents are pipetted into a centrifuge tube containing 10 mLs of media and centrifuged at 1000 rpm for 5 minutes. The supernatant is aspirated and the cells are resuspended in 10 mL of selective media (0.2  $\mu$ m filtered PS20 with 5% 0.2  $\mu$ m diafiltered fetal bovine serum). The cells are then aliquoted into a 100 mL spinner containing 90 mL of selective media. After 1-2 days, the cells are transferred into a 250 mL spinner filled with 150 mL selective growth medium and incubated at 37°C. After another 2-3 days, 250 mL, 500 mL and 2000 mL spinners are seeded with  $3 \times 10^5$  cells/mL. The cell media is exchanged with fresh media by centrifugation and resuspension in production medium. Although any suitable CHO media may be employed, a production medium described in U.S. Patent No. 5,122,469, issued June 16, 1992 may actually be used. A 3L production spinner is seeded at  $1.2 \times 10^6$  cells/mL. On day 0, the cell number pH ie determined. On day 1, the spinner is sampled and sparging with filtered air is commenced. On day 2, the spinner is sampled, the temperature shifted to 33°C, and 30 mL of 500 g/L glucose and 0.6 mL of 10% antifoam (e.g., 35% polydimethylsiloxane emulsion, Dow Corning 365 Medical Grade Emulsion) taken. Throughout the production, the pH is adjusted as necessary to keep it at around 7.2. After 10 days, or until the viability dropped below 70%, the cell culture is harvested by centrifugation and filtering through a 0.22  $\mu$ m filter. The filtrate was either stored at 4°C or immediately loaded onto columns for purification.

For the poly-His tagged constructs, the proteins are purified using a Ni-NTA column (Qiagen). Before purification, imidazole is added to the conditioned media to a concentration of 5 mM. The conditioned media is pumped onto a 6 ml Ni-NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rate of 4-5 ml/min. at 4°C. After loading, the column is washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole. The highly purified protein is subsequently desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCl and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80°C.

Immunoadhesin (Fc-containing) constructs are purified from the conditioned media as follows. The conditioned medium is pumped onto a 5 ml Protein A column (Pharmacia) which had been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column is washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5. The eluted protein is immediately neutralized by collecting 1 ml fractions into tubes containing 275  $\mu$ L of 1 M Tris buffer, pH 9. The highly purified protein is subsequently desalted into storage buffer as described above for the poly-His tagged proteins. The homogeneity is assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation.

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

EXAMPLE 8: Expression of PRO in Yeast

The following method describes recombinant expression of PRO in yeast.

First, yeast expression vectors are constructed for intracellular production or secretion of PRO from the ADH2/GAPDH promoter. DNA encoding PRO and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression of PRO. For secretion, DNA encoding PRO can 5 be cloned into the selected plasmid, together with DNA encoding the ADH2/GAPDH promoter, a native PRO signal peptide or other mammalian signal peptide, or, for example, a yeast alpha-factor or invertase secretory signal/leader sequence, and linker sequences (if needed) for expression of PRO.

Yeast cells, such as yeast strain AB110, can then be transformed with the expression plasmids described 10 above and cultured in selected fermentation media. The transformed yeast supernatants can be analyzed by precipitation with 10% trichloroacetic acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain.

Recombinant PRO can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected cartridge filters. The concentrate containing PRO may further be purified using selected column chromatography resins.

15 Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

EXAMPLE 9: Expression of PRO in Baculovirus-Infected Insect Cells

The following method describes recombinant expression of PRO in Baculovirus-infected insect cells.

20 The sequence coding for PRO is fused upstream of an epitope tag contained within a baculovirus expression vector. Such epitope tags include poly-his tags and immunoglobulin tags (like Fc regions of IgG). A variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pVL1393 (Novagen). Briefly, the sequence encoding PRO or the desired portion of the coding sequence of PRO such as the sequence encoding the extracellular domain of a transmembrane protein or the sequence 25 encoding the mature protein if the protein is extracellular is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is then digested with those selected restriction enzymes and subcloned into the expression vector.

Recombinant baculovirus is generated by co-transfected the above plasmid and BaculoGold™ virus 30 DNA (Pharmingen) into *Spodoptera frugiperda* ("Sf9") cells (ATCC CRL 1711) using lipofectin (commercially available from GIBCO-BRL). After 4 - 5 days of incubation at 28°C, the released viruses are harvested and used for further amplifications. Viral infection and protein expression are performed as described by O'Reilley et al., Baculovirus expression vectors: A Laboratory Manual, Oxford: Oxford University Press (1994).

Expressed poly-his tagged PRO can then be purified, for example, by Ni<sup>2+</sup>-chelate affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert et al., Nature, 362:175-179 (1993). Briefly, Sf9 cells are washed, resuspended in sonication buffer (25 35 mL Hepes, pH 7.9; 12.5 mM MgCl<sub>2</sub>; 0.1 mM EDTA; 10% glycerol; 0.1% NP-40; 0.4 M KCl), and sonicated twice for 20 seconds on ice. The sonicates are cleared by centrifugation, and the supernatant is diluted 50-fold in loading buffer (50 mM phosphate, 300 mM NaCl, 10% glycerol, pH 7.8) and filtered through a 0.45 µm

filter. A Ni<sup>2+</sup>-NTA agarose column (commercially available from Qiagen) is prepared with a bed volume of 5 mL, washed with 25 mL of water and equilibrated with 25 mL of loading buffer. The filtered cell extract is loaded onto the column at 0.5 mL per minute. The column is washed to baseline A<sub>280</sub> with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer (50 mM phosphate; 300 mM NaCl, 10% glycerol, pH 6.0), which elutes nonspecifically bound protein. After reaching 5 A<sub>280</sub> baseline again, the column is developed with a 0 to 500 mM Imidazole gradient in the secondary wash buffer. One mL fractions are collected and analyzed by SDS-PAGE and silver staining or Western blot with Ni<sup>2+</sup>-NTA-conjugated to alkaline phosphatase (Qiagen). Fractions containing the eluted His<sub>10</sub>-tagged PRO are pooled and dialyzed against loading buffer.

10 Alternatively, purification of the IgG tagged (or Fc tagged) PRO can be performed using known chromatography techniques, including for instance, Protein A or protein G column chromatography.

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

EXAMPLE 10: Preparation of Antibodies that Bind PRO

This example illustrates preparation of monoclonal antibodies which can specifically bind PRO.  
15 Techniques for producing the monoclonal antibodies are known in the art and are described, for instance, in Goding, *supra*. Immunogens that may be employed include purified PRO, fusion proteins containing PRO, and cells expressing recombinant PRO on the cell surface. Selection of the immunogen can be made by the skilled artisan without undue experimentation.

Mice, such as Balb/c, are immunized with the PRO immunogen emulsified in complete Freund's 20 adjuvant and injected subcutaneously or intraperitoneally in an amount from 1-100 micrograms. Alternatively, the immunogen is emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) and injected into the animal's hind foot pads. The immunized mice are then boosted 10 to 12 days later with additional immunogen emulsified in the selected adjuvant. Thereafter, for several weeks, the mice may also be boosted with additional immunization injections. Serum samples may be periodically obtained from the mice 25 by retro-orbital bleeding for testing in ELISA assays to detect anti-PRO antibodies.

After a suitable antibody titer has been detected, the animals "positive" for antibodies can be injected with a final intravenous injection of PRO. Three to four days later, the mice are sacrificed and the spleen cells are harvested. The spleen cells are then fused (using 35% polyethylene glycol) to a selected murine myeloma cell line such as P3X63AgU.1, available from ATCC, No. CRL 1597. The fusions generate hybridoma cells 30 which can then be plated in 96 well tissue culture plates containing HAT (hypoxanthine, aminopterin, and thymidine) medium to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.

The hybridoma cells will be screened in an ELISA for reactivity against PRO. Determination of "positive" hybridoma cells secreting the desired monoclonal antibodies against PRO is within the skill in the art.

35 The positive hybridoma cells can be injected intraperitoneally into syngeneic Balb/c mice to produce ascites containing the anti-PRO monoclonal antibodies. Alternatively, the hybridoma cells can be grown in tissue culture flasks or roller bottles. Purification of the monoclonal antibodies produced in the ascites can be accomplished using ammonium sulfate precipitation, followed by gel exclusion chromatography. Alternatively,

affinity chromatography based upon binding of antibody to protein A or protein G can be employed.

**EXAMPLE 11: Purification of PRO Polypeptides Using Specific Antibodies**

Native or recombinant PRO polypeptides may be purified by a variety of standard techniques in the art of protein purification. For example, pro-PRO polypeptide, mature PRO polypeptide, or pre-PRO polypeptide 5 is purified by immunoaffinity chromatography using antibodies specific for the PRO polypeptide of interest. In general, an immunoaffinity column is constructed by covalently coupling the anti-PRO polypeptide antibody to an activated chromatographic resin.

Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway, N.J.). 10 Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A. Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated SEPHAROSE™ (Pharmacia LKB Biotechnology). The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.

15 Such an immunoaffinity column is utilized in the purification of PRO polypeptide by preparing a fraction from cells containing PRO polypeptide in a soluble form. This preparation is derived by solubilization of the whole cell or of a subcellular fraction obtained via differential centrifugation by the addition of detergent or by other methods well known in the art. Alternatively, soluble PRO polypeptide containing a signal sequence may be secreted in useful quantity into the medium in which the cells are grown.

20 A soluble PRO polypeptide-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of PRO polypeptide (*e.g.*, high ionic strength buffers in the presence of detergent). Then, the column is eluted under conditions that disrupt antibody/PRO polypeptide binding (*e.g.*, a low pH buffer such as approximately pH 2-3, or a high concentration of a chaotrope such as urea or thiocyanate ion), and PRO polypeptide is collected.

25

**EXAMPLE 12: Drug Screening**

This invention is particularly useful for screening compounds by using PRO polypeptides or binding fragment thereof in any of a variety of drug screening techniques. The PRO polypeptide or fragment employed in such a test may either be free in solution, affixed to a solid support, borne on a cell surface, or located 30 intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the PRO polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, the formation of complexes between PRO polypeptide or a fragment and the agent being tested. Alternatively, one can examine the diminution in complex 35 formation between the PRO polypeptide and its target cell or target receptors caused by the agent being tested.

Thus, the present invention provides methods of screening for drugs or any other agents which can affect a PRO polypeptide-associated disease or disorder. These methods comprise contacting such an agent with

an PRO polypeptide or fragment thereof and assaying (I) for the presence of a complex between the agent and the PRO polypeptide or fragment, or (ii) for the presence of a complex between the PRO polypeptide or fragment and the cell, by methods well known in the art. In such competitive binding assays, the PRO polypeptide or fragment is typically labeled. After suitable incubation, free PRO polypeptide or fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to PRO polypeptide or to interfere with the PRO polypeptide/cell complex.

5 Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to a polypeptide and is described in detail in WO 84/03564, published on September 13, 1984. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. As applied to a PRO polypeptide, the peptide test compounds are reacted 10 with PRO polypeptide and washed. Bound PRO polypeptide is detected by methods well known in the art. Purified PRO polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies can be used to capture the peptide and immobilize it on the solid support.

15 This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding PRO polypeptide specifically compete with a test compound for binding to PRO polypeptide or fragments thereof. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PRO polypeptide.

#### EXAMPLE 13: Rational Drug Design

20 The goal of rational drug design is to produce structural analogs of biologically active polypeptide of interest (*i.e.*, a PRO polypeptide) or of small molecules with which they interact, *e.g.*, agonists, antagonists, or inhibitors. Any of these examples can be used to fashion drugs which are more active or stable forms of the PRO polypeptide or which enhance or interfere with the function of the PRO polypeptide *in vivo* (*c.f.*, Hodgson, Bio/Technology, 9: 19-21 (1991)).

25 In one approach, the three-dimensional structure of the PRO polypeptide, or of an PRO polypeptide-inhibitor complex, is determined by x-ray crystallography, by computer modeling or, most typically, by a combination of the two approaches. Both the shape and charges of the PRO polypeptide must be ascertained to elucidate the structure and to determine active site(s) of the molecule. Less often, useful information regarding the structure of the PRO polypeptide may be gained by modeling based on the structure of homologous proteins. 30 In both cases, relevant structural information is used to design analogous PRO polypeptide-like molecules or to identify efficient inhibitors. Useful examples of rational drug design may include molecules which have improved activity or stability as shown by Braxton and Wells, Biochemistry, 31:7796-7801 (1992) or which act as inhibitors, agonists, or antagonists of native peptides as shown by Athauda *et al.*, J. Biochem., 113:742-746 (1993).

35 It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and then to solve its crystal structure. This approach, in principle, yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic

antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids would be expected to be an analog of the original receptor. The anti-id could then be used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides would then act as the pharmacore.

By virtue of the present invention, sufficient amounts of the PRO polypeptide may be made available  
5 to perform such analytical studies as X-ray crystallography. In addition, knowledge of the PRO polypeptide amino acid sequence provided herein will provide guidance to those employing computer modeling techniques in place of or in addition to x-ray crystallography.

EXAMPLE 14: Pericyte c-Fos Induction (Assay 93)

10 This assay shows that certain polypeptides of the invention act to induce the expression of c-fos in pericyte cells and, therefore, are useful not only as diagnostic markers for particular types of pericyte-associated tumors but also for giving rise to antagonists which would be expected to be useful for the therapeutic treatment of pericyte-associated tumors. Induction of c-fos expression in pericytes is also indicative of the induction of angiogenesis and, as such, PRO polypeptides capable of inducing the expression of c-fos would be expected to  
15 be useful for the treatment of conditions where induced angiogenesis would be beneficial including, for example, wound healing, and the like. Specifically, on day 1, pericytes are received from VEC Technologies and all but 5 ml of media is removed from flask. On day 2, the pericytes are trypsinized, washed, spun and then plated onto 96 well plates. On day 7, the media is removed and the pericytes are treated with 100  $\mu$ l of PRO polypeptide test samples and controls (positive control = DME +5% serum +/- PDGF at 500 ng/ml; negative control = protein 32). Replicates are averaged and SD/CV are determined. Fold increase over Protein 32 (buffer control)  
20 value indicated by chemiluminescence units (RLU) luminometer reading versus frequency is plotted on a histogram. Two-fold above Protein 32 value is considered positive for the assay. ASY Matrix: Growth media = low glucose DMEM = 20% FBS + 1X pen strep + 1X fungizone. Assay Media = low glucose DMEM + 5% FBS.  
25 The following polypeptides tested positive in this assay: PRO1347 and PRO1340.

EXAMPLE 15: Ability of PRO Polypeptides to Stimulate the Release of Proteoglycans from Cartilage (Assay 97)

The ability of various PRO polypeptides to stimulate the release of proteoglycans from cartilage tissue  
30 was tested as follows.

The metacarpophalangeal joint of 4-6 month old pigs was aseptically dissected, and articular cartilage was removed by free hand slicing being careful to avoid the underlying bone. The cartilage was minced and cultured in bulk for 24 hours in a humidified atmosphere of 95% air, 5% CO<sub>2</sub> in serum free (SF) media (DME/F12 1:1) with 0.1% BSA and 100U/ml penicillin and 100 $\mu$ g/ml streptomycin. After washing three times, approximately 100 mg of articular cartilage was aliquoted into micronics tubes and incubated for an additional 24 hours in the above SF media. PRO polypeptides were then added at 1% either alone or in combination with 18 ng/ml interleukin-1 $\alpha$ , a known stimulator of proteoglycan release from cartilage tissue.

The supernatant was then harvested and assayed for the amount of proteoglycans using the 1,9-dimethyl-methylene blue (DMB) colorimetric assay (Farndale and Buttle, *Biochem. Biophys. Acta* 883:173-177 (1985)). A positive result in this assay indicates that the test polypeptide will find use, for example, in the treatment of sports-related joint problems, articular cartilage defects, osteoarthritis or rheumatoid arthritis.

When various PRO polypeptides were tested in the above assay, the polypeptides demonstrated a marked ability to stimulate release of proteoglycans from cartilage tissue both basally and after stimulation with interleukin-1 $\alpha$  and at 24 and 72 hours after treatment, thereby indicating that these PRO polypeptides are useful for stimulating proteoglycan release from cartilage tissue. As such, these PRO polypeptides are useful for the treatment of sports-related joint problems, articular cartilage defects, osteoarthritis or rheumatoid arthritis. The polypeptides testing positive in this assay are: PRO1565, PRO1693, PRO1801 and PRO10096.

10

**EXAMPLE 16: Detection of Polypeptides That Affect Glucose or FFA Uptake in Skeletal Muscle (Assay 106)**

This assay is designed to determine whether PRO polypeptides show the ability to affect glucose or FFA uptake by skeletal muscle cells. PRO polypeptides testing positive in this assay would be expected to be useful for the therapeutic treatment of disorders where either the stimulation or inhibition of glucose uptake by skeletal muscle would be beneficial including, for example, diabetes or hyper- or hypo-insulinemia.

In a 96 well format, PRO polypeptides to be assayed are added to primary rat differentiated skeletal muscle, and allowed to incubate overnight. Then fresh media with the PRO polypeptide and +/- insulin are added to the wells. The sample media is then monitored to determine glucose and FFA uptake by the skeletal muscle cells. The insulin will stimulate glucose and FFA uptake by the skeletal muscle, and insulin in media without the PRO polypeptide is used as a positive control, and a limit for scoring. As the PRO polypeptide being tested may either stimulate or inhibit glucose and FFA uptake, results are scored as positive in the assay if greater than 1.5 times or less than 0.5 times the insulin control.

The following PRO polypeptides tested positive as either stimulators or inhibitors of glucose and/or FFA uptake in this assay: PRO4405.

25

**EXAMPLE 17: Identification of PRO Polypeptides That Stimulate TNF- $\alpha$  Release In Human Blood (Assay 128)**

This assay shows that certain PRO polypeptides of the present invention act to stimulate the release of TNF- $\alpha$  in human blood. PRO polypeptides testing positive in this assay are useful for, among other things, research purposes where stimulation of the release of TNF- $\alpha$  would be desired and for the therapeutic treatment of conditions wherein enhanced TNF- $\alpha$  release would be beneficial. Specifically, 200  $\mu$ l of human blood supplemented with 50mM Hepes buffer (pH 7.2) is aliquotted per well in a 96 well test plate. To each well is then added 300 $\mu$ l of either the test PRO polypeptide in 50 mM Hepes buffer (at various concentrations) or 50 mM Hepes buffer alone (negative control) and the plates are incubated at 37°C for 6 hours. The samples are then centrifuged and 50 $\mu$ l of plasma is collected from each well and tested for the presence of TNF- $\alpha$  by ELISA assay. A positive in the assay is a higher amount of TNF- $\alpha$  in the PRO polypeptide treated samples as compared to the negative control samples.

The following PRO polypeptides tested positive in this assay: PRO263, PRO295, PRO1282, PRO1063, PRO1356, PRO3543, and PRO5990.

**EXAMPLE 18: Tumor Versus Normal Differential Tissue Expression Distribution**

Oligonucleotide probes were constructed from some of the PRO polypeptide-encoding nucleotide sequences shown in the accompanying figures for use in quantitative PCR amplification reactions. The oligonucleotide probes were chosen so as to give an approximately 200-600 base pair amplified fragment from the 3' end of its associated template in a standard PCR reaction. The oligonucleotide probes were employed in standard quantitative PCR amplification reactions with cDNA libraries isolated from different human tumor and normal human tissue samples and analyzed by agarose gel electrophoresis so as to obtain a quantitative determination of the level of expression of the PRO polypeptide-encoding nucleic acid in the various tumor and normal tissues tested.  $\beta$ -actin was used as a control to assure that equivalent amounts of nucleic acid was used in each reaction. Identification of the differential expression of the PRO polypeptide-encoding nucleic acid in one or more tumor tissues as compared to one or more normal tissues of the same tissue type renders the molecule useful diagnostically for the determination of the presence or absence of tumor in a subject suspected of possessing a tumor as well as therapeutically as a target for the treatment of a tumor in a subject possessing such a tumor. These assays provided the following results.

	<u>Molecule</u>	<u>is more highly expressed in:</u>	<u>as compared to:</u>
20	DNA26843-1389	normal lung rectum tumor	lung tumor normal rectum
25	DNA30867-1335	normal kidney	kidney tumor
30	DNA40621-1440	normal lung	lung tumor
35	DNA40625-1189	normal lung	lung tumor
40	DNA45409-2511	melanoma tumor	normal skin
45	DNA56406-1704	kidney tumor normal skin	normal kidney melanoma tumor
	DNA56410-1414	normal stomach	stomach tumor
	DNA56436-1448	normal skin	melanoma tumor
	DNA56855-1447	normal esophagus rectum tumor	esophageal tumor normal rectum
	DNA56860-1510	normal kidney rectum tumor	kidney tumor normal rectum
	DNA56862-1343	kidney tumor normal lung	normal kidney lung tumor

	<u>Molecule</u>	<u>is more highly expressed in:</u>	<u>as compared to:</u>
	DNA56868-1478	normal stomach normal lung	stomach tumor lung tumor
5	DNA56869-1545	normal esophagus normal skin	esophageal tumor melanoma tumor
	DNA57704-1452	normal stomach rectum tumor	stomach tumor normal rectum
10	DNA58723-1588	normal stomach kidney tumor normal skin	stomach tumor normal kidney melanoma tumor
15	DNA57827-1493	normal stomach normal skin	stomach tumor melanoma tumor
	DNA58737-1473	esophageal tumor normal stomach	normal esophagus stomach tumor
20	DNA58846-1409	lung tumor	normal lung
	DNA58850-1495	esophageal tumor kidney tumor	normal esophagus normal kidney
25	DNA58855-1422	normal stomach rectum tumor	stomach tumor normal rectum
	DNA59211-1450	normal kidney	kidney tumor
30	DNA59212-1627	normal skin	melanoma tumor
	DNA59213-1487	normal stomach normal skin	stomach tumor melanoma tumor
35	DNA59605-1418	melanoma tumor	normal skin
	DNA59609-1470	esophageal tumor	normal esophagus
40	DNA59610-1556	esophageal tumor lung tumor normal skin	normal esophagus normal lung melanoma tumor
	DNA59837-2545	normal skin	melanoma tumor
45	DNA59844-2542	normal skin esophageal tumor	melanoma tumor normal esophagus
	DNA59854-1459	normal esophagus stomach tumor normal lung	esophageal tumor normal stomach lung tumor
50	DNA60625-1507	normal lung	lung tumor
	DNA60629-1481	normal esophagus normal rectum	esophageal tumor rectum tumor

	<u>Molecule</u>	<u>is more highly expressed in:</u>	<u>as compared to:</u>
	DNA61755-1554	normal stomach kidney tumor	stomach tumor normal kidney
5	DNA62812-1594	normal stomach normal lung normal rectum normal skin	stomach tumor lung tumor rectum tumor melanoma tumor
10	DNA62815-1576	esophageal tumor	normal esophagus
	DNA64881-1602	normal stomach normal lung	stomach tumor lung tumor
15	DNA64902-1667	esophageal tumor kidney tumor	normal esophagus normal kidney
	DNA65403-1565	normal esophagus	esophageal tumor
20	DNA66308-1537	normal lung	lung tumor
	DNA66519-1535	kidney tumor	normal kidney
25	DNA66521-1583	normal esophagus normal stomach normal lung normal rectum normal skin	esophageal tumor stomach tumor lung tumor rectum tumor melanoma tumor
30	DNA66658-1584	normal lung melanoma tumor	lung tumor normal skin
	DNA66660-1585	lung tumor	normal lung
35	DNA66674-1599	kidney tumor normal lung	normal kidney lung tumor
	DNA68862-2546	melanoma tumor	normal skin
40	DNA68866-1644	normal stomach	stomach tumor
	DNA68871-1638	lung tumor normal skin	normal lung melanoma tumor
45	DNA68880-1676	normal lung normal skin	lung tumor melanoma tumor
	DNA68883-1691	esophageal tumor	normal esophagus
50	DNA68885-1678	lung tumor	normal lung
	DNA71277-1636	normal stomach	stomach tumor
	DNA73734-1680	normal lung	lung tumor

	<u>Molecule</u>	<u>is more highly expressed in:</u>	<u>as compared to:</u>
	DNA73735-1681	esophageal tumor normal kidney lung tumor normal skin	normal esophagus kidney tumor normal lung melanoma tumor
5	DNA76393-1664	esophageal tumor stomach tumor lung tumor rectum tumor	normal esophagus normal stomach normal lung normal rectum
10	DNA77568-1626	normal stomach lung tumor	stomach tumor normal lung
15	DNA77626-1705	normal rectum	rectum tumor
	DNA81754-2532	normal skin	melanoma tumor
20	DNA81757-2512	esophageal tumor normal stomach melanoma tumor	normal esophagus stomach tumor normal skin
	DNA82302-2529	normal stomach normal lung	stomach tumor lung tumor
25	DNA82340-2530	normal esophagus	esophageal tumor
	DNA85066-2534	lung tumor normal skin	normal lung melanoma tumor
30	DNA87991-2540	esophageal tumor	normal esophagus
	DNA92238-2539	normal skin	melanoma tumor
35	DNA96787-2534	normal kidney	kidney tumor

EXAMPLE 19: Identification of Receptor/Ligand Interactions

In this assay, various PRO polypeptides are tested for ability to bind to a panel of potential receptor or ligand molecules for the purpose of identifying receptor/ligand interactions. The identification of a ligand for a known receptor, a receptor for a known ligand or a novel receptor/ligand pair is useful for a variety of indications including, for example, targeting bioactive molecules (linked to the ligand or receptor) to a cell known to express the receptor or ligand, use of the receptor or ligand as a reagent to detect the presence of the ligand or receptor in a composition suspected of containing the same, wherein the composition may comprise cells suspected of expressing the ligand or receptor, modulating the growth of or another biological or immunological activity of a cell known to express or respond to the receptor or ligand, modulating the immune response of cells or toward cells that express the receptor or ligand, allowing the preparation of agonists, antagonists and/or antibodies directed against the receptor or ligand which will modulate the growth of or a biological or immunological activity of a cell expressing the receptor or ligand, and various other indications which will be readily apparent to the ordinarily skilled artisan.

The assay is performed as follows. A PRO polypeptide of the present invention suspected of being a ligand for a receptor is expressed as a fusion protein containing the Fc domain of human IgG (an immunoadhesin). Receptor-ligand binding is detected by allowing interaction of the immunoadhesin polypeptide with cells (e.g. Cos cells) expressing candidate PRO polypeptide receptors and visualization of bound immunoadhesin with fluorescent reagents directed toward the Fc fusion domain and examination by microscope.

5 Cells expressing candidate receptors are produced by transient transfection, in parallel, of defined subsets of a library of cDNA expression vectors encoding PRO polypeptides that may function as receptor molecules. Cells are then incubated for 1 hour in the presence of the PRO polypeptide immunoadhesin being tested for possible receptor binding. The cells are then washed and fixed with paraformaldehyde. The cells are then incubated with fluorescent conjugated antibody directed against the Fc portion of the PRO polypeptide immunoadhesin (e.g.

10 FITC conjugated goat anti-human-Fc antibody). The cells are then washed again and examined by microscope. A positive interaction is judged by the presence of fluorescent labeling of cells transfected with cDNA encoding a particular PRO polypeptide receptor or pool of receptors and an absence of similar fluorescent labeling of similarly prepared cells that have been transfected with other cDNA or pools of cDNA. If a defined pool of cDNA expression vectors is judged to be positive for interaction with a PRO polypeptide immunoadhesin, the

15 individual cDNA species that comprise the pool are tested individually (the pool is "broken down") to determine the specific cDNA that encodes a receptor able to interact with the PRO polypeptide immunoadhesin.

In another embodiment of this assay, an epitope-tagged potential ligand PRO polypeptide (e.g. 8 histidine "His" tag) is allowed to interact with a panel of potential receptor PRO polypeptide molecules that have been expressed as fusions with the Fc domain of human IgG (immunoadhesins). Following a 1 hour co-incubation with the epitope tagged PRO polypeptide, the candidate receptors are each immunoprecipitated with protein A beads and the beads are washed. Potential ligand interaction is determined by western blot analysis of the immunoprecipitated complexes with antibody directed towards the epitope tag. An interaction is judged to occur if a band of the anticipated molecular weight of the epitope tagged protein is observed in the western blot analysis with a candidate receptor, but is not observed to occur with the other members of the panel of potential receptors.

Using these assays, the following receptor/ligand interactions have been herein identified:

(1) PRO10272 binds to PRO5801.

(2) PRO20110 binds to the human IL-17 receptor (Yao et al., *Cytokine* 9(11):794-800 (1997); also herein designated as PRO1) and to PRO20040.

30 (3) PRO10096 binds to PRO20233.

(4) PRO19670 binds to PRO1890.

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the construct deposited, since the deposited embodiment is intended as a single illustration of certain aspects of the invention and any constructs 35 that are functionally equivalent are within the scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode thereof, nor is it to be construed as limiting the scope of the

claims to the specific illustrations that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

WHAT IS CLAIMED IS:

1. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16),  
5 Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54),  
10 Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92),  
15 Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 20 25 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166) and Figure 168 (SEQ ID NO:168).

2. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence selected from the group consisting of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39), Figure 41 (SEQ ID NO:41), Figure 43 (SEQ ID NO:43), Figure 45 (SEQ ID NO:45), Figure 47 (SEQ ID NO:47), Figure 49 (SEQ ID NO:49), Figure 51 (SEQ ID NO:51), Figure 53 (SEQ ID NO:53), Figure 55 (SEQ ID NO:55), Figure 57 (SEQ ID NO:57), Figure 59 (SEQ ID NO:59), Figure 61 (SEQ ID NO:61), Figure 63 (SEQ ID NO:63), Figure 65 (SEQ ID NO:65), Figure 67 (SEQ ID NO:67), Figure 69 (SEQ ID NO:69), Figure 71 (SEQ ID NO:71), Figure 30 35

73 (SEQ ID NO:73), Figure 75 (SEQ ID NO:75), Figure 77 (SEQ ID NO:77), Figure 79 (SEQ ID NO:79),  
Figure 81 (SEQ ID NO:81), Figure 83 (SEQ ID NO:83), Figure 85 (SEQ ID NO:85), Figure 87 (SEQ ID  
NO:87), Figure 89 (SEQ ID NO:89), Figure 91 (SEQ ID NO:91), Figure 93 (SEQ ID NO:93), Figure 95 (SEQ  
ID NO:95), Figure 97 (SEQ ID NO:97), Figure 99 (SEQ ID NO:99), Figure 101 (SEQ ID NO:101), Figure  
103 (SEQ ID NO:103), Figure 105 (SEQ ID NO:105), Figure 107 (SEQ ID NO:107), Figure 109 (SEQ ID  
NO:109), Figure 111 (SEQ ID NO:111), Figure 113 (SEQ ID NO:113), Figure 115 (SEQ ID NO:115), Figure  
117 (SEQ ID NO:117), Figure 119 (SEQ ID NO:119), Figure 121 (SEQ ID NO:121), Figure 123 (SEQ ID  
NO:123), Figure 125 (SEQ ID NO:125), Figure 127 (SEQ ID NO:127), Figure 129 (SEQ ID NO:129), Figure  
131 (SEQ ID NO:131), Figure 133 (SEQ ID NO:133), Figure 135 (SEQ ID NO:135), Figure 137 (SEQ ID  
NO:137), Figure 139 (SEQ ID NO:1390), Figure 141 (SEQ ID NO:141), Figure 143 (SEQ ID NO:143), Figure  
145 (SEQ ID NO:145), Figure 147 (SEQ ID NO:147), Figure 149 (SEQ ID NO:149), Figure 151 (SEQ ID  
NO:151), Figure 153 (SEQ ID NO:153), Figure 155 (SEQ ID NO:155), Figure 157 (SEQ ID NO:157), Figure  
159 (SEQ ID NO:159), Figure 161 (SEQ ID NO:161), Figure 163 (SEQ ID NO:163), Figure 165 (SEQ ID  
NO:165) and Figure 167 (SEQ ID NO:167).

15           3.        Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence  
selected from the group consisting of the full-length coding sequence of the nucleotide sequence shown in Figure  
1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9  
(SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure  
17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23),  
20          Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID  
NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ  
ID NO:39), Figure 41 (SEQ ID NO:41), Figure 43 (SEQ ID NO:43), Figure 45 (SEQ ID NO:45), Figure 47  
(SEQ ID NO:47), Figure 49 (SEQ ID NO:49), Figure 51 (SEQ ID NO:51), Figure 53 (SEQ ID NO:53), Figure  
55 (SEQ ID NO:55), Figure 57 (SEQ ID NO:57), Figure 59 (SEQ ID NO:59), Figure 61 (SEQ ID NO:61),  
25          Figure 63 (SEQ ID NO:63), Figure 65 (SEQ ID NO:65), Figure 67 (SEQ ID NO:67), Figure 69 (SEQ ID  
NO:69), Figure 71 (SEQ ID NO:71), Figure 73 (SEQ ID NO:73), Figure 75 (SEQ ID NO:75), Figure 77 (SEQ  
ID NO:77), Figure 79 (SEQ ID NO:79), Figure 81 (SEQ ID NO:81), Figure 83 (SEQ ID NO:83), Figure 85  
(SEQ ID NO:85), Figure 87 (SEQ ID NO:87), Figure 89 (SEQ ID NO:89), Figure 91 (SEQ ID NO:91), Figure  
93 (SEQ ID NO:93), Figure 95 (SEQ ID NO:95), Figure 97 (SEQ ID NO:97), Figure 99 (SEQ ID NO:99),  
30          Figure 101 (SEQ ID NO:101), Figure 103 (SEQ ID NO:103), Figure 105 (SEQ ID NO:105), Figure 107 (SEQ  
ID NO:107), Figure 109 (SEQ ID NO:109), Figure 111 (SEQ ID NO:111), Figure 113 (SEQ ID NO:113),  
Figure 115 (SEQ ID NO:115), Figure 117 (SEQ ID NO:117), Figure 119 (SEQ ID NO:119), Figure 121 (SEQ  
ID NO:121), Figure 123 (SEQ ID NO:123), Figure 125 (SEQ ID NO:125), Figure 127 (SEQ ID NO:127),  
Figure 129 (SEQ ID NO:129), Figure 131 (SEQ ID NO:131), Figure 133 (SEQ ID NO:133), Figure 135 (SEQ  
ID NO:135), Figure 137 (SEQ ID NO:137), Figure 139 (SEQ ID NO:1390), Figure 141 (SEQ ID NO:141),  
35          Figure 143 (SEQ ID NO:143), Figure 145 (SEQ ID NO:145), Figure 147 (SEQ ID NO:147), Figure 149 (SEQ  
ID NO:149), Figure 151 (SEQ ID NO:151), Figure 153 (SEQ ID NO:153), Figure 155 (SEQ ID NO:155),

Figure 157 (SEQ ID NO:157), Figure 159 (SEQ ID NO:159), Figure 161 (SEQ ID NO:161), Figure 163 (SEQ ID NO:163), Figure 165 (SEQ ID NO:165) and Figure 167 (SEQ ID NO:167).

4. Isolated nucleic acid having at least 80% nucleic acid sequence identity to the full-length coding sequence of the DNA deposited under any ATCC accession number shown in Table 7.
5. A vector comprising the nucleic acid of Claim 1.
6. The vector of Claim 5 operably linked to control sequences recognized by a host cell transformed with the vector.
10. A host cell comprising the vector of Claim 5.
8. The host cell of Claim 7, wherein said cell is a CHO cell.
15. 9. The host cell of Claim 7, wherein said cell is an *E. coli*.
10. The host cell of Claim 7, wherein said cell is a yeast cell.
11. A process for producing a PRO polypeptides comprising culturing the host cell of Claim 7 under conditions suitable for expression of said PRO polypeptide and recovering said PRO polypeptide from the cell culture.
12. An isolated polypeptide having at least 80% amino acid sequence identity to an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102

(SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166) and Figure 168 (SEQ ID NO:168).

10

13. An isolated polypeptide having at least 80% amino acid sequence identity to an amino acid sequence encoded by the full-length coding sequence of the DNA deposited under any ATCC accession number shown in Table 7.

15

14. A chimeric molecule comprising a polypeptide according to Claim 12 fused to a heterologous amino acid sequence.

15. The chimeric molecule of Claim 14, wherein said heterologous amino acid sequence is an epitope tag sequence.

20

16. The chimeric molecule of Claim 14, wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.

25

17. An antibody which specifically binds to a polypeptide according to Claim 12.

.

18. The antibody of Claim 17, wherein said antibody is a monoclonal antibody, a humanized antibody or a single-chain antibody.

30

19. Isolated nucleic acid having at least 80% nucleic acid sequence identity to:

(a) a nucleotide sequence encoding the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure

58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64),  
Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID  
NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ  
ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88  
(SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure  
5 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102),  
Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ  
ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116),  
Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ  
ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130),  
10 Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ  
ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144),  
Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ  
ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158),  
Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ  
ID NO:166) or Figure 168 (SEQ ID NO:168), lacking its associated signal peptide;

(b) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2  
(SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ  
ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18  
(SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure  
20 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32),  
Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID  
NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ  
ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56  
(SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure  
25 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70),  
Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID  
NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ  
ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94  
(SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100),  
30 Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ  
ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114),  
Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ  
ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128),  
Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ  
ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142),  
35 Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ  
ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156),

Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166) or Figure 168 (SEQ ID NO:168), with its associated signal peptide; or

- (c) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156),  
25 Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166) or Figure 168 (SEQ ID NO:168), lacking its associated signal peptide.

20. An isolated polypeptide having at least 80% amino acid sequence identity to:  
30 (a) an amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58

(SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96  
5 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130),  
10 Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166) or Figure 168 (SEQ ID NO:168), lacking its associated signal peptide;  
15 (b) an amino acid sequence of an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26  
20 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64  
25 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166) or Figure 168 (SEQ ID NO:168), lacking its associated signal peptide;

158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166) or Figure 168 (SEQ ID NO:168), with its associated signal peptide; or

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166) or Figure 168 (SEQ ID NO:168), lacking its associated signal peptide.

21. A method of detecting a polypeptide designated as A, B, C or D in a sample suspected of containing an A, B, C or D polypeptide, said method comprising contacting said sample with a polypeptide designated herein as E, F, G, H or I and determining the formation of a A/E, B/F, B/G, C/H or D/I polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of an A, B, C or D polypeptide in said sample and wherein A is a PRO10272 polypeptide, B is a PRO20110 polypeptide, C is a PRO10096 polypeptide, D is a PRO19670 polypeptide, E is a PRO5801 polypeptide, F is a PRO1 polypeptide, G is a PRO20040 polypeptide, H is a PRO20233 polypeptide and I is a PRO1890 polypeptide.

35

22. The method according to Claim 21, wherein said sample comprises cells suspected of expressing said A, B, C or D polypeptide.

23. The method according to Claim 21, wherein said E, F, G, H or I polypeptide is labeled with a detectable label.

24. The method according to Claim 21, wherein said E, F, G, H or I polypeptide is attached to a solid support.

5

25. A method of detecting a polypeptide designated as E, F, G, H or I in a sample suspected of containing an E, F, G, H or I polypeptide, said method comprising contacting said sample with a polypeptide designated herein as A, B, C or D and determining the formation of a A/E, B/F, B/G, C/H or D/I polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of an A, B, C or D polypeptide in said sample and wherein A is a PRO10272 polypeptide, B is a PRO20110 polypeptide, C is a PRO10096 polypeptide, D is a PRO19670 polypeptide, E is a PRO5801 polypeptide, F is a PRO1 polypeptide, G is a PRO20040 polypeptide, H is a PRO20233 polypeptide and I is a PRO1890 polypeptide.

10 26. The method according to Claim 25, wherein said sample comprises cells suspected of expressing said E, F, G, H or I polypeptide.

15 27. The method according to Claim 25, wherein said A, B, C or D polypeptide is labeled with a detectable label.

20 28. The method according to Claim 25, wherein said A, B, C or D polypeptide is attached to a solid support.

25 29. A method of linking a bioactive molecule to a cell expressing a polypeptide designated as A, B, C or D, said method comprising contacting said cell with a polypeptide designated as E, F, G, H or I that is bound to said bioactive molecule and allowing said A, B, C or D and said E, F, G, H or I polypeptides to bind to one another, thereby linking said bioactive molecules to said cell, wherein A is a PRO10272 polypeptide, B is a PRO20110 polypeptide, C is a PRO10096 polypeptide, D is a PRO19670 polypeptide, E is a PRO5801 polypeptide, F is a PRO1 polypeptide, G is a PRO20040 polypeptide, H is a PRO20233 polypeptide and I is a PRO1890 polypeptide.

30

30. The method according to Claim 29, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

35 31. The method according to Claim 29, wherein said bioactive molecule causes the death of said cell.

32. A method of linking a bioactive molecule to a cell expressing a polypeptide designated as E, F, G, H or I, said method comprising contacting said cell with a polypeptide designated as A, B, C or D that is bound to said bioactive molecule and allowing said A, B, C or D and said E, F, G, H or I polypeptides to bind to one another, thereby linking said bioactive molecules to said cell, wherein A is a PRO10272 polypeptide, B is a PRO20110 polypeptide, C is a PRO10096 polypeptide, D is a PRO19670 polypeptide, E is a PRO5801 polypeptide, F is a PRO1 polypeptide, G is a PRO20040 polypeptide, H is a PRO20233 polypeptide and I is a PRO1890 polypeptide.

5  
33. The method according to Claim 32, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

10

34. The method according to Claim 32, wherein said bioactive molecule causes the death of said cell.

15  
35. A method of modulating at least one biological activity of a cell expressing a polypeptide designated as A, B, C or D, said method comprising contacting said cell with a polypeptide designated as E, F, G, H or I or an anti-A, B, C or D polypeptide antibody, whereby said E, F, G, H or I polypeptide or anti-A, B, C or D polypeptide antibody binds to said A, B, C or D polypeptide, thereby modulating at least one biological activity of said cell, wherein A is a PRO10272 polypeptide, B is a PRO20110 polypeptide, C is a PRO10096 polypeptide, D is a PRO19670 polypeptide, E is a PRO5801 polypeptide, F is a PRO1 polypeptide, G is a PRO20040 polypeptide, H is a PRO20233 polypeptide and I is a PRO1890 polypeptide.

20

36. The method according to Claim 35, wherein said cell is killed.

25

37. A method of modulating at least one biological activity of a cell expressing a polypeptide designated as E, F, G, H or I, said method comprising contacting said cell with a polypeptide designated as A, B, C or D or an anti-E, F, G, H or I polypeptide antibody, whereby said A, B, C or D polypeptide or anti-E, F, G, H or I polypeptide antibody binds to said E, F, G, H or I polypeptide, thereby modulating at least one biological activity of said cell, wherein A is a PRO10272 polypeptide, B is a PRO20110 polypeptide, C is a PRO10096 polypeptide, D is a PRO19670 polypeptide, E is a PRO5801 polypeptide, F is a PRO1 polypeptide, G is a PRO20040 polypeptide, H is a PRO20233 polypeptide and I is a PRO1890 polypeptide.

30

38. The method according to Claim 37, wherein said cell is killed.

## **FIGURE 1**

GGGGCTCGCGCCAGCGGCAGCGCTAGTCGGTCTGGTAAGGATTACAAAAGGTGCAGGTA  
TGAGCAGGTCTGAAGACTAACATTTGTGAAGTTGTAAACAGAAAACCTGTTAGAA**ATGTGG**  
TGGTTTCAGCAAGGCCTCAGTTCTTCAGCCCTGTAATTGGACATCTGCTGCTTTC  
ATATTTCATACATTACTGCAGTAACACTCCACCATATAGACCCGGCTTACCTTATATCAGT  
GACACTGGTACAGTAGCTCCAGAAAAATGCTTATTGGGGCAATGCTAAATATTGCGGCAGTT  
TTATGCATTGCTACCATTATGTTGTTATAAGCAAGTTCATGCTCTGAGTCCTGAAGAGAAC  
GTTATCATCAAATTAAACAAGGCTGGCCTTGTACTTGGAAACTGAGTTGTTAGGACTTCT  
ATTGTGGCAAACCTCCAGAAAACAACCCCTTTGCTGCACATGTAAGTGGAGCTGTGCTTACC  
TTGGTATGGGCTCATTATATATGTTGTTCAGACCATCCTTCTACCAAATGCAGGCCAAA  
ATCCATGGCAAACAAGTCTTCTGGATCAGACTGTTGTTATCTGGTGTGGAGTAAGTGCA  
CTTAGCATGCTGACTTGCTCATCAGTTGCACAGTGGCAATTGGGACTGATTAGAACAG  
AAACTCCATTGGAACCCCGAGGACAAAGTTATGTGCTTCACATGATCACTACTGCAGCAGAA  
TGGTCTATGTCATTTCCTCTTGGTTTTCTGACTTACATTGCTGATTTCAGAAAATT  
TCTTACGGGTGGAAGCCAATTACATGGATTAACCCCTATGACACTGCACCTTGCCTTATT  
AACAAATGAACGAACACGGCTACTTCCAGAGATATT**TGAT**GAAAGGATAAAATATTCTGTAA  
TGATTATGATTCTCAGGGATTGGGAAAGGTTACAGAAGTTGCTTATTCTCTGAAATT  
TCAACCACCTAATCAAGGCTGACAGTAACACTGATGAATGCTGATAATCAGGAAACATGAAAG  
AAGCCATTGATAGATTATTCTAAAGGATATCATCAAGAAGACTATTAAAACACCTATGCCT  
ATACTTTTATCTCAGAAAATAAAGTCAAAAGACTATG

2/168

## **FIGURE 2**

<subunit 1 of 1, 266 aa, 1 stop

<MW: 29766, pi: 8.39, NX(S/T): 0

MWWFQQGLSFLPSALVIWTSAAFIFSYITAVTLHHIDPALPYISDTGTVAPEKCLFGAMLNIA  
AVLCIATIYVRYKQVHALSPEENVIKLNKAGLVLGILSCLGLSIVANFQKTLFAAHVSGAV  
LTFGMGSLYMFVQTILSYQMOPKIHGKQVFIRLLLVIWCVSALSMLTCSVLHSGNFDTDL  
EQKLHWNPEDKGYVLHMITTAAEWSMSFSFFGFFLTYIRDFQKISLRVEANLHGLTLYDTAPC  
PINNERTRLLSRDI

**Important features:**

**Type II transmembrane domain:**

amino acids 13-33

**Other Transmembrane domains:**

amino acids 54-73, 94-113, 160-180, 122-141

**N-myristoylation sites.**

amino acids 57-63, 95-101, 99-105, 124-130, 183-189

## FIGURE 3

CGGACGCGTGGCGGACGCGTGGGGAGAGCCGCAGTCGGCTGCAGCACCTGGAGAAGGC  
AGACCGTGTGAGGGGGCCTGTGGCCCCAGCGTGCTGTGGCCTCGGGAGTGGAAAGTGGAGGC  
AGGAGCCTCCTAACACTTCGCCATGAGTTCCATCGACTCCAGCATCATGATTACCTCCC  
AGATACTATTTTGATTGGCTTGGCTTCATGCGCCAATTGTTAAAGACTATGAGA  
TACGTCAGTATGTTGTACAGGTGATCTCTCCGTGACGTTGCATTTCTGCACCATGTTG  
AGCTCATCATCTTGAAATCTTAGGAGTATTGAATAGCAGCTCCGTTATTTCACTGGAAAA  
TGAACCTGTGTGAATTCTGCTGATCCTGGTTTCATGGTGCCTTTACATTGGCTATTTA  
TTGTGAGCAATATCCGACTACTGCATAAACAAACGACTGCTTTTCCTGTCCTATGGCTGA  
CCTTATGTATTCCTGGAAACTAGGAGATCCCTTCCATTCTCAGCCAAAACATGGGA  
TCTTATCCATAGAACAGCTCATCAGCCGGTTGGTGTGATTGGAGTGACTCTCATGGCTTTC  
TTTCTGGATTGGTGTCAACTGCCACACTACATGTCTACTTCCTCAGGAATGTGA  
CTGACACGGATATTCTAGCCCTGGAACGGCGACTGCTGCAAACCATGGATATGATCATAAGCA  
AAAAGAAAAGGATGGCAATGGCACGGAGAACAAATGTTCCAGAAGGGGAAGTGCATAACAAAC  
CATCAGGTTCTGGGAATGATAAAAGTGTACCTCAGCATCAGGAAGTGAAAATCTTA  
CTCTTATTCAACAGGAAGTGGATGCTTGGAAAGAATTAAGCAGGCAGCTTTCTGGAAACAG  
CTGATCTATATGCTACCAAGGAGAGAACAGAACACTCCAAAACCTCAAGGGAAATATTTA  
ATTTCTGGTTACTTTCTCTATTACTGTGTTGGAAAATTTCATGGCTACCATCAATA  
TTGTTTTGATCGAGTTGGAAAACGGATCCTGTACAAGAGGCATTGAGATCACTGTGAATT  
ATCTGGGAATCCAATTGATGTGAAGTTGGTCCACACATTCCCTCATTCTGGAA  
TAATCATCGTCACATCCATCAGAGGATTGCTGATCACTCTTACCAAGTTCTTATGCCATCT  
CTAGCAGTAAGTCCTCCAATGTCATTGCTGCTATTAGCACAGATAATGGCATGTACTTTG  
TCTCCTCTGTGCTGATCCGAATGAGTATGCCTTACAATACCGCACCATAACTGAAG  
TCCTTGGAGAACTGCAGTTCAACTTCTATCACCGTTGGTGTGATCTCCTGGTCAGCG  
CTCTCTAGCATACTCTCCTCTATTGGCTACAAACAGGCACCAGAGAACAAATGGCAC  
CTTGAACTTAAGCCTACTACAGACTGTTAGAGGCCAGTGGTTCAAAATTAGATATAAGAGG  
GGGGAAAATGGAACCAGGGCCTGACATTATAAACAAACAAATGCTATGGTAGCATT  
CACCTCATAGCATACTCCTCCCCGTAGGTGATACTATGACCATGAGTAGCATCAGCCAGA  
ACATGAGAGGGAGAACTAACTCAAGACAATACTCAGCAGAGAGCATCCGTGATGAGG  
CTGGTAGAGGCCAGAGGCCAGAAACTAAAGGTGAAAATACACTGGAACTCTGGGC  
AAGACATGTCTATGGTAGCTGAGCCAAACACGTAGGATTCCGTTAAGGTTACATGGAAA  
AGGTTATAGCTTGCCTTGAGATTGACTCATTAAATCAGAGACTGTAACAAAAAAA  
AAAAAAAAAGGGCGGCCGCACTCTAGAGTCGACCTGCAGAAGCTGGCCGCATGGCCCAACT  
TGTTTATTGCAGCTTATAATG

4/168

## **FIGURE 4**

MSFLIDSSIMITSQILFFFGWLFFMRQLFKDYEIRQYVVQVIFSVTFAFSCTMFELIIFEIL  
GVLNSSSSRYFHWKMNLCVILLLILVFMPFYIGYFIVSNIRLLHKQRLLFSCLLWLTMYFFWK  
LGDPFPILSPKHGILSIEQLISRGVGIVGVTLMALLSGFGAVNCPTYMSYFLRNVTDTDILAL  
ERRLLQTMDMIISKKRMAMARRTMFQKGEVHNKPSGFWMKSVTSASGSENLTLIQQEVD  
ALEELSRLQLFLETADLYATKERIEYSKTFKGKYFNFLGYFFSIYCVWKIFMATINIVFDRVVK  
TDPVTRGIEITVNYLGIQFDVKFWSQHISFILVGIIIVTSIRGLLITLTKFFYAISSSKSSNV  
IVLLLQAQIMGMYFVSSVLLIRMSMPLYRTIITEVLGELQFNFYHRWFDVIFLVSALSSILFL  
YLAHKQAPEKQMAP

**Important features:**

**Signal peptide:**

amino acids 1-23

**Potential transmembrane domains:**

amino acids 37-55, 81-102, 150-168, 288-311, 338-356, 375-398,  
425-444

**N-glycosylation sites.**

amino acids 67-70, 180-183 and 243-246

**Eukaryotic cobalamin-binding proteins**

amino acids 151-160

5/168

## FIGURE 5

AGCAGGGAAATCCGGATGTCGGTTATGAAGTGGAGCAGTGAGTGTGAGCCTAACATAGTT  
CCAGAACCTCTCCATCCGGACTAGTTATTGAGCATCGCCTCTCATACCAAGTGGCCATCTG  
AGGTGTTCCCTGGCTCTGAAGGGTAGGCACG**A**TGCCAGGTGCTCAGCCTGGTGGTGGCTT  
CTCACTTCCATCTGGACCACGAGGCTCCTGGTCCAAGGCCTTTGCGTGCAGAAGAGCTTCC  
ATCCAGGTGTATGCAGAATTATGGGATCACCTTGTGAGCAAAAAGGCGAACAGCAGCTG  
AATTCACAGAACGTAAGGAGGCCTGAGGCTGCTGGACTAACGTTGGCCGGAACGGACCAA  
GTTGAAACAGCCTGAAAGCTAGCTTGAAGACTTGAGCTATGGCTGGGTTGGAGATGGATT  
GTGGTCATCTCTAGGATTAGCCAAACCCAAAGTGTGGAAAAATGGGTTGGTGCCTGATT  
TGGAAAGGTTCCAGTGAGCCGACAGTTGCAGCCTATTGTTACAACACTCATCTGATACTGGACT  
AACTCGTGCATTCCAGAAATTATCACCACCAAGATCCCATATTCAACACTCAAACGTCAACA  
CAAACAAACAGAACATTATTGTCAGTGACAGTACCTACTCGGTGGCATCCCCTACTCTACAATA  
CCTGCCCTACTACTACTCCTCCTGCTCCAGCTTCACTTCTATTCCACGGAGAAAAAAATTG  
ATTGTCAGAACGTTTATGGAAACTAGCACCAGTCTACAGAAACTGAACCATTGTT  
GAAAATAAAGCAGCATTCAAGAACATGAAGCTGGGTTGGAGGTGCCCCACGGCTCTGCTA  
GTGCTTGCTCTCCTCTTGGTGTGCAGCTGGTCTGGATTTGCTATGTCAAAGGTAT  
GTGAAGGCCTCCCTTTACAAACAAGAACATCAGCAGAAGGAAATGATGAAACCAAAGTAGTA  
AAGGAGGAGAACGCCAATGATAGCAACCTAATGAGGAATCAAAGAAAATGATAAAAACCA  
GAAGAGTCCAAGAGTCCAAGCAAAACTACCGTGCATGCCCTGGAAGCTGAAGTT**TAGATGAGA**  
CAGAAATGAGGAGACACACCTGAGGCTGGTTCTTCATGCTCCTACCTGCCAGCTGG  
GAAATCAAAGGCCAACAACAAAGAACAGAAAGTCCACCCCTGGTCTAACGGAAATCAGC  
TCAGGACTGCCATGGACTATGGAGTGCACCAAAGAGAACATGCCCTCTCCTATTGTAACCT  
GTCTGGATCCTATCCTCCTACCTCCAAAGCTCCACGGCCTTCTAGCCTGGCTATGTCTA  
ATAATATCCCACGGAGAACAGGAGTTTGCAAAGTGCAGGACCTAAACATCTCATCAGTA  
TCCAGTGGTAAAAGGCCCTCTGGCTGTCTGAGGCTAGGTGGGTGAAAGCCAAGGAGTC  
GAGACCAAGGCTTCTACTGATTCGCAGCTCAGACCTTCTCAGCTCTGAAAGAGAAA  
CACGTATCCCACCTGACATGCTCTGAGCCCGTAAGAGCAAAAGAACATGGCAGAAAAGTT  
AGCCCCTGAAAGCCATGGAGATTCTCATAACTTGAGACCTAATCTGTAAAGCTAAATAA  
GAAATAGAACAAAGCTGAGGATAACGACAGTACACTGTCAGCAGGACTGTAACACAGACAGG  
GTCAAAGTGTCTCTGAACACATTGAGTGGAAACTACTGTTAGAACACACACTTACTT  
TTCTGGTCTCTACCACTGCTGATATTTCTCTAGGAAATATACTTTACAAGTAACAAAAT  
AAAAACTCTATAAATTCTATTTATCTGAGTTACAGAAATGATTACTAAGGAAGATTACT  
CAGTAATTGTTAAAAAGTAATAAAATTCAACAAACATTGCTGAATAGCTACTATATGTCA  
AGTGCTGTGCAAGGTATTACACTCTGTAATTGAATATTATCCTCAAAAATGCACATAGTA  
GAACGCTATCTGGGAAGCTATTTTCAGTTGATATTCTAGCTTATCTACTTCAAAC  
AATTTTATTTGCTGAGACTAATCTTATTCTCTAAATATGGCAACCATTATAACCT  
TAATTATTAAACATACCTAACGAGTACATTGTTACCTATATACCAAGCACATTAA  
AAGTGCCATTAACAAATGTATCACTAGCCCTCTTTCCAACAAGAAGGACTGAGAGATGC  
AGAAATATTGTGACAAAAATTAAAGCATTAGAAAACCTT

6/168

## **FIGURE 6**

MARCFSLVLLTSIWTTRLLVQGSLRAEELSIQVSCRIMGITLVSKKANQQLNFTEAKEACRL  
LGLSLAGKDQVETALKASFETCSYGVGDGFVVISRISPNCGKNGVGVLIWKPVSRQFAA  
YCYNSSDTWTNSCIPEIITKDPIFNTQTATQTTEFIVSDSTYSVSPYSTIPAPTPPPAPA  
STSIPRRKKLICVTEVFMETSTMSTETEPFVENKAASKNEAAGFGGVPTALLVLALLFFGAAA  
GLGFCYVKRYVKAFPFTNKNQQKEMIETKVVKEEKANDSNPNEESKKTDFNPEESKSPSKTTV  
RCLEAEV

**Signal sequence:**

amino acids 1-16

**Transmembrane domain:**

amino acids 235-254

**N-glycosylation site.**

amino acids 53-57, 130-134, 289-293

**Casein kinase II phosphorylation site.**

amino acids 145-149, 214-218

**Tyrosine kinase phosphorylation site.**

amino acids 79-88

**N-myristoylation site.**

amino acids 23-29, 65-71, 234-240, 235-239, 249-255, 253-259

7/168

## FIGURE 7

CGCCGCGCTCCCGCACCCGGCCCCGCCACCGCGCCGCTCCGCATCTGCACCCGCAGCCCCG  
GCGGCCTCCC GGCGGGAGCGAGCAGATCCAGTCCGGCCCGCAGCGCAACTCGGTCCAGTCGGG  
GCGGCGGCTGCGGGCGCAGAGCGGAGATGCAGCGGCTGGGGCCACCCTGCTGTGCCTGCTGC  
TGGCGGCGCGGTCCCCACGGCCCCCGCAGCGACCTCGGCTCCAGTCAAGC  
CCGGCCCGGCTCTCAGCTACCCGCAGGAGGCCACCCCTCAATGAGATGTTCCGCAGGGTTG  
AGGAACGTGAGGAGACCGCAGCACAAATTGCGCAGCGCGGTGGAAGAGATGGAGGCAGAAG  
AAGCTGCTGCTAAAGCATCATCAGAAGTGAACCTGGCAAACCTACCTCCAGCTATCACAATG  
AGACCAACACAGACAGAACAGGTTGAAATAATACCATCCATGTGCACCGAGAAATTACAAGA  
TAACCAACAACCAGACTGGACAAATTGGTCTTTCAGAGACAGTTATCACATCTGTGGAGAGC  
AAGAAGGCAGAAGGAGCCACGAGTGATCATCGACGAGGACTGTGGGCCAGAGGATGCTCTGCACCCGGG  
AGTTGCCAGCTCCAGTACACCTGCCAGCCATGCCGGGGCCAGAGGATGCTCTGCACCCGGG  
ACAGTGAGTGCTGGAGACAGCTGTGTCTGGGGTCACTGCACCAAATGCCACCGAGGG  
GCAGCAATGGGACCATCTGTGACAACCAAGAGGGACTGCCAGGCCGGGCTGTGCTGTGCCTTCC  
AGAGAGGCCTGCTGTTCCCTGTGTCACACCCCTGCCGTGGAGGGCGAGCTTGCCATGACC  
CCGCCAGCCGGCTTCTGGACCTCATCACCTGGAGCTAGGCCTGATGGAGCCTTGACCGAT  
GCCCTTGTGCCAGTGGCCTCCTGCCAGCCCCACAGCCACAGCCTGGTGTATGTGTGCAAGC  
CGACCTCGTGGGAGCCGTGACCAAGATGGGAGATCCTGCTGCCAGAGAGGGTCCCCGATG  
AGTATGAAGTTGGCAGCTTCATGGAGGAGGTGCGCCAGGAGCTGGAGGACCTGGAGAGGAGCC  
TGACTGAAGAGATGGCGCTGGGGAGCCTGCCGTGCCGGCTGCCACTGCTGGAGGGGAAG  
AGATTTAGATCTGGACCAGGCTGTGGTAGATGTGCAATAGAAATAGCTAATTATTCCCCA  
GGTGTGCTT TAGGCGTGGGCTGACCAAGGCTTCTTACATCTTCTCCAGTAAGTTCC  
CCTCTGGCTGACAGCATGAGGTGTGTCATTGTCAGCTCCCCCAGGCTGTTCTCCAGGC  
TTCACAGTCTGGTGTCTGGGAGAGTCAGGCAGGGTTAAACTGCAGGAGCAGTTGCCACCCCT  
GTCCAGATTATTGGCTGCTTGCCTCTACAGGTTGGCAGACAGCCGTTGTTCTACATGGCTT  
TGATAATTGTTGAGGGAGAGATGGAAACAATGTGGAGTCTCCCTCTGATTGGTTGGGG  
AAATGTGGAGAAGAGTCCTGCTTGCAAAACATCAACCTGGAAAAATGCAACAAATGAATT  
TTCCACGCAGTTCTTCCATGGCATAGGTAAGCTGTGCTTCAGCTGTTGAGATGAAATGT  
TCTGTTCACCTGCATTACATGTGTTATTCCAGCAGTGTGCTCAGCTCCTACCTCTGT  
GCCAGGGCAGCATTTCATATCCAAGATCAATTCCCTCTCAGCACAGCCTGGGGAGGGGT  
CATTGTTCTCGTCCATCAGGGATCTCAGAGGCTCAGAGACTGCAAGCTGCTTGCCAAGT  
CACACAGCTAGTGAAGACCAAGAGCAGTTCATCTGGTGTGACTCTAAGCTCAGTGTCTCTC  
CACTACCCCACACCAGCCTGGTGCCACCAAAAGTCTCCCCAAAAGGAAGGAGAAATGGGATT  
TTTCTTGAGGCATGCACATCTGGAATTAAAGGTCAAACATAATTCTCACATCCCTCTAAAGTAA  
ACTACTGTTAGGAACAGCAGTGTCTCACAGTGTGGGAGCAGCTGCTTCTAATGAAGACAAT  
GATATTGACACTGTCCCTCTTGGCAGTTGCAATTAGTAACCTTGAAAGGTATATGACTGAGCG  
TAGCATACAGGTTAACCTGCAGAAACAGTACTTAGTAATTGTAGGGCGAGGATTATAAATGA  
AATTGCAAAATCACTTAGCAGCAACTGAAGACAATTATCAACCACTGAGGAAAATCAAACC  
GAGCAGGGCTGTGAAACATGGTTGTAATATGCGACTGCGAACACTGAACACTACGCCACTC  
CACAAATGATTTTCAGGTGTCACTGGACTGTTGCCACCATGTATTCCAGAGTCTTAA  
GTTAAAGTTGCACATGATTGATAAGCATGCTTCTTGAGTTAAATTATGTATAAACAT  
AAGTTGCATTTAGAAATCAAGCATAAAACTCAACTGCAAAAAAAAAAAAAAAA  
AAA

8/168

## **FIGURE 8**

MQRLGATLLCLLAAAVPTAPAPAPTATSAPVKPGPALSYPQEEATLNEMFREVEELMEDTQH  
KLRSAVEEEMEAEEAAKASSEVNLNLPPSYHNETNTDTKVGNNNTIHVHREIHKITNNQTGQM  
VFSETVITSVGDEEGRRSHECIIDECDGPSMYCQFASFQYTCQPCRGQRMLCTRSECCGDQL  
CVWGHCTKMATRGSNGTICDNQRDCQPGCCAFCQRGLLFPVCTPLPVEGELCHDPASRLLDLI  
TWELEPDGALDRCPASCGLLCQPHSHSLVYVCKPTFVGSRDQDGIELLPREVDEYEVGSFME  
EVROELEDLERSLTEEMALGEAAAAALLGEEI

**Signal sequence:**

amino acids 1-19

**N-glycosylation site.**

amino acids 96-100, 106-110, 121-125, 204-208

**Casein kinase II phosphorylation site.**

amino acids 46-50, 67-71, 98-102, 135-139, 206-210, 312-316,  
327-331

**N-myristoylation site.**

amino acids 202-208, 217-223

**Amidation site.**

amino acids 140-144

9/168

## **FIGURE 9**

**CGG**ACGCGTGGCGGACGCGTGGGGCTGTGAGAAAGTCCAATAATACATCATGCAACCCC  
ACGGCCCACCTTGTGAACTCCTCGTGCCTCAGGGCTGATGTGCGTCTCCAGGGCTACTCATCC  
AAAGGCCTAATCCAACGTTCTGTCTCAATCTGAAATCTATGGGGTCTGGGGCTCTTCTGG  
ACCCTTAACTGGGTACTGCCCTGGCCAATGCGCCTCGCTGGAGCCTTGCCCTTCTAC  
TGGGCCTTACAAGCCCCAGGACATCCCTACCTCCCTTAATCTCTGCCTTCATCCGCACA  
CTCCGTTACCACACTGGGTATTGGCATTGGAGCCCTCATCCTGACCCTGTGCAGATAGCC  
CGGGTCATCTGGAGTATTGACCAAGCTCAGAGGAGTGCAGAACCTGTAGCCCGCTGC  
ATCATGTGCTGTTCAAGTGCTGCCTCTGGTGTCTGGAAAAATTATCAAGTTCTAAACCGC  
AATGCATACATCATGATGCCATCTACGGGAAGAACCTGTGCTCAGCCAAAATGCGTTC  
ATGCTACTCATGCAAACATTGTCAGGGTGGTCGTGGACAAAGTCACAGACCTGCTGCTG  
TTCTTGGGAAGCTGCTGGTGGTCGGAGGCCTGGGGCTGTCCCTTTCTCCGGT  
CGCATCCGGGCTGGTAAAGACTTTAACAGAGCCCCCACCTCAACTATTACTGGCTGCCATC  
ATGACCTCCATCCTGGGGCCTATGTCATGCCAGCGGCTTCTCAGCGTTTCGGCATGTGT  
GTGGACACGCTCTCCTCTGCTTCTGGAAAGACCTGGAGCGAACACGGCTCCCTGGACCG  
CCCTACTACATGTCAAAGAGCCTTCTAAAGATTCTGGCAAGAAGAACGAGGCGCCCCGGAC  
AACAAAGAGAGGAAGTGACAGCTCCGGCCCTGATCCAGGACTGCACCCACCCACCGT  
CCAGCCATCCAACCTCACTCGCCTACAGGTCTCCATTGTGGAAAAAGGTTAGGC  
CAGGCGCCGTGGCTCACGCCGTAAATCCAACACTTGAGAGGCTGAGGCGGGCGGATCACCTG  
AGTCAGGAGTTGAGACCAGCCTGGCAACATGGTAAACCTCCGTCTATTAAAAATCAA  
AAATTAGCCGAGAGTGGTGGCATGCACCTGTCACTCCAGCTACTCGGGAGGCTGAGGCAGGAG  
AATCGCTGAACCCGGAGGCAGAGGTTGCAGTGAGCCAGATCGGCCACTGCACTCCAACC  
TGGGTGACAGACTCTGTCTCCAAAACAAACAAACAAAAAGATTATTAAAGATATT  
TGTAACTC

10/168

## **FIGURE 10**

RTRGRTRGGCEKVPINTSCNPTAHVNSSCPGLMCVFQGYSSKGLIQRSVFNLQIYGVLGLFW  
TLNWVLALGQCVLAGAFASYWAFHKPQDIPTFPLISAFIRTLRYHTGSLAFGALILTLVQIA  
RVILEYIDHKLRGVQNPVARCIMCCFKCCLWCLEKFIKFLNRNAYIMIAIYGKNFCVSAKNAF  
MLLMRNIVRVVVLKDVTLLLFFGKLLVVGGVGVLSSFFFSGRIPGLGKDFKSPHLNYYWLPI  
MTSILGAYVIASGFFSVFGMCVDTLFLCFLEDLERNNNGSLRPYYMSKSLLKILGKKNEAPPD  
NKKRKK

**Important features:**

**Transmembrane domains:**

amino acids 57-80 (type II), 110-126, 215-231, 254-274

**N-glycosylation sites.**

amino acids 16-20, 27-31, 289-293

**Hypothetical YBR002c family proteins.**

amino acids 276-288

**Ammonium transporters proteins.**

amino acids 204-231

**N-myristoylation sites.**

amino acids 60-66, 78-84

**Amidation site.**

amino acids 306-310

11/168

## **FIGURE 11**

GCCCCGCGCCGGCGCCGGCGCCGGAGCCACCGCC**ATG**GGGGCCTGCCTGGAG  
CCTGCTCCCTGCTCAGCTGCAGCTGCCTCTGCAGCTCTGCCCTGCATCCTGTGCAGCT  
GCTGCCCGCCAGCCGAACCTCCACCGTGAGCCGCCTCATCTCACGTTCTCCTTCTGG  
GGGTGCTGGTGTCCATCATTATGCTGAGCCCAGGGTGAGAGTCAGCTACAAGCTGCCCT  
GGGTGTGTGAGGAGGGGGCCGGATCCCCACCGTCCTGCAGGGCACATCGACTGTGGCTCCC  
TGCTTGCTACCGCGCTGCTACCGCATGTGCTTCGCCACGGCGCCTTCTTCTTCTTCTT  
TCACCCCTGCTCATGCTCTGGTGAGCAGCAGCCGGGACCCCCGGGCTGCCATCCAGAATGGGT  
TTTGGTTCTTAAGTTCTGATCCTGGTGGCCTCACCGTGGTGCCTCTACATCCCTGACG  
GCTCCTTCACCAACATCTGGTTCTACTCAGGCGTCGTGGCTCCTTCCTTCATCCTCATCC  
AGCTGGTGCTGCTCATCGACTTGCGCACTCCTGGAACCAGCGGTGGCTGGCAAGGCCGAGG  
AGTGCATTCCCGTGCCTGGTACGCAGGCCTTTCTTCTTACTCTCCTTACTTGCTGT  
CGATCGCGCCGTGGCGCTGATGTTCATGTACTACACTGAGCCAGCGGCTGCCACGAGGGCA  
AGGTCTTCATCAGCCTAACCTCACCTCTGTGCTGCGTGTCCATCGCTGCTGTCCCTGCCA  
AGGTCCAGGACGCCAACGCCAACCTGGGTCTGCTGCAGGCCTCGTCATCACCTCTACACCA  
TGTTTGTACCTGGTCAGCCCTATCCAGTATCCCTGAACAGAAATGCAACCCCCATTGCCAA  
CCCAGCTGGCAACGAGACAGTTGTGGCAGGCCCGAGGGCTATGAGACCCAGTGGTGGGATG  
CCCCGAGCATTGTGGCCTCATCATCTCCTCTGTGCAACCCCTTCTCATCAGTCTCGCTCCT  
CAGACCACCGCAGGTGAACAGCCTGATGCAGACCGAGGGACTGCCACCTATGCTAGACGCCA  
CACAGCAGCAGCAGCAGCAGGTGGCAGCCTGTGAGGGCCGGGCTTGACAACGAGCAGGACG  
GCGTCACCTACAGCTACTCCTCTTCCACTCTGCCTGGTGCCTGCCTCACTGCACGTCATGA  
TGACGCTACCAACTGGTACAAGCCGGTGAGACCCGGAAGATGATCAGCACGTGGACCGCCG  
TGTGGGTGAAGATCTGTGCCAGCTGGCAGGGCTGCTCCTTACCTGTGGACCCCTGGTAGGCC  
CACTCCTCTGCGAACCGCGACTTCAGC**TGA**GGCAGCCTCACAGCCTGCCATCTGGTGCCTC  
CTGCCACCTGGTGCCTCTCGGCTCGGTGACAGCCAACCTGCCCTCCCCACACCAATCAGCC  
AGGCTGAGCCCCACCCCTGCCAGCTCCAGGACCTGCCCTGAGCCGGCCTTAGTCGT  
AGTGCCTTCAGGGTCCGAGGAGCATCAGGCTCTGCAGAGCCCCATCCCCCGCCACACCCAC  
ACGGTGGAGCTGCCCTTCCTCCCTCCCTGTTGCCACTCAGCATCTCGGATGAAA  
GGGCTCCCTGTCCCTCAGGCTCCAGGGAGCGGGCTGCTGGAGAGAGCGGGGAACCTCCACC  
ACAGTGGGCATCCGGCACTGAAGCCCTGGTGTTCCTGGTACGTCCCCAGGGACCCCTGCC  
CCCTCCTGGACTCGTGCCTTACTGAGTCTAAGACTTTCTAATAAACAAAGCCAGTGC  
TGTAAAAAAA

12/168

## **FIGURE 12**

MGACLGACSLSCASCLCGSAPCILCSCCPASRNSTVSRLIFTFFLFLGVLVSIIMLSPGVES  
QLYKLPWVCEEGAGIPTVLQGHIDCGSLLGYRAVYRMCFATAAFFFFFLLMLCVSSSRDPR  
AAIQNGFWFFKFLILVGLTVGAFYIPDGSFTNIWFYFGVVGSFLFILIQLVLLIDFAHSWNQR  
WLGAEECDRSAWYAGLFFTLLFYLLSIAAVALMFMYYTEPSGCHEGKVFISLNLTFCVCVS  
IAAVLPKVQDAQPNSGLLQASVITLYTMFVTWSALSSIPEQKCNPHLPTQLGNETVAGPEGY  
ETQWWWDAPSIVGLIIFLLCCTLFISLRSSDHQRQVNSLMQTEECPPMLDATQQQQQQVAACEGRA  
FDNEQDGVTYSYSFFHFCLVLASLHVMMTLTNWYKPGETRKMISTWTAVWKICASWAGLLL  
LWTLVAPLLLNRDFS

**Signal sequence:**

amino acids 1-20

**Transmembrane domains:**

amino acids 40-58, 101-116, 134-150, 162-178, 206-223, 240-257,  
272-283, 324-340, 391-406, 428-444

## **FIGURE 13**

CGGGCCAGCCTGGGGCGGCCGGCCAGGAACCACCCGTTAAGGTGTCTCTCTTTAGGGATGGT  
GAGGTTGGAAAAAGACTCCTGTAACCCTCCTCCAGGATGAACCACCTGCCAGAAGACATGGAG  
AACGCTCTCACCGGGAGCCAGAGCTCCCAGTCTCTCTGCGCAATATCCATTCCATCAACCCC  
ACACAACTCATGGCCAGGATTGAGTCCTATGAAGGAAGGGAAAAGAAAGGCATATCTGATGTC  
AGGAGGACTTCTGTTGTCACCTTGACCTCTTATTGTAACATTACTGTGGATAATA  
GAGTTAAATGTGAATGGAGGCATTGAGAACACATTAGAGAAGGAGGTGATGCAGTATGACTAC  
TATTCTTCATATTGATATATTCTCTGGCAGTTTCGATTAAAGTGTTAATACTTGCA  
TATGCTGTGTGCAGACTGCCATTGGTGGCAATAGCGTTGACAACGGCAGTGACCAAGTGCC  
TTTTACTAGCAAAGTGAATCCTTCGAAGCTTTCTCAAGGGCTTTGGCTATGTGCTG  
CCCATCATTTCATTTCATCCTGCCTGGATTGAGACGTGGCTCTGGATTCAAAGTGTACCT  
CAAGAACAGAAGAACAGACTCCTGATAGTTAGGATGCTCAGAGAGGGCAGCACTT  
ATACCTGGTGGTCTTCTGATGGTCAGTTATTCCCTCCTGAATCCGAAGCAGGATCTGAA  
GAAGCTGAAGAAAACAGGACAGTGAGAAACCACTTTAGAACTATTGACTACTTTGTTA  
AATGTGAAAACCCCTCACAGAAAGTCATCGAGGCCAAAAGAGGCAGGCAGTGGAGTCCTG  
TCGACAGTAAAGTTGAAATGGTGACGTCCACTGCTGGCTTATTGAACAGCTAATAAGATT  
ATTTATTGTAATACCTCACAAACGTTGACCATATCCATGCACATTAGTTGCCTGCCTGTGG  
CTGGTAAGGTAATGTCATGATTTCATCCTCTTCAGTGAGACTGAGCCTGATGTGTTAACAAA  
TAGGTGAAGAAAAGTCTTGTGCTGTATTCTAACACTCTACATTCCCTGTTTTAACTCATGCACA  
TGTGCTTTGTACAGTTAAAAGTGTAAATAAAACTGACATGTCAATGTGGTAGTTTA  
TTTTCTGTTTGCATTATGTGATGGCCTGAAGTGTGGACTTGCAAAAGGGAAAGAAAGG  
AATTGCGAATACATGTAAAATGTCACCAGACATTGTATTATTTATCATGAAATCATGTT  
TTCTCTGATTGTTCTGAAATGTTCTAAACTCTTATTGAAATGCACAAATGACTAAACC  
ATTCATATCATGTTCTTGCCTCAGCCAATTCAATTAAATGAACTAAATTAAAAA

14/168

## **FIGURE 14**

MNHLPEDMENALTGSQSSHASLRNIHSINPTQLMARIESYEGREKKGISDVRRTFCLFVTFDL  
LFVTLLWIIELNVNGGIENTLEKEVMQYDYYSSYFDIFLLAVFRFKVLILAYAVCRLRHWAI  
ALTTAVTSAFLAKVILSKLFSQGAFGYVLPIISFILA WIETWFIDFKVL PQEAEENRLLIV  
QDASERAALIPGGLSDGQFYSPPESEAGSEEAEKQDSEKPLLEL

**Important features of the protein:**

**Signal peptide:**

amino acids 1-20

**Transmembrane domains:**

amino acids 54-72, 100-118, 130-144, 146-166

**N-myristylation sites.**

amino acids 14-20, 78-84, 79-85, 202-208, 217-223

## FIGURE 15

ACTCGAACGCAGTTGCTTCGGGACCCAGGACCCCCTCGGGCCGACCCGCCAGGAAAGACTGA  
GGCCGCGGCCCTGCCCGCCGGCTCCCTGCGCCGCCGCTCCCGGGACAGAAGATGTGCT  
CCAGGGTCCCTCTGCTGCTGCCGCTGCTCCTGCTACTGGCCCTGGGCTGGGTGCAGGGCT  
GCCCATCCGGCTGCCAGTGCAAGCCACAGACAGTCTTCTGCACTGCCGCCAGGGGACCA  
CGGTGCCCGAGACGTGCCACCCGACACGGTGGGCTGTACGTCTTGAGAACGGCATCACCA  
TGCTCGACGCAGGCAGTTGCCGGCTGCCGGCTGCAAGCTCTGGACCTGTACAGAACCC  
AGATCGCCAGCCTGCCAGCGGGTCTTCCAGGCCACTGCCAACCTCAGCAACCTGGACCTGA  
CGGCCAACAGGCTGCATGAATACCAATGAGACCTTCCGTGGCTGCGGCCCTGAGCGCC  
TCTACCTGGCAAGAACCGCATCCGCCACATCCAGCCTGGTGCCTTCGACACGCTGACCGCC  
TCCTGGAGCTCAAGCTGCAGGACAACGAGCTGCCACTGCCCTGGAGCCGGCATCCTGGACACTG  
CCAACGTGGAGGCCCTGCCGCTGGCTGGCTGGGCTGCAGCAGTGGACGAGGGCTTTCA  
GCCGCTTGCACACCTCACGACCTGGATGTGTCCGACAACCAGCTGGAGCGAGTGCCACCTG  
TGATCCGAGGCCTCCGGGGCTGACGCCCTGCCGGCTGGCCGGCAACACCCGATTGCCAGC  
TGCAGGCCGAGGACCTGGCCGGCTGGCTGCCCTGCAAGGAGCTGGATGTGAGCAACCTAACGCC  
TGCAGGCCCTGCCCTGGCGACCTCTGGGCCTCTTCCCCGCCCTGCCGGCTGCTGGCAGCTGCC  
GCAACCCCTCAACTGCGTGTGCCCTGAGCTGGTTGGCCCTGGTGCAGGAGAGCCACG  
TCACACTGGCCAGCCCTGAGGAGACGCCACTTCCGCCAAGAACGCTGGCCGGCTGC  
TCCTGGAGCTTGAACAGCCACTTGGCTGCCAGCCACCACACCAGCCACAGTGCCCA  
CCACGAGGCCCGTGGTGCAGGCCACAGCCTGTCTAGCTTGGCTCCTACCTGGCTTA  
GCCCCACAGGCCGGCCACTGAGGCCAGGCCCTCCACTGCCCAACCGACTGTAGGGC  
CTGTCCCCCAGCCCCAGGACTGCCACCGTCCACCTGCCCTAATGGGGCACATGCCACCTGG  
GGACACGGCACCCACTGGCGTCTGTGCCAGGCCACAGCCCTGTACTGTGAGAGGCC  
AGATGGGGCAGGGACACGCCAGGCCACACCAGTCACGCCAGGCCACACGGCTTGA  
CCCTGGCATTGAGGCCGGTGAGCCCCACCTCCCTGCCGGTGGGGCTGCCGGCTACCTCCAGG  
GGAGCTCCGTGCAGCTCAGGAGCCTCCGTCTCACCTATGCAACCTATGGCCCTGATAAGC  
GGCTGGTACGCTGCACTGCCCTGCCCTCGCTGAGTACACGGTACCCAGCTGCCGGCCA  
ACGCCACTTACTCCGTCTGTGTATGCCATTGGGGCCGGGCGGGTGCAGGCCAGGCC  
CCTGCAGGGGAGGCCATACACCCCAAGCCGTCACCTCAACCACGCCAGTCACCCAGGCC  
GCGAGGGCAACCTGCCCTCCATTGCCGCCCTGCCAGGCCGGTGCCTGGCCGGCTGG  
CTGCCGGTGGGGCAGCCTACTGTGTGCCGGGGCGGGCATGGCAGCAGCGCTCAGGACA  
AAGGGCAGGTGGGGCAGGGGCTGGCCCTGGAACTGGAGGGAGTGAAGGTCCCCTGGAGC  
CAGGCCGAAGGCAACAGAGGGCGGTGGAGAGGCCCTGCCAGCGGGCTGAGTGTGAGGTGC  
CACTCATGGGCTTCCCAGGGCCTGCCCTCCAGTCACCCCTCCACGCAAAGCCCTACATCTAAG  
CCAGAGAGAGACAGGGCAGCTGGGGCGGGCTCTCAGCCAGTGAGATGCCAGCCCCCTCCTG  
CTGCCACACCACGTAAGTCTCAGTCCAAACCTCGGGATGTGTGCAGACAGGGCTGTGTGAC  
CACAGCTGGCCCTGTCCTCTGGACCTCGGTCTCCTCATCTGTGAGATGCTGTGGCCAGC  
TGACGAGCCCTAACGTCCCCAGAACCGAGTGCCTATGAGGACAGTGTCCGCCCTGCCCTCCGC  
AACGTGCAGTCCCTGGCACGGCGGGCCCTGCCATGTGCTGGTAACGCATGCCCTGGGTCTGC  
TGGGCTCTCCCACCTCCAGGGGACCCCTGGGGGCCAGTGAAGGAAGCTCCCGAAAGAGCAGAG  
GGAGAGCGGGTAGGCAGGCTGTGACTCTAGTCTTGGCCCCAGGAAGCGAAGGAACAAAAGAA  
ACTGGAAAGGAAGATGCTTGGAAACATGTTGCTTTTAAATATATATTTATAAGAG  
ATCCTTCCCATTATTCTGGGAAGATGTTTCAAACCTCAGAGACAAGGACTTGGTTTG  
TAAGACAAACGATGATATGAAGGCCTTGTAAAGAAAAAATAAAGATGAAGTGTGAAA

16/168

## **FIGURE 16**

MCSRVPLLLPLLLLLALGPGVQGCPSCQCSQPQTVFCTARQGTTVPRDVPPDTVGLYVFENG  
ITMLDAGSFAGLPGLQLLDSQNQIASLPSGVFQPLANLSNLDLTANRLHEITNETFRGLRRL  
ERLYLGKNRIRHIQPGAFDTLDRLLELKLQDNELRALPPLRLPRLLLLDLHSNSLLALEPGIL  
DTANVEALRLAGLGLQQLDEGLFSRLRNLDLVDSDNQLERVPPVIRGLRGLTRLRLAGNTRI  
AQLRPEDLAGLAALQELDVSNLSQLPGDLSGLFPRLRLLAAARNPNFNCVCPLSWFGPWRE  
SHVTLASPEETRCHFPPKNAGRLLLELDYADFGCPATTTATVPTTRPVVREPTALSSSLAPT  
WLSPTAPATEAPSPPSTAPPTVGVPQPQDCPPSTCLNGGTCHLGTRHHLACLCPEGFTGLYC  
ESQMGQGTRPSPTPVTPRPPRSLTGLIEPVSPSLRVGLQRYLQGSSVQLRSLRLTYRNLSGP  
DKRLVTLRLPASLAEYTVTQLRPNATYSVCVMPGLPGRVPEGEEACGEAHTPPAVHSNHAPVT  
QAREGNLPLLIAPALAAVLLAALAAVGAAYCVRRGRAMAAAQDKGQVGPAGPLELEGVKVP  
LEPGPKATEGGEALPSGSECEVPLMGFPGPGLQSPLHAKPYI

**Important features:**

**Signal peptide:**

amino acids 1-23

**Transmembrane domain:**

amino acids 579-599

**EGF-like domain cysteine pattern signature.**

amino acids 430-442

**Leucine zipper pattern.**

amino acids 197-219, 269-291

**N-glycosylation sites.**

amino acids 101-105, 117-121, 273-277, 500-504, 528-532

**Tyrosine kinase phosphorylation sites.**

amino acids 124-131, 337-345

**N-myristoylation sites.**

amino acids 23-29, 27-33, 70-76, 142-148, 187-193, 348-354,  
594-600, 640-646

## FIGURE 17

18/168

## **FIGURE 18**

MRVRIGLTLLLCAVLLSLASASSDEEGSQDESLDSTTTSDESVKDHTTAGRVVAGQIFLDS  
ESELESSIQEEDSLKSQEGESVTEDISFLESPNPNKDYEPPKKVRKPALTAIEGTAHGE  
CHFPFLFLDKEYDECTS DGDREDGRLWCATTYDYKADEKWGFCETEEEAKRRQMQEAEEMMYQT  
GMKILNGSNKKSQKREAYRYLQKAASMNHTKALERVSYALLFGDYLQPNIQAAREMFEKLTEE  
GSPKGQTALGFLYASGLGVNSSQAKALVYYTFALGGNLIAHMVLVSRL

**Important features:**

**Signal peptide:**

amino acids 1-21

**N-glycosylation sites.**

amino acids 195-199, 217-221, 272-276

**Tyrosine kinase phosphorylation site.**

amino acids 220-228

**N-myristoylation sites.**

amino acids 120-126, 253-259, 268-274, 270-274, 285-291, 289-295

**Glycosaminoglycan attachment site.**

amino acids 267-271

**Microbodies C-terminal targeting signal.**

amino acids 299-303

**Type II fibronectin collagen-binding domain protein.**

amino acids 127-169

**Fructose-bisphosphate aldolase class-II protein.**

amino acids 101-119

19/168

## **FIGURE 19**

AATTCAAGATTTAAGCCCATTCTGCAGTGGAAATTCATGAAC TAGCAAGAGGACACCACCTTC  
TTGTATTATAACAAGAAAGGAGTGTACCTATCACACACAGGGGGAAAAATGCTTTGGGTGC  
TAGGCCTCCTAATCCTCTGTGGTTCTGTGGACTCGTAAAGGAAA ACTAAAGATTGAAGACA  
TCACTGATAAGTACATTTATCACTGGATGTGACTCGGGCTTGGAAACTGGCAGCCAGAA  
CTTTGATAAAAAGGGATTCATGTAATCGCTGCCTGTACTGAATCAGGATCAACAGCTT  
TAAAGGCAGAAACCTCAGAGAGACTCGTACTGTGCTCTGGATGTGACCGACCCAGAGAATG  
TCAAGAGGACTGCCAGTGGTGAAGAACCAAGTTGGGAGAAAGGTCTCTGGGTCTGATCA  
ATAATGCTGGTGTCCCGCGTGCTGGCTCCACTGACTGGCTGACACTAGAGGACTACAGAG  
AACCTATTGAAGTGAACCTGTTGGACTCATCAGTGTGACACTAAATATGCTCCTTGGTCA  
AGAAAGCTCAAGGGAGAGTTATTAAATGTCTCCAGTGTGGAGGTGCCTTGAATCGTTGGAG  
GGGGCTATACTCCATCCAAATATGCACTGGAGGTTCAATGACAGCTTAAGACGGGACATGA  
AAGCTTTGGTGTGCACGCTCATGCATTGAACCAGGATTGTTCAAAACAAACTGGCAGATC  
CAGTAAAGGTAAATTGAAAAAAACTGCCATTGGGAGCAGCTGTCTCCAGACATCAAACAAAC  
AATATGGAGAAGGTTACATTGAAAAAAAGTCTAGACAAACTGAAAGGCAATAATCCTATGTGA  
ACATGGACCTCTCCGGTGGTAGAGTGCATGGACCACGCTCAACAGTCTCTCCCTAAGA  
CTCATTATGCCGCTGGAAAAGATGCCAAATTTCTGGATACCTCTGTCTCACATGCCAGCAG  
CTTGCAAGACTTTATTGTTGAAACAGAAAGCAGAGCTGGCTAATCCAAGGCAGTGTGAC  
TCAGCTAACCAACAAATGTCCTCCAGGCTATGAAATTGGCGATTCAAGAACACATCTCCT  
TTCAACCCCATTCTTATCTGCTCCAACCTGGACTCATTAGATCGTGCCTATTGGATTGC  
AAAAGGGAGTCCCACCATCGCTGGTGTATCCAGGGTCCCTGCTCAAGTTCTTGAAAAG  
GAGGGCTGGAATGGTACATCACATAGGCAAGTCCTGCCCTGTATTAGGCTTGCCTGCTGG  
TGTGATGTAAGGGAAATTGAAAGACTTGCCCATTCAAAATGATCTTACCGTGGCCTGCCCA  
TGCTTATGGTCCCCAGCATTTACAGTAACCTGTGAATGTTAAGTATCATCTTATCTAAATA  
TTAAAAGATAAGTCAACCCAAAAAAAGAAAAAAAAAAAAAA

20/168

## **FIGURE 20**

MLFWVLGLLILCGFLWTRKGKLKIEDITDKYIFITGCDSGFGNLAARTFDKKGFHVIACLTE  
SGSTALKAETSERLRTVLLDVTDPENVKRTAQWVKNQVGEKGLWGLINNAGVPGVLAPTDWLT  
LEDYREPIEVNLFGGLISVTLNMLPLVKKAQGRVINVSSVGGRLAIVGGGYTPSKYAVEGFNDS  
LRRDMKAFGVHVSCIEPGLFKTNLADPVKVIEKKLAIWEQLSPDIKQQYGEGYIEKSLDKLKG  
NKSYVNMDLSPVVECMDHALTSLFPKTHYAAGKDAKIFWIPLSHMPAALQDFLLLKQKAELAN  
PKAV

**Important features of the protein:**

**Signal peptide:**

amino acids 1-17

**Transmembrane domain:**

amino acids 136-152

**N-glycosylation sites.**

amino acids 161-163, 187-190 and 253-256

**Glycosaminoglycan attachment site.**

amino acids 39-42

**N-myristoylation sites.**

amino acids 36-41, 42-47, 108-113, 166-171, 198-203 and 207-212

## **FIGURE 21**

CTGAGGC GGCGGTAGC**ATG**GAGGGGAGAGTACGTGGCGGTGCTCTCGGGCTTGTGCTCGG  
CGCACTCGCTTCCAGCACCTCAACACGGACTCGGACACGGAAGGTTTCTTGGGGAAAGT  
AAAAGGTGAAGCCAAGAACAGCATTACTGATTCCCAAATGGATGATGTTGAAGTTGTTATAC  
AATTGACATTCA GAAATATATTCCATGCTATCAGTTTAGCTTTATAATTCTTCAGGCAG  
AGTAAATGAGCAAGCACTGAAGAAAATATTATCAAATGTCAAAAAGAATGTGGTAGGGTGGTA  
CAAATTCCGTCGT CATT CAGATCAGATCATGACGTTAGAGAGAGGCTGCTCACAAAAACTT  
GCAGGAGCATTTCAAACCAAGACCTTGTTCTGCTATTACACCAAGTATAAACAGA  
AAGCTGCTCTACTCATCGACTGGAACATTCTTATATAAACCTCAAAAAGGACTTTCACAG  
GGTACCTTAGTGGTTGCCAATCTGGCATGTCGAACA ACTGGTTATAAAACTGTATCAGG  
TTCCTGTATGTCCACTGGTTAGCCGAGCAGTACAAACACACAGCTCTAAATTGGTAAGA  
AGATGGATCCTTAAAGGAGGTACATAAGATAAATGAAATGTATGCTTCATTACAAGAGGAATT  
AAAGAGTATATGCAAAAAGTGGAGACAGTGAACAAGCAGTAGATAAAACTAGTAAAGGATGT  
AACAGATAAAACGAGAAATTGAGAAAAGGAGAGGAGCACAGATT CAGGCAGCAAGAGAGAA  
GAACATCCAAAAGACCCTCAGGAGAACATTCTTCTTCAGGCATTACGGACCTTTCC  
AAATTCTGAATTCTTCATT CATGTGTTATGTCTTAAAAAATAGACATGTTCTAAAAGTAG  
CTGTA ACTACAACCACCATCTCGATGTAGACAATCTGACCTTAATGGTAGAACACACTGA  
CATT CCTGAAGCTAGTCCAGCTAGTACACCACAAATCATTAAGCATAAAGCCTTAGACTTAGA  
TGACAGATGGCAATTCAAGAGATCTGGTTGTTAGATAACACAAGACAAACGATCTAAAGCAA  
TACTGGTAGTAGTAACCAAGATAAACGATCCAAAATGAGCAGGCCAGAAACAGATGAAGAAAT  
TGAAAAGATGAAGGGTTTGGTGAATATT CACGGTCTCCTACATT**TGA**TCTTTAACCTTA  
CAAGGAGATTTTTATTGGCTGATGGTAAAGCCAAACATTCTATTGTTTACTATGTT  
GAGCTACTGCAGTAAGTCATTGTTTACTATGTTCACCTGTTGCAGTAATACACAGAT  
AACTCTAGTGCATTACTTCACAAAGTACTTTCAAACATCAGATGCTTTATTCCAAAC  
CTTTTTCACCTTCACTAAGTGTGAGGGGAAGGCTACACAGACACATTCTTAGAATT  
GGAAAAGTGAGACCAGGCACAGTGGCTCACACCTGTAATCCCAGCACTAGGGAAAGACAAGTC  
AGGAGGATTGATTGAAGCTAGGAGTTAGAGACCAGCCTGGCAACGTATTGAGACCATGTCTA  
TTAAAAAATAAAATGGAAAAGCAAGAATAGCCTTATTCTAAAGTGTACTTTAGAAGTACATTATGGC  
TAGAGTTGCCAGATAAAATGCTGGATATCATGCAATAATTGCAAAACATCATCTAAAATT  
AAAAAAAAAAAAAAAAAAAAAA

22/168

## **FIGURE 22**

MEGESTSAVLSGFVLGALAFQHLNTDSDEGFLGEVKGEAKNSITDSQMDDVEVVYTIDIQK  
YIPCYQLFSFYNSGEVNEQALKKILSNVKKNVVGWYKFRRHSDQIMTFRERLLHKNLQEHS  
NQDLVFLLLTPSIITESCSTHRLEHSLYKPQKGLFHRVPLVVANLGMSEQLGYKTVGSCMST  
GFSRAVQTHSSKFFEEGSLKEVHKINEMYASLQEELKSICKVEDSEQAVDKLVKDVNRLKR  
EIEKRRGAQIQAAREKNIQKDPQENIFLCQALRTFFPNSEFLHSCVMSLKNRHVSKSSCNYNH  
HLDVVVDNLTLTLMVEHTDIPPEASPASTPQIIKHKALLDWRQFKRSRLLDTQDKRSKANTGSSN  
QDKASKMSSPETDEEIEKMKGFGEYSRSPTF

**Important features:**

**Signal peptide:**

amino acids 1-19

**N-glycosylation sites.**

amino acids 75-79, 322-326

**N-myristoylation site.**

amino acids 184-154

**Growth factor and cytokines receptors family.**

amino acids 134-150

23/168

## **FIGURE 23**

GGCACAGCCGCGCGCGGAGGGCAGAGTCAGCCGAGCCAGTCCAGCCGGACGAGCGGACCAGCGCAGGGCAGCC  
CAAGCAGCCGCAGCGAACGCCCGCCGCCACACCCCTCTGCGTCCCCGCGCGCTGCCACCCTCCCTCC  
TTCCCCCGCGTCCCCGCCCTCGCCGGCCAGTCAGCTGCCGGGTTGCGTCCCCCGCGAAACCCCGAGGTACCCAGCC  
CGCGCCTCTGCTTCCCTGGGCCGCCGCCACGCCCTCCTCTCCCTGGCCCGCCCTGGCACCGGGG  
ACCGTTGCCTGACCGCAGGGCCCAGCTCTACTTTGCCCGCGTCTCCCTGCCCTGCTGCCCTCTCCACCAACT  
CCAACCTCTTCTCCCTCCAGCTCCACTCGTAGTCCCCGACTCCGCCAGCCCTCGGCCGCTGCCGTAGGCCGC  
TTCCCGTCCGGTCCCAAAGGTGGAACCGTCCGCCCGGCCGACCATGGCACGGTTCGGCTTGCCCGCCTT  
CTCTGCACCCCTGGCAGTGCTCAGCGCCGCGTGTGGCTGCCGAGCTCAAGTCGAAAAGTGTGCTCGGAAGTGC  
CGTCTTACGTGTCCAAAGGCTCAACAAGAACGATGCCCTCCACGAGATCAACGGTGTACATTGAAGATC  
TGTCCCCAGGGTTCTACCTGCTGCTCTCAAGAGATGGAGGAGAAGTACAGCCTGCAAAGTAAAGATGATTCAA  
AGTGTGGTACCGAACAGTCAATCATTTGCAAGCTGTCTTGCTCACGTTACAAGAAGTTGATGAATTCTTC  
AAAGAACTACTTGAATGAGAATCCCTGAATGATATGTTGTGAAGACATATGGCATTATACATGCAA  
AATTCTGAGCTATTTAAAGATCTTCGTAGAGTTGAAACGTTACTACGTGGTGGGAAATGTGAACCTGGAAGAA  
ATGCTAAATGACTTCTGGCTCGCTCCTGGAGCGGATGTTCCGCTGGTAACCTCCAGTACCTTACAGAT  
GAGTATCTGAATGAGCAAGTATACTGGAGCAGCTGAAGCCCTCGGAGATGTCCTCGCAAATTGAAGCTC  
CAGGTTACTCGTGTCTTGAGCAGCCGTACTTCGCTCAAGGCTTAGCGGTTGCGGGAGATGTCGTGAGCAAG  
GTCTCCGTGGTAAACCCACAGCCCAGTGACCCATGCCCTGTTGAAGATGATCTACTGCTCCACTGCCGGGGT  
CTCGTGAAGCCATGTTACAACATACTGCTCAAACATCATGAGAGGCTGTTGGCAACCAAGGGGATCTC  
GATTTGAATGAAACAATTCTAGATGCTATGCTGATGGTGGCAGAGAGGCTAGAGGGTCTTCAACATTGAA  
TCGGTCATGGATCCATCGATGTGAAGATTCTGATGCTATTATGAACATGCAAGATAATAGTGTCAAGTGTCT  
CAGAAGGTTTCCAGGGATGTGGACCCCCCAAGCCCCTCCAGCTGGACGAATTCTCGTCCATCTGAAAGT  
GCCCTCAGTGCTCGCTCAGACCACATCCCCGAGGAACGCCAACACAGCAGCTGGCACTAGTTGGACCGA  
CTGGTTACTGATGTCAAGGAGAAACTGAAACAGGCAAGAAATTCTGGCTCCCTCCGAGCAACGTTGCAAC  
GATGAGAGGATGGCTGCAGGAAACGCAATGAGGATGACTGTTGAATGGAAAGGCAAAGCAGGTACCTGTT  
GCAGTGACAGGAAATGGATTAGCCAACCAGGGCAACAACCCAGAGGTCCAGGTTGACACCAGCAAACCAAGACATA  
CTGATCCTCGTCAAATCATGGCTCTCGAGTGATGACCAGCAAGATGAAGAATGCATAACATGGGAACGACGTG  
GACTTCTTGATATCAGTGATGAAAGTAGTGGAGAAGGAAGTGGAGTGGCTGTGAGTATCAGCAGTGCCCTCA  
GAGTTTGACTACAATGCCACTGACCATGCTGGAGAGTGCCAATGAGAAAGCCGACAGTGCTGGTGTCCGTCTT  
GGGGCACAGGCCAACCTCTCACTGTCATCTGCTTCTGCTTGTGTTATGCAGAGAGAGTGGAGATAATTCTCA  
AACTCTGAGAAAAAGTGTCTCATAAAAAGTAAAGGCACCAGTTATCACTTTCTACCATCCTAGTGACTTTG  
TTTTAAATGAATGGACAACAATGTACAGTTTACTATGTTGCACTGGTTAAGAAGTGTGACTTTGTT  
TCATTCAAGTTGGAGGAAAGGGACTGTGCATTGAGTTGGCTCTGCTCCCCAAACCATGTTAACGTGGCT  
AACAGTGAGGTACAGAACTATAGTTAGTTGTGCATTGATTTATCACTCTATTATTGTTGATGTTTT  
TTCTCATTTCGTTGTGGTTTTTCAACTGTGATCTGCCCTGTTCTTACAAGCAAACCAAGGGTCCCTT  
CTTGGCACGTAACATGTACGTATTCTGAAATATTAAATAGCTGTACAGAACAGGTTTATTATCATGTTATC  
TTATTAAAAGAAAAAGCCAAAAAGC

24/168

## **FIGURE 24**

MARFGLPALLCTLAVLSAÄLLAAELKSKCSEVRRLYVSKGFNKNDAPLHEINGDHLKICPQG  
STCCSQEMEEKYSIQLSKDDFKSVVSEQCNHLQAVFASRYKKFDEFFKELLENAEKS LNDMFVK  
TYGHLYMQNSELFKDLFVELKRYYVVGNVNLEEMLNDFWARLLERMFR LVNSQYHFTDEYLEC  
VSKYTEQLKPGDVRKLKLQVTRAFVAARTFAQGLAVAGDVSKVSVNPTAQCTHALLKMI  
YCSHCRLVTKPCNYCSNIMRGCLANQGDLDFEWNNFIDAMLMVAERLEGPFNIESVMDPI  
DVKISDAIMNMQDNSVQVSQKV FQGCGPPKPLPAGRISRS ISESAFSARFRPHHPEERPTAA  
GTSLDRLVTDVKEKLKQAKKFWSLPSNV CNDERMAAGNGNE DDWNGKGKS RYLFAVTGNGL  
ANQGNNPEVQVDTSKPDILILRQIMALRVMTSKMKNAYNGNDVDFFDISDESSGEGSGSGCEY  
QQCPSEFDYNATDHAGKSANEKA DSA GVRPGA QAYLLTVFCILFLVMQREWR

**Important features:**

**Signal peptide:**

amino acids 1-22

**ATP/GTP-binding site motif A (P-loop).**

amino acids 515-524

**N-glycosylation site.**

amino acids 514-518

**Glycosaminoglycan attachment sites.**

amino acids 494-498, 498-502

**N-myristoylation sites.**

amino acids 63-69, 224-230, 276-282, 438-444, 497-503, 531-537

**Glypicans proteins.**

amino acids 54-75, 105-157, 238-280, 309-346, 423-460, 468-506

25/168

**FIGURE 25**

CTCGCCCTCAAATGGGAACGCTGGCCTGGGACTAAAGCATAGACCACCAGGCTGAGTATCCTG  
ACCTGAGTCATCCCCAGGGATCAGGAGCCTCCAGCAGGAACCTCCATTATATTCTCAAGC  
AACTTACAGCTGCACCGACAGTTGCGATGAAAGTTCTAATCTCTCCCTCCTGTTGCTGC  
CACTAATGCTGATGTCCATGGTCTCTAGCAGCCTGAATCCAGGGTCGCCAGAGGCCACAGGG  
ACCGAGGCCAGGCTCTAGGAGATGGCTCCAGGAAGGCGGCCAAGAATGTGAGTGCAAAGATT  
GGTTCCCTGAGAGCCCCGAGAAGAAAATTCATGACAGTGTCTGGGCTGCCAAAGAAGCAGTGCC  
CCTGTGATCATTCAAGGGCAATGTGAAGAAAACAAGACACCAAAGGCACCCACAGAAAGCCAA  
ACAAGCATTCCAGAGCCTGCCAGCAATTCTCAAACAATGTCAGCTAAGAAGCTTGCTCTGC  
CTTGTAGGAGCTCTGAGGCCACTCTCCAATTAAACATTCTCAGCCAAGAAGACAGTGAG  
CACACCTACCAGACACTCTTCTCCCACCTCACTCTCCACTGTACCCACCCCTAAATCAT  
TCCAGTGCTCTCAAAAGCATGTTTCAGATCATTGTTGCTCTCTAGTGTCTT  
CTTCTCTCGTCAGTCTTAGCCTGTGCCCTCCCTACCCAGGCTTAGGCTTAATTACCTGAAA  
GATTCCAGGAAACTGTAGCTCCTAGCTAGTGTCAATTAAACCTAAATGCAATCAGGAAAGTA  
GCAAACAGAAGTCAATAAATATTTAAATGTCAAAAAAAAAAAAAAA

26/168

## **FIGURE 26**

MKVLISLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAPRRK  
FMTVSGLPKKQCPCDHFKGNNVKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL

**Important features:**

**Signal peptide:**

amino acids 1-22

**N-myristoylation sites.**

amino acids 27-33, 46-52

27/168

## **FIGURE 27**

GGACGCCAGCGCCTGCAGAGGCTGAGCAGGGAAAAAGCCAGTGCCCAAGCGGAAGCACAGCTC  
AGAGCTGGTCTGCCATGGACATCCTGGTCCCACCTCCTGCAGCTGCTGGTGTGCTTACCC  
TGCCCCCTGCACCTCATGGCTCTGCTGGGCTGCTGGCAGCCCCTGTGCAAAAGCTACTTCCC  
ACCTGATGGCCGTGCTGACTCCAAGAGCAACCGCAAGATGGAGAGCAAGAACGGGAGCTCT  
TCAGCCAGATAAAGGGGCTTACAGGAGCCTCCGGAAAGTGGCCCTACTGGAGCTGGGCTGCG  
GAACCGGAGCCAACTTCAAGTTCTACCCACCAGGGCTGCAGGGTACCTGCCTAGACCCAAATC  
CCCACTTGAGAAGTTCTGACAAAGAGCATGGCTGAGAACAGGCACCTCCAATATGAGCGGT  
TTGTGGTGGCTCCTGGAGAGGACATGAGACAGCTGGCTGATGGCTCCATGGATGTGGTGTCT  
GCACTCTGGTGCTGTGCTCTGTGCAAGGCCAAGGAAGGTCTGCAGGAGGTCCGGAGAGTAC  
TGAGACCGGGAGGTGTGCTCTTCTGGGAGCATGTGGCAGAACCATATGGAAGCTGGCCT  
TCATGTGGCAGCAAGTTCAAGCCCACCTGGAAACACATTGGGATGGCTGCTGCCTCACCA  
GAGAGACCTGGAAGGATCTTGAGAACGCCAGTTCTCGAAATGGAACGACAGCCCC  
CTCCCTGAAGTGGCTACCTGTTGGCCCCACATCATGGAAAGGCTGTCAAACAATCTTCC  
CAAGCTCCAAGGCACTCATTCCTCCCCAGCCTCCAATTAGAACAGCCACCCACCAGC  
CTATCTATCTTCACTGAGAGGGACTAGCAGAATGAGAGAACATTCAATGTACCACTACT  
AGTCCCTCTCCCCAACCTCTGCCAGGGCAATCTCAACTCAATCCGCCTCGACAGTGA  
AAAAGCTCTACTTCTACGCTGACCCAGGGAGGAAACACTAGGACCTGTTGTATCCTCAACTG  
CAAGTTCTGGACTAGTCTCCAACGTTGCCTCCAAATGTTGTCCTTCCCTCGTTCCCAT  
GGTAAAGCTCCTCTCGCTTCCCTGAGGCTACACCCATGCGTCTTAGGAACGTGGTCACAA  
AAGTCATGGTGCCTGCATCCCTGCCAAGCCCCCTGACCCCTCTCTCCCCACTACCACCTTCTT  
CCTGAGCTGGGGCACCAGGGAGAACATCAGAGATGCTGGGATGCCAGAGCAAGACTCAAAGAG  
GCAGAGGTTTGTCTCAAATATTTTAATAAATAGACGAAACCACG

28/168

## **FIGURE 28**

MDILVPLLQLLVLLLTLPLHLMALLGCWQPLCKSYFPYLMAVLTPKSNRKMEKKRELFSQIK  
GLTGASGKVALLELGCCTGANFQFYPPGCRVTCLDPNPHFEKFLTKSMAENRHLQYERFVVAP  
GEDMRQLADGSMDVVVCTLVLCSVQSPRKVLQEVRRLRPGGVLFFWEHVAEPYGSWAFMWQQ  
VFEPTWKHIGDGCCLTRETWKDLENAQFSEIQMERQPPPLKWLPVGPHIMGKAVKQSFPSKA  
LICSFPSLQLEQATHQPIYLPLRGT

**Important features:**

**Signal peptide:**

amino acids 1-23

**Leucine zipper pattern.**

amino acids 10-32

**N-myristoylation sites.**

amino acids 64-70, 78-84, 80-86, 91-97, 201-207

29/168

## **FIGURE 29**

CAATTTGCCTATCCACCTCCCCAAGCCCCTTACCTATGGCTGCTGCTAACGCTGCTGCTG  
CTGCTGCTGCTGCTTAAAGGCTCATGCTTGGAGTGGGACTGGTCGGTGCCCAGAAAGTCTCT  
TCTGCCACTGACCCCCCATCAGGGATTGGGCCTTCTTCCCCCTCCTTCTGTGTCTCCTG  
CCTCATCGGCCTGCCATGACCTGCAGCCAAGCCCAGCCCCGTGGGAAGGGGAGAAAGTGGGG  
GATGGCTAAGAAAGCTGGAGATAGGAAACAGAAGAGGGTAGTGGTAGGGCTAGGGGGCTGC  
CTTATTAAAGTGGTTGTTATGATTCTTATACTAATTACAAAGATATTAAGGCCCTGTT  
CATTAAGAAATTGTTCCCTCCCTGTGTTCAATGTTGTAAAGATTGTTCTGTGTAAATATG  
TCTTTATAATAAACAGTTAAAGCTGAAAAA

30/168

## **FIGURE 30**

MLLLTL<sub>n</sub>LLLKGSCLEWGLVGAQKVSSATDAPIRDWAFFPPSFLCLLPHRPAMTC<sub>n</sub>SQAQP  
RGEGEKVGDG

**Important features:**

**Signal peptide:**

amino acids 1-15

**Growth factor and cytokines receptors family:**

amino acids 3-18

## FIGURE 31

GTTCGAATTCTTCAACTATACCCACAGTCCAAAAGCAGACTCACTGTGTCCCAGGCTACCAG  
TTCCCTCCAAGCAAGTCATTTCCCTTATTAAACCGATGTGTCCCTCAAACACCTGAGTGCTACT  
CCCTATTGCATCTGTTTGATAAAATGATGTTGACACCCCTCCACCGAATTCTAAGTGGAATCA  
TGTCGGGAAGAGATACAATCCTGGCCTGTGTATCCTCGCATTAGCCTGTCTTGGCCATGA  
TGTTACCTCAGATTCATCACCAACCCCTCTGGTCACATTTCATTCATTGGTTATTTGG  
GATTGTTGTTGTCCTGCGGTGTTATGGTGGCTGTATTATGACTATAACCAACGACCTCAGCA  
TAGAATTGGACACAGAAAGGGAAAATATGAAGTGCCTGCTGGGTTGCTATCGTATCCACAG  
GCATCACGGCAGTGCTCGTCTTGATTTGTTCTCAGAAAGAGAATAAAATTGACAGTTG  
AGCTTTCAAATCACAAATAAAGCCATCAGCAGTGCTCCCTCCTGCTGTTCCAGCCACTGT  
GGACATTGCCATCCTCATTCTGGTCTCTGGTGGCTGTGCTGCTGAGCCTGGAA  
CTGCAGGAGCTGCCAGGTTATGGAAGGCGCCAAGTGGAAATATAAGCCCCTTCGGGCATTC  
GGTACATGTGGTCGTACCATTAAATTGGCCTCATCTGGACTAGTGAATTCATCCTGGCTGCC  
AGCAAATGACTATAGCTGGGCAGTGGTTACTGTTATTCAACAGAAGTAAAATGATCCTC  
CTGATCATCCCATCCTTCGTCTCTCCATTCTCTTCTACCATCAAGGAACC GTGTGA  
AAGGGTCATTTAATCTCTGTGGTAGGATTCCGAGAACATCATTGTCATGTACATGCAAACG  
CACTGAAAGAACAGCAGCATGGTCATTGTCCAGGTACCTGTTCCGATGCTGACTGCTGTT  
TCTGGTGTCTTGACAAATACCTGCTCCATCTCAACCAGAACATGCATATACTACAACGTCTATT  
ATGGGACAGATTTCTGTACATCAGAAAAGATGCATTCAAATCTGTCCAAGAACACTCAAGTC  
ACTTTACATCTATTAACTGCTTGAGACTTCATAATTCTAGGAAAGGTGTTAGTGGTGT  
GTTTCACTGTTTGAGGACTCATGGCTTTAACTACAATCGGCATTCCAGGTGTGGCAG  
TCCCTGTATTGGTAGCTTTGCCTACTTAGTAGCCCAGTCTGTGTT  
AAACTGTGCTGGATGCACTTCTGTGTTGCTGTTGATCTGGAAACAAATGATGGATCGT  
CAGAAAAGCCCTACTTATGGATCAAGAACATTCTGAGTTCGAAAAGGAGCAACAAATTAA  
ACAATGCAAGGGCACAGCAGGACAAGCACTCATTAAGGAATGAGGAGGGAACAGAACACTCCAGG  
CCATTGTGAGATAGATACCCATTAGGTATCTGTACCTGGAAAACATTCTCAAGAGCCA  
TTTACAGAATAGAAGATGAGACCCTAGAGAAAAGTTAGTGAATTTTTTAAAAGACCTAA  
TAAACCCATTCTCCTCAAAA

32/168

## **FIGURE 32**

MSGRDTILGLCILALALSIAMMFTFRFITTLLVHIFISLVLGLLFVCGLVWWLYYDYTNDLS  
IELDTERENMKCVLGFAIVSTGITAVLLVLIFVLRKRIKLTVELFQITNKAISAPFLLFQPL  
WTFFAILIFFWVLWVAVLLSLGTAGAAQVMEGGQVEYKPLSGIRYMWSYHLIGLIWTSEFILAC  
QQMTIAGAVVTCYFNRSKNDDPDHPILSSLSILFFYHQGTVVKGFLISVVRIPRIIVMYMQN  
ALKEQQHGALSRYLFRCYCFCWCLDKYLLHLNQNAYTTAINGTDFCTSAKDAFKILSKNSS  
HFTSINCFCDFIIIFLGKVLVVCFTVFGGLMAFNYNRAFQVWAVPLLLVAFFAYLVAHSFLSVF  
ETVLDALFLCFAVDLETNDGSSEKPYFMDQEFLSFVKRSNKLNNARAQQDKHSLRNEEGTELQ  
AIVR

**Important features:**

**Signal peptide:**

amino acids 1-20

**Putative transmembrane domains:**

amino acids 35-54, 75-97, 126-146, 185-204, 333-350, 352-371

**N-glycosylation sites.**

amino acids 204-208, 295-299, 313-317

**N-myristoylation sites.**

amino acids 147-153, 178-184, 196-202, 296-275, 342-348

## FIGURE 33

GTTCGATTAGCTCCTCTGAGAAGAAGAAAAGGTTCTGGACCTCTCCCTGTTCTCCTTA  
GAATAATTGTATGGATTGTGATGCAGGAAAGCCTAACGGAAAAGAATATTCAATTCTGTG  
TGGTAAAATTGAAAAAAATTGCCTCTTCAAACAAGGGTGTCAATTCTGATATTAT**A**  
GAGGACTGTTGTCACTATGAAGGCATCTGTTATTGAAATGTTCTTGTGCTGGTGAC  
TGGAGTACATTCAAACAAAGAAACGGCAAAGAAGATTAAAGGCCAAGGTTCACTGTGCCTCA  
GATCAACTGCGATGTCAAAGCCGAAAGATCATGATCCTGAGGTTCAATTGTGAAATGTCCAGC  
AGGATGCCAAGACCCAAATACCATGTTATGGCACTGACGTGTATGCATCCTACTCCAGTGT  
GTGTCGGCTGCCGTACACAGTGGTGCTGATAATTCAAGGAGGGAAAATACTGTTCCGAA  
GGTGTGGACAGTCTGGTTACAAAGGGAGTTATTCCAACGGTGTCCAATCGTTATCCCTACC  
ACGATGGAGAGAACTCTTATCGTCTTAGAAAGTAAACCCAAAAGGGTGTAAACCTACCCATC  
AGCTCTTACATACATCATCGAAAAGTCCAGCTGCCAAGCAGGTGAGACCAAAAGCCTA  
TCAGAGGCCACCTATTCCAGGGACAACACTGCACAGCCGGTCACTCTGATGCAGCTCTGGCTGT  
CACTGTAGCTGTGGCCACCCCCACCACCTGCCAAGGCCATCCCTCTGCTGCTTCTACCAC  
CAGCATCCCCAGACCACAAATCAGTGGCCACAGGAGCCAGGAGATGGATCTCTGGTCCACTGC  
CACCTACACAAGCAGCCAAACAGGCCAGAGCTGATCCAGGTATCCAAGGCAAGATCCTTC  
AGGAGCTGCCTTCAGAAACCTGTTGGAGCGGATGTCAGCCTGGACTTGTCCAAAAGAAGA  
ATTGAGCACACAGTCTTGGAGCCAGTATCCCTGGGAGATCCAACACTGCAAAATTGACTTGT  
GTTTTAATTGATGGGAGCACCAGCATTGCCAACGGCGATTCCAATCAGAACAGCAGCTCC  
GGCTGATGTTGCCAAGCTCTGACATTGGCCCTGCCGGTCACTGATGGGTGTTGTCCAGTA  
TGGAGACAACCTGCTACTCACTTAACCTCAAGACACACGAATTCTGAGATCTGAAGAC  
AGCCATAGAGAAAATTACTCAGAGAGGAGGACTTTCTAATGTAAGTCGGCCATCTCCTTGT  
GACCAAGAACTCTTCCAAAGCCAATGGAAACAGAACAGCAGGGCTCCAAATGTTGGTGGTGGT  
GATGGTGGATGGCTGCCAACGGACAAAGTGGAGGAGGCTTCAAGACTTGCAGAGAGTCAGG  
AATCAACATTTCATCACCATTGAAGGTGCTGCTGAAAATGAGAACAGTATGTTGGTGG  
GCCCAACTTGCACAAAGCCGTGTCAGAACAAACGGCTTCACTCGTCCACGTGCAGAG  
CTGGTTGGCTCCACAAGACCTGAGCCTGAGCATTGGCTCGTCACTGACGGCTCCAGCAG  
TGTGGGACGGCAACTCCGCACCGTCTCAGTTGTGACCAACCTCACCAAGAGTTGA  
GATTTCCGACACGGACACCGCATGGGGCCGTGCAGTACACCTACGAACAGCGCTGGAGTT  
TGGGTTGACAAGTACAGCAGCAAGCCTGACATCCTCAACGCCATCAAGAGGGTGGCTACTG  
GAGTGGTGGCACAGCACGGGGCTGCCATCAACTCGCCCTGGAGCAGCTCTCAAGAACG  
CAAGCCAACAGAGGAAGTTAATGATCCTCATCACCGACGGAGGTCTACGACGGACGTCCG  
GATCCCAGCCATGGCTGCCCATCTGAAGGGAGTGTACCTATGCGATAGGCGTTGCCTGGG  
TGCCCAAGAGGAGCTAGAAGTCATGCCACTCACCCGCCAGAGACCACTCCTCTTGTGGA  
CGAGTTGACAACCTCCATCAGTATGTCCTCAGGATCATCCAGAACATTGTACAGAGTTCA  
CTCACAGCCTCGAACTGAATTCAAGAGCAGGCAGAGCACCAGCAAGTGTGCTTACTA  
ACGTGTTGGACCAACCCACCGCTTAATGGGGCACGCACGGTGCATCAAGTCTGGCAGGGCA  
TGGAGAAAACAAATGTCTTGTATTATTCTTGCCTCATGCTTTCTATATTCCAAAACATTGG  
AGTTACAAAGATGATCACAAACGTATAGAATGAGCAAAGGCTACATCATGTTGAGGGTGT  
GGAGATTTCACATTGACAATTGTTCAAAATAATGTTGGAATACAGTGCAGCCCTAC  
GACAGGCTACGTAGAGCTTGTGAGATTAAAGTGTATTCTGATTGAACTCTGTAA  
CCCTCAGCAAGTTCTATTGTCATGACAATGTAGGAATTGCTGAATTAAATGTTAGAAGG  
ATGAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAG  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAG

34/168

## FIGURE 34

MRTVVLTMKASVIEMFLVLLVTGVHSNKETAKKIKRPKFTVPQINC DVKAGKIIDPEFIVKCP  
AGCQDPKYHVGTDVYASYSSVC GAAVHSGVLDNSGGKILVRKVAGQSGYKGSYSNGVQSLSL  
PRWRESFIVLESKP KGVTVPSALTYSSSKSPAAQAGETTKAYQR PPIPGTTAQPVTL MQLLA  
VTVA VATPTTLP RPSPSAASTTSIPRPQSVG HRSQEMDLWSTATYTSSQN RPRADPGIQR QDP  
SGAAFQKPVGADVSLGLVPKEELSTQSLEPVSLGDPNCKIDLSFLIDGSTSIGKRRFR I QKQL  
LADVAQALD IGPAGPLMGVVQYGDNPATHFNLKHTNSRDLKTAIEKITQRGG LSNVGRAIS F  
VTKNFFSKANGNRSGAPNVVVVMVDGWPTDKVEEASRLARESGINIFFITIEGAAENEKQYVV  
EPNFANKAVCRTNGFYSLHVQSWFGLHKT LQPLVKRVCDTDRLACSKTCLNSADIGFVIDGSS  
SVGTGNFR TVLQFVTNL TKEFEIS DTDTRIGAVQYTYEQRLEFGFD KYSSKPD ILNAIKRVGY  
WSGGTSTGAA INF ALEQLFKKS KPNKR KLMILITDGRSYDDV RI PAMA AHLKG VITYAIGVAW  
AAQEELEVIATHPARDHSFFVDEF DNLHQYV PRI IQNICTEFNSQPRN

**Important features:**

**Signal peptide:**

amino acids 1-26

**Transmembrane domain:**

amino acids 181-200

**N-glycosylation sites.**

amino acids 390-394, 520-524

**N-myristoylation sites.**

amino acids 23-29, 93-99, 115-121, 262-268, 367-373, 389-395,  
431-437, 466-472, 509-515, 570-576, 571-577, 575-581, 627-633

**Amidation site.**

amino acids 304-308

## FIGURE 35

CCGAGCACAGGAGATTGCCCTGCCTTAGGAGGTGGCTGCCTGTGGAAAAGCTATCAAGGAA  
GAAATTGCCAACCATGTCTTTCTGTTTCAGAGTAGTCACAACAGATCTGAGTGT  
TAATTAAGCATGGAATACAGAAAACAACAAAAACTTAAGCTTAATTCTGGAATTCCA  
CAGTTTCTTAGCTCCCTGGACCCGGTTGACCTGTTGGCTCTTCCCCTGGCTGCTCTAC  
GTGGTGCTCTCCGACTACTCACCCCGAGTGTAAAGAACCTTCGGCTCGCGTGTGCTGAGCTG  
CTGTGGATGGCCTCGGCTCTGGACTGTCTCCGAGTAGGATGTCAGTGAGATCCCTCAA  
TGGAGCCTCCTGCTGCTGTCACTCCTGAGTTCTTGATGTGGTACCTCAGCCTCCCCAC  
TACAATGTGATAGAACCGCGTGAACGGATGTACTTCTATGAGTATGAGCCGATTTACAGACAA  
GACTTTCACTTCACACTTCGAGAGCATTCAAACACTGCTCTCATCAAACCCATTCTGGTCATT  
CTGGTGACCTCCCACCCTCAGATGTGAAAGCCAGGCAGGCCATTAGAGTTACTGGGGTGAA  
AAAAAGTCTGGTGGGGATATGAGGTCTTACATTTCTTATTAGGCCAAGAGGCTGAAAAG  
GAAGACAAAATGTTGGCATTGCTTAGAGGATGAACACCTTCTTATGGTACATAATCCGA  
CAAGATTTTAGACACATATAAACCTGACCTTGAAAACCATTATGGCATTCAAGGTGGTA  
ACTGAGTTTGCCCCAATGCCAAGTACGTAATGAAGACAGACACTGATGTTCTCAAAACT  
GGCAATTAGTGAAGTATCTTAAACCTAAACCACTCAGAGAAGTTTACAGGTTATCCT  
CTAATTGATAATTATTCTATAGAGGATTACCAAAAAACCCATTCTTACCAAGGAGTAT  
CCTTCAGGTGTTCCCTCCATACTGCAGTGGTTGGGTATATAATGTCAGAGATTGGT  
CCAAGGATCTATGAAATGATGGTCACGTAAACCCATCAAGTTGAAGATGTTATGCGGG  
ATCTGTTGAATTATTAAAAGTGAACATTCAATTCCAGAAGACACAAATCTTCTTCTA  
TATAGAATCCATTGGATGTCGTCAACTGAGACGTGTGATTGCAGCCATGGCTTTCTCC  
AAGGAGATCATCACTTTGGCAGGTCAAGGAACACCACATGCCATTATTAACTTCAC  
ATTCTACAAAAGCCTAGAAGGACAGGACACCTGTGGAAAGTGTAAATAAGTAGGTACTG  
TGGAAAATTGATGGGGAGGTACACTGTGATTATTAGTCAGGCCCTCAAAGATGATATGTT  
GACTGGAGACTGGAGGGTTACACTGTGATTATTAGTCAGGCCCTCAAAGATGATATGTT  
AGGAATTAAATATAAGGAATTGGAGGTTTGCTAAAGAAATTAAATAGGACCAACAAATTG  
GACATGTCATTCTGTAGACTAGAATTCTAAAGGGTGTACTGAGTTATAAGCTCACTAGG  
CTGTAAAAACAAACATGTAGAGTTATTGAACAATGTAGTCACTTGAAGGTTTG  
GTATATCTTATGTGGATTACCAATTAAAAATATGTAGTTCTGTGTCAAAAAACTCTTCA  
CTGAAGTTACTGAACAAAATTACCTGTTTGGTCATTATAAGTACTTCAGATGTT  
GCAGTATTTCACAGTTATTATTAAATTACTCAACTTGTGTTTAAATGTTGAC  
GATTCAATACAAGATAAAAGGATAGTGAATCATTACATGCAAACATTCCAGTTAC  
TTAACTGATCAGTTATTATTGATACATCACTCCATTAAATGTAAAGTCAGGTCAATTG  
ATATCAGTAATCTCTGGACTTTGTAAATATTACTGTGGTAATATAGAGAAGAATTAAAG  
CAAGAAAATCTGAAAA

36/168

## **FIGURE 36**

MASALWTVLPSRMSLRLSLKWSLLLLSLLSFFVMWYLSLPHYNVIERVNWMYFYEYEPIYRQDF  
HFTLREHSNC SHQNPFLVILVTSHPSDVKARQAIRVTWGEKKSWWGYEVLTFFLLGQEAEKED  
KMLALSLEDEHLLYGDIIHQDFLDTYNNLT LKTI MAFRWVTEFC PNAKYVMKTDTDVFINTGN  
LVKYLLNLNHSEKFFTGYPLIDNYSYRGFYQKTHISYQEYPFKVFPPYCGLGYIMSRDLVPR  
IYEMMGHVKPIKFEDVYVGICLNLLKVNIHIPEDTNLFFLYRIHLDVCQLRRVIAAHGFSSKE  
IITFWQVMLRNTTCHY

**Important features:**

**Type II transmembrane domain:**

amino acids 20-39

**N-glycosylation sites.**

amino acids 72-76, 154-158, 198-202, 212-216, 326-330

**Glycosaminoglycan attachment site.**

amino acids 239-243

**Ly-6 / u-PAR domain proteins.**

amino acids 23-37

**N-myristoylation site.**

amino acids 271-277

## **FIGURE 37**

## FIGURE 38

MELGCWTQLGLTFLQLLLISLSPREYTVINEACPGAEWNIMCRECCEYDQIECVCPGKREVVG  
YTIPCCRNEENECDSCLIHPGCTIFENCKSCRNGSWGGTLDDFYVKGFYCAECRAGWYGGDCM  
RCGVQLRAPKGQILLESYPLNAHCEWTIHAKPGFVIQLRFVMLSLEFDYMCQYDYVEVRDGDN  
RDGQIIKRVCGNERPAPIQSIGSSLHVLFHSDGSKNFDGFHAIYEEITACSSSPCFHDGTCVL  
DKAGSYKCACLAGYTGQRCENLLEERNCSDPGGPVNGYQKITGGPLINGRHAKIGTVVSFFC  
NNSYVLSGNEKRTCQQNGEWSGKQPICIKACREP KISDLVRRVLPMQVQSRETPLHQLYSAA  
FSKQKLQSAPTKKPALPFGDLPMGYQHLHTQLQYECISPFYRRLGSSRRTCLRTGKWSGRAPS  
CIPICGKIENITAPKTQGLRW PWQAAIYRRTSGVHDGSLHKGAWF LVCS GALVNERTVVVAAH  
CVTDLGKV TMK TADLK VVLGKF YR D D RDE KT IQSL QI SAI ILHP NYD PI LDADIA I LKLL  
DKARI STRV QPI CLA ASR DL STSF QES HITVAG WNV LAD VR SP GF KND TL RG VV SV DS LLC  
EEQHEDHGIPVSVTDNMFCASWEPTAPS DICT AETGGIAAVSFPGRASPEPRW HLMGLVWSY  
DKTCSHRLSTAFTKVL PKDW IERN MK

**Important features of the protein:**

**Signal peptide:**

amino acids 1-23

**EGF-like domain cysteine pattern signature.**

amino acids 260-272

**N-glycosylation sites.**

amino acids 96-100, 279-283, 316-320, 451-455, 614-618

**N-myristoylation sites.**

amino acids 35-41, 97-103, 256-262, 284-290, 298-304, 308-314,  
474-480, 491-497, 638-644, 666-672

**Amidation site.**

amino acids 56-60

**Serine proteases, trypsin family.**

amino acids 489-506

**CUB domain proteins profile.**

amino acids 150-167

## FIGURE 39

GGTCCTACATCCTCATCTGAGAATCAGAGAGATAATCTTCTACGGGCCGTATTATTAACGTGGCTTA  
ATCTGAAGTTCTCAGTCATAATTCTTGTGATCTACTGATTGTGGGGCATGGCAAGGTTGCTAAAGGAGCTT  
GGCTGGTTGGGCCCTGTAGCTGACAGAAGGTGGCCAGGGAGAATGCAGCACACTGCTCGGAGAATGAAGGCGC  
TTCTGTTGCTGGCTTGCCCTGGCTCAGTCCTGCTAACTACATTGACAATGTGGCAACCTGCACCTCCTGTATT  
CAGAACTCTGTAAAGGTGCCTCCACTACGGCCTGACCAAAGATAAGGAAGAGGGCGCTACAAGATGGCTGTCCAG  
ACGGCTGTGCGAGCCTCACGCCACGGCTCCCTCCCCAGAGGTTCTGCAGCTGCCACCCTCCTTAATGACAG  
ACGAGCCTGGCTAGACAACCTGCCTACGTGTCCTGGCAGAGGACGGGAGCCAGCAATCAGCCCAGTGGACT  
CTGGCCGGAGCAACCGAAGTAGGGCACGCCCTTGAGAGATCCACTATTAGAACAGATCATTTAAAAAAATAA  
ATCGAGCTTGAGTGTCTCGAAGGACAAGAGCGGGAGTCAGTTGCCAACCATGCCGACCAGGGAGGGAAA  
ATTCTGAAAACACCACTGCCCTGAAGTCTTCCAAGGTTGATTCCAGATGGTAAATTACAGCA  
TCAAGATCAATCGAGTAGATCCCAGTGAAAGCCTCTATTAGGCTGGTGGGAGGTAGCGAAACCCACTGGTCC  
ATATCATTATCAAACACATTATCGTATGGGTGATGCCAGAGACGGCCGGCTACTGCCAGGAGACATCATT  
TAAAGGTCAACGGGATGGACATCAGCAATGCCCTCACAACTACGCTGTGCGTCTCTGGCAGCCCTGCCAGG  
TGCTGTGGCTGACTGTGATGCGTAACAGAAGTCCGAGCAGGAACAATGGACAGGCCCGGATGCCCTACAGAC  
CCCGAGATGACAGCTTCATGTGATTCTCAACAAAGTAGCCCCGAGGAGCAGCTTGAATAAAACTGGTGC  
AGGTGGATGAGCCTGGGTTTCATCTTCAATGTGCTGGATGGCGGTGTCGATATCGACATGGTCA  
AGAATGACCGTGTGTTAGCCATCAATGGACATGATCTCGATATGGCAGCCCAGAAAGTGCAGCTCATCTGATT  
AGGCCAGTGAAAGACGTGTTCACCTCGTCGTGTCAGGCCAGGTTGGCAGCGGAGCCCTGACATCTTCAGGAAG  
CCGGCTGGAACAGCAATGGCAGCTGGTCCCCAGGGCCAGGGGAGAGGAGCAACACTCCAAGCCCTCATCCTA  
CAATTACTGTGAGAAGGTGTTAAATATCCAAAAGACCCGGTGAATCTCGGATGACCGTGCAGGG  
GAGCATCACATAGAGAATGGATTGCTATCTATGTGTCAGTGTGAGGCCGGAGGAGTCATAAGCAGAGATG  
GAAGAATAAAACAGGTGACATTGTTGAATGTGGATGGGTCGAACACTGACAGAGTCAGCCGGAGTGAGG  
TGGCATTATTGAAAAGAACATCATCCTCGATAGTACTCAAAGCTTGAAGTCAGAGTATGAGGCCAGGAAG  
ACTGCAGCAGCCAGGCCAGCCCTGGACTCCAACCACACATGGCCCCACCCAGTGACTGGTCCCCATCTGGTCA  
TGTGGCTGGAATTACACGGTGTGTTATACTGTAAAGATATTGTATTACGAAGAACACAGCTGAAAGTCTGG  
GCTTCTGCATTGAGGTTATGAAGAATACAATGGAAACAAACCTTTTCTCAAATCCATTGTTGAAGGAA  
CACCAGCATACATGATGGAAGAATTAGATGTGGTATATTCTCTGCTGTCAATGGTAAAGTACATCAGGAA  
TGATACATGCTTGCTGGCAAGACTGCTGAAAGAACTTAAAGGAAGAATTACTCTAATATTGTTCTGGCCTG  
GCACTTTTTTAGAATCAATGATGGGTCAAGGAAAACAGAAAATCACAAATAGGCTAAGAAGTGAACACT  
ATATTTATCTGTCAGTTTATATTAAAGAAAGAATACATTGTAAGGAAACTGTCAGGAAAGTATGATCATCTAA  
TGAAAGCCAGTTACACCTCAGAAAATATGATTCAAAGGAAACTGTCAGGAAAGTATGATCATCTAA  
TTCTCATTACTCTACAACATTGTTATATTCTATTCAATAAGGAAACACTAAATGATTGATT  
TGTATACCCACTGAATTCAAGCTGATTAAATTAAAGGTTATGCTGAAGTCTGCCAAGGGTACATT  
GGCCATTAAATTACAGCTAAAGAATTCTTAAAGGTTCAATTGCTGAGAAACGTTGCTTCAACACAAGAAT  
AAATATTTCAGAAGTTAAA

40/168

## FIGURE 40

MKALLLLVLPWLSPANYIDNVGNLHFLYSELCKGASHYGLTKDRKRRSQDGCPDGCASLTATA  
PSPEVSAATISLMTDEPGLDNPAYVSSAEDGQPAISPVDGRSNRTRARPFERSTIRSRSK  
KINRALSVLRRTKSGSAVANHADQGRENTTAPEVFPRLYHLIPDGEITSIKINRVDPSES  
LSIRLVGGSETPLVHIIIQHIYRDGVIARDGRLLPGDIILKVNGMDISNVPHNYAVRLLRQPC  
QVLWLTVMREQKFRSRNNGQAPDAYRPRDDSFHVILNKSSPEEQLGIKLVRKVDEPGVFIFNV  
LDGGVAYRHGQLEENDRVLAINGHDLRYGSPESAHLIQASERRVHLVVSQRSPDI FQE  
AGWNSNGSWSPGPERSNTPKPLHPTITCHEKVVNIQKDPGESLGMTVAGGASHREWDLPIYV  
ISVEPGGVISRDGRIKTGDILLNDGVELTEVSRSEAVALLKRTSSSIVLKALEVKEYEPQED  
CSSPAALDSNHNMAPPSDWSPSWVMWLELPRCLYNCKDIVLRRNTAGSLGFCIVGGYEEYNGN  
KPFFIKSIVEGTPAYNDGRIRC DILLAVNGRSTSGMIHACLARLLKELKGRITLTIVSWPGTFL

**Important features:**

**Signal peptide:**

amino acids 1-15

**N-glycosylation sites.**

amino acids 108-112, 157-161, 289-293, 384-388

**Tyrosine kinase phosphorylation sites.**

amino acids 433-441, 492-500

**N-myristoylation sites.**

amino acids 51-57, 141-147, 233-239, 344-350, 423-429, 447-453,  
467-473, 603-609

## FIGURE 41

ACCAGGCATTGTATCTTCAGTTGTCATCAAGTTCGCAATCAGATTGGAAAAGCTCAACTTGAA  
GCTTCTGCCTGCAGTGAAGCAGAGAGATAGATATTATTACAGTAATAAAAACATGGGCTT  
CAACCTGACTTCCACCTTCCTACAAATTCCGATTACTGTTGCTGTTGACTTGTGCCTGAC  
AGTGGTTGGGTGGGCCACCAGTAACTACTCGTGGGTGCCATTCAAGAGATTCCTAAAGCAAA  
GGAGTTCATGGCTAATTCCATAAGACCCCTCATTTGGGAAGGGAAAAACTCTGACTAATGA  
AGCATCCACGAAGAAGGTAGAACCTGACAACGTGCTTCTGTGTCCTTACCTCAGAGGCCA  
GAGCAAGCTCATTTCAAACCAAGATCTCACTTGGAAAGAGGTACAGGCAGAAAATCCAAAGT  
GTCCAGAGGCCGGTATGCCCTCAGGAATGTAAGCTTACAGAGGGTGCCTACCTCGTTCC  
CCACCGGAACAGAGAGAACACCTGATGTACCTGCTGGAACATCTGCATCCCTCCTGCAGAG  
GCAGCAGCTGGATTATGGCATCTACGTACCCACCAGGCTGAAGGTAAAAGTTAACCGAGC  
CAAACCTTGAATGTGGCTATCTAGAACGCCCTCAAGGAAGAAAATTGGACTGCTTATATT  
CCACGATGTGGACCTGGTACCCGAGAATGACTTAAACCTTACAAGTGTGAGGAGCATCCAA  
GCATCTGGTGGTGGCAGGAACAGCACTGGTACAGGTTACGTTACAGTGGATATTTGGGG  
TGTACTGCCCTAACGAGAGAGCAGTTTCAAGGTGAATGGATTCTAACAAACTACTGGGG  
ATGGGGAGGCGAACGACGATGACCTCAGACTCAGGGTTGAGCTCCAAGAATGAAAATTCCCG  
GCCCTGCCTGAAGTGGTAAATATAACATGGCTTCCACACTAGAGACAAAGGCAATGAGGT  
GAACGCAGAACGGATGAAGCTCTCACACCAAGTGTACAGGACTGGAGCTGGTGA  
TAGTTGTTCTATAAAATTAGTATCTGTGGAACACAATCCTTATATACACATCACAGTGG  
TTTCTGGTTGGTGCATTGACCTGGATTTGGTATTTGGAAAGAACTGATTCTTGT  
GCAATAATTGGCCTAGAGACTTCAAATAGTAGCACACATTAAGAACCTGTTACAGCTCATT  
GTTGAGCTGAATTTCCTTTGTATTTCTAGCAGAGCTCCTGGTGAATGTAGAGTATAAA  
ACAGTTGTAACAAGACAGCTTCTTAGTCATTTGATCATGAGGGTTAAATATTGTAATATGG  
ATACTGAAAGGACTTATATAAAAGGATGACTCAAAGGATAAAATGAACGCTATTGAGGACT  
CTGGTTGAAGGAGATTATTAAATTGAAGTAATATATTATGGATAAAAGGCCACAGGAAA  
TAAGACTGCTGAATGTCTGAGAGAACAGAGTTGTTCTCGTCCAAGGTAGAAAGGTACGAAGA  
TACAATACTGTTATTCAATTATCCTGTACAATCATCTGTGAAGTGGTGGTGTCAAGTGAGAAG  
GCGTCCACAAAAGAGGGAGAAAAGGCGACGAATCAGGACACAGTGAACCTGGGAATGAAGAG  
GTAGCAGGAGGGTGGAGTGTGGCTGCAAAGGCAGCAGTAGCTGAGCTGGTGCAGGTGCTGA  
TAGCCTTCAGGGGAGGACCTGCCAGGTATGCCCTCCAGTGATGCCACCAGAGAATACATTC  
TCTATTAGTTAAAGAGTTTGAAATGATTTGACAAGTAGGATATGAATTAGCAGT  
TTACAAGTTACATATTAACATAAAATATGTCTATCAAATACCTCTGTAGTAAAATGTG  
AAAAAGCAAA

42/168

## FIGURE 42

MGFNLTFHLSYKFRLLLLLTLCLTVVGWATSNYFVGAIQEIPKAKEFMANFHKTLLGKGKTL  
TNEASTKKVELDNCPSVSPYLRGQSKLIFKPDLTLEEVQAENPKVSRGRYRPQECKALQRVAI  
LVPHRNREKHLMYLLEHLHPFLQRQQLDYGIYVIHQAEGKKFNRAKLLNVGYLEALKEENWDC  
FIFHDVDLVPENDFNLYKCEEHPKHLVVGRNSTGYRLRSGYFGGVTAWSREQFFKVNGFSNN  
YWGWGGE-DDDLRLRVELQRMKISRPLPEVGKYTMVFHTRDKGNEVNAERMKLLHQVSRVWRTD  
GLSSCSYKLVSVEHNPLYINITVDFWFGA

**Important features:**

**Signal peptide:**

amino acids 1-27

**N-glycosylation sites.**

amino acids 4-8, 220-224, 335-339

**Xylose isomerase proteins.**

amino acids 191-202

43/168

**FIGURE 43**

GCTCAAGACCCAGCAGTGGGACAGCCAGACAGACGGCACGATGGCACTGAGCTCCCAGATCTG  
GGCCGCTTGCCTCCTGCTCCTCCTCCTGCCAGCCTGACCAGTGGCTCTGTTTCCCACA  
ACAGACGGACAACCTGCAGAGCTGCAACCCCAGGACAGAGCTGGAGCCAGGGCCAGCTGGAT  
GCCCATGTTCCAGAGGCGAAGGAGGCGAGACACCCACTTCCCCATCTGCATTTCTGCTGCGG  
CTGCTGTATCGATCAAAGTGTGGATGTGCTGCAAGACGTAGAACCTACCTGCCCTGCC  
GTCCCCCTCCCTCCTTATTATTCCTGCTGCCAGAACATAGGTCTTGAATAAAATGGCTG  
GTTCTTTGTTTCCAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAA

44/168

**FIGURE 44**

MALSSQIWAACLLLLLLASLTSGSVFPQQTGQLAELQPQDRAGARASWMPMFQRRRRDTHF  
PICIFCCGCCHRSKCGMCCKT

**Important features:**

**Signal peptide:**

amino acids 1-24

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 58-59

**N-myristoylation site.**

amino acids 44-50

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 1-12

45/168

**FIGURE 45**

GTGGCTTCATTCAGTGGCTGACTTCCAGAGAGCAATATGGCTGGTTCCCCAACATGCCCTCAC  
CCTCATCTATATCCTTGGCAGCTCACAGGGTCAGCAGCCTCTGGACCCGTGAAAGAGCTGGT  
CGGTTCCGTTGGTGGGGCCGTGACTTCCCCCTGAAGTCAAAGTAAAGCAAGTTGACTCTAT  
TGTCTGGACCTTCAACACACAACCCCTCTTGTACCACAGCCAGAAGGGGGCACTATCATAGT  
GACCCAAAATCGTAATAGGGAGAGAGTAGACTTCCCAGATGGAGGCTACTCCCTGAAGCTCAG  
CAAACGTGAAGAAGAATGACTCAGGGATCTACTATGTGGGGATATACTACAGCTCATCACTCCAGCA  
GCCCTCCACCCAGGGAGTACGTGCTGCATGTCTACGAGCACCTGTCAAAGCCTAAAGTCACCAT  
GGGTCTGCAGAGCAATAAGAATGGCACCTGTGACCAATCTGACATGCTGCATGGAACATGG  
GGAAGAGGGATGTGATTTACCTGGAAGGCCCTGGGCAAGCAGCCAATGAGTCCCATAATGG  
GTCCATCCTCCCCATCTCCTGGAGATGGGAGAAAGTGATATGACCTTCATCTGCCTGCCAG  
GAACCCCTGTCAGCAGAAACTTCTCAAGCCCCATCCTGCCAGGAAGCTCTGTGAAGGTGCTGC  
TGATGACCCAGATTCCCTCATGGCCTCCTGTGTCTCCTGTTGGTGCCTCCTGCTCAGTCT  
CTTGACTGGGCTATTCTTGGTTCTGAAGAGAGAGACAAGAAGAGTACATTGAAGA  
GAAGAAGAGAGTGGACATTGTCGGAAACTCTTAACATATGCCCTATTCTGGAGAGAACAC  
AGAGTACGACACAATCCCTCACACTAATAGAACAACTCTAAAGGAAGATCCAGCAAATACGGT  
TTACTCCACTGTGGAAATACCGAAAAAGATGGAAAATCCCCACTCACTGCTCACGATGCCAGA  
CACACCAAGGCTATTGCCTATGAGAATGTTATCTAGACAGCAGTGCACTCCCCTAAGTCTCT  
GCTCA

46/168

## **FIGURE 46**

MAGSPTCLTLIYILWQLTGSAAASGPVKELVGSVGGAVTFPLKSKVKQVDSIVWTFNTTPLVTI  
QPEGGTIIVTQNRRERVDFPDGGYSLKLSKLKKNDSGIYYVGIYSSSLQQPSTQEYVLHVE  
HLSKPKVTMGLQSNKNGTCVTNLTCMEHGEEDVIYTWKALGQAANESHNGSILPISWRWGES  
DMTFICVARNPVSRFSSPILARKLCEGAADDPDSSMVLCLLLVPLLLSLFVLGLFLWFLKR  
ERQEEYIEEKKRVDICRETPNICPHSGENTEYDTIPHTNRTILKEDPANTVYSTVEIPKKMEN  
PHSLLTMPDTPRLFAYENVI

**Important features:**

**Signal peptide:**

amino acids 1-22

**Transmembrane domain:**

amino acids 224-250

**Leucine zipper pattern.**

amino acids 229-251

**N-glycosylation sites.**

amino acids 98-102, 142-146, 148-152, 172-176, 176-180, 204-208,  
291-295

47/168

**FIGURE 47**

GGCTCGAGCGTTCTGAGCCAGGGTGACCATGACCTGCTGCGAAGGATGGACATCCTGCAAT  
GGATTCA~~G~~CCTGCTGGTTCTACTGCTGTTAGGAGTAGTCTCAATGCGATA~~C~~CTCAATTGTC  
AGCTTAGTTGAGGAAGACCAATTCTCAAAACCCATCTCTGCTTGAGTGGTGGTCCCA  
GGAATTATAGGAGCAGGTCTGATGCCATTCCAGCAACAACAATGTCCTGACAGCAAGAAAA  
AGAGCGTGCTGCAACA~~A~~CAGAACTGGAATGTTCTTCATCATTTTCAGTGTGATCACAGTC  
ATTGGTGCTCTGTATTGCATGCTGATATCCATCCAGGCTCTCTAAAAGGTCTCATGTGT  
AATTCTCCAAGCAACAGTAATGCCAATTGTGAATTTCATTGAAAAACATCAGTGACATTCA  
CCAGAATCCTTCAACTTGCA~~G~~TGGTTTTCAATGACTCTGTGCACCTCCTACTGGTTCAAT  
AAACCCACCAGTAACGACACC~~A~~GGCGAGTGGCTGGAGAGCATCTAGTTCCACTTCGATTCT  
GAAGAAAACAAACATAGGCTTATCCACTTCTCAGTATTAGGTCTATTGCTTGGAAATT  
CTGGAGGTCTGTTGGCTCAGTCAGATAGTCATGGTTCTGGCTGTGTGGAGTC  
TCTAAGCGAAGAAGTCAAATTGTGTAGTTAATGGGAATAAAATGTAAGTATCAGTAGTTGA  
AAAAAAAAAA

48/168

## FIGURE 48

MTCCEGWTSCNGFSLLVLLLLGVVLNAIPLIVSLVEEDQFSQNPISCFEWWFPGIIGAGLMAI  
PATTMSLTARKRACCNNRTGMFLSSFFSVITVIGALYCMLISIQALLKGPLMCNSPSNSNANC  
EFSLKNISDIHPESFNQLQWFFNDSCAPPTGFNKPTSNDTMASGWRASSFHFDSEENKHRLIHF  
SVFLGLLLGVILEVLFGLSQIVIGFLGCLCGVSKRRSQIV

**Important features:**

**Transmembrane domains:**

amino acids 10-31 (type II), 50-72, 87-110, 191-213

**N-glycosylation sites.**

amino acids 80-84, 132-136, 148-152, 163-167

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 223-227

**N-myristoylation sites.**

amino acids 22-28, 54-60, 83-89, 97-103, 216-222

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 207-218

**TNFR/NGFR family cysteine-rich region protein.**

amino acids 4-12

49/168

**FIGURE 49**

ATCCGTTCTCTGCCTGCCAGCTCAGGTGAGCCCTGCCAAGGTGACCTCGCAGGACACTGGT  
GAAGGAGCAGTGAGGAACCTGCAGAGTCACACAGTTGCTGACCAATTGAGCTGTGAGCCTGGA  
GCAGATCCGTGGCTGCAGACCCCCGCCCCAGTGCCTCTCCCCCTGCAGCCCTGCCCTCGAA  
CTGTGACATGGAGAGAGTGACCCCTGGCCCTTCTCCTACTGGCAGGCCTGACTGCCTTGGAAAGC  
CAATGACCCATTCCAATAAAGACGATCCCTCTACTATGACTGGAAAAACCTGCAGCTGAG  
CGGACTGATCTGCGGAGGGCTCCTGCCATTGCTGGATCGCGCAGTTCTGAGTGGCAAATG  
CAAATACAAGAGCAGCCAGAACGCAGCACAGTCTGTACCTGAGAAGGCCATCCCACTCATCAC  
TCCAGGCTCTGCCACTACTTGCTTGAGCACAGGACTGGCCTCCAGGGATGGCCTGAAGCCTAAC  
ACTGGCCCCCAGCACCTCCTCCCCCTGGGAGGCCTTATCCTCAAGGAAGGACTTCTCCAAGG  
GCAGGCTGTTAGGCCCTTCTGATCAGGAGGCTTCTTATGAATTAAACTGCCACCACC  
CCCTCA

50/168

## FIGURE 50

MERVTLALLLAGLTALLEANDPFANKDDPFYYDWKNLQLSGLICGGLAIAGIAAVLSGKCKY  
KSSQKQHSPVPEKAIPLITPGSATTC

**Important features:**

**Signal peptide:**

amino acids 1-16

**Transmembrane domain:**

amino acids 36-59

**N-myristoylation sites.**

amino acids 41-47, 45-51, 84-90

**Extracellular proteins SCP/Tpx-1/Ag5/PR-1/Sc7.**

amino acids 54-67

## FIGURE 51

## **FIGURE 52**

MKFQGPLACLLLALCLGSGEAGPLQSGEESTGTNIGEALGHGLGDALSEGVGKAIGKEAGGAA  
GSKVSEALGQGTREAVGTGVRQVPGFGAADALGNRVGEAAHALGNTGHEIGRQAEDVIRHGAD  
AVRGSWQGVPGHSGAWETSGGHGIFGSQGGLGGQQGQNPGLGTPWVHGYPGNSAGSFGMNPQ  
GAPWGQGGNGGPPNFGTNTQGAVAQPGYGSVRASNQNEGCTNPPPSGSGGSSNSGGSGSQS  
GSSGSGSNGDNNNGSSSGSSGSSGSSGGSSGGSSGNSGSRGDSGSESSWGSSTG  
SSSGNHGGSGGGNGHKPGCEKPGNEARGSGESGIQGFRGQGVSSNMREISKEGNRLGGSGDN  
YRGQGSSWGSGGGDAVGGVNTVNSETSPGMNFDTFWKNFKSKLGFINWDAINKDQRSSRIP

**Signal peptide:**

amino acids 1-21

**N-glycosylation site.**

amino acids 265-269

**Glycosaminoglycan attachment site.**

amino acids 235-239, 237-241, 244-248, 255-259, 324-328, 388-392

**Casein kinase II phosphorylation site.**

amino acids 26-30, 109-113, 259-263, 300-304, 304-308

**N-myristoylation site.**

amino acids 17-23, 32-38, 42-48, 50-56, 60-66, 61-67, 64-70,  
74-80, 90-96, 96-102, 130-136, 140-146, 149-155, 152-158,  
155-161, 159-165, 163-169, 178-184, 190-196, 194-200, 199-205,  
218-224, 236-242, 238-244, 239-245, 240-246, 245-251, 246-252,  
249-252, 253-259, 256-262, 266-272, 270-276, 271-277, 275-281,  
279-285, 283-289, 284-290, 287-293, 288-294, 291-297, 292-298,  
295-301, 298-304, 305-311, 311-317, 315-321, 319-325, 322-328,  
323-329, 325-331, 343-349, 354-360, 356-362, 374-380, 381-387,  
383-389, 387-393, 389-395, 395-401

**Cell attachment sequence.**

amino acids 301-304

53/168

## FIGURE 53

GGAGAAGAGGTTGTGGACAAGCTGCTCCGACAGAAGG**ATG**TCGCTGCTGAGCCTGCCCT  
GGCTGGGCCTCAGACCGGTGGCAATGTCCCCATGGCTACTCCTGCTGCTGGTTGTGGGCTCCT  
GGCTACTCGCCCGCATCCTGGCTTGGACCTATGCCTCTATAACAACTGCCGCCGGCTCCAGT  
GTTTCCCACAGCCCCAAAACGGAACCTGGTTGGGTACCTGGGCCTGATCACTCCTACAG  
AGGAGGGCTTGAAGGACTCGACCCAGATGTCGGCACCTATTCCCAGGGCTTACGGTATGGC  
TGGGTCCCACATCCCCTT~~C~~ATCGTTTATGCCACCCCTGACACC~~A~~CCATCCGGTCTATC~~A~~CCAATG  
CCTCAGCTGCCATTG~~C~~ACCC~~A~~AGGATAATCTT~~C~~ATCAGGTTCTGAAGCC~~T~~GGCTGGGAG  
AAGGGATACTGCTGAGTGGCGGTGACAAGTGGAGGCCACCGTCGGATGCTGACGCCGCC  
TCCATTCAACATCCTGAAGTCCTATATAACGATCTTCAACAAAGAGTGCAAACATCATGCTT  
ACAAGTGGCAGCACCTGGCCTCAGAGGGCAGCAGTCGCTGGACATGTTGAGCACATCAGCC  
TCATGACCTTGGACAGTCTACAGAAATGCATCTCAGCTT~~G~~ACAGCCATTGTCAGGAGAGGC  
CCAGTGAATATATTGCCACCATCTGGAGCTCAGTGCCTTGTAGAGAAAAGAACGCCAGCATA  
TCCTCCAGCACATGGACTTCTGTATTACCTCTCCATGACGGCGGCGCTCCACAGGGCCT  
GCCGCCTGGTGCATGACTTCACAGACGCTGT~~C~~ATCCGGAGCGGGCTCGCACCC~~T~~CCCCACTC  
AGGGTATTGATGATTTTCAAAGACAAAGCCAAGTCCAAGACTTGGATT~~C~~ATTGATGTGC  
TTCTGCTGAGCAAGGATGAAGATGGGAAGGCATTGTCAGATGAGGATATAAGAGCAGAGGCTG  
ACACCTTCATGTTGGAGGCCATGACACCACGCCAGTGGCTCTCCTGGGTCTGTACAACC  
TTGCGAGGCACCCAGAATACCAGGAGCGCTGCCACAGGAGGTGCAAGAGCTTCTGAAGGACC  
GCGATCTAAAGAGATTGAATGGGACGACCTGGCCAGCTGCCCTCCTGACC~~A~~TGTGCGTGA  
AGGAGAGCCTGAGGTTACATCCCCAGCTCCCTCATCTCCGATGCTGCACCCAGGACATTG  
TTCTCCAGATGGCGAGTCATCCCCAAAGGCATTACCTGCCTCATCGATATTAGGGGTCC  
ATCACAACCCAACTGTGTGGCCGGATCCTGAGGTCTACGACCCCTCCGCTTGACCCAGAGA  
ACAGCAAGGGAGGT~~C~~ACCTCTGGCTTTATTCTCCGACAGGGCCAGGAAC~~T~~GCATCG  
GGCAGGC~~G~~T~~C~~GCCATGGCGAGATGAAAGTGGCCTGGCGTTGATGCTGCTGCAC~~T~~CCGGT  
TCCTGCCAGACCACACTGAGCCCCGAGGAAGCTGGAATTGATCATGCGGCCAGGGCGGGC  
TTTGGCTGCCGGTGGAGCCCTGAATGTAGGCTGCA~~G~~T~~C~~ATTCTGACCCATCCACCTGTT  
TTTTGCA~~G~~ATTGTCATGAATAAAACGGTGCTGTCAAA

54/168

## FIGURE 54

MSLLSLPWGLRPVAMSPWLLLLLVVGSWLLARILAWTYAFYNNCRLQCFPQPPKRNWFWGH  
LGLITPTEEGLKDSLQMSATYSQGFTVWLGPPIIPFIVLCHPDTIRSITNASAAIAPKDNLFIR  
FLKPWLGEGLGGDKWSRHRMLTPAFHFNILKSYITIFNKSANIMLDKWQHLASEGSSRL  
DMFEHISLMTLDSLQKCIFSFDHCQERPSEYIATILELSALVEKRSQHILQHMDFLYYLSHD  
GRRFHRACRLVHDFTDAVIREERRTLPTQGIDDFFKDKAKSKTLDFIGDVLSSKDEDGKALSD  
EDIRAEADTFMFGGHDTTASGLSWVLYNLRHPEYQERCRCQEVQELLKDRDPKEIEWDDLAQL  
PFLTMCVKESLRLHPPAPFISRCCTQDIVLPDGRVIPKGITCLIDIIGVHHNPTVWPDPPEVYD  
PFRDPENSKGRSPLAFIPFSAGPRNCIGQAFAMAEMKVVLALMLLHFRFLPDHTEPRRKLEL  
IMRAEGGLWLRVEPLNVGLQ

**Important features:**

**Transmembrane domains:**

amino acids 13-32 (type II), 77-102

**Cytochrome P450 cysteine heme-iron ligand signature.**

amino acids 461-471

**N-glycosylation sites.**

amino acids 112-116, 168-172

## **FIGURE 55**

ATCGCATCAATTGGGAGTACCATCTCCTCATGGGACCAGTGAACAGCTGAAGCGAATGTTT  
GAGCCTACTCGTTGATTGCAACTATCATGGTGCTGTGTTGCACTTACCCGTGTTCT  
GCCCTTTGGTGGCATAACAAGGGACTTGCACTTATCTCTGCATTTGCAGTCTTGGCATTG  
ACGTGGTACAGCCTTCCTCATACCATTGCAAGGGATGCTGTGAAGAAGTGTGTTGCCGTG  
TGTCTTGCATAATTCATGCCAGTTATGAAGCTTGGAAAGGCACTATGGACAGAAGCTGGT  
GGACAGTTTGTAACTATCTCGAACCTCTGTCTTACAGACATGTGCCTTATCTGCAGC  
AATGTGTTGCTTGTGATTGAACATTGAGGGTTACTTTGGAAGCAACAATACATTCTCGAA  
CCTGAATGTCAGTAGCACAGGATGAGAAGTGGTTCTGTATCTGTGGAGTGAATCTCCTC  
ATGTACCTGTTCTCTGGATGTTGTCCTGAATTCCCAGTGAATACAAACCTATTCAAGC  
AACAGCAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAA

56/168

**FIGURE 56**

MGPVKQLKRMFEPTRLIATIMVLLCFALTLCASFWWHNKGLALIFCILQSLALTWYSLSFIPF  
ARDAVKKCFAVCLA

**Important features:**

**Signal peptide:**

amino acids 1-33

**Type II fibronectin collagen-binding domain protein.**

amino acids 30-72

57/168

## FIGURE 57

CGGCTCGAGCTCGAGCCGAATCGGCTCGAGGGGCAGTGGAGCACCAGCAGGCCAAC**ATG**CTCTGTCTGTGC  
CTGTACGTGCCGGTCATCGGGGAAGCCCAGACCGAGTCCAGTACTTTGAGTCGAAGGGCTCCCTGCCAGCTG  
AAGTCCATTCAAGCTCAGTGTCTCATCCCCCTCCAGGAATTCTCACCTACCGCCAGTGGAAAGCAGAAAATT  
GTACAAGCTGGAGATAAGGACCTTGATGGCAGCTAGACTTGAGAAGATTGTCATTATCTCAAGATCATGAG  
AAGAAGCTGAGGCTGGTTAAGATTGGACAAAAGAATGATGGACGCATTGACGCCAGGAGATCATGCAG  
TCCCTGCCGGACTTGGGAGTCAAGATATCTAACAGCAGGAGAAAAAATTCTCAAGAGCATGGATAAAAACGGC  
ACGATGACCATCGACTGGAACGAGTGGAGAGACTACCAACCTCCACCCGTGGAAAACATCCCCGAGATCATC  
CTCTACTGGAAGCATTCCACGATCTTGATGTGGGTGAGAATCTAACGGTCCCGATGAGTCAACAGTGGAGGAG  
AGGCAGACGGGGATGTGGTGGAGACACCTGGTGGCAGGGAGTGGGGCAGGGGGCGTATCCAGAACCTGCC  
CCCTGGACAGGCTCAAGGTGTCATGCAGGCCATGCCCTCCCGCAGCAACAAACATGGGCATCGTGGCTTC  
ACTCAGATGATTGAGAAGGAGGGGCCAGGTCACTCTGGGGGGCAATGGCATCAACGTCCTCAAATTGCCCC  
GAATCAGGCCATCAAATTGAGGCCATGAGCAGATCAAGGCCCTTGGTAGTGGACTGACCGAGAGACTTGAGGATT  
CACAGAGGGCTGTGGCAGGGTCTTGGCAGGGGCATGCCAGAGCAGCATCTACCAATGGAGGTCTGAG  
ACCCGGATGGCGCTCGGAAGACAGGCCAGTACTCAGGAATGCTGGACTGCCAGGAGGATCTGGCAGAGAG  
GGGGTGGCCGCCTCTACAAAGGCTATGTCCTAACATGCTGGGCATCATCCCCATGCCGCATGCCACCTTGCA  
GTCTACGAGACGCTCAAGAATGCCCTGGCTGAGCACTATGCACTGAGTAACAGCGCCGACCCGGCTGTTGTGCTC  
CTGGCCTGTGGCACCATGTCCAGTACCTGTGGCCAGCTGGCCAGTACCCCTGGCCCTAGTCAGGACCCGGATG  
CAGGCAGACGCTCTATTGAGGGCGCTCCGGAGGTGACCATGAGCAGCCTCTAACATATCCTGCCAGCGAG  
GGGGCCTCGGGCTGTACAGGGGCTGGCCCCAACCTCATGAAGGTCACTCCAGCTGTGAGCATCAGCTACGTG  
GTCTACGAGAACCTGAAGATCACCTGGCGTGCAGTCAG**TG**ACGGGGGGAGGGCCGCCAGTGGACTCG  
CTGATCCTGGGCCGCAGCCTGGGTGTGCAGCCATCTCATTCTGTGAATGTGCAACACTAAGCTGTCAGGCC  
AAGCTGTAAAACCTAGACGCCACCCGCAGGGAGGGTGGGAGAGCTGGCAGGCCAGGGCTTGTCTGCTGACC  
CCAGCAGACCCCTCTGTTGGTCCAGCGAAGACCCACAGGCCATCCCTAGGGTCCAGGGTCAAGGCTCCGGGCT  
CACATGTGAAGGACAGGACATTCTGCAGTCCTGCCAATAGTGGAGCTGGACCTGGAGGGCTAGTTC  
TTCCATTACCCCTGCAGGCCAGCTGGCCACGGCCCCCTGCCCTCTGCTGCCGTCATCTCCCTGTGCCCT  
CTTGTGCCCTGCTGCTGAGGTAAAGGGAGGGCTACAGGCCACATCCCACCCCTCGTCCAATCCC  
ATAATCCATGATGAAAGGTGAGGTACCGTGGCTCCAGGCTGACTTCCAAACCTACAGCATTGACGCCAACTT  
GGCTGTGAAGGAAGAGGAAGGATCTGGCTTGTGGTCACTGGCATCTGAGCCCTGCTGATGGCTGGGCTCTCG  
GGCATGCTGGAGTGCAGGGGCTGGCTGCCCTGGCTGCACAGAAGGCAAGTGTGGGGCTATGGT  
CTCTGAGCTGGCTGGACCCGTCAAGGATGGGCCCCACCTCAGAACCAAACACTGTCCCCACTGTGGCATGAG  
GGCAGTGGAGCACCAGTTGAGGGCAAGGGCAGAGCCTTGTGTTCTGGGAGGGAGGAAAGAAAAGGTGTTGG  
AGGCCTTAATTATGGACTGTTGGAAAAGGGTTTGTCCAGAAGGACAAGCCGACAAATGAGCAGCTCTGTGC  
TTCCAGAGGAAGACGAGGGAGCAGGAGCTGGCTGACTGCTCAGAGTGTGTTCTGACGCCCTGGGGTCTCTGTC  
CAACCCCAAGCAGGGGCCAGCGGGACCAGCCCCACATCCACTTGTGCACTGCTGGAACCTATTATTGTA  
TTTATTGAAACAGAGTATGCTCTAACTATTGTTATAGATTGTTAATTAAATAGCTGTGTCATTTCAGTT  
TTTTTATTGATTTGTTATGTCAGGGTATTGTCACCTTCCCAAGCCGCCAGGGATGGGAGGGAGGAGGAGAA  
GGGGGCCCTGGGCCGTGAGTCACATCTGCCAGAGAAATTCTTGGGACTGGAGGCCAGAAAAGGGCCAG  
AAGGCAGCAGCCCTGCCCTTCTGGAGGGAGGAAACCTCAATAACCTTGAGGTGGAATCCAGTTATTGCGCTGCG  
GAAGTGGGGCGTGGAGAGAGAGGGAGGAACCTCAATAACCTTGAGGTGGAATCCAGTTATTGCGCTGCG  
GGTTTCTTATTGTCAGCTTCTGAGGTGAGGTGCGCTCTGCTGCCCTGCTGCTGCTGCTGCTGCTGCTGCTG  
GGCTGGAGGGAGGGGGCTGGCTGCCCTCCAGCCTGCTGCCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG  
CTGGCGACCTCACGGTGCACCTCCATTCCACCAAGAATGACCTGATGAGGAATCTTCAATAGGATGCAAAGATC  
AATGCAAAATTGTTATATGAACATATAACTGGAGTCGTCAAAAAGCAAATTAGAAGAATTGGACGTTAGA  
AGTGTGTCATTAAAGCAGCTTCTAATAAAAGTGTGTTCAAAGCTGAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAA

58/168

## FIGURE 58

MLCLCLYVPVIGEAQTEFQYFESKGLPAELKSIFKLSVFIPSQEESTYRQWKQKIVQAGDKDL  
DGQLDFEEFVHYLQDHEKKLRLVFKIILDKNDGRIDAQEIMQSLRDLGVKISEQQAEKILKSM  
DKNGTMTIDWNEWRDYHLLHPVENIPEIILYWKHSTIFDVGENLTVPDEFTVEERQTGMWWRH  
LVAGGGAGAVSRTCTAPLDRLKVLMQVHASRSNNMGIVGGFTQMIREGGARSLWRGNGINVLK  
IAPESAIKFMAYEQIKRLVGSDQETLRIHERLVAGSLAGAIAQSSIYPMEVLKTRMALRKTGQ  
YSGMLDCARRILAREGVAAFYKGYVPNMLGIIPYAGIDLAVYETLNAWLQHYAVNSADPGVF  
VLLACGTMSSTCGQLASYPLALVRTRMQAQASIEGAPEVTMSSLFKHILRTATEGAFGLYRGLAP  
NFMKVIPAVSISYVVYENLKITLGVQSR

**Important features:**

**Signal peptide:**

amino acids 1-16

**Putative transmembrane domains:**

amino acids 284-304, 339-360, 376-394

**Mitochondrial energy transfer proteins signature.**

amino acids 206-215, 300-309

**N-glycosylation sites.**

amino acids 129-133, 169-173

**Elongation Factor-hand calcium-binding protein.**

amino acids 54-73, 85-104, 121-140

## **FIGURE 59**

GGAAGGCAGCGGCAGCTCCACTCAGCCAGTACCCAGATACGCTGGGAACCTCCCCAGCC**ATG**  
GCTTCCCTGGGGCAGATCCTCTTCTGGAGCATAATTAGCATCATCATTATTCTGGCTGGAGCA  
ATTGCACTCATCATTGGCTTGGTATTCAGGGAGACACTCCATCACAGTCACTACTGTCGCC  
TCAGCTGGGAACATTGGGGAGGATGGAATCCTGAGCTGCACTTAACCTGACATCAAACCTT  
TCTGATATCGTGTACAATGGCTGAAGGAAGGTGTTAGGCTTGGTCCATGAGTTCAAAGAA  
GGCAAAGATGAGCTGCGGAGCAGGATGAAATGTTCAGAGGCCGGACAGCAGTGTGCTGAT  
CAAGTGATAGTTGCAATGCCCTTGGCTGAAAAACGTGCAACTCACAGATGCTGGCACC  
TACAAATGTTATATCATCATTCTAAAGGCAAGGGGAATGCTAACCTGAGTATAAAACTGGA  
GCCTTCAGCATGCCGGAAAGTGAATGTGGACTATAATGCCAGCTCAGAGACCTTGCAGGTTGAG  
GCTCCCCGATGGTCCCCCAGCCCACAGTGGTCTGGCATCCAAAGTTGACCAGGGAGCCAAC  
TTCTCGGAAGTCTCCAATACCAGCTTGAGCTGAACACTCTGAGAATGTGACCATGAAGGTTGTG  
TCTGTGCTCTACAATGTTACGATCAACAAACACATACTCCTGTATGATTGAAAATGACATTGCC  
AAAGCAACAGGGGATATCAAAGTGACAGAACTGGAGATCAAAGGCCGGAGTCACCTACAGCTG  
CTAAACTCAAAGGCTTCTGTGTCTTCTTGCATCAGCTGGCACTTGCCT  
CTCAGCCCTTACCTGATGCTAAAAT**TAA**TGTGCCTTGGCCACAAAAAGCATGCAAAGTCATTG  
TTACAACAGGGATCTACAGAACTATTCACCACAGATATGACCTAGTTATATTCTGGGA  
GGAAAATGAATTCATATCTAGAAAGTCTGGAGTGAGCAAACAAGAGCAAGAAACAAAAAGAAGCC  
AAAAGCAGAAGGCTCCAATATGAACAAGATAAAATCTATCTCAAAGACATATTAGAAGTTGGG  
AAAATAATTATGTGAACTAGACAAGTGTGTTAAGAGTGATAAGTAAAATGCACGTGGAGACA  
AGTGCATCCCCAGATCTCAGGGACCTCCCCCTGCCTGTCACCTGGGAGTGAGAGGACAGGAT  
AGTGCATGTTCTTGTCTCTGAATTAGTTATATGTGCTGTAATGTTGCTCTGAGGAAGCC  
CCTGGAAAGTCTATCCAACATATCCACATCTTATATTCCACAAATTAGCTGTAGTATGTAC  
CCTAACAGCTGCTAAATTGACTGCCACTCGCAACTCAGGGCGGCTGCATTTAGTAATGGG  
TCAAATGATTCACTTTATGATGCTTCAAAGGTGCCTGGCTCTTCCAACTGACAAA  
TGCCAAAGTTGAGAAAAATGATCATAATTAGCATAAACAGAGCAGTCGGGACACCGATTT  
TATAAATAAAACTGAGCACCTCTTTAAACAAAAAAACAAAAAAACAAAAAAACAAAAAA  
AAAAAAAAAAAAAAAAAAAAAA

60/168

## **FIGURE 60**

MASLGQILFWSIISIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEPDIK  
LSDIVIQWLKEGVILGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNVQLTDAG  
TYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVVWASQVDQGA  
NFSEVSNTSFELNSENVTMKVSVLYNVTINNTYSCMIENDIAKATGDIKVTESEIKRRSHLQ  
LLNSKASLCVSSFFAISWALLPLSPYILMLK

**Important features:**

**Signal peptide:**

amino acids 1-28

**Transmembrane domain:**

amino acids 258-281

**N-glycosylation sites.**

amino acids 112-116, 160-164, 190-194, 196-200, 205-209, 216-220,  
220-224

**N-myristoylation sites.**

amino acids 52-58, 126-132, 188-194

## FIGURE 61

TGACGTAGAACATCACCATGCCAGCTATCCTTACCGCAGGGCTGCCAGGAGCTGCAGGACA  
AGCACCAAGGAGCCCTCCGGTAGCTACTACCCTGGACCCCCAATAGTGAGGGCAGTATGG  
TAGTGGCTACCCCTGGTGGTTATGGGGCTCTGCCCTGGAGGGCCTATGGACCACC  
AGCTGGTGGAGGGCCCTATGGACACCCAATCCTGGATGTTCCCTCTGGAACCTCAGGAGG  
ACCATATGGCGGTGCAGCTCCGGGGCCCTATGGTCAGCCACCTCCAAGTTCTACGGTGC  
CCAGCAGCCTGGCTTATGGACAGGGTGGCCCTCCAATGTGGATCCTGAGGCCTACTC  
CTGGTTCAGTCGGTGGACTCAGATCACAGTGGCTATATCTCATGAAGGAGCTAAAGCAGGC  
CCTGGTCACTGCAATTGGTCTTCATTCAATGATGAGACCTGCCTCATGATGATAAACATGTT  
TGACAAGACCAAGTCAGGCCGCATCGATGTCTACGGCTCTCAGCCCTGTGGAAATTCA  
GCAGTGGAAAGAACCTCTCCAGCAGTATGACCGGGACCGCTGGCTCCATTAGCTACACAGA  
GCTGCAGCAAGCTCTGTCCAAATGGCTACAACCTGAGCCCCCAGTCACCCAGCTCTGGT  
CTCCCGCTACTGCCACGCTCTGCCAATCCTGCCATGCAGCTTGACCGCTTCATCCAGGTGTG  
CACCCAGCTGCAGGTGCTGACAGAGGCCTCCGGAGAAGGACACAGCTGTACAAGGCAACAT  
CCGGCTCAGCTCGAGGACTCGTCACCATGACAGCTCTCGGATGCTTGACCCAACCATCT  
GTGGAGAGTGGAGTGCACCAGGGACCTTCCTGGCTTCTAGAGTGAGAGAAGTATGTGGACA  
TCTCTTCTTCTGTCCCTCTAGAAGAACATTCTCCCTGCTTGATGCAAACACTGTTCCAAA  
AGAGGGTGGAGAGTCCTGCATCATAGCCACAAATAGTGAGGACCGGGCTGAGGCCACACAG  
ATAGGGGCTGATGGAGGAGGGATAGAAGTTGAATGTCCTGATGCCATGAGCAGTGAGTG  
GCACAGCCTGGCACCCAGGAGCAGGTCTTGTAAATGGAGTTAGTGCCAGTCAGCTGAGCTCCA  
CCCTGATGCCAGTGGTAGTGTCTGCCATCGGCCTGTTACCGTTAGTACCTGTGTTCCCTCACCAG  
GCCATCCTGTCAAACGAGCCCATTCTCAAAGTGGAACTGACCAAGCATGAGAGAGATCT  
GTCTATGGGACCAGTGGCTGGATTCTGCCACACCCATAAATCCTGTGTTAACTCTAGC  
TGCCTGGGCTGGCCCTGCTCAGACAAATCTGCTCCCTGGCATCTTGCCAGGCTCTGCC  
CCCTGCAGCTGGACCCCTCACTTGCCCTGCCATGCTCTGCTCGGCTTCAGTCTCCAGGAGACA  
GTGGTCACCTCTCCCTGCCAATACTTTTTAATTGCACTTTTTCAATTGGGCCAAAG  
TCCAGTGAAATTGTAAGCTCAATAAAAGGATGAAACTCTGA

62/168

## **FIGURE 62**

MASYPYRQGCPGAAGQAPGAPPGSYYPGPPNSGGQYGSGLPPGGYGGPAPGGPYGPPAGGGP  
YGHPNPGMFPSSGTPGGPYGGAAPGGPYGQPPPSSYGAQQPGLYQOGGAPPNVDPEAYSWFQSV  
DSDHSGYISMKELKQALVNCNWSSFNDETCLMMINMFDKTSGRIDVYGFSAWKFIQQWKNL  
FQQYDRDRSGSISYTELQQALSQMGYNLSPQFTQLLVSRYCPRSANPAMQLDRFIQVCTQLQV  
LTEAFREKDTAVQGNIRLSFEDFVTMTASRML

**Important features of the protein:**

**Signal peptide:**

amino acids 1-19

**N-glycosylation site.**

amino acids 147-150

**Casein kinase II phosphorylation sites.**

amino acids 135-138, 150-153, 202-205, 271-274

**N-myristoylation sites.**

amino acids 9-14, 15-20, 19-24, 33-38, 34-39, 39-44, 43-48, 61-  
66, 70-75, 78-83, 83-88, 87-92, 110-115

63/168

## FIGURE 63

CAGGATGCAGGGCCCGTGGCAGGGAGCTGCCTCCTCTGGGCCTGCTCCTGGTCTGTCTTC  
TCTCCCAGGCCTCTTGCCCCGGAGCAGCGTGTGGAGGAGAAAGTTCCAAAACCTCGG  
GACCAACTGCCTCAGCTCGAACCTCCACTGGCCCTCTAACTCTGAACATCCGCA  
GCCCGCTCTGGACCCTAGGTCTAATGACTTGGCAAGGGTTCCTCTGAAGCTCAGCGTGCCTCC  
ATCAGATGGCTTCCCACCTGCAGGAGGTTCTGCAGTCAGTGAGGTGGCCTCCATCGTGGGGC  
GCCTGCCATGGATTCCCTGGCCCCCTGAGGATCCTTGGCAGATGATGGCTGCTGCGGCTGAGGA  
CCGCCTGGGGAAGCGCTGCCTGAAGAACTCTTACCTCTCCAGTGCTGCGGCCCTCGCTCC  
GGGCAGTGGCCCTTGCCTGGGAGTCTCTCCGATGCCACAGGCCTCTCACCTGAGGCTTC  
ACTCCTCCACCAGGACTCGGAGTCCAGACGACTGCCCGTTCTAATTCACTGGAGGCCGGGG  
AAAAATCCTTCCAACGCCCTCCCTGGTCTCTCATCCACAGGGTCTGCCTGATCACCCCTG  
GGGTACCTGAATCCCAGTGTGTCCTGGGAGGTGGAGGCCCTGGGACTGGTGGGAACGAG  
GCCCATGCCACACCCCTGAGGAAATCTGGGTATCAATAATCAACCCCCAGGTACCAAGCTGGGG  
AAATATTAATCGGTATCCAGGAGGCAGCTGGGAAATATTAATCGGTATCCAGGAGGCAGCTG  
GGGAATATTAATCGGTATCCAGGAGGCAGCTGGGAAATATTACATCTACCCAGGTATCAA  
TAACCCATTCCCTGGAGTTCTCCGCCCTGGCTCTTGGAACATCCCAGCTGGCTT  
CCCTAACCTCCAAGCCCTAGGTTGCAGTGGGCTTAGAGCACGATAGAGGGAAACCAACATT  
GGGAGTTAGAGTCCTGCTCCGCCCTTGCTGTGGCTCAATCCAGGCCCTGTTAACATGT  
TTCCAGCACTATCCCCACTTTCAAGTGCCTCCCTGCTCATCTCAATAAAATAAAAGCACTT  
ATGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

64/168

## **FIGURE 64**

MQGRVAGSCAPLGLLVCLHLPGLFARSIGVVEEKVSQNFGTNLPQLGQPSSTGPSNSEHPQP  
ALDPRSNDLARVPLKLSVPPSDGFPPAGGSAVQRWPPSWGLPAMDSWPPEDPWQMMAAAEDR  
LGEALPEELSYLSSAAALAPGSGPLPGESSPDATGLSPEASLLHQDSESRRLPRNSLHGAGGK  
ILSQRPPWSLIHRVLPDHPWGTLNPSVSWGGGPWTGWGTRPMPHPEGIWGINNQPPGTSWGN  
INRYPGGSWGNINRYPGGSWGNINRYPGGSWGNIHLYPGINNPFFPGVLRPPGSSWNI PAGFP  
NPPSPRLQWG

**Important features of the protein:**

**Signal peptide:**

amino acids 1-26

**Casein kinase II phosphorylation sites.**

amino acids 56-59, 155-158

**N-myristoylation sites.**

amino acids 48-53, 220-225, 221-226, 224-229, 247-252, 258-263,  
259-264, 269-274, 270-275, 280-285, 281-286, 305-310

65/168

**FIGURE 65**

AAGGAGAGGCCACCGGGACTTCAGTGTCTCCTCCATCCCAGGAGCGCAGTGGCCACTATGGGG  
TCTGGGCTGCCCTTGCTCCTCCTTGCACCTCCTGGCAGCTCACATGGAACAGGGCCGGGT  
ATGACTTGCAACTGAAGCTGAAGGAGTCTTTCTGACAAATTCCCTCATGAGTCCAGCTTC  
CTGGAATTGCTTAAAAGCTCTGCCTCCTCCATCTCCCTCAGGGACCAGCGTCACCCTC  
CACCATGCAAGATCTAACACCATGTTGTCTGCAACACATTGACAGCCATTGAAGCCTGTGTCC  
TTCTTGGCCCGGGCTTTGGCCGGGGATGCAGGAGGCAGGCCCGACCCTGTCTTCAGCAG  
GCCCCCCACCCCTCCTGAGTGGCAATAAATAAAATT CGGTATGCTG

66/168

## **FIGURE 66**

MGSGLPLVLLTLLGSSHGTGPGMTLQLKLKESFLTNSSYESSFLELLKLCLLLHLPSGTSV  
TLHHARSQHHVVCNT

**Important features:**

**Signal peptide:**

amino acids 1-19

**N-glycosylation site.**

amino acids 37-41

**N-myristoylation sites.**

amino acids 15-21, 19-25, 60-66

67/168

**FIGURE 67**

ACGGACCGAGGGTTCGAGGGAGGGACACGGACCAGGAACCTGAGCTAGGTCAAAGACGCCCGG  
GCCAGGTCCCCGTCGCAGGTGCCCTGGCGAGATGCGGTAGGAGGGCGAGCGCGAGAAG  
CCCCTCCTCGCGCTGCCAACCCGCCACCCAGCCC**ATG**GCGAACCCGGCTGGGCTGCTT  
CTGGCGCTGGGCCTGCCGTTCTGCTGGCCGCTGGGGCGAGCCTGGGGCAAATACAGACC  
ACTTCTGCAAATGAGAATAGCACTGTTGCCTCATCCACCAGCTCCAGCTCCGATGGCAAC  
CTGCGTCCCGAAGCCATCACTGCTATCATCGTGGTCTTCTCCCTCTGGCTGCCTGCTCCTG  
GCTGTGGGCTGGCACTGTTGGTGCAGCTCGGGAGAAGCGGCAGACGGAGGGCACCTAC  
CGGCCCAAGTAGCGAGGAGCAGTTCTCCATGCAGCCGAGGCCGGCCCTCAGGACTCCAAG  
GAGACGGTGCAAGGCTGCCCTGCCAT**TAG**GTCCCTCTCCTGCATCTGTCTCCATTGC  
TGTGTGACCTTGGGAAAGGCAGTGCCCTCTGGGCAGTCAGATCCACCCAGTGCTTAATAG  
CAGGGAAGAAGGTACTTCAAAGACTCTGCCCTGAGGTCAAGAGAGGATGGGCTATTCACTT  
TTATATATTATATAAAATTAGTAGTGAGATGTAAAAAAAAAAAAAAA

68/168

## **FIGURE 68**

MANPGLGLLLALGLPFLARWGRAWGQIQTTSANENSTVLPSSTSSSDGNLRPEAITAIIVV  
FSLLAALLLAVGLALLVRKLREKRQTEGTYRPSSEEQFSHAAEARAPQDSKETVQGCLPI

**Important features:**

**Signal peptide:**

amino acids 1-19

**Transmembrane domain:**

amino acids 56-80

**N-glycosylation site.**

amino acids 36-40

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 86-90

**Tyrosine kinase phosphorylation site.**

amino acids 86-94

**N-myristoylation sites.**

amino acids 7-13, 26-32

## FIGURE 69

GCCAGGAATAACTAGAGAGGAACAATGGGGTTATTCAGAGGTTTGTCTCTTAGTTCTGTGCCTGCTGCAC  
CAGTCAAATACTTCCTCATTAAGCTGAATAATAATGGCTTGAGATATTGTCATTGTTAGATCCTAGTGTG  
CCAGAAGATGAAAAAAATTGAACAAATAGAGGATATGGTACTACAGCTTACGTACCTGTTGAAGCCACA  
GAAAAAAAGATTTTTCAAAAATGTATCTATATTAACTCCTGAGAATTGGAAGGAAATCCTCAGTACAAAAGG  
CCAAAACATGAAAACCATAAACATGCTGATGTTAGTTCACCACCTACACTCCCAGGTAGAGATGAACCACATC  
ACCAAGCAGTTCACAGAATGTGGAGAGAAGGCGAATACTACATTCACTCACCCTGACCTTACTTGGAAAAAAA  
CAAATGAATATGGACCAACCAGGAAACTGTTGTCCATGAGTGGGCTCACCTCCGGTGGGAGTGTGATGAG  
TACAATGAAGATCAGCCTTCTACCGTCTAAGTCAAAAAAATCGAAGCAACAAGGTGTTCCGCAGGTATCTCT  
GGTAGAAATAGAGTTATAAGTGTCAAGGAGGCAGCTGTTAGTAGAGCATGCGAATTGATTCTACAAACAAA  
CTGTATGAAAAGATTGTCAATTCTTCCTGATAAAAGTACAAACAGAAAAGCATCCATAATGTTATGCAAAGT  
ATTGATTCTGTGTTGAATTTGTAACGAAAAAACCCATAATCAAGAAGCTCCAAGCCTACAAAACATAAAAGTGC  
AATTTAGAAGTACATGGGAGGTGATTAGCAATTCTGAGGATTTAAAACACCATACCCATGGTGACACCACCT  
CCTCACCTCTCATGCTGAAGATCAGTCAGGAAATTGCTGCTTAGTCTGATAAGTCTGGAAGCATG  
GGGGTAAGGACGCCAATCGAATGCAAGCAGCAAACATTCTGCTGCAGACTGTTGAAAATGGATCC  
TGGGTGGGATGGTTCACTTGATAGTACTGCCACTATTGTAATAAGCTAATCCAAATAAAAGCAGTGTGAA  
AGAAACACACTCATGGCAGGATTACCTACATATCCTGGGAGGAACCTCAGTCTGGAAATTAAATATGCA  
TTTCAGGTGATTGGAGAGCTACATTCCAACTCGATGGATCCGAAGTACTGCTGCTGACTGATGGGAGGATAAC  
ACTGCAAGTTCTGTATTGATGAAGTGAACAAACTGGGCCATTGTTCATTTATTGCTTGGGAAGAGCTGCT  
GATGAAGCAGTAATAGAGATGAGCAAGATAACAGGAGGAAGTCATTGTTAGTTCAGATGAAGCTCAGAACAT  
GCCCTCATTGATGCTTTGGGCTCTACATCAGGAAATACTGATCTCTCCAGAAGTCCCTCAGCTCGAAAGT  
AAGGGATTAACACTGAATAGTAATGCCCTGGATGAACGACACTGTCATAATTGATAGTACAGTGGAAAGGACACG  
TTCTTCTCATCACATGGAACAGCTGCCTCCAGTATTCTCTGGGATCCAGTGGAAACAATAATGGAAAAT  
TTCACAGTGGATGCAACTCCAAATGGCCTATCTCAGTATTCCAGGAACCTGCAAAGGTGGCACTTGGGCATAC  
AATCTCAAGCCAAGCGAACCCAGAAACATTAACCTACAGTAACCTCTCGAGCAGCAGCAAATTCTCTGTGCCT  
CCAATCACAGTGAATGCTAAATGAATAAGGACCTAAACAGTTCCCCAGCCCAATGATTGTTACGCAGAAATT  
CTACAAGGATATGACTCTGGAGCCAATGTGACTGCTTCATTGAATCACAGAATGGACATACAGAAGTT  
TTGGAACCTTGGATAATGGCAGGCTGATTCTTCAGGAGGAGCTACTCCAGGTATTACAGCA  
TATACAGAAAATGGCAGATATAGCTTAAAGGCTGGGCTCATGGAGGAGCAACACTGCCAGGCTAAATTACGG  
CCTCCACTGAATAGGCCCGTACATACCGCTGGTAGTGAACGGGGAAATTGAAGCAAACCCGCCAGACCT  
GAAATTGATGAGGATACTCAGACCCATTGGAGGATTTAGCCGAACAGCATCCGGAGGTGCATTGGGTATCA  
CAAGTCCCAAGCCTCCCTGACCAATACCCACCAAGTCAAATCACAGACCTGATGCCACAGTCATGAG  
GATAAGATTATTCTTACATGGACAGCACCAGGAGATAATTGATGTTGGAAAAGTCAACGTTATATCATAAGA  
ATAAGTGCAGTATTCTGATCTAAGAGACAGTTGATGATGCTCTCAAGTAATAACTACTGATCTGCACCA  
AAGGAGGCCAACTCCAAGGAAGCTTGCAATTAAACAGAAAATCTCAGAAGAAAATGCAACCCACATATT  
ATTGCCATTAAAGTATAGATAAAAGCAATTGACATCAAAGTATCCAACATTGCAAGTAACCTTGTATC  
CCTCAAGCAAATCTGATGACATTGATCCTACACCTACTCCTACTCCTACTCTGATAAAAGTCATAAT  
TCTGGAGTTAATATTCTACGCTGGTATTGCTGATGGGTCTGTTGTAATTGTTAACTTTATTAAAGTACC  
ACCATTTGAACCTTAACGAAGAAAAAAATCTCAAGTAGACCTAGAAGAGAGTTTAAAAACAAAACATGTA  
GTAAAGGATATTCTGAATCTTAAATTCACTCCATGTTGATCATAAAACTCATAAAATTAATTAAAGATGTCG  
GAAAAGGATACTTGATTAATAAAACACTCATGGATATGTAAGGAAACTGTCAAGATTAAATTTAATGTTCA  
TTTATTGTTATTGTTGTAAGAAATAGTGTGATGAACAAAGATCCTTTCTACTGATACCTGGTTATATT  
ATTGATGCAACAGTTCTGAATGATATTCAAAATTGCAAGAAATTAAATCATCTATCTGAGTAGTCAA  
AATACAAGTAAAGGAGAGCAAATAACACATTGGAAAAAAMAAAAAAMAAAAAAMAAAAAAMAAAAAAMAAAAA  
AAMAAAAAAMAAAAAAMAAAAAAMAAAAAAMAAAAAAMAAAAAAMAAAAAAMAAAAAAMAAAAAAMAAAAA

70/168

## FIGURE 70

MGLFRGFVFLLVLCLLHQSNTSFIKLNNNGFEDIVIVIDPSVPEDEKIIEQIEDMVTASTYL  
FEATEKRFKKNVSILIPENWKENPQYKRPKHENKHADVIVAPPTLPGRDEPYTKQFTECGE  
KGEYIHFTPDLGGKKQNEYGPPGKLFVHEWAHLRGVFDEYNEDQPFYRAKSKKIEATRCSA  
GISGRNRVYKCQGGSCLSACRIDSTKLYGKDCQFFPDKVQTEKASIMFMQSIDSVVEFCNE  
KTHNQEAPSLQNIKCNFRSTWEVISNSEDFKNTIPMVTPPPPVFSLLK1SQRIVCLVLDKSG  
SMGGKDRLNRMNQAAKHFLQLQTVENGSWGMVHFDSTATIVNKLIQIKSSDERNTLMAGLPTY  
PLGGTSICSGIKYAFQVIGELHSQDGSEVLLTDGEDNTASSCIDEVKQSGAIVHFIALGRA  
ADEAVIEMSKITGGSHFYVSDEAQNNGLIDAFGALTSGNTDLSQKSLQLESKGTLNSNAWMN  
DTVIIDSTVGKDTFFLITWNSLPPSISLWDPSGTIMENFTVDATSKMAYLSIPGTAKVGTWAY  
NLQAKANPETLTITVTSRAANSSVPPITVNAKMNDVNSFPSPMIVYAEILQGYVPVLGANVT  
AFIESQNGHTEVLELLDNGAGADSFKNQDGVYSRYFTAYTENGRLKVRAGGANTARLKLKP  
PLNRAAYIPGWVVNGEIEANPPRPEIDEDTQTTLEDFSRTASGGAFVVSQVPSLPLPDQYPPS  
QITDLDATVHEDIKIIWTAPGDNFDVGKVQRYIIRISASILDLRDSFDDALQVNNTDLSPKE  
ANSKESFAFKPENISEENATHIFIAIKSIDKSNLTSKVSNIAQVTLFIPQANPDDIDPTPTPT  
PTPTPDKSHNSGVNISTLVLSVIGSVVIVNFILSTTI

**Signal peptide:**

amino acids 1-21

**Putative transmembrane domains:**

amino acids 284-300, 617-633

**Leucine zipper pattern.**

amino acids 469-491, 476-498

**N-glycosylation site.**

amino acids 20-24, 75-79, 340-344, 504-508, 542-546, 588-592,  
628-632, 811-815, 832-836, 837-841, 852-856, 896-900

## **FIGURE 71**

CTCCTTAGGTGAAACCCCTGGGAGTAGAGTACTGACAGCAAAGACCGGGAAAGACCATACTGCCCGGGCAGGGG  
TGACAACAGGTGTCATCTTTGATCTCGTGTGGCTGCCTCTATTCAAGGAAAGACGCCAAGGTAACTTT  
GACCCAGAGGAGCAATGATGTAGGCCACCTCTAACCTCCCTGAACCCCCAGTTATGCCAGGATTTACTAG  
AGAGTGTCAACTCAACCAGCAAGCGGCTCTCGGCTTAACCTGTGGTTGGAGGAGAGAACCTTGTGGGGCTGC  
GTTCTTAGCAGTGTCTAGAAGTGACTTGCTGAGGGTGGACCAGAAGAAAGGAAAGGTCCCCTCTGCTGTTG  
GCTGCACATCAGGAAGGCTGTGATGGGAATGAAGGTGAAAACCTGGAGATTCACTTCAGTCATTGCTCTGCCT  
GCAAGATCATCCTTAAAGTAGAGAAGCTGCTCTGTGTGGTTAECTCCAAGAGGCCAGAACTCGTTCTAGAA  
GGAAATGGATGCAAGCAGCTCCGGGGCCCAAACGCATGCTCTGTGTAGGCCAGGGAAAGCCTTCCGTG  
GGGGCCCCGGTTTGAGGGATGCCACCGGGTCTGGACGCATGGCTGATTCTGAA**TG**ATGATGGTTGGCCGGGG  
CTGCTTGCCTGGATTCCCGGGTGGTTTGCTGGTCTCTGCTGTGCTATCTGCTCTGTACATGTT  
GCCTGCACCCAAAAGGTGACCGAGGAGCAGCTGGCACTGCCAGGGCAACAGCCCCACGGGGAAAGGAGGGTAC  
CAGGCCGTCTCAGGAGTGGGAGGAGCAGCCGAACTACGTCAGGAGCAGCTGAAGGCCAGATGCCACAGCTC  
AAGGAGGAGCTGCAGGAGAGGAGTCAGGAGCTCAGGAATGGGAGTACCAACCCAGCGATGCTGCTGGCTGGG  
CTGGACAGGAGCCCCCAGAGAAAACCCAGGGCAGCTCTGGCCTCTGCACTCGCAGGTGGACAAGGCAGAG  
GTGAAATGCTGGCTCAAGCTGGCACAGAGTATGCAGCAGTGCCTTCGATAGCTTACTCTACAGAAGGTGTAC  
CAGCTGGAGACTGGCTTACCCGCCACCCGAGGAGAAGCCTGTGAGGAAGGACAAGCGGGATGAGTTGGTGGAA  
GCCATTGAATCAGCTTGGAGACCTGAACAATCTGCAAGAGAACAGCCCCAATCACCGCTTACACGGCTCT  
GATTTCATAGAAGGGATCTACCGAACAGAAAGGGACATTGTATGAGCTCACCTCAAAGGGGACAC  
AAACACGAATTCAAACGGCTCATCTTATTGACCATTCAGCCCCATCATGAAAGTAAAAATGAAAAGCTAAC  
ATGGCAACACGTTATCAATGTTATCGTGCCTCTAGCAAAAGGGTGGACAAGTCCGGCAGTTCATGCAGAA  
TTCAGGGAGATGTGCAATTGAGCAGGATGGGAGACTCCATCTCACTGTTGTTACTTGGGAAAGAAGAAATAA  
GAAGTCAAAGGAATACTTGAACAAACTTCAAAGCTCCAACCTCAGGAACCTTACCTTATCCAGCTGAATGGA  
GAATTTCCTGGGAAAGGGACTTGTATGTTGGAGCCGCTCTGGAAGGGAAAGCAACGTCCTCTCTTTCTGT  
GATGTGGACATCTACTCACATCTGAATTCTCAATACGTCAGGCTGAATACACGCCAGGGAAAGGATTT  
TATCCAGTTCTTTCAGTCAGTACAATCTGGCATAATATACGCCACCATGATGCACTCCCTCCCTGGAAACAG  
CAGCTGGCTATAAGAAGGAACACTGGATTGGAGAGACTTGGATTGGGATGACGTGCTAGTATGGTCAAGAC  
TTCATCAATATAGGTGGTTGATCTGGACATCAAAGGCTGGGGAGAGGATGTCACCTTATCGCAAGTAT  
CTCCACAGAACCTCATAGTGGTACGGACGCCGTGCGAGGACTCTCCACCTCTGGCATGAGAACGCTGCA  
GACGAGCTGACCCCCGAGCAGTACAAGATGTGCATGCACTGCCAAAGGCCATGAACGCCAGGGCAGCTG  
GGCATGCTGGTCTAGGCCAGGAGATAGGGCTACCTTCGCAACAGAACAGAACAGAACAGAACAGAAC  
**TGA**ACTCCCAGAGAAGGATTGTGGAGACACTTTCTTCTTCAATTACTGAAAGTGGCTGCAACAGAGA  
AAAGACTTCCATAAAGGACGACAAAAGAATTGGACTGATGGGTCAAGAGATGAGAAAGCCTCGATTCTCTGT  
TGGCTTTACAACAGAAATCAAATCTCCGTTGCCTGCAAAAGTAACCCAGTTGCACCCCTGTAAGTGTCT  
GACAAAGGCAGAATGTTGTGAGATTATAAGCTTAAGGTGTGGAGGTTTGATGGTGTAACTACACTGAGA  
CCTGTTGTTGTGCTCATGAAATATTGATTTAAGAGCAGTTTGTAAGGAAAGGAAAGGAAAGGAAAG  
CAAGCATATTCTCCTCATATGAATGAGCCTATCAGCAGGGCTCTAGTTCTAGGAATGCTAAATATCAGAAG  
CAGGAGAGGAGATAGGCTTATTATGATACTAGTGTGAGTACATTAAGTAAAATGGGACAGAAAGAAAAGAA  
ACCATAAATATCGTGTCAATTCTCCCAAGATTAAACCAAAATACTGCTTATCTTTGGTTGTCTTTAA  
CTGTCTCCGTTTTCTTTATTAAATGCACTTTCTTCTTGTGAGTTAGTCTGCTTATTTAATTAC  
CACTTGCAGCCTAACAGAGAGCACAAGTGGCCTACATTCTTATTTAAGAAGATACTTGTGAGATGCC  
TTATGAGAACTTCACTGTCAGTCAGGACATCAAATTGATGCCATATCCAAGGACATGCCAAATGCTATTGCTCAGGC  
ACTGAATGTCAGGCCATTGAGACATAGGGAGGAATGGTTGACTAATACAGACGTACAGACATATTCTCTGTGAG  
AGTATTTCAGAAGAGGGAGCACTGAACACTGGAGGAAAAGAAAAGACACTTCTGCTTACAGAAAAGGAAAC  
CATTCAAGACTGGTGTGATCTGATGTCACCTAAAGTCAGAAACCACTTCTCCTCAGAAGTAGGGACCGCTT  
CTTACCTGTTAAATAACCAAAAGTATACCGTGTGACCAAAACAACTCTTTCAAAACAGGGTGTCTCTCTGG  
CTTCTGGCTTCCATAAGAAGAAATGGAGAAAATATATATATATATATTGTGAAAGATCAATCCATCTG  
CCAGAACATCTAGTGGGATGGAGTTTGCTACATGTTATCCACCCCAAGGCCAGGTGGAAAGTAACGAA  
TTAAATAAGCAGTTCTACTCAATCACCAAGATGCTCTGAAAGTGCATTCTTATTACCAATTCAAACATTTT  
AAAAATAAAATACAGTTAACATAGAGTGGTTCTCATTGATGAAAGTATTAGCCAGCACCAGATGCA  
CTAATTATCTCTTGAGTCCTGCTCTGTTGCTCACAGTAAACACTCATTGTTAAAGCTTCAAGAACATTCAA  
GCTGTTGGTGTGTTAAAAATGCAATTGATTGATTGACTGGTAGTTATGAAATTAAATTAAACACAGGCCA  
TGAATGGAAGGGTGTATTGACAGCTAACAAATATGATTGTTGGGATATGAA

72/168

## **FIGURE 72**

MMMVRRGLLAWISRVVVLLVLLCCAISVLYMLACTPKGDEEQLALPRANSPTGKEGYQAVLQE  
WEEQHRNYVSSLKRQIAQLKEELQERSEQLRNGQYQASDAAGLGLDRSPPEKTQADLLAFLHS  
QVDKAEVNAGVKLATEYAAVPFDSFTLQKVYQLETGLTRHPEEKPVRKDKRDELVEAIESALE  
TLNNPAENSPNHRPYTASDFIEGIYRTERDKGTLYLELTFKGDHKHEFKRLILFRPFSPIMKVK  
NEKLNMANTLINVIVPLAKRVDKFRQFMQNREMCIEQDGRVHLTVVYFGKEEINEVKGILEN  
TSKAANFRNFTFIQLNGEFSRGKGLDVGARFWKGSNVLLFFCDVDIYFTSEFLNTCRLNTQPG  
KKVFYPVLFSQYNPGIIYGHHDADVPPLEQQLVIKKETGFWRDFGFGMTQCYRSDFINIGGFDL  
DIKGWGGEDVHLYRKYLHSNLIVVRTPVRGFLFHLWHEKRCMDELTPEQYKMCMSKAMNEASH  
GQLGMLVFRHEIEAHLRKQKQKTSSKKT

**Important features:**

**Signal peptide:**

amino acids 1-27

**N-glycosylation sites.**

amino acids 315-319, 324-328

**N-myristoylation sites.**

amino acids 96-102, 136-142, 212-218, 311-317, 339-345, 393-399

**Amidation site.**

amino acids 377-381

73/168

## **FIGURE 73**

GAGACTGCAGAGGGAGATAAAGAGAGAGGGCAAAGAGGGCAGCAAGAGATTGTCCTGGGATC  
CAGAAACCCATGATAACCTACTGAACACCGAATCCCCTGGAAGCCCACAGAGACAGAGACAGC  
AAGAGAAGCAGAGATAAATACACTCACGCCAGGAGCTCGCTCGCTCTCTCTCTCA  
CTCCTCCCTCCCTCTCTGCCTGTCCTAGTCCTCTAGTCCTCAAATTCCCAGTCCCTGC  
ACCCCTCCTGGGACACTATGTTGTTCTCCGCCCTGCTGGAGGTGATTGGATCCTGGCT  
GCAGATGGGGTCAACACTGGACGTATGAGGGCCCACATGGTCAGGACCATTGCCAGCCTCT  
TACCCCTGAGTGTGAAACAATGCCAGTCGCCATCGATATTCAAGACAGACAGTGTGACATT  
GACCCCTGATTGCTGCTGCAGCCCCACGGATATGACCAGCCTGGCACCGAGCCTTGGAC  
CTGCACAACAATGCCACACAGTCAACTCTCTGCCCTTACCCCTGTATCTGGTGGACTT  
CCCCGAAAATATGTAGCTGCCAGCTCACCTGCACTGGGTCAAGAAAGGATCCCCAGGGGG  
TCAGAACACCAAGATCAACAGTGAAGCCACATTGAGCAGCTCCACATTGTACATTATGACTCT  
GATTCCATGACAGCTTGAGTGAGGCTGCTGAGAGGCCTCAGGGCCTGGCTGCTGGC  
CTAATTGAGGTGGGTGAGACTAAGAATATAGCTTATGAACACATTCTGAGTCATTGCA  
GTCAGGCATAAAGATCAGAAGACCTCAGTGCCCTTCAACCTAACAGAGAGCTGCT  
CAGCTGGGCAGTACTCCGCTACAATGGCTCGCTCACAACTCCCCCTGCTACCAGAGTGT  
CTCTGGACAGTTTTATAGAAGGTCCCAGATTCAATGGAACAGCTGGAAAAGCTTCAGGG  
ACATTGTTCTCCACAGAAGAGGGAGCCCTTAAGCTTCTGGTACAGAAACTACCGAGCCTTCAG  
CCTCTCAATCAGCGCATGGCTTGCCTTCAAGCAGGATCCTCGTATACCACAGGT  
GAAATGCTGAGTCTAGGTGTAGGAATCTGGTTGGCTGCTCTGCCTCTGGCTGTTAT  
TTCATTGCTAGAAAGATTGGAAGAAGAGGGCTGGAAAACCGAAAGAGTGTGGTCTTCACCTCA  
GCACAAGCCACGACTGAGGCTAAATTCCCTCTCAGATACCATGGATGTGGATGACTTCC  
CATGCCTATCAGGAAGCCTCTAAATGGGTGAGGATCTGCCAGAAACACTGTAGGAGTAG  
TAAGCAGATGTCCTCCCTCCCTGGACATCTCTAGAGAGGAATGGACCCAGGCTGTCATTCC  
AGGAAGAACTGCAAGGCCTCAGCCTCTCAAACATGTAGGAGGAATGAGGAAATCGCTGTG  
TTGTTAATGCAGAGANCAAACCTGTTAGTGCAAGGGAAAGTTGGATATACCCCAAAGTC  
CTCTACCCCTCACTTTATGCCCTTCCCTAGATATACTGCGGGATCTCCCTAGGATAA  
AGAGTTGCTGTTGAAGTTGTATATTTGATCAATATATTGAAATTAAAGTTCTGACTTT

74/168

## FIGURE 74

MLFSALLLEVIWILAADGGQHWTYEGPHGQDHWPASYPECGNNAQSPIDIQTDSVTFDPLPA  
LQPHGYDQPGTEPLDLHNNGHTVQLSLPSTLYLGGLPRKYVAAQLHLHWGQKGSPGGSEHQIN  
SEATFAELHIVHYDSDSYDSLSEAAERPQGLAVLGILIEVGETKNIAYEHILSHLHEVRHKDQ  
KTSVPPFNLRRELLPKQLGQYFRYNGSLTPPCYQSVLWTVFYRRSQISMEQLEKLQGTLFSTE  
EEPSKLLVQNYRALQPLNQRMVFASFIQAGSSYTTGEMLSLGVGILVGCLCLLLAVYFIARKI  
RKKRLENRKSVVFTSAQATTEA

**Important features of the protein:**

**Signal peptide:**

amino acids 1-15

**Transmembrane domain:**

amino acids 291-310

**N-glycosylation site.**

amino acids 213-216

**Eukaryotic-type carbonic anhydrases proteins**

amino acids 197-245, 104-140, 22-69

**FIGURE 75**

TGCCGCTGCCGCCGCTGCTGCTGTTGCTCCTGGCGGCCCTGGGGACGGGCAGTCCTGTG  
TCTCTGGGTTTGCTAAACCTGAAACATCACCTTCTATCCATCAACATGAAGA**ATG**TCC  
TACAATGGACTCCACCAGAGGGCTTCAAGGAGTTAAAGTTACTTACACTGTGCAGTATTCA  
TCACAAATTGGCCCACCAGAGGTGGCACTGACTACAGATGAGAAGTCCATTCTGTTGCCTG  
ACAGCTCCAGAGAAGTGGAAAGAGAAATCCAGAACGACCTCCTGTTCCATGCAACAAATATAC  
TCCAATCTGAAGTATAACGTGCTGTTGAATACTAAATCAAACAGAACGTGGTCCAGTGT  
GTGACCAACCACACGCTGGTCTCACCTGGCTGGAGGCCAACACTCTTACTGCGTACACGTG  
GAGTCCTCGTCCCAGGGCCCCCTGCCGTGCTCAGCCTCTGAGAACAGCAGTGTGCCAGGACT  
TTGAAAGATCAATCATCAGAGTTCAAGGCTAAAATCATCTCTGGTATGTTGCCATATCT  
ATTACCGTGTCTTTCTGTGATGGCTATTCCATCTACCGATATATCCACGTTGGCAAA  
GAGAACACCCCAGCAAATTGATTTGATTGAAATGAATTGACAAAAGATTCTTGTG  
CCTGCTGAAAAATCGTGAATTAACTTATCACCTCAATATCTGGATGATTCTAAAATTCT  
CATCAGGATATGAGTTACTGGAAAAAGCAGTGATGTATCCAGCCTTAATGATCCTCAGCCC  
AGCAGGGAACCTGAGGCCCTCAGGAGGAAGAGGAGGTGAAACATTAGGGTATGCTCGCAT  
TTGATGAAATTGGTACTCTGAAGAAAACCGGAAGGTACTTCTCTCACCCAGCAAGAG  
TCCCTCAGCAGAACAAATACCCCGATAAAACAGTCATTGAATATGAATATGATGTCAGAAC  
ACTGACATTGTGCGGGGCCTGAAGAGCAGGAGCTCAGTTGCAGGAGGAGGTGTCACACAA  
GGAACATTATTGGAGTCGCAGGCAGCGTTGGCAGTCTGGGCCGCAAACGTTACAGTACTCA  
TACACCCCTCAGCTCAAGACTTAGACCCCTGGCGCAGGAGCACACAGACTCGGAGGGAGGG  
CCGGAGGAAGGCCATCGACGACCTGGTCAGTGGATCCCCAAACTGGCAGGCTGTGTATT  
CCTTCGCTGTCCAGCTCGACCAGGATTCAAGAGGCTGCGAGCCTCTGAGGGGGATGGGCTC  
GGAGAGGAGGGTCTCTATCTAGACTCTAGAGGAGGCCGCTCCAGACAGGCCACCAGGAGAA  
AATGAAACCTATCTCATGCAATTCACTGGAGGAATGGGGTTATATGTGCAGATGGAAA**TGA**  
TGCCAAACACTCCTTGCCTTGTGCAAACAAAGTGAGTCACCCCTTGATCCCA  
GCCATAAAAGTACCTGGGATGAAAGAAGTTTCCAGTTGTCAGTGTCTGTGAGAATTACTT  
ATTCTTTCTCTATTCTCATAGCACGTGTGATTGGTTCATGCATGTAGGTCTCTAACAA  
TGATGGTGGGCCTCTGGAGTCCAGGGCTGGCCGGTTGTTCTATGCAGAGAAAGCAGTCATA  
AATGTTGCCAGACTGGGTGCAGAATTATTCAAGGTGGGTGT

76/168

## **FIGURE 76**

MSYNGLHQRFKELKLLTLCISISSQIGPPEVALTTDEKSISVVLTAPEKWKRNPEDLPVSMQQ  
IYSNLKYNVSVLNTKSNRTWSQCVTNHTLVLWLEPNLTYCVHVESFVPGPPRRAQPSEKQCA  
RTLKDQSSEFKAKIIFWYVLPISITVFLFSVMGYSIYRYIHVGKEKHPANLILLYGNEFDKRF  
FVPAEKIVINFITLNISDDSKISHQDMSLLGKSSDVSSLNDPQPSGNLRPPQEEEVHLGYA  
SHLMEIFCDSEENTEGTSLTQQESLSRTIPPDKTVIEYEYDVRTTDICAGPEEQELSILQEEVS  
TQGTLLESQAALAVLGPQLQSYTPQLQDLDPLAQEHDTSEEGPEEPSTTLVDWDPQTGRL  
CIPSLSSFDQDSEGCEPSEGDSLGEGLSRLYEEPAPDRPPGENETYLMQFMEEWGLYVQMEN

**Important features:**

**Signal peptide:**

amino acids 1-28

**Transmembrane domain:**

amino acids 140-163

**N-glycosylation sites.**

amino acids 71-74, 80-83, 89-92, 204-207, 423-426

77/168

**FIGURE 77**

GAGGAGCGGGCCGAGGACTCCAGCGTCCCCAGGTCTGGCATCCTGCACTTGCTGCCCTCTGAC  
ACCTGGGAAG**TG**CCGGCCGTGGACCTTCACCCTCTGTGGTTGCTGGCAGCCACCTT  
GATCCAAGCCACCCTCAGTCCCCTGCAGTTCTCATCCTCGGCCAAAAGTCATCAAAGAAAA  
GCTGACACAGGAGCTGAAGGACCACAACGCCACCAGCATCCTGCAGCAGCTGCCGCTGCTCAG  
TGCCATGCGGGAAAAGCCAGCCGGAGGCATCCCTGTGCTGGGCAGCCTGGTAACACCGTCCT  
GAAGCACATCATCTGGCTGAAGGTCACTCACAGCTAACATCCTCCAGCTGCAGGTGAAGCCCTC  
GCCAATGACCAGGAGCTGCTAGTCAGATCCCCCTGGACATGGTGGCTGGATTCAACACGCC  
CCTGGTCAAGACCATCGTGGAGTTCCACATGACGACTGAGGCCAAGCCACCATCCGCATGGA  
CACCACTGCAAGTGGCCCCACCCGCCTGGCCTCAGTGACTGTGCCACCAGCCATGGGAGCCT  
GCGCATCCAAGTGTATAAGCTCTCCTCCTGGTAACGCCTTAGCTAACAGGTCACTGAA  
CCTCCTAGTGCCATCCCTGCCAATCTAGTGAAAACCAGCTGTGCTCCGTGATCGAGGCTTC  
CTTCAATGGCATGTATGCAGACCTCCTGCAGCTGGTAAGGTGCCATTCCCTCAGCATTGA  
CCGTCTGGAGTTGACCTTCTGTATCCTGCCATCAAGGGTGACACCATTAGCTTACCTGGG  
GGCAAGTTGTTGGACTCACAGGAAAGGTGACCAAGTGGTCAATAACTCTGCAGCTCCCT  
GACAATGCCACCCTGGACAACATCCCGTTAGCCTCATCGTGAGTCAGGACGTGGTAAAGC  
TGCAGTGGCTGCTGTGCTCTCCAGAAGAATTGATGGCCTGTTGACTCTGTGCTTCTGA  
GAGTGCCCATGGCTGAAGTCAAGCATCGGCTGATCAATGAAAAGGCTGCAGATAAGCTGGG  
ATCTACCCAGATCGTGAAGATCCTAACTCAGGACACTCCGAGTTTATAGACCAAGGCCA  
TGCCAAGGTGGCCCAACTGATCGTGGAGTGTGTTCCCTCCAGTGAAGCCCTCCGCCCTT  
GTTCACCCCTGGGATCGAAGCCAGCTCGGAAGCTCAGTTTACACCAAAGGTGACCAACTTAT  
ACTCAACTTGAATAACATCAGCTCTGATCGGATCCAGCTGATGAACTCTGGGATTGGCTGGTT  
CCAACCTGATGTTCTGAAAAACATCATCACTGAGATCATCCACTCCATCCTGCTGCCAACCA  
GAATGGCAAATTAAAGATCTGGGTCCAGTGTGATTGGTAAGGCCTGGGATTGAGGCAGC  
TGAGTCCTCACTGACCAAGGATGCCCTGTGCTTACTCCAGCCTCTGTGAAACCCAGCTC  
TCCTGTCTCCAG**TG**AAGACTTGGATGGCAGCCATCAGGGAAAGGCTGGTCCAGCTGGAGT  
ATGGGTGTGAGCTATAGACCATCCCTCTGCAATCAATAACACTTGCTGTAAAAA

78/168

## FIGURE 78

MAGPWTFTLLCGLLAATLIQATLSPTAVLILGPKVKEKLTQELKDHNATSILQQLPLLSAMR  
EKPAGGI PVLGSLVNTVLKHIIWLKVITANILQLQVKPSANDQELLVKIPLDMVAGFNTPLVK  
TIVEFHMTTEAQATIRMDTSASGPTRLVLSDCATSHGSLRIQLLYKLSFLVNALAKQVMNLLV  
PSLPNLVKNQLCPVIEASFNGMYADLLQLVKVPISLSIDRLEFDLLYPAIKGDTIQLYLGAKL  
LDSQGKVTKWFNNASAASLTMP TLNDNIPFSLIVSQDVVKAAVAAVLSPEEFMVLLDSVLPEAH  
RLKSSIGLINEKAADKLGSTQIVKILTQDTPEFFIDQGHAKVAQLIVLEVFPSSEALRPLFTL  
GIEASSEAQFYTKGDQLILNLNNISSDRIQLMNSGIGWFQPDVLKNIITEIIHSILLPNQNGK  
LRSGVPVSLVKALGFEEAAESSLTKDALVLTPASLWKPSSPVSQ

**Important features of the protein:**

**Signal peptide:**

amino acids 1-21

**N-glycosylation sites.**

amino acids 48-51, 264-267, 401-404

**Glycosaminoglycan attachment site.**

amino acids 412-415

**LBP / BPI / CETP family proteins.**

amino acids 407-457

79/168

## FIGURE 79

GAGAGAAGTCAGCCTGGCAGAGAGACTCTGAAATGAGGGATTAGAGGTGTTCAAGGAGCAAGA  
GCTTCAGCCTGAAGACAAGGGAGCAGTCCCTGAAGACGCTTCTACTGAGAGGTCTGCC**ATGGC**  
CTCTCTTGGCCTCCAACTTGTGGCTACATCCTAGGCCTCTGGGGCTTTGGGCACACTGGT  
TGCCATGCTGCTCCCCAGCTGGAAAACAAGTTCTTATGTCGGTGCCAGCATTGTGACAGCAGT  
TGGCTTCTCCAAGGGCTCTGGATGGAATGTGCCACACACAGCACAGGCATCACCCAGTGTGA  
CATCTATAGCACCCCTCTGGGCCTGCCCGCTGACATCCAGGCTGCCAGGCCATGATGGTAC  
ATCCAGTGCATCTCCTCCCTGGCCTGCATTATCTCTGTGGTGGCATGAGATGCACAGTCTT  
CTGCCAGGAATCCCGAGCAAAGACAGAGTGGCGGTAGCAGGTGGAGTCTTTCATCCTTGG  
AGGCCTCCTGGGATTTCATT CCTGTTGCCTGGAATCTCATGGGATCCTACGGGACTTCTACTC  
ACCACTGGTGCCTGACAGCATGAAATTGAGATTGGAGAGGCTTTACTTGGCATTATTC  
TTCCCTGTTCTCCCTGATAGCTGGAATCATCCTCTGCTTTCTGCTCATCCCAGAGAAATCG  
CTCCAACTAACGATGCCTACCAAGCCCAACCTCTGCCACAAGGAGCTCTCCAAGGCCTGG  
TCAACCTCCAAAGTCAAGAGTGAGTTCAATT CCTACAGCCTGACAGGGTATGTG**TGA**AGAAC  
CAGGGGCCAGAGCTGGGGGGTGGCTGGTCTGTGAAAAACAGTGGACAGCACCCCGAGGGCCA  
CAGGTGAGGGACACTACCACGGATCGTGTAGAAGGTGCTGCTGAGGATAGACTGACTTTGG  
CCATTGGATTGAGCAAAGGCAGAAATGGGGCTAGTGTAAACAGCATGCAGGTTGAATTGCCAA  
GGATGCTGCCATGCCAGCCTTCTGTTCTCACCTGCTGCTCCCCTGCCCTAAGTCCCC  
AACCCCTCAACTTGAAACCCATTCCCTTAAGCCAGGACTCAGAGGATCCCTTGCCCTGCGT  
TTACCTGGGACTCCATCCCCAAACCCACTAATCACATCCACTGACTGACCCCTGTGATCAA  
AGACCCTCTCTGGCTGAGGTTGGCTTTAGCTCATTGCTGGGGATGGGAAGGAGAACAGT  
GGCTTTGTGGCATTGCTCTAACCTACTTCTCAAGCTCCCTCAAAGAAACTGATTGGCCC  
TGGAACCTCCATCCACTCTTGTATGACTCCACAGTGTCCAGACTAATTGTGCATGAAC  
AAATAAAACCATCCTACGGTATCCAGGGAACAGAAAGCAGGATGCAGGATGGGAGGACAGGAA  
GGCAGCCTGGGACATTAAAAAAATA

80/168

## FIGURE 80

MASLGLQLVGYILGLLGLLGTIVAMLLPSWKTSYVGASIVTAVGFSKGLWMECATHSTGITQ  
CDIYSTLLGLPADIQAAQAMMVTSVSSAISLACIISVVGMRCTVFCQESRAKDRVAVAGGVFFI  
LGGLLGFIIPVAWNLHGILRDFYSPLVPSMKEIGEALYLGIISSLFSLIAGIILCFSCSSQR  
NRSNYYDAYQAQPLATRSSPRPGQPPKVSEFNSYSLTGYV

**Important features of the protein:**

**Signal peptide:**

amino acids 1-24

**Transmembrane domains:**

amino acids 82-102, 117-140, 163-182

**N-glycosylation site.**

amino acids 190-193

**PMP-22 / EMP / MP20 family proteins.**

amino acids 46-59

**FIGURE 81**

CCACGCGTCCGCCTCTCCCTCTGCTGGACCTCCTCGTCTCCATCTCCCTCCTT  
TCCCCCGCGTTCTCTTCCACCTTCTCTTCCACCTAGACCTCCCTGCCCTCCTT  
TCCTGCCAACCGCTGCTCCCTGGCCCTCTCCGACCCGCTCTAGCAGCAGACCTCCTGGGGT  
CTGTGGGTTGATCTGTGGCCCTGTGCCCTCGTGTCTCCCTCCGACTCC  
GCTCCC GGACCAGCGGCCTGACCCTGGGGAAAGGATGGTCCCAGGGTGAAGGGCCTCTCCTC  
CTTGCTGGGACTCGCGCTGCTCTGGTCCCCCTGGACTCCCACGCTCGAGCCCAGACAT  
GTTCTGCCTTTCCATGGGAAGAGATACTCCCCCGCGAGAGCTGGCACCCCTACTGGAGCC  
ACAAGGCCTGATGTACTGCCTGCGCTGTACCTGCTCAGAGGGCGCCATGTGAGTTTACCG  
CCTCCACTGTCCGCCTGTCCACTGCCCGCCTGTGACGGAGCCACAGCAATGCTGTCCCAA  
GTGTGTGGAACCTCACACTCCCTCTGGACTCCGGCCCAACAAAGTCCTGCCAGCACACGG  
GACCATGTACCAACACGGAGAGATCTCAGTGCCCATGAGCTGTTCCCCTCCGCCTGCCCAA  
CCAGTGTGTCCTCTGCAGCTGCACAGAGGGCCAGATCTACTGCCGCCTCACAAACCTGCCCGA  
ACCAGGCTGCCAGCACCCCTCCACTGCCAGACTCCTGCTGCCAAGCCTGCAAAGATGAGGC  
AAGTGAGGAATCGGATGAAGAGGACAGTGTGCAGTCCTCATGGGTGAGACATCCTCAGGA  
TCCATGTCCAGTGTGCTGGGAGAAAGAGAGGGCCGGCACCCAGCCCCACTGGCCTCAG  
CGCCCTCTGAGCTTCATCCCTGCCACTTCAGACCCAAGGGAGCAGGCAGCACACTGTCAA  
GATCGTCCCTGAAGGAGAAACATAAGAAAGCCTGTGTCATGGCGGGAAAGACGTACTCCACGG  
GGAGGTGTGGCACCCGGCCTCCGTGCCCTCGGCCCTTGCCCTGCATCCTATGCACCTGTGA  
GGATGGCGCCAGGACTGCCAGCGTGTGACCTGTCCCACCGAGTACCCCTGCCGTACCCCGA  
GAAAGTGGCTGGGAAGTGCTGCAAGATTGCCAGAGGACAAAGCAGACCCGGCACAGTGA  
GATCAGTTCTACCAGGTGTCCAAGGCACCGGGCCGGTCCTCGTCCACACATCGGTATCCCC  
AAGCCCAGACAACCTGCGTCGCTTGGCCTGGAACACGAGGCCTGGACTTGGTGGAGATCTA  
CCTCTGGAAGCTGGTAAAAGATGAGGAAACTGAGGCTCAGAGAGGTGAAGTACCTGGCCAAG  
GCCACACAGCCAGAATCTCCACTTGACTCAGATCAAGAAAGTCAGGAAGCAAGACTTCCAGA  
AAGAGGCACAGCACTCCGACTGCTCGTGGCCCCACGAAGGTCACTGGAACGTCTCCTAG  
CCCAGACCCGGAGCTGAAGGTACGGCAGTCCAGACAAAGTGACCAAGACATAACAAAGAC  
CTAACAGTTGCAGATATGAGCTGTATAATTGTTATTATATTAAATAAAAGAAGTTGC  
ATTACCCCTCAAAAAAAAAAAAAAAA

82/168

## **FIGURE 82**

MVPEVRVLSSLLGLALLWFPLDSHARARPDMFCLFHGKRYSPGESWHPYLEPQGLMYCLRCTC  
SEGAHVSCYRLHCPPVHCPQPVTEPQQCCPKCVEPHTPSGLRAPPKSCQHNGTMYQHGEIFSA  
HELPFPSRLPNQCVLCSCTEGQIYCGLTTCEPGCPAPLPLPDSCCQACKDEASEQSDEEDSVQ  
SLHGVRHPQDPCSSDAGRKRGPGTAPTGLSAPLSFIPRHFRPKGAGSTTVKIVLKEHKKAC  
VHGGKTYSHGEVWHPAFRAFGPLPCILCTCEDGRQDCQRVTCPTEYPCRHPEKVAGKCKICP  
EDKADPGHSEISSTRCPKAPGRVLVHTSVSPSPDNLRRALEHEASDLVEIYLWKLVKDEETE  
AQRGEVPGPRPHSQNLPLSDQESQEARNPERGTALPTARWPPRSLERLPSPDPGAEGHGQS  
RQSDQDITKT

**Signal peptide:**

amino acids 1-25

## **FIGURE 83**

84/168

**FIGURE 84**

MALMLSIVSLLKLGSQWQVFGPDKPVQALVGEDAASFCLSPKTNAEAMEVRFFRGQFSSV  
VHLYRDGKDQPFMQMPQYQGRTKLVKDSIAEGRISLRLENITVLDAGLYGCRISSQSYYQKAI  
WELQVSALGSVPPLISITGYVDRDIQLLCQSSGWFPRTAKWKGPQGQDLSTDRTNRDMHGLF  
DVEISLTQENAGSISCSMRHAHLSREVESRVQIGDTFFEPISWHLATKVLGILCCGLFFGIV  
GLKIFFSKFQWKIQAELDWRRKHGQAEELRDKHAVEVTLDPETAHPKLCVSDLKTVTHRKAP  
QEVPHSEKRFTRKSVASQSFQAGKHYWEVDGGHNKRWRVGVCRDDVDRRKEYVTLSPDHGYW  
VLRLNGEHLYFTLNPRFISVFPPRTPTKIGVFLDYECGTISFFNINDQSLIYTLTCRFEGLLR  
PYIEYPSYNEQNGTPIVICPVTQESEKEASQRASAIPETSNSESSSQATTPFLPRGEM

**Signal peptide:**

amino acids 1-17

**Transmembrane domain:**

amino acids 239-255

## FIGURE 85

AACAGACGTTCCCTCGCGGCCCTGGCACCTCTAACCCAGAC**ATG**CTGCTGCTGCTGCC  
CTGCTCTGGGGAGGGAGAGGGCGGAAGGACAGACAAGTAAACTGCTGACGATGCAGAGTTCC  
GTGACGGTGCAGGAAGGCCTGTGTCCATGTGCCCTGCTCCTCCTACCCCTGCATGGC  
TGGATTACCTGCCAGTAGTTCATGGCTACTGGTCCGGAAAGGGCCAATACAGACCAG  
GATGCTCCAGTGGCCACAAACAACCCAGCTCGGGCAGTGTGGAGGAGACTCGGGACCGATT  
CACCTCCTGGGGACCCACATACCAAGAATTGCACCCCTGAGCATCAGAGATGCCAGAAGAAGT  
GATGCGGGGAGATACTTCTTCGTATGGAGAAAGGAAGTATAAAATGAAATTATAAACATCAC  
CGGCTCTGTGAATGTGACAGCCTGACCCACAGGCCAACATCCTCATCCCAGGCACCC  
GAGTCCGGCTGCCCTCAGAATCTGACCTGCTCTGTGCCCTGGCCTGTGAGCAGGGACACCC  
CCTATGATCTCCTGGATAGGGACCTCCGTGTCCCCCTGGACCCCTCCACCACCCGCTCCTCG  
GTGCTACCCCTCATCCCACAGCCCCCAGGACCATGGCACCCAGCCTCACCTGTCAAGGTGACCTTC  
CCTGGGCCAGCGTGACCACGAACAAGACCGTCCATCTAACGTGTCCTACCCGCTCAGAAC  
TTGACCATGACTGTCTTCAAGGAGACGGCACAGTATCCACAGTCTGGAAATGGCTCATCT  
CTGTCACTCCCAGAGGCCAGTCTGCGCTGGTCTGTGAGTTGATGCAGTTGACAGCAAT  
CCCCCTGCCAGGCTGAGCCTGAGCTGGAGAGGCCGTGACCTGTGCCCTCACAGCCCTCAAAC  
CCGGGGGTGCTGGAGCTGCCCTGGGTGCACCTGAGGGATGCAGCTGAATTACCTGCAGAGCT  
CAGAACCCCTCGGCTCTCAGCAGGTCTACCTGAACGTCTCCCTGCAGAGCAAAGCCACATCA  
GGAGTGACTCAGGGGTGGTCGGGGAGCTGGAGGCCACAGCCCTGGTCTTCCCTGCTCCT  
GTCATCTCGTTGAGGTCTGCAGGAAGAAATCGGCAAGGCCAGCAGCGGGCTGGGA  
GATACGGGCATAGAGGATGCAAACGCTGTCAGGGTTCAGCCTCTCAGGGGCCCTGACTGAA  
CCTTGGGCAGAAGACAGTCCCCCAGACCAGCCTCCCCAGCTTCTGCCGCTCCTCAGTGGG  
GAAGGAGAGCTCAGTATGCATCCCTCAGCTTCCAGATGGTGAAGCCTGGACTCGCGGGGA  
CAGGAGGCCACTGACACCGAGTACTCGGAGATCAAGATCCACAGA**TGA**GAAACTGCAGAGACT  
CACCCCTGATTGAGGGATCACAGCCCTCCAGGAAGGGAGAAGTCAGAGGCTGATTCTGTAG  
AATTAACAGCCCTAACGTGATGAGCTATGATAACACTATGAATTATGTGAGGTGAAAGC  
ACACAGGCTTAGAGTCAAAGTATCTCAAACCTGAATCCACACTGTGCCCTCCCTTTATTT  
TTTAACAAAAGACAGACAAATTCTA

86/168

**FIGURE 86**

MLLLLPLLWGRERAEGQTSKLLTMQSSVTVQEGLCVHVPSCFSYPSHGWIYPGPVVHGYWFR  
EGANTDQDAPVATNNPARAVWEETRDRFHLLGDPHTKNCTLISIRDARRSDAGRYFFRMEKGSI  
KWNYKHHRLSVNVTALTHRPNILIPGTLESGCPQNLTCSPWACEQGTPPMISWIGTSVSPLD  
PSTTRSSVLTLPQPQDHGTSLTCQVTFPGASVTTNKTVHLNVSYPPQNLTMTVFQGDGTVST  
VLGNNGSSLPEGQSLRLVCADVDAVDSNPPARLSLSWRGLTLCPSQPSNPGVLELPWVHLRDA  
AEFTCRAQNPLGSQQVYLNVSILQSKATSGVTQGVVGGAGATALVFLSFCVI FVVVRSCRKKSA  
RPAAGVGDTGIEDANAVRG SASQGPLTEPWAEDSPPDQPPPASARSSVGEGEELQYASLSFQMVK  
KPWDSRGQEATDTEYSEIKIHR

**Signal peptide:**

amino acids 1-15

**Transmembrane domain:**

amino acids 351-370

87/168

**FIGURE 87**

AGAAAGCTGCACTCTGTTGAGCTCCAGGGCGCAGTGGAGGGAGGGAGTGAAGGGAGCTCTCTGT  
ACCCAAGGAAAGTCAGCTGAGACTCAGACAAGATTACA**TGA**ACCAACTCAGCTTCTGCTG  
TTTCTCATAGCGACCACCAGAGGATGGAGTACAGATGAGGCTAATACTTACTTCAAGGAATGG  
ACCTGTTCTCGTCTCCATCTCTGCCAGAAGCTGCAAGGAAATCAAAGACGAATGTCTAGT  
GCATTTGATGGCCTGTATTTCTCCGCACTGAGAATGGTGTATCTACCAGACCTTCTGTGAC  
ATGACCTCTGGGGTGGCGCTGGACCCCTGGTGGCCAGCGTGCATGAGAATGACATGCGTGGG  
AAGTGCACGGTGGCGATCGCTGGTCCAGTCAGCAGGGCAGCAAAGCAGACTACCCAGAGGGG  
GACGGCAACTGGGCCAACTACAAACACCTTGGATCTGCAGAGGCCACGAGCGATGACTAC  
AAGAACCCCTGGCTACTACGACATCCAGGCCAAGGACCTGGCATCTGGCACGTGCCAATAAG  
TCCCCCATGCAGCACTGGAGAACAGCTCCCTGCTGAGGTACCGCACGGACACTGGCTTCCTC  
CAGACACTGGGACATAATCTGTTGGCATCTACCAGAAATATCCAGTGAATATGGAGAAGGA  
AAGTGTGGACTGACAACGCCCGGTGATCCCTGTGGTCTATGATTTGGCAGGCCAGAAA  
ACAGCATCTTATTACTCACCTATGCCAGCGGAATTCACTGCCGGATTGTTAGTCAGGG  
GTATTTAATAACGAGAGAGCAGCCAACGCCCTGTGCTGGAATGAGGGTACCGGATGTAAC  
ACTGAGCATCACTGCATTGGTGGAGGAGGATACTTCCAGAGGCCAGTCCCAGCAGTGTGGA  
GATTTCTGGTTTGATTGGAGTGGATATGGAACTCATGTTGGTTACAGCAGCAGCCGTGAG  
ATAACTGAGGCAGCTGTGCTTCTATTCTATCGT**TGA**GAGTTGTGGAGGGAACCCAGACCT  
CTCCTCCCAACCATGAGATCCAAGGATGGAGAACAACTTACCCAGTAGCTAGAATGTTAATG  
GCAGAAGAGAAAACAATAATCATATTGACTCAAGAAAAAAA

88/168

## FIGURE 88

MNQLSFLLFLIATTRGWSTDEANTYFKEWTCSSSPSLPRSCKEIKDECPSAFDGLYFLRTENG  
VIYQTFCDMTSGGGGWTLVASVHENDMRGKCTVGDRSSQQGSKADYPEGDGNWANYNTFGSA  
EAATSDDYKNPGYYDIQAKDLGIWHVPNKSPMQHWRNSLLRYRTDTGFLQTLGHNLFGIYQK  
YPVKYGEKGKWTDNGPVI PVVYDFGDAQKTASYYSPYGQREFTAGFVQFRVFNNERAANALCA  
GMRVTGCNTEHHCIGGGGYFPEASPQQCGDFSGFDWSGYGTHVGYSSSREITEAAVLLFYR

**Important features:**

**Signal peptide:**

amino acids 1-16

**N-glycosylation site.**

amino acids 163-167

**Glycosaminoglycan attachment sites.**

amino acids 74-78, 289-293

**N-myristoylation sites.**

amino acids 76-82, 115-121, 124-130, 253-259, 292-298

89/168

**FIGURE 89**

CTAGATTGTCGGCTTGCAGGGAGACTTCAGGAGTCGCTGTCTGAACCTCCAGCCTCAGAG  
ACCGCCGCCCTTGTCCCCGAGGGCC**ATG**GGCCGGTCTCAGGGCTTGTGCCCTCTCGCTTCCT  
GACGCTCCTGGCGCATCTGGTGGTCGTACACCTTATTCTGGTCCCAGGGACAGAACATACA  
GGCCTGCCTGCCTCTCACGTTACCCCCGAGGAGTATGACAAGCAGGACATTAGCTGGTGGC  
CGCGCTCTGTCAACCTGGCCTCTTGAGTGGAGCTGGCCGGTTCTCAGGAGTCTC  
CATGTTAACAGCACCCAGAGCCTCATCTCCATTGGGCTCACTGTAGTGCATCCGTGGCCCT  
GTCCTTCTTCATATTGAGCGTTGGGAGTGCACTACGTATTGGTACATTTGTCTTCTGCAG  
TGCCCTTCCAGCTGTCACTGAAATGGCTTATTGTCACCGTCTTGGGCTGAAAAGAAACC  
CTTC**TGATT**ACCTTCATGACGGAACCTAACGGACGAAGCCTACAGGGCAAGGGCCGCTCGT  
ATTCCCTGGAAGAAGGAAGGCATAGGCTTCGGTTTCCCTCGAAACTGCTCTGCTGGAGGA  
TATGTGTGGAATAATTACGTCTTGAGTCTGGGATTATCCGCATTGTATTAGTGCCTTGAA  
TAAAATATGTTTAGTAACATTAAGACTTATACAGTTAGGGACAATTAAAAAAA  
AAA

90/168

**FIGURE 90**

MGRVSGLVPSRFLTLLAHLVVVITLFWSRDSNIQACLPLTFTPEEYDKQDIQLVAALSVTLGL  
FAVELAGFLSGVSMFNSTQSLISIGAHCSASVALSFFIFERWECTTYWYIFVFCSALPAVTEM  
ALFVTVFGLKKPF

**Transmembrane domain:**

amino acids 12-28 (type II), 51-66, 107-124

91/168

**FIGURE 91**

CTGGGACCCCGAAAAGAGAAGGGGAGAGCGAGGGGACGAGAGCGGAGGAAGATGCAACTG  
ACTCGCTGCTGCTCGTGTTCCTGGTGCAGGGTAGCCTCTATCTGGTCATCTGTGCCAGGAT  
GATGGTCCTCCCGCTCAGAGGACCCTGAGCGTGATGACCACGAGGGCCAGCCCCGGCCCCGG  
GTGCCTCGGAAGCGGGGCCACATCTCACCTAACGTCAGTCCCCTCATGGCAATTCACTCTCCTA  
GGGCTGCTGGCCCCGCTGGGGAGGCTTGGGCATTCTGGCAGCCCCCAACCGCCCGAAC  
CACAGCCCCCACCCTCAGCCAAGGTGAAGAAAATCTTGGCTGGGCAGCTTCACTCCAAAC  
ATCAAGACGGTGGCCCTGAACCTGCTCGTCACAGGAAGATTGTGGACCATGGCAATGGACC  
TTCAGCGTCCACTTCAAACACAATGCCACAGGCCAGGGAAACATCTCATCAGCCTCGTGC  
CCCAGTAAAGCTGTAGAGTCCACCAGGAACAGCAGATCTCATCGAACGCCAAGGCCTCCAAA  
ATCTTCAACTGCCGGATGGAGTGGGAGAAGGTAGAACGGGCCGGACCTCGCTTGCACC  
CACGACCCAGCCAAGATCTGCTCCCGAGACCACGCTCAGAGCTCAGCCACCTGGAGCTGCTCC  
CAGCCCTCAAAGCTGTCTGTGTCTACATGCCCTTCTACAGCACGGACTATGGCTGGTCCAG  
AAGGTGTGCCAGATTACAACATACCATAGTGTACCCCTACTACCCATCTGGGTGACCCCGG  
GCAGGCCACAGAGGCCAGGGCTGGAAGGACAGGCCGGCATGCAGGAGACCATCTGG  
ACACCGGGCAGGGAAAGGGTTGGCCTCAGGCAGGGAGGGGGTGGAGACGAGGAGATGCCAA  
GTGGGGCCAGGGCCAAGTCTCAAGTGGCAGAGAAAGGGTCCAAGTGTGGTCCAAACCTGAA  
GCTGTGGAGTGAATAGATCACAGGAGCACTGGAGGAGGTGGCTCTGTGCAGCCTCACA  
GGGCTTGCCACGGAGCCACAGAGAGATGCTGGTCCCCGAGGCCGTGGCAGGCCGATCAG  
TGTGGCCCCAGATCAAGTCATGGAGGAAGCTAACGCCCTGGTTCTGCCATCCTGAGGAAAG  
ATAGCAACAGGGAGGGGGAGATTTCATCAGTGTGGACAGCCTGTCAACTTAGGATGGATGGCT  
GAGAGGGCTTCCTAGGAGCCAGTCAGCAGGGTGGGTGGGCCAGAGGAGCTCCAGGCCCTG  
CCTAGTGGCGCCCTGAGCCCTTGTGCTGTGAGCATGGCATGAGGCTGAAGTGGCAACC  
CTGGGTCTTGATGTCTTGACAGATTGACCATCTGTCTCCAGCCAGGCCACCCCTTCCAAA  
ATTCCCTTTCTGCCAGTACTCCCCCTGTACCAACCCATTGCTGATGGCACACCCATCCTTAAG  
CTAACAGACAGGACGATTGTGGCCTCCCACACTAACGCCACAGCCATCCGCGTGTGTGTC  
CCTCTCCACCCCAACCCCTGCTGGCCTCTGGAGCATCCATGTCCGGAGAGGGTCCCT  
CAACAGTCAGCCTCACCTGTCAGACCGGGTTCTCCGGATCTGGATGGCGCCGCCCTCAG  
CAGCGGGCACGGGTGGGGCGGGCGAGAGCATGTGCTGGATCTGTTCTGTGTGTC  
GTCTGTGGGTGGGGAGGGAGGGAAAGTCTGTGAAACCGCTGATTGCTGACTTTGTGTGA  
AGAATCGTGTCTGGAGCAGGAAATAAGCTGCCCGGGCA

92/168

## **FIGURE 92**

MQLTRCCFVFLVQGSILVLICGQDDGPPGSEDPERDDHEGQPRPRVPRKRGHISPKSRPMANS  
TLLGLIAPPGEAWGILGQPPNRPNHSPPSAKVKKIFGWGDFYSNIKTVANLLVTGKIVDHG  
NGTFSVHFQHNATGQGNISISLVPPSKAVEFHQEQQIFIIEAKASKIFNCRMEWEKVERGRRTS  
LCTHDPAKICSRDHAQSSATWSCSQPFKVVCVYIAFYSTDYRLVQKCPDNYHSDTPYYPSG

**Important features of the protein:**

**Signal peptide:**

amino acids 1-14

**N-glycosylation sites.**

amino acids 62-65, 127-130, 137-140, 143-146

**2-oxo acid dehydrogenases acyltransferase**

amino acids 61-71

93/168

**FIGURE 93**

CGGTGGCCATGACTGC GG CGT GTT CTT CGG CT GCG CCT ATT GC C TT CGG C CT GCG C T CG  
CCCTTTATGTCTTACCATGCCATCGAGCCGTTGCGTATCATCTCCTCATGCCGGAGCTT  
TCTTCTGGTTGGTGTCTACTGATT CGTCCCTGTTGGTTATGGCAAGAGTCATTATTG  
ACAACAAAGATGGACCAACACAGAAATATCTGCTGATCTTGAGCGTTGTCTGTCTATA  
TCCAAGAAATGTTCCGATTGCATATTATAAACTCTTAAAAAAAGCCAGTGAAGGTTGAAGA  
GTATAAACCCAGGTGAGACAGCACCCCTATGCAGCTGCTGGCCTATGTTCTGGCTGGGCT  
TTGGAATCATGAGTGGAGTATTTCCCTTGTGAATACCCATCTGACTCCTGGGCCAGGCA  
CAGTGGCATTCATGGAGATTCTCCTCAATTCTCCTTATT CAGCTTCATGACGCTGGTCA  
TTATCTGCTGCATGTATTCTGGGCATTGTATTTTGATGGCTGTGAGAAGAAAAGTGGG  
GCATCCTCCTTATCGTTCTCCTGACCCACCTGCTGGTGT CAGCCCAGACCTTCATAAGTTCTT  
ATTATGGAATAAACCTGGCGTCAGCATTATAATCCTGGTGT CATGGCACCTGGCATTCT  
TAGCTGCGGGAGGCAGCTGCCGAAGCCTGAAACTCTGCCCTGCTGCCAAGACAAGAACTTTC  
TTCTTACAACCAGCGCTCCAGATAACCCTCAGGGAACCAGCACTCCCAAACCGCAGACTACA  
TCTTCTAGAGGAAGCACA ACTGTGCCTTTCTGAAAATCCCTTTCTGGTGGATTGAGAAA  
GAAATAAAACTATGCAGATA

94/168

## **FIGURE 94**

MTAAVFFGCAFIAFGPALALYVFTIAIEPLRIIFLIAGAFFWLVSSLISSLVWFMARVIIDNK  
DGPTQKYLIFGAFVSVYIQEMFRFAYYKLLKKASEGLKSINPGETAPSMRLLAYVSGLGFGI  
MSGVFSFVNTLSLDPGTVGIGHDSPQFFLYSAFMTLVIILLHVFWGIVFFDGCEKKKGIL  
LIVLLTHLLVSAQTFIISYYGINLASAFIILVLMGTWAFLAAGGSCRSLKLCLLCQDKNFLLY  
NQRSR

**Important features of the protein:**

**Signal peptide:**

amino acids 1-19

**Transmembrane domains:**

amino acids 32-51, 119-138, 152-169, 216-235

**Glycosaminoglycan attachment site.**

amino acids 120-123

**Sodium:neurotransmitter symporter family protein**

amino acids 31-65

95/168

**FIGURE 95**

AATTTTCACCAGAGTAAACTGAGAAACCAACTGGACCTTGAGTATTGTACATTTGCCTCG  
TGGACCCAAAGGTAGCAATCTGAAACATGAGGAGTACGATTCTACTGTTTGTCTTAGGAT  
CAAUUCGGTCATTACCACAGCTCAAACCTGCTTGGACTCCCTCCCACAAAAGTGGCTCCGG  
ATCAGGGAACACTACCAAAACCAACAGCAGTCAAATCAGGTCTTCCTTAAAGTCTGATAC  
CATTAACACAGATGCTCACACTGGGCCAGATCTGCATCTGTTAAATCCTGCTGCAGGAATGA  
CACCTGGTACCCAGACCCACCCATTGACCTGGGAGGGTTGAATGTACAACAGCAACTGCACC  
CACATGTGTTACCAATTTCACACAACTGGAGCCCAGGGCACTATCCTAAGCTCAGAGG  
AATTGCCACAAATCTCACGAGCCTCATCATCCATTCTGTTCCGGAGGCATCCTGCCCA  
CCAGTCAGGCAGGGCTAATCCAGATGTCCAGGATGGAAGCCTCCAGCAGGAGGAGCAGGTG  
TAAATCCTGCCACCCAGGGAACCCCAGCAGGCCCTCCAACACTCCAGTGGCACAGATGACG  
ACTTTGCAGTGACCACCCCTGCAGGCATCCAAAGGAGCACACATGCCATCGAGGAAGGCCACCA  
CAGAATCAGCAAATGGAATTCAGTAAGCTGTTCAAATTTCACACTAAGCTGCCTCGAATT  
TGGTGATAATGTGAATCTTATCATGATTATATTATGGAATAGATTGAGACACATTGGATA  
GTCTTAGAAGAAATTAATTCTTAATTACCTGAAAATATTCTGAAATTTCAGAAAATATGTT  
CTATGTAGAGAATCCAACTTTAAAAACAATAATTCAATGGATAATCTGTCTTGAAATAT  
AACATTATGCTGCCTGGATGATATGCATATTAAAACATATTGGAAAATGGAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

96/168

**FIGURE 96**

MRSTILLFCLLGSTRSLPQLKPALGLPPTKLAPDQGTLPNQQQSNQVFPSLSLIPLTQM  
LTLGPDLHLLNPAAGMTPGTQTHPLTLGGLNVQQQLHPHVLPIFVTQLGAQGTILSSEE  
LPQIFTSLIIHSLFPGGILPTSQAGANPDVQDGSLPAGGAGVNPATQGTPAGRPLPTSG  
TDDDFAVTTPAGIQQRSTHAIIEATTESANGIQ

**Signal peptide:**

amino acids 1-16

97/168

**FIGURE 97**

GCTCAAGTGCCTGCCCTGCCCCACCCAGCCAGCCTGGCCAGAGCCCCCTGGAGAAGGAGCT  
 CTCTTCTTGCTTGGCAGCTGGACCAAGGGAGCCAGTCTTGGCCTGGAGGGCTGTCTGAC  
CATGGTCCCTGCCTGGCTGTGGCTGCTTGTCTCCGTCCCCCAGGCTCTCCCCAAGGCCA  
 GCCTGCAGAGCTGTCTGTGGAAAGTCCAGAAAACTATGGTGGAAATTCCCTTATACTGAC  
 CAAGTTGCCGCTGCCCGTGAGGGGGCTGAAGGCCAGATCGTGTGTCAGGGACTCAGGCAA  
 GGCAACTGAGGGCCCATTGCTATGGATCCAGATTCTGGCTTCCCTGCTGGTGACCAGGGCCCT  
 GGACCGAGAGGAGCAGGCAGAGTACCGACTACAGGTACCCCTGGAGATGCAGGATGGACATGT  
 CTTGTGGGTCCACAGCCTGTGCTTGTGACGTGAAGGATGAGAAATGACCAGGTGCCCATTT  
 CTCTCAAGCCATCTACAGAGCTCGGCTGAGCCGGGTACCAAGGCCCTGGCATCCCCTCCT  
 CCTTGAGGCTTCAGACCGGGATGAGCCAGGCACAGCCAACTCGGATCTCGATTCACATCCT  
 GAGCCAGGCTCCAGCCCAGCCTCCCCAGACATGTTCCAGCTGGAGCCTCGGCTGGGGCTCT  
 GCCCCTCAGCCCCAAGGGGAGCACCAGCCTGACCACGCCCTGGAGAGGACCTACCAGCTGTT  
 GGTACAGGTCAAGGACATGGGTGACCAGGCCCTAGGCCACCAGGCCACTGCCACCGTGGAACT  
 CTCCATCATAGAGAGCACCTGGGTGTCCTAGAGCCTATCCACCTGGCAGAGAACTCAAAGT  
 CCTATACCCGCACCACATGGCCAGGTACACTGGAGTGGGGGTGATGTGCACTATCACCTGGA  
 GAGCCATCCCCGGGACCCCTTGAAGTGAATGCAGAGGAAACCTCTACGTGACCAGAGAGCT  
 GGACAGAGAAGCCCAGGCTGAGTACCTGCTCCAGGTGCCGGCTCAGAAATTCCATGGCAGGA  
 CTATGCGGCCCTCTGGAGCTGCACGTGCTGGATGGATGAGAAATGACAACGTGCCATCTG  
 CCCTCCCGTACCCCCACAGTCAGCATCCCTGAGCTCAGTCCACCAGGTACTGAAGTGA  
 ACTGTCAAGCAGAGGATGCAGATGCCCGGCTCCCCAACCTCCACGTTGTATCAGCTCCT  
 GAGCCCTGAGCCTGAGGATGGGTAGAGGGGAGAGCCTCCAGGTGGACCCACTCAGGCAG  
 TGTGACGCTGGGGTGTCCCCTCCAGGTGAGCTGACGAGTGTGGATGGCTGGCCAT  
 GGACCTGGCAGGCGCAGAGGGTGGCTCAGCAGCACGTGTGAAGTCGAAGTCGCAGTCACAGA  
 TATCAATGATCACGCCCTGAGTTCATCACTTCCAGATTGGGCTATAAGCCTCCCTGAGGA  
 TGTGGAGCCCGGGACTCTGGTGGCCATGCTAACAGCATTGATGCTGACCTCGAGCCCGCCT  
 CCGCCTCATGGATTTCGCATTGAGAGGGAGACACAGAAGGGACTTTGGCCTGGATTGGGA  
 GCCAGACTCTGGCATGTTAGACTCAGACTCTGCAAGAACCTCAGTTATGAGGCAGCTCCAAG  
 TCATGAGGTGGTGGTGGTGCAGAGTGTGGCAAGCTGGTGGCCAGGCCAGGGCTGG  
 AGCCACGCCACGGTGAETGTCTAGTGGAGAGAGTGTGGCAAGCTGGCACCAGGA  
 GAGCTACGGGCCAGTGTCCCCATCAGTGCCTCAGGCCAGCGGCTCTTCTGCTGACCATCCAGCC  
 CTCCGACCCATCAGCGAACCTCAGGTTCTCCCTAGTCAATGACTCAGAGGGCTGGCTCTG  
 CATTGAGAAATTCTCCGGGAGGTGCACACCAGCTCCAGTCCCTGCAGGGGCCAGCCTGGGA  
 CACCTACACGGTCTGTGGAGGCCAGGATACAGCCCTGACTCTTGCCTGTGCCCTCCA  
 ATACCTCTGCACACCCGCCAAGACCATGGCTGATCGTAGTGGACCCAGCAAGGACCCGA  
 TCTGGCCAGTGGCACGGTCCCTACAGCTTGCACCCCTGGTCCAACCCACGGTGCACGGGA  
 TTGGCCTCCAGACTCTCAATGGTCCCCTGCTACCTCACCTGGCCCTGATTGGTGG  
 GCCACGTGAACACATAATCCCCGTGGTGGTCAGCCACAATGCCAGATGTGGCAGCTCTGGT  
 TCGAGTGATCGTGTGCTGCAACGTGGAGGGCAGTGCATGCGCAAGGTGGCCGATGAA  
 GGGCATGCCACGAAGCTGCGCAGTGGCATTGCTAGGCACCCCTGGTAGCAATAGGAAT  
 CTTCTCATCCTCATTTCACTGGACCATGTCAGGAAGAAGGACCCGGATCAACCAGC  
 AGACAGCGTGCCCTGAAGGCAGTGTCTGAATGAATGGCCAGGCAGCTAGCTGGAGCTTGGC  
 CTCTGGCTCCATCTGAGTCCCCTGGGAGAGAGGCCAGCACCAAGATCCAGCAGGGACAGGA  
 CAGAGTAGAAGCCCTCCATCTGCCCTGGGGTGGAGGCACCATCACCACCAAGGCATGTCT  
 GCAGAGCCTGGACCCAACCTTATGGACTGCCCATGGGAGTGCTCAAATGTCAGGGTGG  
 CCCAATAATAAGCCCCAGAGAACTGGCTGGCCCTATGGAAAAAAGAAAAAAGAAAAA  
 AAAAAAAAG

98/168

## FIGURE 98

MVPAWLWLLCVSVPQALPKAQPAELSVEVPENYGGNPLYLTKLPLPREGAEGQIVLSGDSGK  
ATEGPFAMDPDSGFLLVTRALDREEQAQEYQLQVTLEMQDGHVLWGPQPVLVHVKDENDQVPHF  
SQAIYRARLSRGTRPGIPFLFLEASDRDEPGTANSDLRFHILSQAPAQPSPDMFQLEPRLGAL  
ALSPKGSTSLDHALERTYQLLVQVKDMGDQASGHQATATVEVSIIESTWVSLPEIHLAENLK  
LYPHHMAQVHWSGGDVHYHLESHPPGPFEVNAEGNLYVTRELDREAQAEYLLQVRAQNSHGED  
YAAPPLEHVLVMDENDNPICPPRDPTVSIPELSPPGTEVTRLSAEDADAPGSPNSHVYQOLL  
SPEPEDGVEGRAFQVDPTSGSVTLGVPLRAGQNILLVLAMDLAGAEGGFSSTCEVEVAVTD  
INDHAPEFITSQIGPISLPEDVEPGTLVAMLTAIDADLEPAFRIMDFAIERGDTEGTFGLDWE  
PDSGHVRLRLCKNLSYEAPSHEVVVVVQSVAKLVGPGPGATATVTVLVERVMPPPKLDQE  
SYEASVPISAPAGSFLLTIQPSDPISRTLRFSLVNDSEGWLICIEKFSGEVHTAQSLQGAQPGD  
TYTVLVEAQDTALT LAPVPSQYLCTPRQDHGLIVSGPSKDPDLASGHGPYSFTLGPNPTVQRD  
WRLQTLNGSHAYLT LALHWV EPREHII PVVVSHNAQM WQLLVRVIVCRCNVEGQCMRKVGRMK  
GMPTKLSAVGILVGTLVAIGIFLILIFT HWTMSRKKDQPADSVPLKATV

**Signal peptide:**

amino acids 1-18

**Transmembrane domain:**

amino acids 762-784

99/168

## FIGURE 99

GGCTGACCGTGCTACATTGCCCTGGAGGAAGCCTAAGGAACCCAGGCATCCAGCTGCCACGCC  
TGAGTCCAAGATTCTCCCAGGAACACAAACGTAGGAGACCCACGCTCTGGAAAGCACCAGCC  
TTTATCTCTCACCTTCAGTCCCCTTCTCAAGAACAAACGTAGGAGACCCACGCTCTGGAAAGCACCAGCC  
TGGTACATCTAGGACCCAGGCATCTGCTTCCAGCCACAAAGAGACAGA**ATGA**AAGATGCAGAA  
AGGAAATGTTCTCCTTATGTTGGTCACTATTGCATTAGAAGCTGCAACAAATTCCAATGA  
GAATGACCTCTGCCAACACTGGATCCAGTGTGATCTCAGTGGAGCCAGCACAGCCACCAA  
CTCTGGTCCAGTGTGACCTCCAGTGGGTCAAGCACAGCCACCATCTCAGGGTCCAGCGTGC  
CTCCAATGGGGTCAGCATAGTCACCAACTCTGAGTCCATACAACCTCCAGTGGATCAGCAC  
AGCCACCAACTCTGAGTTCAGCACAGCGTCCAGTGGGATCAGCATAGCCACCAACTCTGAGTC  
CAGCACACCTCCAGTGGGCCAGCACAGCCACCAACTCTGAGTCCAGCACACCCCTCAGTGG  
GGCCAGCACAGTCACCAACTCTGGGTCCAGTGTGACCTCCAGTGGAGCCAGCACTGCCACCAA  
CTCTGAGTCCAGCACAGTGTCCAGTAGGGCCAGCACTGCCACCAACTCTGAGTCTAGCACACT  
CTCCAGTGGGCCAGCACAGCCACCAACTCTGACTCCAGCACAAACCTCCAGTGGGCTAGCAC  
AGCCACCAACTCTGAGTCCAGCACAACTCCAGTGGGCCAGCACAGCCACCAACTCTGAGTC  
CAGCACAGTGTCCAGTAGGGCCAGCACTGCCACCAACTCTGAGTCCAGCACAAACCTCCAGTGG  
GGCCAGCACAGCCACCAACTCTGAGTCCAGAACGACCTCCAAATGGGGCTGGCACAGCCACCAA  
CTCTGAGTCCAGCACGACCTCCAGTGGGCCAGCACAGCCACCAACTCTGAGTCCAGCACAGT  
GTCCAGTGGGCCAGCACTGCCACCAACTCTGAGTCCAGCACACCTCCAGTGGGCCAGCAC  
AGCCACCAACTCTGAGTCCAGCACGACCTCCAGTGGGCCAGCACAGCCACCAACTCTGACTC  
CAGCACACCTCCAGTGGGCCAGCACAGCCACCAACTCTGAGTCCAGCACAGTGTCCAGTGG  
GATCAGCACAGTCACCAATTCTGAGTCCAGCACACCTCCAGTGGGCCAACACAGCCACCAA  
CTCTGAGTCCAGTACGACCTCCAGTGGGCCAACACAGCCACCAACTCTGAGTCCAGCACAGT  
GTCCAGTGGGCCAGCACTGCCACCAACTCTGAGTCCAGCACACCTCCAGTGGGCTAGCAC  
AGCCACCAACTCTGAGTCCAGCACACCTCCAGTGGGCCAGCACAGCCACCAACTCTGACTC  
CAGCACACCTCCAGTGGGCCAGCACAGCCACCAACTCTGAGTCTAGCACAGTGTCCAGTGG  
GATCAGCACAGTCACCAATTCTGAGTCCAGCACACCTCCAGTGGGCCAACACAGCCACCAA  
CTCTGGTCCAGTGTGACCTCTGCAGGCTCTGAAACAGCAGCTCTGACTGGAATGCACACAAAC  
TTCCCATAGTCATCTACTGCAGTGAATGAGGAAAGCTGGTGGGCTGGTGGCTGGGGAA  
AATCTTCCTCATCACCCCTGGTCTCGGTTGTGGCGGCCGTGGGGCTTTGCTGGGCTTTCTT  
CTGTGTGAGAACACGCCCTGTCCCTGAGAAACACCTTTAACACAGCTGTCTACCACCCCTCATGG  
CCTCAACCATGGCCTTGGTCCAGGCCCTGGAGGGAAATCATGGAGCCCCCACAGGCCAGGTG  
GAGTCCTAACTGGTTCTGGAGGGAGACCAAGTATCATCGATGCCATGGAGATGAGCAGGGAGGAA  
CAGCGGGCC**TGAG**CAGCCCCGGAAGCAAGTGCCGATTCTCAGGAAGGAAGAGACCTGGGC  
ACCAAGACCTGGTTCTTCATTCATCCCAGGAGACCCCTCCAGCTTGTGAGATC  
GAAAATCTTGAAGAAGGTATTCTCATCACCCTTCTGCCTTACCAAGACACTGAAAGAGAATAC  
TATATTGCTCATTAGCTAAGAAATAATACATCTCATTAACACACAGCACAAAGAGAAGCT  
GTGCTTGGCCCGGGGTGGGTATCTAGCTGTGAGATGAACCTAGTTAGGAGAAAACCTCCAT  
GCTGGACTCCATGGCATTCAAATCTCCACAGTAAATCCAAAGACCTCAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

100/168

## **FIGURE 100**

MKMQKGNVLLMFGLLLHLEAATNSNETSTSANTGSSVISSGASTATNSGSSVTSSGVSTATIS  
GSSVTSNGVSIVTNSEFHTTSSGISTATNSEFSTASSGISIATNSESSTTSSGASTATNSESS  
TPSSGASTVTNGSSVTSSGASTATNSESSTVSSRASTATNSESSTLSSGASTATNSDSSTTS  
SGASTATNSESSTSSGASTATNSESSTVSSRASTATNSESSTTSSGASTATNSESRTTSNGA  
GTATNSESSTTSSGASTATNDSSTVSSGASTATNSESSTTSSGASTATNSESSTTSSGASTA  
TNSDSSTTSSGAGTATNSESSTVSSGISTVTNSESSTPSSGANTATNSESSTTSSGANTATNS  
ESSTVSSGASTATNSESSTTSSGVSTATNSESSTTSSGASTATNDSSTSSEASTATNSESS  
TVSSGISTVTNSESSTTSSGANTATNSGSSVTSAGSGTAALTGMHTTSHSASTAVSEAKPGGS  
LVPWEIFLITLVSVVAAVGLFAGLFFCVRNSLSLRNTFNTAVYHPHGLNHGLGPGPGGNHGAP  
HRPRWSPNWFWRPVSSIAMEMSGRNSGP

**Signal peptide:**

amino acids 1-20

**Transmembrane domain:**

amino acids 510-532

## FIGURE 101

GGCGGGACGCCTCCCGTACGGGATGAATTAAACGGCGGGTCCGCACGGAGGTTGTGACCCC  
TACGGAGCCCCAGCTGCCACGCACCCACTCGCGTCGCACGGCGTGCCTGCTTGCA  
GGTGGGAGGCTGGAACATATCAGGCTGAAAAACAGAGTGGGTACTCTCTGGAAAGCTGGCA  
ACAAATGGATGATGTGATATATGCATTCCAGGGAAAGGGAAATTGTGGTGCTCTGAACCCAT  
GGTCAATTAAACGAGGCAGTTCTAGCTACTGCACGTACTCATAAAGCAGGACTCTAAAGCT  
TTGGAATCATGGTGTACGGAAAGGGATTTACTTATACTGACTCTGTTGGGAAGCTTT  
TTGGAAGCATTTCATGCTGAGTCCCTTTACCTTGATGTTGAAACCCATCTGGTATC  
GCTGGATCAACAACCGCCTGTGGCAACATGGCTACCCCTACCTGTGGCATTATTGGAGACCA  
TGTTTGGTGTAAAAGTGATTATAACTGGGATGCATTGTCCTGGAGAAAGAAGTGTCA  
TCATGAACCATCGGACAAGAATGGACTGGATGTTCTGTGGAATTGCCTGATGCGATATAGCT  
ACCTCAGATTGGAGAAAATTGCCTCAAAGCGAGTCTCAAAGGTGTTCTGGATTGGTTGGG  
CCATGCAGGCTGCTGCCTATATCTTCATTGATAGGAAATGGAAGGATGACAAGAGCCATTG  
AAGACATGATTGATTACTTTGTGATATTCACGAACCACCTCAACTCCTCATATTCCCAGAAG  
GGACTGATCTCACAGAAAACAGCAAGTCTGAAGTAATGCATTGCTGAAAAAAATGGACTTC  
AGAAATATGAATATGTTTACATCCAAGAACTACAGGCTTACTTTGTGGTAGACCGTCAA  
GAGAAGGTAAAGAACCTTGATGCTGTCCATGATATCACTGTGGCGTATCCTCACGTCCACCG  
AATCAGAGAACCTCCTCCAAGGAGACTTCCCAGGGAAATCCACTTCACGTCCACCG  
ATCCAATAGACACCCCTCCCCACATCCAAGGAGGACCTCAACTCTGGTGCCACAAACGGTGG  
AAGAGAAAAGAGAGAGGCTGCGTCCCTCTATCAAGGGGAGAAGAATTTTATTTACCGGAC  
AGAGTGTCAATTCCACCTTGCAAGTCTGAACTCAGGGCCTGTGGTCAAATTGCTCTATAC  
TGTATTGGACCCCTGTTCACTGCATGCTGCAATGTGCCTACTCATATATTGTACAGTCTGTTA  
GGTATTTTATAATCACCATTGTAATCTTGTGCTGCAAGAGAGAATATTGGTGGACTGGAGA  
TCATAGAACTTGCACTGTTACCGACTTTACACAAACAGCCACATTAAATTCAAAGAAAATG  
AGTAAGATTATAAGGTTGCCATGTGAAAACCTAGAGCATATTGGAAATGTTCAAACCTT  
TCTAAGCTCAGATGCATTTGCATGACTATGTCGAATATTCTACTGCCATCATTATTGT  
TAAAGATATTGCACTTAATTGTGGAAAATATTGCTACAATTTTAAATCTCTGAA  
TGTAATTGCACTGTGACATAGCAGGGAGTGATCGGGGTGAAATAACTGGGCCAGAATA  
TTATTAAACAATCATCAGGCTTTAAA

102/168

## **FIGURE 102**

MHSRGREIVVLLNPWSINEAVSSYCTYFIKQDSKSFGIMVSWKGIYFILTLFWGSFFGSIFML  
SPFLPLMFVNPSWYRWINNRLVATWLTPVALLETMFGVKVIITGDAFVPGERSVIIMNHRTR  
MDWMFLWNCLMRYSYLRLEKICLKASLGPGFWAMQAAAYIFIHRWKDDKSHFEDMIDYF  
CDIHEPLQLLIFPEGTDLTENSRSNAFAEKNGLQKYEYVLHPRTTGFTFVVDRLREGKNLD  
AVHDITVAYPHNIHQSEKHLQGDFPREIHFHVRYPIDLPLTSKEDLQLWCHKRWEKEERL  
RSFYQGEKNFYFTGQSVIPCKSELRLVVKLLSILYWTLFSPAMCLLIYLYSLVKWYFIITI  
VIFVLQERIFGGLEIIELACYRLLHKQPHLNNSKKNE

**Important features of the protein:**

**Signal peptide:**

amino acids 1-22

**Transmembrane domains:**

amino acids 44-63, 90-108, 354-377

## FIGURE 103

CGGCTCGAGCGGCTCGAGTGAAGAGCCTCTCACGGCTCTGCCTGAGACAGCTGGCTGA  
CCTCCAAATCATCCATCCACCCCTGCTGTCACTGTTCTAGTGTGAGATCAACCCACAGG  
AATATCC**ATG**GCTTTGTGCTCATTTGGTCTCAGTTCTACGAGCTGGTGTAGGACAGTG  
GCAAGTCACTGGACCAGGGCAAGTTGTCCAGGCCTGGGGGGAGGACGCCGTGTTCTCCTG  
CTCCCTCTTCTGAGACCAGTGCAGAGGCTATGGAAGTGCCTCTTCAGGAATCAGTCCA  
TGCTGTGGTCCACCTCTACAGAGATGGGAAGACTGGGAATCTAACAGCAGATGCCACAGTATCG  
AGGGAGAACTGAGTTGTGAAGGACTCCATTGCAGGGGGCGTGTCTCTAACGGCTAAAAAA  
CATCACTCCCTCGGACATCGGCCTGTATGGGTGCTGGTCAGTTCCAGATTACGATGAGGA  
GGCCACCTGGGAGCTGCGGGTGGCAGCACTGGCTCACCTCCTCATTTCCATCGTGGGATA  
TGTTGACGGAGGTATCCAGTTACTCTGCCTGCTCAGGCTGGTCCCCCAGCCCACAGCCAA  
GTGGAAAGGTCCACAAGGCAGGATTGTCTTCAGACTCCAGAGCAAATGCAGATGGGTACAG  
CCTGTATGATGTGGAGATCTCATTATAGTCCAGGAAATGCTGGAGCATATTGTGTTCCAT  
CCACCTTGTGAGCAGAGTCATGAGGTGGAATCCAAGGTATTGATAGGAGAGACGTTTCCA  
GCCCTCACCTTGGCGCTGGCTTCTATTTACTCGGGTTACTCTGTGGTGCCTGTGGTGT  
TGTATGGGATGATAATTGTTCTCAATCCAAAGGGAAAATCCAGGGAACTGGACT  
GAGAAGAAAGCACGGACAGGCAGAATTGAGAGACGCCGGAAACACGCAGTGGAGGTGACTCT  
GGATCCAGAGACGGCTCACCGAAGCTCTGCCTTCTGATCTGAAAATGTAACCCATAGAAA  
AGCTCCCCCAGGAGGTGCCTCACTCTGAGAAGAGATTACAAGGAAGAGTGTGGTGGCTTCTCA  
GGGTTCCAAGCAGGGAGACATTACTGGGAGGTGGACGTGGACAAAATGTAGGGTGGTATGT  
GGGAGTGTGTCGGGATGACGTAGACAGGGGAAGAACATGTGACTTGTCTCCAACAATGG  
GTATTGGGTCTCAGACTGACAACAGAACATTGTATTACATTCAATCCCCATTATCAG  
CCTCCCCCCCAGCACCCCTCTACACGAGTAGGGTCTCCTGGACTATGAGGGTGGACCAT  
CTCCTCTTCAATACAAATGACCAGTCCCTTATTACCCCTGCTGACATGTCAGTTGAAGG  
CTTGTGAGACCTATATCCAGCATGCGATGTGACGAGGAAAGGGACTCCATATTCA  
ATGTCCAGTGTCTGGG**ATG**AACAGAGAACCTGTTAAAGGGCCCACACCACAGACC  
CAGACACAGCCAAGGGAGAGTGCTCCCAGCAGGTGGCCCCAGCTTCTCTCCGGAGCCTGC  
ACAGAGAGTCACCCCCCCTCTCCTTAGGGAGCTGAGGTTCTCTGCCCTGAGCCCTGCA  
GCAGCGGCACTCACAGCTTCCAGATGAGGGGGATTGGCCTGACCCCTGTGGAGTCAGAACCC  
ATGGCTGCCCTGAAGTGGGACGGAATAGACTCACATTAGGTTAGTTGTGAAAATCCATC  
CAGCTAACGATCTGAACAAGTCACAACCTCCAGGCTCTCATTGCTAGTCACGGACAGT  
GATTCCCTGCCTCACAGGTGAAGATTAAAGAGACAACGAATGTGAATCATGCTGCAGGTTGA  
GGGCACAGTGTGCTAATGATGTGTTTATATTACATTTCACCAAAACTCTGTT  
GCTTATTCCACATTAATTACTTTCTCTATACCAATCACCATGGAATAGTTATTGAACAC  
CTGCTTGTGAGGCTCAAAGAATAAAGAGGAGGTAGGATTTCACTGATTCTATAAGCCAG  
CATTACCTGATACCAAAACAGGCAAAGAAAACAGAAGAAGAGGAAGGAAACTACAGGTCCA  
TATCCCTCATTAACACAGACACAAAAATTCTAAATAAAATTAAACAATTAAACTAAACAAT  
ATATTAAAGATGATATATAACTACTCAGTGTGGTTGTCCCACAAATGCAGAGTTGGTTAA  
TATTTAAATATCAACCAGTGAATTCAACGACATTAATAAGTAAAAAGAAAACCATAAAAAAA  
AAAAAAAAAA

104/168

## **FIGURE 104**

MAFVLILVLSFYELVSGQWQVTGPGKVFQALVGEDAVFSCSLFPETSAEAMEVRFFRNQFHAV  
VHLYRDGEDWESKQMPQYRGRTEFKDSIAGGRVSLRLKNITPSDIGLYGCWFSSQIYDEEAT  
WELRVAAL GSLPLISIVGYVDGGIQLLCLSSGWFPQPTAKWKGPQGQDLSSDSRANADGYSLY  
DVEISIIVQENAGSILCSIHLAEQSHEVESKVLIGETFFQPSPWRLASILLGLLCALCGVVM  
GMIIVFFKSKGKIQAELDWRRKHGQAEELRDARKHAVEVTLDPETAHPKLCVSDLKTVTHRKAP  
QEVPHSEKRFRTRKSVVVASQGFQAGRHYWEVDVGQNVGVYVGVCRDDVDRGKNNVTLSPPNNGYW  
VLRLTTEHLYFTFNPHFISLPPSTPPTRGVFLDYEGGTISFFNTNDQSLIYTLLTCQFEGLL  
RPYIQHAMYDEEKGTPIFICPVSWG

**Signal peptide:**

amino acids 1-17

**Transmembrane domains:**

amino acids 131-150, 235-259

## **FIGURE 105**

CCTTCACAGGACTCTCATTGCTGGTGGCAATGATGTATCGGCCAGATGTGGTGAGGGCTAG  
GAAAAGAGTTGGGACCCCTGGTTATCGGCCTCGTCATCTCATATCCCTGATTGTCCT  
GGCAGTGTGCATTGGACTCACTGTTCAATTATGTGAGATATAATCAAAAGAACCTACAATTA  
CTATAGCACATTGTCATTACAAC TGACAAACTATATGCTGAGTTGGCAGAGAGGCTTCTAA  
CAATTTACAGAAATGAGCCAGAGACTTGAATCAATGGTAAAAATGCATTTATAAATCTCC  
ATTAAGGGAAGAATTGTCAAGTCTCAGGTTATCAAGTTCAAGCAGAACAGCATGGAGTGTT  
GGCTCATATGCTGTTGATTGTAGATTCACACTACTGAGGATCCTGAAACTGTAGATAAAAT  
TGTTCAACTGTTTACATGAAAAGCTGCAAGATGCTGTAGGACCCCCTAAAGTAGATCCTCA  
CTCAGTTAAAATTAAAAAAATCAACAAGACAGAAACAGACAGCTATCTAAACCATTGCTGCGG  
AACACGAAGAAGTAAAACCTAGGTAGTCAGACTCAGGATCGTGGTGGACAGAAGTAGAAGA  
GGGTGAATGCCCTGGCAGGCTAGCCTGCAGTGGATGGAGTCATCGCTGTGGAGCAACCTT  
AATTAATGCCACATGGCTTGAGTGTGCTGCTACTGTTTACAACATATAAGAACCTGCCAG  
ATGGACTGCTTCCTTGGAGTAACAATAAAACCTCGAAAATGAAACGGGTCTCCGGAGAAT  
AATTGTCCATGAAAATACAAACACCCATCACATGACTATGATATTCTCTGAGCAGACTTC  
TAGCCCTGTTCCCTACACAAATGCAGTACATAGAGTTGCTCCCTGATGCATCCTATGAGTT  
TCAACCAGGTGATGTGATGTTGTGACAGGATTGGAGCACTGAAAATGATGGTTACAGTCA  
AAATCATCTCGACAAGCACAGGTGACTCTCATAGACGCTACAACTGCAATGAACCTCAAGC  
TTACAATGACGCCATAACTCCTAGAATGTTATGTGCTGGCTCCTAGAAGGAAAACAGATGC  
ATGCCAGGGTGACTIONGGAGGACACTGGTTAGTCAGATGCTAGAGATATCTGGTACCTTGC  
TGGAAATAGTGAGCTGGGAGATGAATGTGCGAAACCCAACAAGCCTGGTGTATACTAGAGT  
TACGGCCTTGCAGGACTGGATTACTTCAAAAACTGGTATCTAAGGAGACAAAGCCTCATGGAA  
CAGATAAACATTTTTGTTTGGGTGTGGAGGCCATTTAGAGATAACAGAATTGGAGA  
AGACTTGCAAAACAGCTAGATTTGACTGATCTCAATAAACTGTTGCTGATGCATGTATTT  
CTTCCCAGCTCTGTCGCACGTAAGCATCCTGCTCTGCCAGATCAACTCTGTCATCTGTGA  
GCAATAGTTGAAACTTATGTACATAGAGAAATAGATAACAAATTACATTACAGCCTGTA  
TTCATTTGTTCTCTAGAAGTTGTCAGAATTGACTTGTGACATAAATTGTAATGCATA  
TATACAATTGAAAGCACTCCTTCTCAGTTCTCAGCTCCTCAGCTCTCATTCAGCAAATATCCA  
TTTCAAGGTGCAGAACAGGAGTGAAAGAAAATATAAGAAGAAAAATCCCCTACATTTA  
TTGGCACAGAAAAGTATTAGGTGTTTCTTAGTGGAAATTAGAAATATTGATCATATTCTTAT  
GAAAGGTCAAGCAAAGACAGCAGAACATACCAATCACTTCATCATTAGGAAGTATGGAACTAA  
GTTAAGGAAGTCCAGAAAGAACGCAAGATATATCCTTATTTCAATTCCAAACAACTACTATG  
ATAAAATGTGAAGAAGATTCTGTTTTGTGACCTATAATAATTACAAACTTCATGCAATG  
TACTTGTCTAAGCAAATTAAAGCAAATATTATTTAACATTGTTACTGAGGATGTCAACATA  
TAACAATAAAATATAACCCCA

106/168

**FIGURE 106**

MMYRPDVVRARKRVCWEPWVIGLVIFISLIVLAVCIGLTVHYVRYNQKKTYNYYSTLSFTTDK  
LYAEFGREASNNFTEMSQRLESMVKNAFYKSPLREEFVKSQVIKFQQKHGVLAHMLLICRFH  
STEDPETVDKIVQLVLHEKLQDAVGPPKVDPHSVKIKKINKTETDSYLNHCCGTRRSKTLGQS  
LRIVGGTEVEEGEWPWQASLQWDGSHRCGATLINATWLVSAAHCFTTYKNPARWTASFGVTIK  
PSKMKRGLRRIIVHEKYKHPSHDYDISLAELSSPVPTNAVHRVCLPDASYEFQPGDVMFVTG  
FGALKNDGYSQNHLRQAQVTLIDATTNEPQAYNDAITPRMLCAGSLEGKTDACQGDGGPLV  
SSDARDIWIYLAGIVSWGDECAPNKPGVYTRVTALRDWITSKTGI

**Transmembrane domain:**

amino acids 21-40 (type II)

107/168

## **FIGURE 107**

AGAGAAAGAACGCTCCAGCTGAAGCCAATGCAGCCCTCCGGCTCTCCCGCAAGAAGTCCCC  
TGCCCCGATGAGCCCCCGCCGTGCGTCCCCGACTATCCCCAGGCAGGGCGTGGGGCACCGGGCC  
CAGCGCCGACGATCGCTGCCGTTGCCCTGGAGTAGGATGTGGTAAAGGATGGGCTTC  
TCCCTACGGGCTACAAT**ATG**CCAGAGAAAGATTCCGTAAAGTGTCTGCCTGCCTCTAC  
GCCCTCAATCTGCTCTTGTTAATGTCCATCAGTGTGGCAGTTCTGCTGGATGAGG  
GACTACCTAAATAATGTTCTCACTTAAC TGAGAACGAGGGTAGAGGAAGCAGTCATTTG  
ACTTACTTCCGTGGTCATCCGGTCA TGATTGCTGTTGCTGTTCCCTATCATTGGGG  
ATGTTAGGATATTGTTGAAACGGTAAAAGAAATCTGTTGCTTCTGCATGGTACTTGGAAAGT  
TTGCTTGTCACTTCTGTGTTAGAACTGGCTTGTGGCTTGGACATATGAACAGGAACCTATG  
GTTCCAGTACAATGGTCAGATATGGTCACTTGAAAGCCAGGATGACAAATTATGGATTACCT  
AGATATCGGTGGCTACTCATGCTTGAATTTCAGAGAGAGTTAAGTGTGTGGAGTA  
GTATATTCACTGACTGGTTGAAATGACAGAGATGGACTGGCCCCAGATTCTGCTGTGTT  
AGAGAATTCCCAGGATGTTCAAACAGGCCACCAGGAAGATCTCAGTGACCTTATCAAGAG  
GGTTGTGGGAAGAAAATGATTCTTTGAGAGGAACCAAACACTGCAGGTGCTGAGGGTT  
CTGGGAATCTCCATTGGGTGACACAAATCCTGCCATGATTCTCACCATTACTCTGCTCTGG  
GCTCTGTATTATGATAGAAGGGAGCCTGGACAGACCAATGATGTCCTGAAGAATGACAAC  
TCTCAGCACCTGTCA TGCTTCACTGAGGAGTTAAGGAAACGCTGTCAAGAATCTTGAA  
CACACATCCATGGCAAACAGCTTAATACACACTTGAGATGGAGGAGTTA**TAAA**AGAAATG  
TCACAGAAGAAAACCACAAACTGTTTATTGGACTTGTGAATTGGAGTACATACTATGTG  
TTTCAGAAATATGTAGAAATAAAATGTTGCCATAAAATAACACCTAACATACTATTCTA  
TGCTTAAATGAGGATGGAAAAGTTCATGTCATAAGTCACCACCTGGACAATAATTGATGC  
CCTTAAATGCTGAAGACAGATGTCATACCCACTGTGAGCCTGTATGACTTTACTGAAC  
ACAGTTATGTTGAGGCAGCATGGTTGATTGCACTTCCGCATCCATGCAAACGAGTCACA  
TATGGTGGACTGGAGCCATAGTAAAGGTTGATTTACTTCTACCAACTAGTATATAAGTACT  
AATTAAATGCTAACATAGGAAGTTAGAAAATAACTAAACTTTATTACTCAGCGATCTATTG  
TTCTGATGCTAAATAAAATTATATCAGAAAACCTTCAATATTGGTACTACCTAAATGTGAT  
TTTGCTGGTTACTAAAATATTCTACCACTTAAAGAGCAAGCTAACACATTGTCTTAAGCT  
GATCAGGGATTTTGATATAAGTCTGTGTTAAATCTGTATAATTCACTGCGATTCTAGTT  
GATAATGTTAAGAATAACCATTATGAAAAGGAAATTGTCCTGTATAGCATCATTATTTA  
GCCTTCTGTAAATAAGCTTACTATTCTGTGTCCTGGCTTATATTACACATATAACTGTTA  
TTTAAATACTAACCAACTTTGAAAATTACCACTGATAGCATAGGAATCATTATTCTAGA  
ATGAGTCTGGTCTTAGGAAGTATTAATAAGAAAATTGCACATAACTTAGTTGATTGAGAA  
AGGACTTGTATGCTGTTTCTCCAAATGAAGACTCTTTGACACTAAACACTTTAAAA  
AGCTTATCTTGCCTCTCCAAACAAGAAGCAATAGTCTCCAAGTCATATAAAATTCTACAGA  
AAATAGTGTCTTTCTCCAGAAAATGCTGTGAGAATCATTAAACATGTGACAATTAG  
AGATTCTTGTGTTATTCACTGATTAATAACTGTGGCAAATTACACAGATTATAAATTG  
TTTACAAGAGTATAGTATATTGAAATGGAAAAGTGCATTACTGTATTTGTGAT  
TTTGTGTTATTCTCAGAATATGAAAGAAAATTAAATGTGCAATAAAATTTCTAGAGAG  
TAA

108/168

## **FIGURE 108**

MAREDSVKCLRCLLYALNLLFWLMSISVLAWSAWMRDYLNNVLTLTAETRVEEAVILTYFPVV  
HPVMIAVCCFLIIVGMLGYCGTVKRNLNLLAWYFGSLLVIFCVELACGVWTYEQELMVPVQWS  
DMVTILKARMTNYGLPRYRWLTHAWNFFQREFKCCGVVFYFTDWLEMTEMDWPPDSCCVREFPGC  
SKQAHQEDLSLDLYQEGCGKKMYSFLRGTKQLQVLRFLGISIGVTQILAMILTITLLWALYYDR  
REP GTDQMMSLKNDNSQHLSCPSVELLKPSLSRIFEHTSMANSFNTHFEMEEL

**Signal peptide:**

amino acids 1-33

**Transmembrane domains:**

amino acids 12-35, 57-86, 94-114, 226-248

109/168

## FIGURE 109

CCAAGGCCAGAGCTGTGGACACCTTATCCCACTCATCCTCATCCTCTTCCTCTGATAAAGGCC  
CTACCAGTGCTGATAAAAGTCTTCTCGTAGAGGCCTAGAGGCCTAAAAAAAAGTGTGTTGA  
AAGAGAAGGGACAAAGAACCCAGTATTAGAGGATTTCAGTGTCTGGCAGTTGGTC  
**CAGAAGGATG**CCTCCATTCTGCTTCACTCACAGGCACCTCCGTGTCACC  
CGTGGCCCTAGATCCTGTTCTGCTTACATCAGCCTGAATGAGCCCTGGAGGAACACTGACCA  
CCAGTTGGATGAGTCTCAAGGTCTCCTCTATGTGACAACCAGTGAATGGGGAGTGGTACCA  
CTTCACGGGCATGGCGGGAGATGCCATGCCTACCTCTGCATACCAGAAAACACTGTGGAAC  
CCACGCACCTGTCTGGCTCAATGGCAGCCACCCCCCTAGAAGGCAGGGCATTGTGCAACGCCA  
GGCTTGTGCCAGCTCAATGGGAACGTGCTCTGGAACACACCAGGTGGAAGTCAAGGTTG  
CCCTGGAGGCTACTATGTGATCGTCTGACCAAGCCCAGCGTCTGCTTCCACGTACTGTGG  
TCATTTTATGACATCTGCAGGACTGCCATGGCAGCTGCTCAGATACCAGCAGTGCAC  
ATGCGCTCAGGAACGTGCTAGGCCCTGACAGGCAGACATGCTTGATGAAATGAATGTGA  
GCAAACAAACGGTGGCTGCACTGAGATCTGTGTAACCTCAAAACTCCTACCGCTGTGAGTG  
TGGGTTGCCGTGTGCTAAGAAGTGTGAAAGACTTGGAAGACGTTGAAGGATGCCACAA  
TAACAATGGTGGCTGCAGCCACTCTGCCTGGATCTGAGAAAGGCTACCAGTGTGAATGTCC  
CCGGGGCCTGGTGTCTGAGGATAACACACTTGCCTGGAGCTCCCTGTTGCAAAATCAA  
TGCCATTGAAGTGAACATCCCCAGGGAGCTGGTGGTGGCTGGAGCTTCTGACCAACAC  
CTCCTGCCGAGGAGTGTCCAACGGCACCCATGTCAACATCCTCTCTCAAGACATGTGG  
TACAGTGGTCGATGTGGTGAATGACAAGATTGTGGCCAGCAACCTCGTACAGGTCTACCAA  
GCAGACCCCCGGGGAGCAGCAGGGACTTCATCATCCGAACCAAGCTGCTGATCCGGTGAC  
CTGCGAGTTCCACGCCGTACACCATTCTGAAGGATACTTCCAAACCTTCGAAACTCCCC  
ACTGGAAATCATGAGCCGAAATCATGGGATCTTCCATTCACTCTGGAGATCTCAAGGACAA  
TGAGTTGAAGAGCCTACCGGAAAGCTCTGCCACCCCTCAAGCTCGTACTCCCTACTT  
TGGCATTGAGCCCGTGGTGCACGTGAGCGGCTTGGAAAGCTTGGTGGAGAGCTGCTTGCAC  
CCCCACCTCCAAGATGACGAGGTCCTGAAATACTACCTCATCGGGATGGCTGTGTTCAGA  
TGACTCGGTAAGCAGTACACATCCGGGATCACCTAGCAAAGCACTCCAGGTCCCTGTCTT  
CAAGTTTGTGGCAAAGACCACAAGGAAGTGTCTGCACTGCCGGTTCTGTCTGTTGAGT  
GTTGGACGAGCAGTCCCGCTGTGCCAGGGTTGCCACCGCGAATCGCTGTTGGCAGGAGG  
AGAGGACTCAGCCGGTCTACAGGCCAGACGCTAACAGGGCCCGATCCGATCGACTGGGA  
**GGACTAG**TTCGTAGCCATACCTCGAGTCCCTGCATTGGACGGCTCTGCTTTGGAGCTTCTC  
CCCCCACCGCCCTTAAGAACATCTGCCAACAGCTGGGTCAGACTCACACTGTGAGTCAG  
ACTCCCAGCACCAACTCACTGATTCTGGCCATTCACTGGGACAGGTACAGCACTGCTG  
AACAAATGTGGCCTGGGTGGGTTCATCTTCTAGGGTTGAAACTAAACTGTCCACCCAGAA  
AGACACTCACCCATTCCCTCATTCTTCTACACTTAAATACCTCGTGTATGGTGAATC  
AGACCACAAAATCAGAAGCTGGGTATAATATTCAAGTTACAAACCCCTAGAAAAATTAAACAG  
TTACTGAAATTATGACTTAAATACCCAATGACTCCTTAAATATGTAATTAGTTATACCTT  
GAAATTCAATTCAAATGCAGACTAATTAGGGAATTGGAGTGTATCAATAAACAGTAT  
ATAATT

110/168

## **FIGURE 110**

MPPFLLLTCLFITGTSVSPVALDPCSAYISLNNEPWRNTDHQLDESQGPPLCDNHVNGEWYHFT  
GMAGDAMPTFCIPEHCGTHAPVWLNGSHPLEGDGIVQRQACASFNGNCCLWNTTVEVKACPG  
GYVYVYRLTKPSVCFHVYCGHFYDICDEDCHGSCSDTSECTCAPGTVLGPDRQTCFDENECEQN  
NGGCSEICVNLKNSYRCECGVGRVLRSRGKTCEDVEGCHNNNGGCSHSLGSEKGYQCECPRG  
LVLSEDNHTCQVPVLCKSNAIEVNIPRELVGGLEFLTNTSCRGVSNGTHVNILFSLKTCGTV  
VDVVNDKIVASNLVTGLPKQTPGSSGDFIIRTSKLLIPVTCEFPRLYTISEGYVPNLRNSPLE  
IMSRNHGIFPFTLEIFKDNEFEPYREALPTLKLRLDSLYFGIEPVVHVSGLESLVESCAFATPT  
SKIDEVLKYYLIRDGCVSDDSVKQYTSRDHLAKHFQVPVFVKGKDHEVFLHCRVLVCVLD  
ERSRCAQGCHRRMRRGAGGEDSAGLQGQTLTGGPIRIDWED

**Important features of the protein:**

**Signal peptide:**

amino acids 1-16

**N-glycosylation sites.**

amino acids 89-93, 116-120, 259-263, 291-295, 299-303

**Tyrosine kinase phosphorylation sites.**

amino acids 411-418, 443-451

**N-myristoylation sites.**

amino acids 226-232, 233-239, 240-246, 252-258, 296-302, 300-306,  
522-528, 531-537

**Aspartic acid and asparagine hydroxylation site.**

amino acids 197-209

**ZP domain proteins.**

amino acids 431-457

**Calcium-binding EGF-like proteins.**

amino acids 191-212, 232-253

111/168

## FIGURE 111

GAGAGAGGCAGCAGCTGCTAGCGGACAAGGATGCTGGCGTGAGGGACCAAGGCCTGCCCT  
GCACTCGGGCCTCCTCCAGCCAGTGCTGACCAGGGACTTCTGACCTGCTGGCCAGCCAGGACC  
TGTGTGGGAGGCCCTCCTGCTGCCTGGGTGACAATCTCAGCTCCAGGCTACAGGGAGACC  
GGGAGGATCACAGAGCCAGCATGTTACAGGATCCTGACAGTGATCAACCTCTGAACAGCCTCG  
ATGTCAAACCCCTGCGCAAACCCGTATCCCCATGGAGACCTTCAGAAAGGTGGGATCCCCA  
TCATCATAGCACTACTGAGCCTGGCAGTATCATCATTGTGGTTGTCCTCATCAAGGTGATTC  
TGGATAAAATACTACTTCCTCTGCAGCCTCTCCACTTCATCCCAGGAAGCAGCTGTG  
ACGGAGAGCTGGACTGTCCCTGGGGAGGACGAGGAGCAGTGTCAGAGCTTCCCCGAAG  
GGCCTGCAGTGGCAGTCCGCTCTCCAAGGACCGATCCACACTGCAGGTGCTGGACTCGGCCA  
CAGGGAACTGGTTCTGCCTGTTGACAACCTCACAGAACGCTCGCTGAGACAGCCTGTA  
GGCAGATGGCTACAGCAGAGCTGTGGAGATTGGCCAGACCAGGATCTGGATGTTGAAA  
TCACAGAAAACAGCCAGGAGCTCGCATCGGAACACTCAAGTGGCCCTGTCTCAGGCTCCC  
TGGTCTCCCTGCACTGTCTGCCTGTGGGAAGAGCCTGAAGACCCCCCGTGTGGTGGGG  
AGGAGGCCCTGTGGATTCTTGGCCTTGGCAGGTCAAGCAGTACGACAAACAGCACGTCT  
GTGGAGGGAGCATTGGACCCCCACTGGTCCTCACGGCAGCCCAGTGCCTCAGGAAACATA  
CCGATGTGTTCAACTGGAAGGTGCAGGCTCAGACAAACTGGCAGCTCCCATTCCCTGG  
CTGTGGCCAAGATCATCATCATTGAATTCAACCCATGTACCCAAAGACAAATGACATCGCCC  
TCATGAAGCTGCAGTCCCACTCATTCTCAGGCACAGTCAGGCCATCTGTCTGCCCTCT  
TTGATGAGGAGCTCACTCCAGCCACCCACTCTGGATCATTGGATGGGCTTACGAAGCAGA  
ATGGAGGAAGATGCTGACATACTGCTGCAGGCAGTCAGGTCATTGACAGCACACGGT  
GCAATGCAGACGATGCGTACCAAGGGGAAGTCACCGAGAAGATGATGTGTCAGGCATCCGG  
AAGGGGTGTGGACACCTGCCAGGGTACAGTGGTGGGCCCTGATGTACCAATCTGACCGT  
GGCATGTGGTGGCATCGTAGCTGGGCTATGGCTGCCGGCCAGCAGCCAGGAGTAT  
ACACCAAGGTCTAGCCTATCTCAACTGGATCTACAATGTCTGGAAGGCTGAGCTGTAATGCT  
GCTGCCCTTGCACTGCTGGAGCCGCTTCCCTGCCCTGCCACCTGGGATCCCCAA  
AGTCAGACACAGAGCAAGAGTCCCCTGGTACACCCCTGCCACAGCCTCAGCATTCTT  
GGAGCAGCAAAGGGCTCAATTCTGTAAGAGACCCCTGCAGGCCAGAGCGCCAGAGGAAG  
TCAGCAGCCCTAGCTCGGCCACACTGGTGCTCCAGCATCCCAGGGAGAGACACAGCCACT  
GAACAAGGTCTAGGGTATTGCTAAGCCAAGAAGGAACCTTCCCACACTACTGAATGGAAGC  
AGGCTGTTGTAAGAGCCAGATCACTGTGGGCTGGAGAGGAGAAGGAAGGGTCTGCGCCA  
GCCCTGTCCGTCTCACCCATCCCCAGCCTACTAGAGCAAGAAACCAGTTGTAATATAAAAT  
GCACTGCCCTACTGTTGGTATGACTACCGTTACCTACTGTTGTCATTGTTATTACAGCTATGG  
CCACTATTATTAAAGAGCTGTGTAACATCTGGCAAAAAAA

112/168

**FIGURE 112**

MLQDPDSDQPLNSLDVKPLRKPRIPMETFRKVGIPIIIALLSLASIIIVVVLIKVILDKYFL  
CGQPLHFIPRKQLCDGELDCPLGEDEEHCVKSFPSEGPAVAVRLSKDRSTLQVLDSATGNWFSA  
CFDNFTEALAETACRQMGSRAVEIGPDQDLDVVEITENSQELMRMRNSSGPCLSGSLVSLHCL  
ACGKSLKTPRVVGSEEASVDSWPWQVSIQYDKQHVCAGSILDPHWLTAACFRKHTDVFNWK  
VRAGSDKLGSFPSLAVAKIIIEFNPMYPKDNDIALMKLQFPLTFSGTVRPICLPPFDEELTP  
ATPLWIIGWGFTKQNGGKMSDILLQASVQVIDSTRCNADDAYQGEVTEKMMCAGIPEGGVDT  
QGDGGPLMYQSDQWHVVGIVSWGYYGCAGPSTPGVYTKVSAYLNWIYNVWKAEL

**Transmembrane domain:**

amino acids 32–53 (typeII)

113/168

**FIGURE 113**

GGCTGGACTGGAACCTCTGGTCCAAGTGATCCACCCGCCTCAGCCTCCAAGGTGCTGTGAT  
TATAGGTGTAAGCCACCGTGTCTGGCCTCTGAACAACCTTTCAGCAACTAAAAAGCCACAG  
GAGTTGAAC TGCTAGGATTCTGACTATGCTGTGGTGGCTAGTGCTCCTACTCCTACCTACATT  
AAAAATCTGTTTTGTTCTCTGTAACTAGCCTTACCTCCTAACACAGAGGATCTGTCACT  
GTGGCTCTGGCCCAAACCTGACCTCACTCTGGAACGAGAACAGAGGTTCTACCCACACCGT  
CCCCTCGAAGCCGGGGACAGCCTCACCTGCTGGCCTCTCGCTGGAGCAGTGCCCTACCAAC  
TGTCTCACGTCTGGAGGCAGTGACTCGGGCAGTGCAGGTAGCTGAGCCTCTGGTAGCTGCGG  
CTTCAGGTGGGCTTGCCCTGGCGTAGAAGGGATTGACAAGCCGAAGATTCATAGGCG  
ATGGCTCCACTGCCAGGCATCAGCCTGCTGTAGTCATCACTGCCCTGGGCCAGGACGG  
GCCGTGGACACCTGCTCAGAACAGCAGTGGGTGAGACATCACGCTGCCGCCATCTAACCTTT  
CATGTCCTGCACATCACCTGATCCATGGCTAATCTGAACCTGTCCCAAGGAACCCAGAGCT  
TGAGTGAGCTGTGGCTCAGACCCAGAACAGGGCTGCTTAGACCACCTGGTTATGTGACAGGA  
CTTGCATTCTCCTGGAACATGAGGGAACGCCGGAGGAAGCAAAGTGGCAGGGAAAGGAACCTG  
TGCCAAATTATGGGTCAAGAAAAGATGGAGGTGTGGTTATCACAAGGCATCGAGTCTCCTGC  
ATTCA GTGGACATGTGGGGAAGGGCTGCCGATGGCGATGACACACTCGGGACTCACCTCTG  
GGGCCATCAGACAGCCGTTCCGCCCGATCCACGTACCGCTGCTGAAGGGCAACTGCAGGC  
CGATGCTCTCATGCCAGGCAGCAGCCAAATCTGCATCACGCTGCCAGGGCAGCCGTCTG  
GGAAGGAGCAAGCAAAGTGACCATTCTCCTCCCTCTGGCTTGAGAGGCCCTCTATGT  
CCCTACTAAAGCCACCAGCAAGACATAGCTGACAGGGCTAATGGCTCAGTGGTGGCCAGGA  
GGTCAGCAAGGCCTGAGAGCTGATCAGAACAGGGCTGCTGTGCGAACACGGAAATGCCCTCCAGT  
AAGCACAGGCTGCAAAATCCCCAGGCAAAGGACTGTGTGGCTCAATTAAATCATGTTCTAGT  
AATTGGAGCTGTCCCCAAGACCAAAGGAGCTAGAGCTTGGTCAAATGATCTCCAAGGCCCT  
TATACCCCAGGAGACTTGTGATTGAAACCCCAAATCCAAACCTAACGAAACCAGGTGCA  
TTAAGAACATCAGTTATTGCCGGGTGTGGTGGCTGTAATGCCAACATTGGGAGGCCAGGCG  
GGTAGATCACCTGAGGTCAAGGAGCTGAGGCTGAGACAGCCTGCCAACATGGTGAACAGGGCTGTCTC  
TACTAAAAATAACAAAAACTAGCCAGGCATGGTGGTGTGTGCCTGTATCCCAGCTACTCGGG  
AGGCTGAGACAGGAGAATTACTGAAACCTGGGAGGTGAAGGAGGCTGAGACAGGAGAATCACT  
TCAGCCTGAGCAACACAGCGAGACTCTGTCTCAGAAAAAATAAAAAGAATTATGGTATT  
GTAA

114/168

**FIGURE 114**

MLWWLVLLLLPTLKSVFCSLVTSLYLPNTEDSLWLWPKPDLHSGTRTEVSTHTVPSKPGTAS  
PCWPLAGAVPSPTVSRLEALTRAVQVAEPLGSCGFQGGPCPGRRD

**Signal peptide:**

amino acids 1-15

**FIGURE 115**

CAGCAGTGGTCTCTCAGCCTCTCAAAGCAAGGAAAGAGTACTGTGTGCTGAGAGACC**ATGGC**  
AAAGAATCCTCCAGAGAATTGTGAAGACTGTCACATTCTAAATGCAGAAGCTTTAAATCAA  
GAAAATATGTAAATCACTTAAGATTGTGGACTGGTGTGGTATCCTGGCCCTAACCTAAAT  
TGTCCCTGTTGGGGAGCAAGCAGCTGGCCGGAGGTACCCAAAAAGCCTATGACATGGA  
GCACACTTCTACAGCAATGGAGAGAAGAAGAAGATTACATGGAAATTGATCCTGTGACCAG  
AACTGAAATATTCAAGCGGAAATGGCACTGATGAAACATTGGAAGTGCACGACTTTAAAAA  
CGGATAACACTGGCATCTACTTCGTGGTCTTCAAAAATGTTTATCAAAACTCAGATTAAGT  
GATTCCCTGAATTTCGAACCAGAAGAGGAAATAGATGAGAATGAAGAAATTACCAACTTT  
CTTGAAACAGTCAGTGATTGGTCCCAGCAGAAAAGCCTATTGAAAACCGAGATTCTTAA  
AAATTCCAAAATTCTGGAGATTGTGATAACGTGACCATGTATTGGATCAATCCCACCTAAAT  
ATCAGTTCTGAGTTACAAGACTTTGAGGAGGGAGAAGATCTTCACTTCCCTGCCAACGA  
AAAAAAAGGGATTGAACAAAATGAACAGTGGGTGGTCCCTCAAGTGAAAGTAGAGAAGACCCG  
TCACGCCAGACAAGCAAGTGAGGAAGAACCTCCAATAAATGACTATACTGAAAATGGAATAGA  
ATTGATCCCAGCTGGATGAGAGAGGTTATTGTTGTATTACTGCCGTCGAGGCAACCGCTA  
TTGCCGCCCGTCTGTGAACCTTACTAGGCTACTACCCATATCCACTGCTACCAAGGAGG  
ACGAGTCATCTGTCGTGTCATCATGCCCTGTAAGTGGTGGTGGCCCGCATGCTGGGAGGGT  
**CTAA**ATAGGAGGTTGAGCTAAATGCTTAAACTGCTGGCAACATATAAAATGCATGCTATT  
CAATGAATTCTGCCTATGAGGCATCTGGCCCTGGTAGCCAGCTCCAGAATTACTGTAG  
GTAATTCCCTCTTCATGTTCTAATAAAACTTCTACATTACCAAAAAAAAAAAAAAAA

116/168

## FIGURE 116

MAKNPPENCEDCHILNAEAFSKKICKSLKICGLVFGILALTLIVLFWGSKHFWPEVPKKAYD  
MEHTFYSNGEKKKIYMEIDPVTRTEIFRSGNGTDETLEVHDFKNGYTGIYFVGLQKCFIKTQI  
KVIPEFSEPEEEEIDENEETTTFFEQSVIWVPAEKPIENRDFLKNSKILEICDNVTMYWINPT  
LISVSELQDFEEEGEDLHFPAKEKKGIEQNEQWVVPQVKVEKTRHARQASEEELPINDYTENG  
IEFDPMMLDERGYCCIYCRRGNRYCRRVCEPLLGYYPYCYQGGRVICRVIMPCNWWVARMLGRV

**Important features of the protein:**

**Signal peptide:**

amino acids 1-40

**Transmembrane domain:**

amino acids 25-47 (type II)

**N-glycosylation sites.**

amino acids 94-97, 180-183

**Glycosaminoglycan attachment sites.**

amino acids 92-95, 70-73, 85-88, 133-136, 148-151, 192-195, 239-  
242

**N-myristoylation sites.**

amino acids 33-38, 95-100, 116-121, 215-220, 272-277

**Microbodies C-terminal targeting signal.**

amino acids 315-317

**Cytochrome c family heme-binding site signature.**

amino acids 9-14

117/168

## **FIGURE 117**

GAGCTCCCTCAGGAGCGC~~G~~TAGCTCACACCTCGCAGCAGGAGGGCGCAGCTTCTCGC  
AGGCGGCAGGGCGGGCGGCCAGGATCATGTCCACCACATGCCAAGTGGTGGCGTTCCCTCC  
TGTCCATCCTGGGCTGGCCGGCTGCATCGCGCCACCAGGATGGACATGTGGAGCACCAGG  
ACCTGTACGACAACCCGTCACCTCCGTGTTCCAGTACGAAGGGCTCTGGAGGAGCTGCGTGA  
GGCAGAGTTCAGGCTTCACCGAATGCAGGCCCTATTCACCATCCTGGACTTCCAGGCCATGC  
TGCAGGCAGTGCAGGCCCTGATGATCGTAGGCATCGCCTGGTGCCATTGGCCTCCTGGTAT  
CCATCTTGCCCTGAAATGCATCCGCATTGGCAGCATGGAGGACTCTGCCAAGCCAACATGA  
CACTGACCTCCGGGATCATGTTCATTGTCTCAGGTCTTGCAATTGCTGGAGTGTCTGTGT  
TTGCCAACATGCTGGTACTAACTCTGGATGTCACAGCTAACATGTACACCGGCATGGGTG  
GGATGGTGCAGACTGTTCAGACCAGGTACACATTGGTGCAGCTCTGGCTGGCTGGTGGCG  
CTGGAGGCCTCACACTAATTGGGGTGTGATGATGTGCATGCCCTGCCGGGCCTGGCACCAAG  
AAGAAACCAACTACAAAGCCGTTCTTATCATGCCCTCAGGCCACAGTGTGCCTACAAGCCTG  
GAGGCTCAAGGCCAGCACTGGCTTGGTCCAACACAAAAACAAGAAGATAACGATGGAG  
GTGCCCGCACAGAGGACGAGGTACAATCTTATCCTCCAAGCACGACTATGTGTAATGCTCTA  
AGACCTCTCAGCACGGCGGAAGAAACTCCGGAGAGCTCACCCAAAAACAAGGAGATCCCA  
TCTAGATTCTTCTGCTTTGACTCACAGCTGGAGTTAGAAAAGCCTCGATTCATCTTG  
GAGAGGCCAAATGGCTTAGCCTCAGTCTGTCTAAATATTCCACCATAAACAGCTGAG  
TTATTATGAATTAGAGGCTATAGCTCACATTCAATCCTCTATTCTTTAAATATAA  
CTTTCTACTCTGATGAGAGAATGTGGTTTAATCTCTCTCACATTGATGATCTATTCCCAGCTTATCCCCAAG  
AAAACTTTGAAAGGAAAGAGTAGACCCAAAGATGTTATTCTGCTGTTGAATTGCTC  
CCCACCCCCAACTGGCTAGTAATAACACTTACTGAAGAAGAAGCAATAAGAGAAAGATATT  
TGTAATCTCTCCAGCCCAGTCTCGGTTCTACACTGTGATCTTAAAGTTACCAAACCA  
AAGTCATTTCAGTTGAGGCAACAAACCTTCTACTGCTGTTGACATCTTCTATTACAGC  
AACACCATTCTAGGAGTTCTGAGCTCTCCACTGGAGTCCTTCTGTCGCGGGTCAGAAA  
TTGTCCTAGATGAATGAGAAAATTATTTTTAATTAAAGTCCTAAATATAGTTAAATAA  
ATAATGTTTAGTAAATGATAACTATCTCTGTGAAATAGCCTACCCCTACATGTGGATAG  
AAGGAAATGAAAAATAATTGCTTGTACATTGCTATATGGTACTTGTAAAGTCATGCTTAA  
GTACAAATTCCATGAAAAGCTCACACCTGTAATCCTAGCACCTGGAGGCTGAGGAGGAAGG  
ATCACCTGAGCCCAGAAGTCGAGACTAGCCTGGCAACATGGAGAAGCCCTGTCTCACAAA  
ATACAGAGAGAAAAATCAGCCAGTCATGGTGCATACACCTGTAGTCCCAGCATTCCGGGAG  
GCTGAGGTGGGAGGATCACTTGAGCCCAGGGAGGTTGGGCTGCAGTGAGCCATGATCACACC  
ACTGCACCTCCAGCCAGGTGACATAGCAGAGATCCTGTCTAAAAAAATAAAATAATGGA  
ACACAGCAAGTCCTAGGAAGTAGGTTAAACTAATTCTTAA

118/168

## **FIGURE 118**

MSTTTCQVVAFLLSILGLAGCIAATGMDMWSTQDLYDNPVTSVFQYEGLWRSCVRQSSGFTEC  
RPYFTILGLPAMLQAVRALMIVGIVLGAIGLLVSIFALKCIRIGSMEDSAKANMTLTSIMFI  
VSGLCIAIGVSVFANMLVTNFWMSTANMYTGMGGMVQTVQTRYTFGAALFVGWVAGGLTLIGG  
VMMCIACRGLAPEETNYKAVSYHASGHSVAYKPGGFCASTGFGSNTKNKKIYDGGARTEDEVQ  
SYPSKHDYV

**Signal peptide:**

amino acids 1-23

**Transmembrane domains:**

amino acids 81-100, 121-141, 173-194

119/168

## FIGURE 119

GGAAAAACTGTTCTTCTGTGGCACAGAGAACCGTCAAAGCAGAAGTAGCAGTCCGG  
AGTCCAGCTGGCTAAAACATCCCAGAGGATAATGGCAACCCATGCCTAGAAATCGCTGGG  
CTGTTCTGGTGGTGGAAATGGGGCACAGTGGCTGCACTGTCATGCCAGTGGAGA  
GTGTCGGCCTTCATTGAAAACAACATCGTGGTTTGAAAACCTCTGGGAAGGACTGTGGATG  
AATTGCGTGAGGCAGGCTAACATCAGGATGCAGTGCAAAATCTATGATTCCCTGCTGGCTT  
TCTCCGGACCTACAGGCAGCCAGAGGACTGATGTGCTGCTCCGTGATGTCCTCTGGCT  
TTCATGATGGCCATCCTGGCATGAAATGCACCAGGTGCACGGGGACAATGAGAAGGTGAAG  
GCTCACATTCTGCTGACGGCTGGAATCATCTCATCATCACGGCATGGTGGTGCATCCCT  
GTGAGCTGGGTTGCCATGCCATCATCAGAGATTCTATAACTCAATAGTGAATGTTGCCAA  
AAACGTGAGCTGGAGAAGCTCTACTTAGGATGGACCACGGCACTGGTGTGATTGTTGGA  
GGAGCTGTTCTGCTGCGTTTGCAACGAAAAGAGCAGTAGCTACAGATACTCGATA  
CCTTCCCATCGCACACCCAAAAAGTTATCACACCGGAAAGAAGTCACCGAGCGTCTACTCC  
AGAAGTCAGTATGTGTAGTTGTATGTTTTTAACTTACTATAAGCCATGCAAATGACA  
AAAATCTATATTACTTCTAAAATGGACCCAAAGAAACTTGTGATTACTGTTCTTAACTGC  
CTAATCTTAATTACAGGAACTGTGCATCAGCTATTATGATTCTATAAGCTATTCAGCAGAA  
TGAGATATTAAACCAATGCTTGATTGTTCTAGAAAGTATAGTAATTGTTCTAAGGTGG  
TTCAAGCATCTACTCTTTATCATTACTTCAAAATGACATTGCTAAAGACTGCATTATTT  
ACTACTGTAATTCTCCACGACATAGCATTATGTACATAGATGAGTGTAAACATTATCTCA  
CATAGAGACATGTTATATGTTTATTAAAATGAAATGCCAGTCCATTACACTGAATAAAAT  
AGAACTCAACTATTGCTTTAGGGAAATCATGGATAGGGTTGAAGAAGGTTACTATTAAATTG  
TTTAAAACAGCTAGGGATTAAATGCTCCATTATAATGAAGATTAAAATGAAGGCTTAA  
TCAGCATTGTAAGGAAATTGAATGGCTTCTGATATGCTGTTTAGCCTAGGAGTTAGAA  
ATCCTAACTCTTATCCTCTCCAGGGCTTTCTGATTAAACATT  
TTTAAAACGCAGATATTGTCAGGGCTTGCATTCAAACGTCTTCCAGGGCTATACTC  
AGAAGAAAGATAAAAGTGTGATCTAAGAAAAAGTGTGTTAGGAAAGTGAAGGTTAA  
GTTTTGTATTGAAGAAGAATGATGCATTGACAAGAAATCATATATGTATGGATATA  
TAATAAGTATTGAGTACAGACTTGGAGGTTCAATATAAATAAAAGAGCAGAAAAATAT  
GTCTGGTTTCATTGCTTACCAAAAAACAACAACAAAAAGTTGTCCTTGAGAAGCTTC  
ACCTGCTCCTATGTGGTACCTGAGTCAAAATTGTCATTGTTCTGTGAAAAATAATT  
CTTCTGTACCATTCTGTTAGTTACTAAAATCTGAAATACTGTATTCTGTTATT  
CCAAATTGATGAAACTGACAATCCAATTGAAAGTTGTCGACGTCTGTCTAGCTTAAAT  
GAATGTGTTCTATTGCTTATACATTATTAATAAAATTGTACATTCTAATT

120/168

**FIGURE 120**

MATHALEIAGLFLGGVGMVGTVAVTVMPQWRVSAFIENNIVVFENFWEGLWMNCVRQANIRMQ  
CKIYDSLLALSPDLQAARGLMCAASVMSFLAFMMAILGMKCTRGTGDNEKVKAHILLTAGIIF  
IITGMVVLIPVSWANAIIRDYNSIVNVAQKRELGEALYLGWTTALVLIVGGALFCCVFCCN  
EKSSSYRYSIPSHRTTQKSYHTGKKSPSVYSRSQYV

**Signal peptide:**

amino acids 1-17

**Transmembrane domains:**

amino acids 82-101, 118-145, 164-188

121/168

## FIGURE 121

GGAGAGAGGCAGCGCGGGTGAAAGGCGCATTGATGCAGCCTGCAGCGGGCTCGGAGCGCGGGCG  
AGCCAGACGCTGACCACGTTCTCCTCCCTCGGTCTCCGCCTCCAGCTCCGCCTGCCCGGC  
AGCCGGGAGCC**ATG**CGACCCCAGGGCCCCGCCGCCTCCCCGAGCGGCTCCGCAGCGCTCCTGC  
TGCTCCTGCTGCTGCAGCTGCCGCCTCGAGCGCCTCTGAGATCCCCAAGGGGAAGCAAA  
AGGCGCAGCTCCGGCAGAGGGAGGTGGACCTGTATAATGGAATGTGCTTACAAGGGCCAG  
CAGGAGTGCCTGGTCGAGACGGGAGCCCTGGGGCCAATGTTATTCCGGGTACACCTGGGATCC  
CAGGTGGGATGGATTCAAAGGAGAAAAGGGGGAAATGTCAGGGAAAGCTTGAGGGAGTCCT  
GGACACCCAACTACAAGCAGTGTTCATGGAGTTCAATTGAATTATGGCATAGATCTGGGAAAA  
TTGCGGAGTGTACATTACAAAGATGCGTCAAATAGTGCTCTAAGAGTTGTTCAAGTGGCT  
CACTTCGGCTAAAATGCAGAAATGCATGCTGCAGCGTTGGTATTTCACATTCAATGGAGCTG  
AATGTTCAAGGACCTTCCATTGAAGCTATAATTATTGGACCAAGGAAGCCCTGAAATGA  
ATTCAACAATTAAATTACATCGCACTCTTCTGGAAGGACTTTGTGAAGGAATTGGTGTG  
GATTAGTGGATGTTGCTATCTGGGTGGCACTGTTCACTTGAAGAACCTACCAAAAGGAGATGCT  
CTGGATGGAATTCACTTCTCGCATCATTGAAGAACCTACCAAA**TAA**ATGCTTTAATT  
CATTGCTACCTTTTTATTATGCCCTGGAATGGTCACTTAAATGACATTAAATAAG  
TTTATGTATACATCTGAATGAAAAGCAAAGCTAAATATGTTACAGACCAAGTGTGATTCA  
CACTGTTTAAATCTAGCATTATTCAATTGCTCAATCAAAAGGTTCAATATT  
TAGTTGGTTAGAATACTTCTCATAGTCACATTCTCAACCTATAATTGGAATATTGTTG  
TGGTCTTTGTTCTCTAGTATAGCATTAAAAAAATATAAAAGCTACCAATCTTG  
TACAATTGTAATGTTAAGAATTCTTATATGTTAAATAAAATTATTCCAACA

122/168

**FIGURE 122**

MRPQGPAASPQRRLRGLLLLLQLPAPSSASEIPKGKQKAQLRQREVVDLYNGMCLQGPAGVP  
GRDGSPGANVIPGTPGI PGRDGFKGEKGECLRESFEESWTPNYKQCSWSSLNYGIDLGKIAEC  
TFTKMRNSNSALRVLFGSLRLKCRNACCQRWYFTFNGAECSGPLPIEAIYLDQGSPEMNSTI  
NIHRTSSVEGLCEGIGAGLVDVAIWVGTCSDYPKGDASTGWNSVSRIIIIEELPK

**Signal peptide:**

amino acids 1-30

**Transmembrane domain:**

amino acids 195-217

123/168

## FIGURE 123

GCTGAGCGTGTGCGCGGTACGGGCTCTCCTGCCTCTGGGCTCCAACGCAGCTCTGTGGCTG  
AACTGGGTGCTCATCACGGGAAC TGCTGGGCTATGGAATACAGATGTGGCAGCTCAGGTAGCC  
CCAAATTGCCCTGGAAGAACATACATCATGTTTCGATAAGAAGAAATTGATGGATCCAGTTTT  
TTTTAACCGCCCCCTCCCCACCCCCAAAAACTGTAAAGATGCAAAACGTAATATCCAT  
GAAGATCCTATTACCTAGGAAGATTTGATGTTTGCTGCGAATGCGGTGTTGGGATTATTT  
GTTCTGGAGTGTCTGCGTGGCTGGCAAAGAACATATGTCaaaATCGGTCCATCTCCAAG  
GGGTCCAATTTCCTGGGTGTCAGCGAGCCCTGACTCACTACAGTGCAGCTGACAGGGG  
CTGTCATGCAACTGGCCCCTAACGCCAAGCAGAAAGACCTAACGGACGACCTTGAACAATACAA  
AGGATGGGTTCAATGTAATTAGGCTACTGAGCGGATCAGCTGTAGCACTGGTTATAGCCCCC  
ACTGTCTTACTGACAATGCTTCTGCGAACGAGGATGCCCTAACGGCTGTAGGTGTGAA  
GGCAAATGGTATATTGTGAATCTCAGAAATTACAGGAGAACCTCAAGTATATCTGCTGGT  
TGCTTAGGTTGTCCTTCGCTATAACAGCCTAACAAACTTAAGTATAATCAATTAAAGGG  
CTCAACCAGCTCACCTGGCTATAACCTGACCATAACCATATCAGCAATATTGACGAAATGCT  
TTAATGGAATACGAGACTCAAAGAGCTGATTCTTAGTCCAATAGAACATCTCCTATTTCTT  
AACAAACCTTCAGACCTGTGACAAATTACGGAACCTGGATCTGCTCTATAATCAGCTGCAT  
TCTCTGGGATCTGAACAGTTGGGGCTTGCAGGACTGCTGAGTTACATTACGGCTAAC  
TCCCTGAGAACCATCCCTGCGAATATTCCAAGACTGCGCAACCTGGAACTTTGGACCTG  
GGATATAACCGGATCCGAAGTTAGCCAGGAATGTCTTGCTGGCATGATCAGACTCAAAGAA  
CTTCACCTGGAGCACAATCAATTTCAGCTAACCTGCCCTTTCCAAGGTTGGTCAGC  
CTTCAGAACCTTACTTGCACTGGAAATAAAACTAGTGTCAAGGACAGACCATGTCCTGGACC  
TGGAGCTCTTACAAAGGCTGATTATCAGGCAATGAGATCGAAGCTTCAAGGCT  
GTTTCCAGTGTGTCCTGAATCTGCAGCGCCTCAACCTGGATCTCCAACAAGCTCACATTATT  
GGTCAAGAGATTTGGATTCTGGATATCCCTCAATGACATCAGTCTGCTGGGAATATATGG  
GAATGCAGCAGAAATATTGCTCCCTGTAACACTGGCTGAAAAGTTAAAGGTCTAAGGGAG  
AATAACATTATCTGCCCCAGCTGCAAGGAGTAAATGTGATCGATGCAGTGAAG  
AACTACAGCATCTGTCAGCTGGCAAAAGACTACAGAGAGGTTGATCTGCCAGGGCTCTCCCAAAG  
CCGACGTTAACGCCAAGCTCCCAGGCCGAAGCATGAGAGCAAAACCCCTTGCCCCGACG  
GTGGGAGCCACAGAGCCCCGCCAGAGACCGATGCTGACGCCGAGCACATCTTCCATAAA  
ATCATGCGGGCAGCGTGGCGCTTTCCCTGTCCTGCTCGTCATCCTGCTGGTTATCTACGTG  
TCATGGAAGCGGTACCCCTGCGAGCATGAAGCAGCTGCAAGCGCTCCCTCATGCGAAGGCAC  
AGGAAAAGAAAAGACAGTCCCTAAAGCAAATGACTCCAGCACCCAGGAATTTATGTAGAT  
TATAAACCCACCAACACGGAGACCAGCGAGATGCTGCTGAATGGGACGGACCTGCACCTAT  
AACAAATCGGGCTCCAGGGAGTGTGAGGTATTGAACCATTGTGATAAAAAGAGCTCTAAAGC  
TGGGAAATAAGTGGCTTTATTGAACCTGGTGAATCAAGGGAACGCGATGCCCTTC  
CCCTTCCCTCTCCCTCACTTGGTGGCAAGATCCTCCTGTCCTGCTGGTTAGTCATTCATA  
ATACTGGTCATTTCTCATACATAATCAACCCATTGAAATTAAATACCACAATCAATGT  
GAAGCTTGAACCTGGTTAAATATAATACCTATTGTATAAGACCTTACTGATTCCATTAAT  
GTCGCATTGTTAAGATAAAACTCTTCATAGGTAAAAAAAAAA

124/168

## **FIGURE 124**

MGFNVIRLLSGSAVALVIAPTVLLTMSSAERGCPKGRCCEGMVYCESQKLQEIPSSISAGC  
LGLSLRYNSLQKLKYNQFKGLNQLTWLYLDHNHISNIDENAFNGIRRLKELILSSNRISYFLN  
NTFRPVTNLRNLDLSYNQLHSLGSEQFRGLRKLLSLHLRSNSLRTIPVRIFQDCRNLELLDLG  
YNRIRSLARNVFAGMIRLKELHLEHNQFSKLNIALFPRLVSLQONLYLQWNKISVIGQTMSWTW  
SSLQRLDLSGNEIEAFSGPSVFQCVPNLQRLNLDSNKLTFIGQEILDWSWISLNDISLAGNIWE  
CSRNICSLVNWLKSFKGLRENTIICASPKELQGVNVIDAVKNYSICGKSTTERFDLARALPKP  
TFKPKLPRPKHESKPLPPPTVGATEPGPETDADAEHISFHKIIAGSVALFLSVLVILLVIYVS  
WKRYPASMKQLQQRSLMRRHRKKRQSLKQMTPSTQEFYVDYKPTNTETSEMLLNGTGPCTYN  
KSGSRECEV

**Important features of the protein:**

**Signal peptide:**

amino acids 1-33

**Transmembrane domain:**

amino acids 420-442

**N-glycosylation sites.**

amino acids 126-129, 357-360, 496-499, 504-507

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 465-468

**Tyrosine kinase phosphorylation site.**

amino acids 136-142

**N-myristoylation sites.**

amino acids 11-16, 33-38, 245-250, 332-337, 497-502, 507-512

125/168

**FIGURE 125**

CCGTTATCGTCTTGCCTACTGCTGAATGTCCGTCGGAGGAGGGAGAGGCTTTGCCGC  
TGACCCAGAGATGGCCCCGAGCGAGCAAATTCTACTGTCCGGCTGCGCGCTACCGTGGCCG  
AGCTAGCAACCTTCCCCTGGATCTCACAAAAACTCGACTCCAAATGCAAGGAGAACAGCTC  
TTGCTCGGTTGGGAGACGGTGCAAGAGAATCTGCCCCCTATAGGGGAATGGTGCGCACAGCCC  
TAGGGATCATTGAAGAGGAAGGCTTCTAAAGCTTGGCAAGGAGTGACACCCGCCATTACA  
GACACGTAGTGTATTCTGGAGGTCGAATGGTCACATATGAACATCTCGAGAGGTTGTGTTG  
GCAAAAGTGAAGATGAGCATTATCCCCTTGGAAATCAGTCATTGGAGGGATGATGGCTGGTG  
TTATTGGCCAGTTTAGCCAATCCAACGTGACCTAGTGAAGGTTCAGATGCAAATGGAAGGAA  
AAAGGAAACTGGAAGGAAAACCATTGCGATTCGTGGTGTACATCATGCATTGCAAAATCT  
TAGCTGAAGGAGGAATACGAGGGCTTGGCAGGCTGGTACCCAAATAACAAAGAGCAGCAC  
TGGTGAATATGGGAGATTAACCACCTATGATACAGTGAACACTACTTGGTATTGAATACAC  
CACTTGAGGACAATATCATGACTCACGGTTATCAAGTTATGTTCTGGACTGGTAGCTCTA  
TTCTGGAACACCAGCCGATGTCATCAAAAGCAGAATAATGAATCAACCACGAGATAAACAAAG  
GAAGGGGACTTTGTATAAATCATCGACTGACTGCTGATTCAAGGCTGTTCAAGGTGAAGGAT  
TCATGAGTCTATATAAAGGCTTTACCATCTGGCTGAGAATGACCCCTGGTCAATGGTGT  
TCTGGCTTACTTATGAAAAAATCAGAGAGATGAGTGGAGTCAGTCATTTAA

126/168

## **FIGURE 126**

MSVPEEEERLLPLTQRWPRASKFLLSGCAATVAELATFPLDLTKTRLQMQGEAALARLGDGAR  
ESAPYRGMVRTALGIIEEGFLKLWQGVTPAIYRHVVYSGGRMVTYEHLRREVVFGKSEDEHYP  
LWKSVIGGMMAGVIGQFLANPTDLVKVQMQUEGKRKLEGKPLRFRGVHHAFAKILAEGGIRGL  
WAGWVPNIQRAALVNMGDLTTYDTVKHYLVNLNTPLEDNIMTHGLSSLCSGLVASILGTPADVI  
KSRIMNQPRDKQGRGLLYKSSTDCLIQAVQGEGFMSLYKGFLPSWLRMTPWSMVFWLTYEKIR  
EMSGVSPF

**Transmembrane domains:**

amino acids 25-38, 130-147, 233-248

127/168

## FIGURE 127

CGCGGATCGGACCCAAGCAGGTGGCGGCGGCAGGAGAGCGGCCGGCGTCAGCTCCTCG  
ACCCCCGTGTCGGGCTAGTCCAGCGAGGCAGGACGGGCGGCGTGGGCCCATGCCAGGCC  
ATGGAGCGGTGGCGCGACCGGCTGGCGCTGGTACGGGGCCTCGGGGGCATCGGCGGCC  
GTGGCCCAGGCCCTGGTCCAGCAGGGACTGAAGGTGGTGGCTGCGCCCGACTGTGGCAAC  
ATCGAGGAGCTGGCTGCTGAATGTAAGAGTGCAGGCTACCCGGACTTGATCCCCTACAGA  
TGTGACCTATCAAATGAAGAGGACATCCTCTCCATGTTCTCAGCTATCCGTTCTCAGCACAGC  
GGTAGACATCTGCATCAACAATGCTGGCTGGCCGGCCTGACACCCCTGCTCTCAGGCAGC  
ACCAGTGGTTGGAAGGACATGTTCAATGTGAACGTGCTGGCCCTCAGCATCTGCACACGGAA  
GCCTACCAGTCCATGAAGGAGCGGAATGTGGACGATGGCACATCATTAAACATCAATAGCATG  
TCTGCCACCGAGTGTACCCCTGTCTGTGACCCACTTCTATAGTGCCACCAAGTATGCCGTC  
ACTGCCTGACAGAGGGACTGAGGCAAGAGCTCGGGAGGCCAGACCCACATCCGAGCCACG  
TGCATCTCTCAGGTGTGGAGACACAATTGCCCTCAAACACTCCACGACAAGGACCTGAG  
AAGGCAGCTGCCACCTATGAGCAAATGAAGTGTCTCAAACCCGAGGATGTGCCGAGGCTGTT  
ATCTACGTCCCTCAGCACCCCCGACACATCCAGATTGGAGACATCCAGATGAGGCCACGGAG  
CAGGTGACCTAGTGAATGTGGAGCTCCCTCCCTCCACCCCTCATGGCTTGCCCTG  
CCTCTGGATTTAGGTGTTGATTTCTGGATCACGGATAACCACCTCCTGTCCACACCCGACC  
AGGGGCTAGAAAATTGTTGAGATTATCATCTTGTCAAATTGCTCAGTTGAAATG  
TGAAAAATGGCTGGGAAAGGAGGTGGTGTCCCTAATTGTTACTTGTAACTTGTCTTG  
TGCCCTGGGACTTGGCCTTGTCTGCTCTCAGTGTCTCCCTTGACATGGAAAGGAGTT  
GTGGCCAAAATCCCCATCTTGTCCCTAACGTCTGGCTCAGGGCTGGGTGGCAGAGG  
GAGGCCTCACCTATATCTGTGTTATCCAGGGCTCCAGACTCCTCCTGCCTGCC  
ACTGCACCCCTCTCCCCCTATCTATCTCCTCTCGGCTCCAGCCAGTCTGGCTTGT  
CCCCCTGGGTGATCCCTCCACTCTGACTATGGCAGCAGAACACCAGGGCCTGGC  
CCAGTGGATTCATGGTGATCATTAAAAAGAAAATCGCAACCAAAAAAAAAAAA

128/168

## FIGURE 128

MARPGMERWRDRLALVTGASGGIGAAVARALVQQGLKVVG CARTVGNIEELAAECKSAGYPGT  
LIPYRCDLSNEEDI LSMFSAIRSQHSGVDICINNAGLARPDTLLSGSTSGWKDMFNVLALS  
ICTREAYQSMKERNVDDGHIININSMSGHRVLPLSVTHFY SATKYAVTALTEGLRQELREAQT  
HIRATCISPGVVETQFAFKLHDKDPEKAATYEQMKCLKPEDVAEAVIYVLSTPAHIQIGDIQ  
MRPTEQVT

**Important features of the protein:**

**Signal peptide:**

amino acids 1-17

**N-myristoylation sites.**

amino acids 18-24, 21-27, 22-28, 24-30, 40-46, 90-96, 109-115,  
199-205

**Short-chain alcohol dehydrogenase.**

amino acids 30-42, 104-114

129/168

## **FIGURE 129**

AACTTCTACATGGGCCTCCTGCTGCTGGTGTCTTCCTCAGCCTCCTGCCGGTGGCCTACACC  
ATCATGTCCCTCCCACCCCTCCTTGACTGCAGGCCGTTAGGTGCAGAGTCAGTTGCCCGG  
GAGCACCTCCCCTCCCGAGGCAGTCTGCTCAGAGGCCCTGGCCAGAATTCCAGTTCTGGTT  
TCATGCCAGCCTGTAAAAGGCCATGGAACCTTGGGTGAATCACCGATGCCATTAAAGAGGGTT  
TTCTGCCAGGATGAAATGTTAGGTCGTTCTGTGTCTGCCTGTTCATTCAGTAGCCACCAG  
CCACCTGTGGCCGTTGAGTGCTGAAATTGAGGAACTGAGAAAATTAAATTCTCATGTATTTT  
CTCATTATTATTAAATTAAACTGATAGTTGACATATTGGGGTACATGTGATATTGG  
ATACATGTATAACAATATAATGATCAAATCAGGGTAACGGGATATCCATCACATCAAACAT  
TTATTTTATTCTTTAGACAGAGTCTCACTCTGTCACCCAGGCTGGAGTGCAGTGGTGCC  
ATCTCAGCTTACTGCAACCTGCTGCCAGGTTCAAGCGATTCTCATGCCCTCACCTCCAA  
GTAGCTGGGACTACAGGCATGCACCACAATGCCAACTAATTTGTATTTAGTAGAGACG  
GGGTTTGCCATGTTGCCAGGCTGGCCTGAACTCCTGCCCTCAAACAATCCACTGCCTCG  
GCCTCCAAAGTGTATGATTACAGGCGTGAGCCACCGTGCCTGGCCTAACATTTATCTTT  
CTTGTGTTGGAACTTGAAATTATAACATGAATTATTGTTACTGTCATCTCCCTGCTGTG  
CTATGGAACACTGGGACTTCTTCCCTCTATCTAACTGTATATTGTAACAGTTAACCAACCGT  
ACTTCATCCCCACTCCTCTATCCTCCACCTCTGATCACCTCATTCTACTCTACCTC  
CATGAGATCCACTTTAGCTCCACATGTGAGTAAGAAAATGCAATTGTCTTCTGTG  
CCTGGCTTATTCACTTAACATAATGACTTCCTGTTCCATGTTGCTGCAAATGACAGGA  
TTTCGTTCTTAATTCAATTAAAATAACCACACATGGCAAAAA

130/168

## **FIGURE 130**

MGLLLLVLFLSLLPVAYTIMITSLPPSFDCGPFRCRVSVAREHLP SRGSLLRGPRPRI PVLVSCQ  
PVKGHGTILGESPMPPFKRVFCQDG NVRSFCVCAVFSSHQPPVAVECLK

**Important features of the protein:**

**Signal peptide:**

amino acids 1-18

**N-myristoylation site.**

amino acids 86-92

**Zinc carboxypeptidases, zinc-binding region 2 signature.**

amino acids 68-79

## **FIGURE 131**

TTCTGAAGTAACGGAAGCTACCTGTATAAAGACCTAACACTGCTGACC**ATG**ATCAGCGCAG  
CCTGGAGCATCTCCTCATCGGGACTAAAATTGGGCTGTTCAAGTAGCACCTCTATCAG  
TTATGGCTAAATCCTGTCCATCTGTGTGCGATGCCGGTTCATTTACTGTAATGATC  
GCTTCTGACATCCATTCAAACAGGAATACCAGAGGATGCTACAACCTCTACCTCAGAAC  
ACCAAATAATAATGCTGGGATTCCCTCAGATTGAAAAACTTGCTGAAAGTAGAAAGAAAT  
ACCTATACCAACAGTTAGATGAATTCCCTACCAACCTCCAAAGTATGTAAGAGTTAC  
ATTGCAAGAAAATAACATAAGGACTATCACTTATGATTCACTTCACCCATCTGG  
AAGAATTACATTTAGATGACAACACTCTGTCTGCAGTTAGCATAGAAGAGGGAGCATTCCGAG  
ACAGCAACTATCTCCGACTGCTTTCCGTCCCGTAATCACCTAGCACAATTCCCTGGGTT  
TGCCCAGGACTATAGAAGAACTACGCTGGATGATAATCGCATATCCACTATTCATCACCAT  
CTCTTCAAGGTCTCACTAGTCTAAACGCCTGGTCTAGATGGAAACCTGTTGAACAATCATG  
GTTTAGGTGACAAAGTTCTAACCTAGTTAATTGACAGAGCTGTCCTGGTGCAGAATT  
CCCTGACTGCTGCACCAAGTAAACCTCCAGGCACAAACCTGAGGAAGCTTATCTCAAGATA  
ACCACATCAATCGGGTCCCCAAATGCTTTCTATCTAAGGCAGCTATCGACTGGATA  
TGTCCAATAATAACCTAACGTAATTACCTCAGGGTATCTTGATGATTGGACAATATAACAC  
AACTGATTCTCGCAACAATCCCTGGTATTGCGGGTGCAAGATGAAATGGGTACGTGACTGGT  
TACAATCACTACCTGTGAAGGTCAACGTGCGTGGGCTATGTGCCAAGCCCCAGAAAAGGTTC  
GTGGGATGGCTATTAAGGATCTCAATGCAGAACTGTTGATTGTAAGGACAGTGGGATTGTA  
GCACCATTAGATAACCAACTGCAATACCCAAACACAGTGTATCCTGCCAAGGACAGTGGCAG  
CTCCAGTGCACAAACAGCCAGATATTAAGAACCCCAAGCTCACTAAGGATCAACAAACCACAG  
GGAGTCCCTCAAGAAAAACAATTACAATTACTGTGAAGTCTGTCACCTCTGATACCATTATA  
TCTCTGGAAACTTGCTCACCTATGACTGCTTGAGACTCAGCTGGCTAAACTGGGCCATA  
GCCCGGCATTGGATCTATAACAGAAACAATTGTAACAGGGGACGCAGTGAGTACTTGGTCA  
CAGCCCTGGAGCCTGATTCACCTATAAAAGTATGCATGGTCCATGGAAACCAGCAACCTCT  
ACCTATTGATGAAACTCCTGTTGATTGAGACTGAAACTGCACCCCTCGAATGTACAACC  
CTACAACCACCCCTCAATCGAGAGCAAGAGAAACCTACAAAAACCCAAATTACCTTGG  
CTGCCATCATTGGTGGGCTGTGCCCTGGTACCATGCCCTTCTGCTTAGTGTGGT  
ATGTTCATAGGAATGGATCGCTCTCAAGGAACTGTGCATATAGCAAAGGGAGGAGAAGAA  
AGGATGACTATGCAGAAGCTGGCACTAAGAAGGACAACCTATCCTGGAAATCAGGGAAACTT  
CTTTTCAGATGTTACCAATAAGCAATGAACCCATCTCGAAGGAGGAGTTGTAATACACACCA  
TATTCCTCCTAATGGAATGAATCTGTACAAAAACAATCACAGTGAAGCAGTAGTAACCGAA  
GCTACAGAGACAGTGGTATTCCAGACTCAGATCACTCACACT**CATG**TGCTGAAGGACTCACA  
GCAGACTTGTGTTGGTTTTAACCTAACGAGGTGATGGT

132/168

## **FIGURE 132**

MISAAWSIFLIGTKIGLFLQVAPLSVMAKSCPSVCRCDAAGFIYCNDRFLTSIPTGIPEDATTLYLQNNQINNAGIPSIDLKNLLKVERIYLYHNSLDEFPTNLPKYVKEHLHQENNIRTITYDSLKIPIYLEELHLDNSVSAVSIEEGAFRDSNYLRLFLSRNHLSLTIWPGLPRTIEELRLDDNRISTISSPSLQGLTSLKRLVLDGNLLNNHGLGDKVFFNLVNLTELSVRNSLTAAPVNLPGTNLRKLYLQDNHINRVPPNAFSYLRQLYRLDMSNNNLSNLPGQIFDDLDNITQLILRNNPWYCGCKMKWVRDWLQSLPVKVNVRGGLMCQAPEKVRGMAIKDLNAELFDCKDGSIVSTIQITTAIPNTVYPAQGQWPAPVTQPDIKNPKLTKDQQTTGSPSRKTITITVKSVTSDTIHISWKLALPMTALRLSWKLGHSPAFGSITETIVTGERSEYLVTALEPDSPYKVCMPMETSNLYLFDETPVCIETETAPLRMYNPTTTLNREQEKEPYKNPNLPLAAIIGGAVALVTIALLALVCWYVHRNGSLFSRNCAYSKGRRRKDDYAEAGTKKDNSILEIRETSFQMLPISNEPISKEEFVIHTIFPPNGMNLYKNNHSESSENRSYRDSGIPDSDHSHS

**Important features of the protein:**

**Signal peptide:**

amino acids 1-28

**Transmembrane domain:**

amino acids 531-552

**N-glycosylation sites.**

amino acids 226-229, 282-285, 296-299, 555-558, 626-629, 633-636

**Tyrosine kinase phosphorylation site.**

amino acids 515-522

**N-myristoylation sites.**

amino acids 12-17, 172-177, 208-213, 359-364, 534-539, 556-561, 640-645

**Amidation site.**

amino acids 567-570

**Leucine zipper pattern.**

amino acids 159-180

**Phospholipase A2 aspartic acid active site.**

amino acids 34-44

133/168

## FIGURE 133

CCGTCATCCCCCTGCAGCCACCCCTCCCAGAGTCCTTGCCAGGCCACCCAGGCTTCTGG  
CAGCCCTGCCGGGCCACTTGTCTTCATGTCTGCCAGGGGGAGGTGGGAAGGAGGTGGGAGGAG  
GGCGTGCAGAGGCAGTCTGGGCTTGGCCAGAGCTCAGGGTGTGAGCGTGTGACCAGCAGTGA  
GCAGAGGCCGGCATGCCAGCCTGGGCTGCTGCTCTGCTTACTGACAGCACTGCCACC  
GCTGTGGTCTCCTCACTGCCTGGCTGGACACTGCTGAAAGTAAAGCCACCATTGCAGACCT  
GATCCTGTCTGCGCTGGAGAGAGCCACCGTCTTCTAGAACAGAGGCTGCCTGAAATCAAACCT  
GGATGGCATGGTGGGGTCCGAGTGCTGGAAGAGCAGCTAAAAAGTGTCCGGAGAAGTGGGC  
CCAGGAGCCCCTGCTGCAGCCGCTGAGCCTGCGCGTGGGATGCTGGGGAGAAGCTGGAGGC  
TGCCATCCAGAGATCCCTCCACTACCTCAAGCTGAGTGATCCAAAGTACCTAACAGAGAGTTCCA  
GCTGACCCCTCAGCCCAGGTTTGGAAAGCTCCACATGCCCTGGATCCACACTGATGCCCTCCTT  
GGTGTACCCCACGTTGGGCCCCAGGACTCATTCTCAGAGGAGAGAAGTGACGTGTGCCCTGGT  
GCAGCTGCTGGAACCGGGACGGACAGCAGCAGCCCTGCCCTCAGACCTCTGAGGAG  
CCTCATGACCAAGCCGGCTGCTCAGGCTACTGCCCTGCCCACCAACTGCTCTTCTCTG  
GGCCAGAATGAGGGGATGCACACAGGGACCCTCAACAGAGCCAGGACTATATCAAACCTCTT  
CTGCGCCAACATGATGGACTTGAACCGCAGAGCTGAGGCCATGGATA CGCCTACCCCTACCG  
GGACATCTCATGGAAAACATCATGTTCTGTGGAATGGCGGTTCTCGACTTACAAGCT  
CCGGTGGCTGGAGGCCATTCTCAGCTGGCAGAAACAGCAGGAAGGATGCTCGGGAGCCTGA  
TGCTGAAGATGAAGAATTATCTAAAGCTATTCAATATCAGCAGCATTTCGAGGAGAGTGAA  
GAGGCAGAAAAACAATTCCAGATTCTCGCTCTGTTGCTCAGGCTGGAGTACAGTGGCGCAA  
TCTCGGCTCACTGCACACCTTGCCTCCTGGTTCAAGCAATTCTTGCCTCATCCTCCGAG  
TAGCTGGACTACAGGAGCGTGCCACCACCTGGCTAATTTTATATTTTAGTAGAGAC  
AGGGTTCATCATGTTGCTCATGCTGGCTCGAACCTCTGATCTCAAGAGATCCGCCACCTC  
AGGCTCCAAAGTGTGGATTTAGGTGTGAGCCACCGTGTGGCTGAAAGCACTTCAAA  
GAGACTGTGTTGAATAAAGGCCAAGGTTCTGCCACCCAGCACTCATGGGGCTCTCTCCCC  
TAGATGGCTGCTCCTCCCACAACACAGCCACAGCAGTGGCAGCCCTGGGTGGCTCTATACA  
TCCCTGGCAGAATACCCCCCAGCAAACAGAGGCCACACCCATCCACACCGCCACCACAGCA  
GCCGCTGAGACGGACGGTCCATGCCAGCTGCCCTGGAGGAGGAACAGACCCCTTAGTCTCA  
TCCCTTAGATCCTGGAGGGCACGGATCACATCCTGGGAAGAAGGCATCTGGAGGATAAGCAA  
GCCACCCGACACCCAAATCTTGGAAAGCCCTGAGTAGGCAGGGCCAGGGTAGGTGGGGCCGG  
AGGGACCCAGGTGTGAACGGATGAATAAAGTTCAACTGCAACTGAAACTGAAAAAA

134/168

## **FIGURE 134**

MSARGRWEGGGRRACRGSLGLARAQGAERVTSSEQRPMASLGLLLLLTLAPPLWSSSLPG  
LDTAESKATIADLIISALERATVFLEQRLPEINLDGMVGVRVLEEQLKSVREKWAQEPLLQPL  
SLRVGMLGEKLEAAIQRSIHYLKLSDPKYLREFQLTLQPGFWKLPHAWIHTDASLVYPTFGPQ  
DSFSEERSDVCLVQLLGTGTDSEPCGLSDLRSLMTKPGCSGYCLSHQLLFFLWARMRGCTQ  
GPLQQSQDYINLFCANMMDLNRRAEAIGYAYPTRDIFMENIMFCGMGGFSDFYKLRWLEAILS  
WQKQQEGCFGEPDAEDEELSKAIQYQQHFSRRVKRREKQFPDSRSVAQAGVQWRNLGSLQPLP  
PGFKQFSCLILPSSWDYRSVPPYLANFYIFLVETGFHHVAHAGLELLISRDPPTSGSQSVGL

**Important features of the protein:**

**Signal peptide:**

amino acids 1-26

**Transmembrane domain:**

amino acids 39-56

**Tyrosine kinase phosphorylation sites.**

amino acids 149-156, 274-282

**N-myristoylation sites.**

amino acids 10-16, 20-26, 63-69, 208-214

**Amidation site.**

amino acids 10-14

**Glycoprotein hormones beta chain signature 1.**

amino acids 230-237

135/168

## FIGURE 135

GGTCTGAGTGCAGAGCTGCTGTCATGGCGGCCGCTCTGTGGGGCTCTTCCCCTGCTGC  
TGCTGCTGCTATCGGGGATGTCCAGAGCTCGGAGGTGCCCGGGCTGCTGCTGAGGGATCGG  
GAGGGAGTGGGTCGGCATAGGAGATCGCTCAAGATTGAGGGCGTGCAGTTGTTCCAGGGG  
TGAAGCCTCAGGACTGGATCTGGCGCCCGAGTGCTGGTAGACGGAGAAGAGCACGTCGGTT  
TCCTTAAGACAGATGGAGTTGTGGTTCATGATATACTTCTGGATCTTATGTAGTGGAAAG  
TTGTATCTCCAGCTTACAGATTGATCCCGTTGAGTGGATATCACTCGAAAGGAAAAATGA  
GAGCAAGATATGTGAATTACATCAAACATCAGAGGTTGTCAGACTGCCCTATCCTCTCCAAA  
TGAAATCTCAGGTCCACCTCTTACTTATTAAAAGGGAATCGTGGGCTGGACAGACTTTC  
TAATGAACCCAATGGTTATGATGATGGTTCTCCTTATTGATATTGTGCTCTGCCTAAAG  
TGGTCAACACAAGTGATCCTGACATGAGACGGAAATGGAGCAGTCATGAATATGCTGAATT  
CCAACCATGAGTGGCTGATGTTCTGAGTTCATGACAAGACTCTCTCTCAAATCATCTG  
GCAAATCTAGCAGCGGCAGCAGTAAACAGGAAAAGTGGGCTGGCAAAGGAGGTAGTCAG  
GCCGTCCAGAGCTGGCATTGCACAAACACGGCAACACTGGTGGCATCCAAGTCTGGAAAA  
CCGTGTGAAGCAACTACTATAAAACTTGAGTCATCCGACGTTGATCTTACAACGTGTATGTT  
AACTTTTAGCACATTTGTACTTGGTACAGGAGAAACCCAGCTTCATCTTGTCTGT  
ATGAGGTCAATATTGATGTCACTGAATTAATTACAGTGTCTATAGAAAATGCCATTAATAAA  
TTATGAACTACTATACTATGTATTTAATTAAAACATCTTAATCCAGAAATCAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAA

136/168

## **FIGURE 136**

MAAALWGFFPVLLLLLSDVQSSEVPGAAAEGSGGSGVGIGDRFKIEGRAVVPGVKPQDWIS  
AARVLVDGEEHVGFLKTDGSFVVHDIPSGSYVVEVSPAYRFDPVRVDITSKGKMRARYVNYI  
KTSEVVRLPYPLQMKGSSGPPSYFIKRESWGWTDFLMNPMMMVPLLIFVLLPKVVNTSDPD  
MRREMEQSMNMLNSNHELPDVSEFMTRLFSSKSSGKSSGSSKTGSGAGKRR

**Important features of the protein:**

**Signal sequence:**

amino acids 1-23

**Transmembrane domain:**

amino acids 161-182

**N-glycosylation site.**

amino acids 184-187

**Glycosaminoglycan attachment sites.**

amino acids 37-40, 236-239

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 151-154

**N-myristoylation sites.**

amino acids 33-38, 36-41, 38-44, 229-234

**Amidation site.**

amino acids 238-241

**ATP/GTP-binding site motif A (P-loop).**

amino acids 229-236

137/168

## **FIGURE 137**

GATGGCGCAGCCACAGCTTCTGTGAGATTGATTCGATTCTCCCCAGTTCCCTGTGGGTCTGAGGG  
GACCAGAAGGGTGAGCTACGTTGGCTTCTGGAAGGGGAGGCTATAATGCGTCAATTCCCCAAA  
ACAAGTTTGACATTCCCCTGAAATGTCATTCTATCTATTCACTGCAAGTGCCTGCTGTT  
CCAGGCCTTACCTGCTGGCACTAACGGCGAGGCCAGGATGGGGACAGAATAAAGGAGGCCACG  
ACCTGTGCCACCAACTCGCACTCAGACTCTGAACACTCAGACCTGAAATCTTCTTCACGGGAG  
GCTTGGCAGTTTCTTAECTCCTGTGGTCTCCAGATTCAGGCCTAAGATGAAAGCCTCTAGT  
CTTGCCTTCAGCCTCTCTGCTGCGTTTATCTCCTATGGACTCCTTCCACTGGACTGAAG  
ACACTCAATTGGGAAGCTGTGTGATGCCACAAACCTTCAGGAAATACGAAATGGATTTCT  
GAGATACGGGGCAGTGTGCAAGCCAAGATGGAAACATTGACATCAGAATCTAAGGAGGACT  
GAGTCTTGCAAGACACAAAGCCTGCGAATCGATGCTGCCTCCTGCGCCATTGCTAAGACTC  
TATCTGGACAGGGTATTTAAAAACTACCAGACCCCTGACCATTATACTCTCCGAAGATCAGC  
AGCCTCGCCAATTCTTCTTACCATCAAGAAGGACCTCCGGCTCTCATGCCACATGACA  
TGCCATTGTGGGGAGGAAGCAATGAAGAAATACAGCCAGATTCTGAGTCACTTGAAAAGCTG  
GAACCTCAGGCAGCAGTTGTGAAGGCTTGGGGAACTAGACATTCTCTGCAATGGATGGAG  
GAGACAGAATAGGAGGAAAGTGATGCTGCTGCTAAGAATATTGAGGTCAAGAGCTCCAGTCT  
TCAATACCTGCAGAGGAGGCATGACCCAAACCACCATCTTACTGTACTAGTCTTGTGCT  
GGTCACAGTGTATCTTATTCATGCATTACTTGCTTCTGCATGATTGTCTTATGCATCCCC  
AATCTTAATTGAGACCATACTTGTATAAGATTTGTAATATCTTCTGCTATTGGATATATT  
TATTAGTTAATATATTATTATTGCTATTAATGTATTATTTTACTTGGACATG  
AAACTTAAAAAAATTACAGATTATTTATAACCTGACTAGAGCAGGTGATGTATTTTAT  
ACAGTAAAAAAAAACCTGTAAATTCTAGAAGAGTGGCTAGGGGGTTATTCAATTGTAT  
TCAACTAAGGACATATTACTCATGCTGATGCTGTGAGATATTGAAATTGAACCAATGAC  
TACTTAGGATGGTTGTGGAATAAGTTGATGTGGAATTGCACATCTACCTACAATTACTG  
ACCATCCCCAGTAGACTCCCCAGTCCCATATTGTGTATCTCAGGCCAGGAATCCTACACGG  
CCAGCATGTATTCTACAAATAAGTTCTTGCATACCAAAAAAAAAAAAAAA

138/168

## **FIGURE 138**

MRQFPKTSFDISPEMSFSIYSLQVPAVGLTCWALTAEPGWGQNKGATTCATNSHSDSELRPE  
IFSSREAWQFFLLLWSPDFRPKMKASSLAFSLLAAFYLLWTPSTGLKTLNLGSCVIATNLQE  
IRNGFSEIRGSVQAKDGNIDIRILRRTESLQDTK PANRCCLLRHLLRLYLDRVFKNYQTPDHY  
TLRKISSLANSFLTICKDLRLSHAHMTCHCGEEAMKKYSQILSHFEKLEPQAAVKALGELDI  
LLQWMEETE

**Important features of the protein:**

**Signal peptide:**

amino acids 1-42

**cAMP- and cGMP-dependent protein kinase phosphorylation sites.**

amino acids 192-195, 225-228

**N-myristoylation sites.**

amino acids 42-47, 46-51, 136-141

## FIGURE 139

CCTGGAGCCGGAAGCGCGCTGCAGCAGGGCGAGGCTCCAGGTGGGTCGGTCCGCATCCAG  
CCTAGCGTGTCCACG**ATG**CGGCTGGCTCCGGACTTCGCTACCTGTTGCGTAGCGATCGAG  
GTGCTAGGGATCGCGGTCTTCCTCGGGATTCTTCCCAGCAGCCGAACCCCTCGCTGGAGCCAGTCTAACTGGACC  
GCGGAACACGGAGCGGAGCCCCAGCAGCCGAACCCCTCGCTGGAGCCAGTCTAACTGGACC  
ACGCTGCCACCACCTCTTCAGTAAAGTTATTGTTCTGATAGATGCCTTGAGAGATGAT  
TTTGTGTTGGGTCAAAGGGTGTGAAATTATGCCCTACACAACCTACCTTGAGAAAAAGGA  
GCATCTCACAGTTGTGGCTGAAGCAAAGCCACCTACAGTTACTATGCCTCGAATCAAGGCA  
TTGATGACGGGGAGCCTCCTGGCTTGTGACGTCATCAGGAACCTCAATTCTCCTGCACTG  
CTGGAAGACAGTGTGATAAGACAAGCAAAGCAGCTGGAAAAAGAATAGTCTTTATGGAGAT  
GAAACCTGGGTTAAATTATTCCAAAGCATTTGTGGAATATGATGGAACAAACCTCATTTTC  
GTGTCAGATTACACAGAGGTGGATAATAATGTCACGAGGCATTGGATAAAGTATTAAAAAGA  
GGAGATTGGGACATATTAATCCTCCACTACCTGGGGCTGGACCACATTGGCACATTTCAGGG  
CCAACAGCCCCCTGATTGGCAGAAGCTGAGCGAGATGGACAGCGTGTGATGAAGATCCAC  
ACCTCACTGCACTGCAAGGAGAGAGAGACGCCATTACCCAATTGCTGGTTCTTGTGGTGA  
CATGGCATGTCGAAACAGGAAGTCACGGGGCCTCCACCGAGGAGGTGAATAACACCTCTG  
ATTAAATCAGTTCTGCGTTGAAAGGAAACCCGGTGAATATCCGACATCCAAGCACGTC  
**TAG**ACGGATGTGGCTGCGACACTGGCGATAGCATTGGCTACCGATTCCAAGAACAGTGT  
GGGAGCCTCTATTCCAGTTGTGGAAGGAAGACCAATGAGAGAGCAGTTGAGATTTCACAT  
TTGAATACAGTGCAGCTTAGTAAACTGTTGCAAGAGAATGTGCCGTATATGAAAAGATCCT  
GGGTTGAGCAGTTAAATGTCAGAAAGATTGCACTGGGACTGGATCAGACTGTACTGGAG  
GAAAAGCATTCAAGACTCCTATTCAACCTGGCTCCAAGGTTCTCAGGCAGTACCTGGATGCT  
CTGAAGACGCTGAGCTTGTCCCTGAGTGCACAAGTGGCCAGTTCTCACCTGCTCTGCTCA  
GCGTCCCACAGGCACTGCACAGAAAGGCTGAGCTGGAAGTCCCAGTGTCACTCCTGGGTTT  
CTCTGCTCTTTATTGGTGAACACACTGGCTCTGGCTTCTTCGGCGGTTCACTGATTGTG  
CTGAAAGTTCTGTGCTACTCTGTGGCTCTCGTGGCTGGCGCAGGCTGCCTTCGTTACCA  
GACTCTGGTTGAACACACTGGCTGTGCAAGTGTGGCAGTGCCTGGACAGGGGGCCTCAGG  
GAAGGACGTGGAGCAGCCTTATCCAGGCCTCTGGGTGTCAGACAGGTGTTACATCTGT  
GCTGTCAAGTCAGATGCCCTAGTTCTGGAAAGCTAGGTTCTGCACTGTTACCAAGGTGAT  
TGTAAAGAGCTGGGGTCACAGAGGAACAAGCCCCCAGCTGAGGGGGTGTGTAATCGGACA  
GCCTCCCAGCAGAGGTGTGGAGCTGCAGCTGAGGGAAAGAGAGACAATCGGCTGGACACTC  
AGGAGGGTCAAAGGAGACTTGGTCGACCAACTCATCCTGCCACCCCCAGAATGCATCCTGCC  
TCATCAGGTCCAGATTCTTCCAAGGGGACGTTTCTGTTGGAATTCTTAGTCCTGGCCT  
CGGACACCTCATTGTTAGCTGGGAGTGGTGGTGAAGGAGTGAAGAAGAGGGCGGATGGTCA  
CACTCAGATCCACAGAGGCCAGGATCAAGGGACCCACTGCAGTGGCAGCAGGACTGTTGGCC  
CCACCCCAACCCCTGCACAGCCCTCATCCCCTCTGGCTTGAAGGCTCAGAGGCCCTGCTG  
AGTGTCTGACCGAGACACTCACAGCTTGTCACTAGGGCACAGGCTCCTCGGAGCCAGGATG  
ATCTGTGCCACGCTTGCACCTCGGGCCATCTGGCTCATGCTCTCTGCTATTGAATT  
AGTACCTAGCTGCACACAGTATGTAGTTACCAAAAGAATAAACGGCAATAATTGAGAAAAAAA

140/168

## **FIGURE 140**

MRLGSGTFATCCVAIEVLGIAVFLRGFFPAPVRSSARAEGAEPPAPEPSAGASSNWTLLPPP  
LFSKVVIVLIDLALRDDFVFGSKGVKFMPYTTYLVEKGASHSFVAEAKPPTVTMPRIKALMTGS  
LPGFVDVIRNLNSPALLEDSVIRQAKAAGKRIVFYGDETWVKLFPKHFVEYDGTSFFVSDYT  
EVDDNNVTRHLDKVLKRGDWDLILHLHYLGLDHIGHISGPNSPLIGQKLSEMDSVLMKIHTSLQS  
KERETPLPNLLVLCGDHGMSETGSHGASSTEEVNTPLILISSAFERKPGDIRHPKHVQ

**Important features of the protein:**

**Signal peptide:**

amino acids 1-34

**Transmembrane domain:**

amino acids 58-76

**N-glycosylation sites.**

amino acids 56-60, 194-198

**N-myristoylation sites.**

amino acids 6-12, 52-58, 100-106, 125-131, 233-239, 270-276,  
275-281, 278-284

**Amidation site.**

amino acids 154-158

**Cell attachment sequence.**

amino acids 205-208

141/168

**FIGURE 141**

GGCACGAGGAAGCCTCCAGTTATCGTGACGCACCTGAAAGTCTGAGAGCTACTGCCCTA  
CAGAAAGTTACTAGTGCCTAAAGCTGGCGCTGGCACT**ATGTT**ACTGCTGCTGTTGGAGTAC  
AACTTCCCTATAGAAAACAACGCCAGCACCTTAAGACCACTCACACCTCAGAGTGAAGAAC  
TTAAACCGAAGAAATTCA~~G~~CATTGACCAGGATCACAAAGTACTGGTCCTGGACTCTGGG  
AATCTCATAGCAGTCCAGATAAAA~~A~~CTACATACGCCAGAGATCTCTTG~~C~~ATTAGCCTCA  
TCCTTGAGCTCAGCCTCTGCGGAGAAAGGAAGTCCGATTCTCCTGGGGTCTCTAAAGGGAG  
TTTGTCTCTACTGTGACAAGGATAAAGGACAAAGTCATCCATCCCTCAGCTGAAGAAGGAG  
AAACTGATGAAGCTGGCTGCCAAAAGGAATCAGCACGCCGGCCCTCATCTTATAGGGCT  
CAGGTGGGCTCCTGGAACATGCTGGAGTCGGCGGCTCACCCGGATGGTCATCTGCACCTCC  
TGCAATTGTAATGAGCCTGTTGGGTGACAGATAAATTGAGAACAGGAAACACATTGAATTT  
TCATTTCAACCAGTTGCAAAGCTGAAATGAGCCCCAGTGAGGTAGCGATT**TAG**GAAACTGCC  
CCATTGAACGCCTCCTCGCTAATTGAACTAATTGTATAAAAACACCAACCTGCTCACT

142/168

**FIGURE 142**

MLLLLEYNFPIENNQHLKTTHTFRVKNLNPKKFSIHDDQDHKVLVLDGNLIAVPDKNYIRPEIFFALASSLSSASAEGSPILLGVSKGEFCLYCDKDKGQSHPSLQLKKEKLMKLAQQESARRPFI FYRAQVGWSNMLESAAHPGWFICTSCNCNEPVGVTDKFENRKHIEFSFQPVCKAEMSPSEVSD

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 33-36

**N-myristoylation site.**

amino acids 50-55, 87-92

**Interleukin-1**

amino acids 37-182

143/168

**FIGURE 143**

CTAGAGAGTATAGGCAGAAGGATGGCAGATGAGTGACTCCACATCCAGAGCTGCCTCCCTT  
AATCCAGGATCCTGTCCTCCTGTCCTGTAGGAGTGCCTGTTGCCAGTGTGGGTGAGACAAG  
TTTGTCCCACAGGGCTGTCTGAGCAGATAAGATAAGGGCTGGGTCTGTGCTCAATTAACTCC  
TGTGGCACGGGGCTGGAAAGAGCAAAGTCAGCGGTGCCTACAGTCAGCACCAATGCTGGGCC  
TGCCGTGGAAGGGAGGTCTGTCCTGGCGCTGCTGCTGCTCTTAGGCTCCAGATCCTGC  
TGATCTATGCCTGGCATTCCACGAGCAAAGGGACTGTGATGAACACAATGTCATGGCTCGTT  
ACCTCCCTGCCACAGTGGAGTTGCTGTCCACACATTCAACCAACAGAGCAAGGACTACTATG  
CCTACAGACTGGGCACATCTGAATTCTGGAAGGAGCAGGTGGAGTCCAAGACTGTATTCT  
CAATGGAGCTACTGCTGGGAGAACTAGGTGTGGAAATTGAAGACGACATTGACAAC TGCC  
ATTTCCAAGAAAGCACAGAGCTGAACAATACTTACCTGCTTCTTACCATCAGCACCGGC  
CCTGGATGACTCAGTCAGTCAGCCTCTGAACAAGACCTGCTGGAGGGATTCCACTGAGTGAAAC  
CCACTCACAGGCTTGTCCATGTGCTGCTCCCACATTCCGTGGACATCAGCACTACTCTCCTGA  
GGACTCTTCAGTGGCTGAGCAGCTTGGACTTGGTTATCCTATTTGCATGTGTTGAGA  
TCTCAGATCAGTGTGTTAGAAAATCCACACATCTTGAGCCTAATCATGTAGTGTAGATCATT  
AACATCAGCATTAAAGAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAA

144/168

**FIGURE 144**

MLGLPWKGGLSWALLLLLGSQILLIYAWHFHEQRDCDEHNVMARYLPATVEFAVHTFNQQSK  
DYYAYRLGHILNSWKEQVESKTVFSMELLGRTRCGKFEDDIDNCHFQESTELNNTFTCFFT  
STRPWMTQFSLLNKTCLEGFH

**Important features of the protein:**

**Signal peptide:**

amino acids 1-25

**N-glycosylation sites.**

amino acids 117-121, 139-143

**N-myristoylation site.**

amino acids 9-15

145/168

## **FIGURE 145**

CTGTGCAGCTCGAGGCTCCAGAGGCACACTCCAGAGAGGCCAAGGTTCTGACGCGATGAGGA  
AGCACCTGAGCTGGTGGTGGCTGGCCACTGTCTGCATGCTGCTCTCAGCCACCTCTGCGG  
TCCAGACGAGGGGCATCAAGCACAGAAATCAAGTGGAACCGGAAGGCCCTGCCAGCACTGCC  
AGATCACTGAGGCCAGGTGGCTGAGAACCGCCGGAGCCTTCATCAAGCAAGGCCGCAAGC  
TCGACATTGACTTCGGAGCCAGGGCAACAGGTACTACGAGGCCAACTACTGGCAGTCCCCG  
ATGGCATCCACTACAACGGCTGCTCTGAGGCTAATGTGACCAAGGAGGCATTGTCACCGGCT  
GCATCAATGCCACCCAGGCGCGAACCAAGGGGAGTTCCAGAAGCCAGACAACAAGCTCCACC  
AGCAGGTGCTCTGGCGCTGGTCCAGGAGCTTGCTCCCTCAAGCATTGCGAGTTGGTTGG  
AGAGGGCGCAGGACTTCGGGTACCATGCACCAGCCAGTGCTCCTCTGCCTCTGGCTTGA  
TCTGGCTCATGGTAAATAAGCTTGCCAGGAGGCTGGCAGTACAGAGCGCAGCAGCAGCAA  
TCCTGGCAAGTGACCCAGCTCTCTCCCCAAACCCACGCGTGTGAAGGTGCCAGGAGC  
GGCGATGCACTCGCACTGCAAATGCCGCTCCCACGTATGCCCTGGTATGCGCTGCGTTCT  
GATAGATGGGGACTGTGGCTTCTCCGTCACTCCATTCTCAGCCCTAGCAGAGCGTCTGGCA  
CACTAGATTAGTAGTAAATGCTTGTAGAGAACACATCAGGCAGTGCGCCACCTGCTTCAC  
AGTACTTCCAACAACCTTAGAGGTAGGTGTATTCCCGTTTACAGATAAGGAAACTGAGGC  
CCAGAGAGCTGAAGTACTGCACCCAGCATCACCAGCTAGAAAGTGGCAGAGGCCAGGATTCAAC  
CCTGGCTTGTCTAACCCAGGTTCTGCTCTGCTTAATCCAGAGCTGTCTGGTATCATT  
TATGTCTCACAGGGACCCACATCCAAACATGTATCTTAATGAAATTGTGAAAGCTCCATGTT  
TAGAAATAATGAAAACACCTGA

146/168

## **FIGURE 146**

MRKHLSWWLATVCMLLFSHLSAVQTRGIKHRIKWRKALPSTAQITEAQVAENRPGAFIKQG  
RKLDIDFGAEGNRYYEANYWQFPDGIHYNGCSEANVTKEAFVTGCINATQAANQGEFQKPDNK  
LHQQLWLRLVQELCSLKHFCEFWLERGAGLRVTMHQPVLLCLLALIWLVMVK

**Important features of the protein:**

**Signal peptide:**

amino acids 1-26

**Transmembrane domain:**

amino acids 157-171

**N-glycosylation sites.**

amino acids 98-102, 110-114

**Tyrosine kinase phosphorylation site.**

amino acids 76-83

**N-myristoylation sites.**

amino acids 71-77, 88-94, 93-99, 107-113, 154-160

**Amidation site.**

amino acids 62-66

147/168

**FIGURE 147**

GCCTTGGCCTCCAAAGGGCTGGGATTATAGCGTGACCACCATGTCTGGTCCAGAGTCTCAT  
TTCCTGATGATTATAGACTCAAAGAAAACTCA**TGTT**CAGAAGCTCTCTCTGGCCTC  
CTCTCTGTCTTCTTCCCTTTCTTATTAAATTAGTAGCATCTACTCAGAGTCATGCA  
AGCTGGAAATCTTCATTTGCTTGTCAAGTGGGGTAGGTCACTGAGTCTTAGTTTATT  
TGAAATTCAACTTCAGATTCAAGGGGTACATGTGAAGGTTGTTATGAGTATATTGC**AT**  
**GAT**GCTGAGGTTGGGT

148/168

**FIGURE 148**

MFRSSLLFWPPLCLLSLFLLILISSIYSESCKLEIFHFACQWGRSLSLSFYFLKFQLSDSGGT  
CEGLFYEYIA

**Important features of the protein:**

**Signal peptide:**

amino acids 1-25

**N-myristoylation site.**

amino acids 62-68

## FIGURE 149

GTCTCCGCGTCACAGGAACCTTCAGCACCCACAGGGCGGACAGCGCTCCCTCTACCTGGAGAC  
TTGACTCCCAGCGCCCCAACCCCTGCTTATCCCTGACCCTGAGTGTAGAGATCCTGCAGC  
CGCCCACTCCGGCCCTCTCCGCCAACACCCACCCACCCCTCTGGCTCTCCTGTTTACTCC  
TCCTTTCAATTATAACAAAAGCTACAGCTCCAGGAGCCCAGCGCCGGCTGTGACCCAAGCC  
GAGCGTGGAAAGA**AT**GGGGTCTCGGGACCCTGAGTGTAGTGCTCCCGATT  
CAAGCTTCCCCAACCTGGAGGAAGCCAAGACAAATCTACATAATAGAGAATTAAGTGCA  
GAAAGACCTTGAATGAACAGATTGCTGAAGCAGAAGACAAGAGATTAACATATCCT  
CCAGAAAACAAGCCAGGTAGAGCAACTATTCTTGTGATAACTTGAACTGCTAAAGGC  
ATAACAGAAAAGGAAAAATTGAGAAAGAAAGACAATCTACATAAGAAGCTCCCACTTGATAAT  
AAGTTGAATGTGGAAGATGTTGATTCAACCAAGAATCGAAAATGATCGATGATTATGACTCT  
ACTAAGAGTGGATTGGATCATAAATTCAAGATGATCCAGATGGTCTTCATCAACTAGACGGG  
ACTCCTTAACCGCTGAAGACATTGTCATAAAATCGCTGCCAGGATTATGAAGAAAATGAC  
AGAGCCGTGTTGACAAGATTGTTCTAAACTACTTAATCTGGCCTTATCACAGAAAGCCAA  
GCACATACACTGGAAGATGAAGTAGCAGAGGTTTACAAAATTAATCTCAAAGGAAGCCAA  
AATTATGAGGAGGATCCAATAAGCCCACAAGCTGGACTGAGAATCAGGCTGGAAAAATACCA  
GAGAAAGTGACTIONGCAGCAATTCAAGATGGCTTGCTAAGGGAGAAAACGATGAAACA  
GTATCTAACACATTAACCTTGACAAATGGCTTGAAAGGAGAACTAAAACCTACAGTGAAGAC  
AACTTGAGGAACCTCAATATTCCAAATTCTATGCGCTACTGAAAAGTATTGATTGAGAA  
AAAGAAGCAAAAGAGAAAGAAACACTGATTACTATCATGAAAACACTGATTGACTTTGTGAAG  
ATGATGGTGAATAATGGAACAATATCTCCAGAAGAAGGTGTTCTACCTGAAAAGTGGAT  
GAAATGATTGCTCTCAGACCAAAACAAGCTAGAAAAAAATGCTACTGACAATATAAGCAAG  
CTTTCCCAGCACCATCAGAGAAGAGTCATGAAGAACAGACAGTACCAAGGAAGAAGCAGCT  
AAGATGGAAAAGGAATATGGAAGCTGAGGATTCCACAAAGATGATAACTCCAACCCAGGA  
GGAAAGACAGATGAACCCAAAGGAAAACAGAAGCCTATTGGAAGCCATCAGAAAAATATT  
GAATGGTTGAAGAAACATGACAAAAAGGAAATAAGAAGATTATGACCTTCAAAGATGAGA  
GACTTCATCAATAACAAAGCTGATGCTTATGTGGAGAAAGGCATCCTGACAAGGAAGAAGCC  
GAGGCCATCAAGCGCATTATAGCAGCCTG**TAA**AAATGGCAAAAGATCCAGGAGTCTTCAAC  
TGTGTTAGAAAACATAATAGCTAAACACTCTAATTCTGTGATTAAATTTTGACCC  
AAGGGTTATTAGAAAAGTGTGAATTACAGTAGTTAACCTTACAAGTGGTAAACATAGC  
TTTCTCCGTAAAAACTATCTGAAAGTAAAGTTGTATGTAAGCTGAAAAA  
AAA

150/168

## **FIGURE 150**

MGFLGTGTWILVLVLPIQAFPKPGGSQDKSLHNRELSAERPLNEQIAEAEEDKIKKTYPPENK  
PGQSNYSFVDNLNLLKAITEKEKIEKERQSIRSSPLDNKLNVEDVDSTKNRKLIDDYDSTKSG  
LDHKFQDDPDGLHQLDGTPLTAEDIVHKIAARIYEENDRAVFDFKIVSKLLNLGLITESQAHTL  
EDEVAEVVLQKLISKEANNYEEDPNKPTSWTENQAGKIPFKTPMAAIQDGGLAKGENDETVSNT  
LTLTNGLERRTKTYSEDNFEELQYFPNFYALLKSIDSEKEAKEKETLITIMKTLIDFVKMMVK  
YGTISPEEGVSYLENLDEMIALQTKNKLEKNATDNISKLFPAPSEKSHEETDSTKEAAKMEK  
EYGSLKDKDSTKDDNSNPGGKTDEPKGTEAYLEAIRKNIEWLKKHDKGKGNKEDYDLSKMRDFIN  
KQADAYVEKGILDKEEAEAIIKRIYSSL

**N-glycosylation sites:**

amino acids 68-71, 346-349, 350-353

**Casein kinase II phosphorylation site:**

amino acids 70-73, 82-85, 97-100, 125-128, 147-150, 188-191, 217-  
220, 265-268, 289-292, 305-308, 320-323, 326-329, 362-365, 368-  
341, 369-372, 382-385, 386-389, 387-390

**N-myristoylation sites:**

amino acids 143-148, 239-244

## **FIGURE 151**

CGGCTCGAGGCTCCGCCAGGAGAAAGGAACATTCTGAGGGGAGTCTACACCCGTGGAGCTC  
AAG**ATGG**TCCCTGAGTGGGGCGCTGTGCTTCCGAATGAAGGACTCGCATTGAAGGTGCTTTAT  
CTGCATAATAACCAGCTTAGCTGGAGGGCTGCATGCAGGGAAGGTCAATTAAAGGTGAAGAG  
ATCAGCGTGGTCCCCAATCGGTGGCTGGATGCCAGCCTGCCCCCGTCATCCTGGGTGTCCAG  
GGTGGAAAGCCAGTGCCTGTATGTGGGTGGGCCAGGAGCCACTCTAACACTAGAGCCAGTG  
AACATCATGGAGCTCTATCTTGGTGCCAAGGAATCCAAGAGCTCACCTTACCGGGCAGGAC  
ATGGGGCTCACCTCCAGCTCGAGTCGGCTGCCTACCCGGCTGGTCTGTGCACGGTGCCT  
GAAGCCGATCAGCCTGTCAAGACTCACCCAGCTTCCCAGAATGGTGGCTGGAATGCCCCATC  
ACAGACTTCTACTTCCAGCAGTGTCA**TAGGG**CAACGTGCCCCCCAGAACACTCCCTGGCAGAG  
CCAGCTCGGGTGAGGGGTGAGTGGAGGAGACCCATGGCGACAATCACTCTCTGCTCTCAG  
GACCCCCACGTCTGACTTAGTGGGCACCTGACCACTTGTCTTCTGGTCTCCAGTTGGATAA  
ATTCTGAGATTGGAGCTCAGTCCACGGTCTCCCCACTGGATGGTGTACTGCTGTGGAAC  
CTTGTAAAAACCATGTGGGGTAAACTGGGAATAACATGAAAAGATTCTGTGGGGGTGGGTG  
GGGGAGTGGTGGGAATCATTCTGCTTAATGGTAAGTGACAAGTGTACCCCTGAGCCCCGAG  
GCCAACCCATCCCCAGTTGAGCCTTATAGGGTCAGTAGCTCTCCACATGAAGTCCTGTCACTC  
ACCACTGTGCAGGGAGGGAGGTGGTCATAGAGTCAGGGATCTATGCCCTGGCCAGCCCC  
ACCCCCCTCCCTTAATCCTGCCACTGTCTATGGCTACCTTCTATCTCTCCATCATC  
TTGTTGTGGCATGAGGAGGTGGTGTAGTCAGAAGAAATGGCTGAGCTCAGAAGATAAAAGA  
TAAGTAGGGTATGCTGATCCTCTTTAAAAACCCAAGATAACATCAAATCCAGATGCTGGT  
CTCTATTCCCATGAAAAAGTGTCTCATGACATATTGAGAAGACCTACTTACAAAGTGGCATATA  
TTGCAATTATTTAATTAAAAGATAACCTATTATATTTCTTATAGAAAAAGTCTGAA  
GAGTTACTTCATGAGCAATGTCAGGGTGGCAGTAGAGGTGATTTCTTTAATT  
TGTTAATTATCTGTATTCTTAATTCTACAATGAAGATGAATTCTGTATAAAAATAA  
GAAAAGAAATTAACTTGAGGTAAGCAGAGCAGACATCATCTGTGATTGCTCAGCCTCAC  
TTCCCCAGAGTAAATTCAAAATTGAATCGAGCTCTGCTCTGGTTGGTTGTAGTAGTGATCA  
GGAAACAGATCTCAGCAAAGCCACTGAGGAGGGCTGTGCTGAGTTGTGGCTGGAATCT  
CTGGGTAAAGGAACTAAAGAACAAAAATCATCTGTAATTCTTCTAGAAGGATCACAGCCC  
CTGGGATTCCAAGGCATTGGATCCAGTCTCAAGAAGGCTGCTGTACTGGTTGAATTGTGTCC  
CCCTCAAATTCACATCCTCTTGGAAATCTCAGTCTGTGAGTTATTGGAGATAAGGTCTCTG  
CAGATGTAGTTAGTTAAGACAAGGTCTGCTGGATGAAGGTAGACCTAAATTCAATATGACTG  
GTTTCCCTGTATGAAAAGGAGAGGACACAGAGACAGAGGAGACGCCGGGAAGACTATGAAAG  
ATGAAGGCAGAGATGGAGTTGCAGCCACAAGCTAAGAAACACCAAGGATTGGCAACCA  
TCAGAAGCTTGGAAAGAGGCAAAGAAGAAATTCTCCCTAGAGGTTAGAGGGATAACGGCTCT  
GCTGAAACCTTAATCTCAGACTTCCAGCCTCTGAACGAAGAAAGAATAAATTCTGGCTGTT  
TAAGCCACCAAGGATAATTGGTTACAGCAGCTCTAGGAAACTAATACAGCTGCTAAATGATC  
CCTGTCTCCTCGTGTACATTCTGTGTGTCCTCCACAATGTACCAAAGTTGTCTTG  
TGACCAATAGAATATGGCAGAAGTGATGGCATGCCACTTCAAGATTAGGTATAAAAGACAC  
TGCAGCTCTACTTGAGGCCCTCTCTGCCACCCACGCCGGCAATCTATCTGGCTCACT  
CGCTCTGGGGAAAGCTAGCTGCCATGCTATGAGCAGGCCTATAAAGAGACTTACGTGGAAAA  
AATGAAGTCTCCTGCCACAGCCACATTAGTGAACCTAGAAGCAGAGACTCTGTGAGATAATC  
GATGTTGTTGTTAAGTTGCTCAGTTGGTCTAATTGTTATGCAGCAATAGATAAAATAA  
TATGCAGAGAAAGAG

152/168

## **FIGURE 152**

MVLSGALCFRMKDSALKVLYLHNNQLLAGGLHAGKVIKGEIISVVPNRWLDASLSPVILGVQG  
GSQCLSCGVGQEPTLTLEPVNIMELYLGAKESKSFTFYRRDMGLTSSFESAAYPGWFLCTVPE  
ADQPVRLTQLPENGGWNAPITDFYFQQCD

**N-myristoylation sites.**

amino acids 29-34, 30-35, 60-65, 63-68, 73-78, 91-96, 106-111

**Interleukin-1 signature.**

amino acids 111-131

**Interleukin-1 proteins.**

amino acids 8-29, 83-120, 95-134, 64-103

153/168

## FIGURE 153

CTTCAGAACAGGTTCTCCTTCCCCAGTCACCAGTTGCTCGAGTTAGAATTGTCTGCAATGGCC  
GCCCTGCAGAAATCTGTGAGCTTTCTTATGGGGACCCCTGGCCACCAGCTGCCTCCTCTC  
TTGGCCCTCTGGTACAGGGAGGAGCAGCTGCCCATCAGCTCCACTGCAGGCTTGACAAG  
TCCAACCTCCAGCAGCCCTATATCACCAACCGCACCTTATGCTGGCTAAGGAGGCTAGCTTG  
GCTGATAACAAACACAGACGTCGTCTCATTGGGGAGAAACTGTTCCACGGAGTCAGTATGAGT  
GAGCGCTGCTATCTGATGAAGCAGGTGCTGAACCTCACCTTGAAGAAGTGTGTTCCCTCAA  
TCTGATAGGTTCCAGCCTTATATGCAGGAGGTGGTGCCTGGCCAGGCTCAGAACAGG  
CTAACGCACATGTCATATTGAAGGTGATGACCTGCATATCCAGAGGAATGTGCAAAAGCTGAAG  
GACACAGTGAAAAAGCTGGAGAGAGTGGAGAGATCAAAGCAATTGGAGAACTGGATTGCTG  
TTTATGTCTCTGAGAAATGCCTGCATTTGACCAGAGCAAAGCTGAAAATGAATAACTAACCC  
CCTTTCCCTGCTAGAAATAACAATTAGATGCCCAAAGCGATTTTTAACAAAAGGAAGA  
TGGGAAGCCAAACTCCATCATGATGGGTGGATTCCAAATGAACCCCTGCGTAGTTACAAAGG  
AAACCAATGCCACTTTGTTATAAGACCAGAAGGTAGACTTCTAACGATAGATATTATTG  
ATAACATTTCATTGTAACTGGTGTCTATACACAGAAAACAATTATTTAAATAATTGTC  
TTTTCCATAAAAAAGATTACTTTCCATTCCCTTAGGGAAAAACCCCTAAATAGCTTCATG  
TTCCATAATCAGTACTTATATTATAATGTATTATTATTATAAGACTGCATT  
TTATATCATTATTAATATGGATTATTATAGAAACATCATTGCGATATTGCTACTTGAGTG  
TAAGGCTAATATTGATATTATGACAATAATTATAGAGCTATAACATGTTATTTGACCTCAA  
TAAACACTTGGATATCCC

154/168

## FIGURE 154

MAALQKS VSSFLMGT LATSCLLL ALLVQGGAAPISSHCR LDKSNFQQPYITNRTFMLAKEA  
SLADNNNTDVR LIGEKL FHGVSM SERCYLMQV LNF TLEEVLF P QSDRF QPYM QEV VPFLARLS  
NRLSTCHIEGDDLH IQRNVQKLKDTVK KLGE SGEIKAIGEL DLLFMSLRNACI

**Important features of the protein:**

**Signal peptide:**

amino acids 1-33

**N-glycosylation sites.**

amino acids 54-58, 68-72, 97-101

**N-myristoylation sites.**

amino acids 14-20, 82-88

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 10-21

155/168

## **FIGURE 155**

GGCTTGCTGAAATAAAATCAGGACTCCTAACCTGCTCCAGTCAGCCTGCTTCCACGAGGCCT  
GTCAGTCAGTGCCCGACTTGTGACTGAGTGTGCAGTGCCCAGCATGTACCAGGTCA  
GGGCTGCCTGAGGGCTGTGCTGAGAGGGAGAGGAGCAGAGATGCTGCTGAGGGTGGAGGGAGG  
CCAAGCTGCCAGGTTGGGCTGGGCCAAGTGGAGTGAGAACTGGGATCCCAGGGGAGG  
GTGCAGATGAGGGAGCGACCCAGATTAGGTGAGGACAGTCTCTCATTAGCCTTCTACAG  
GTGGTTGCATTCTGGCAATGGTCATGGGAACCCACACCTACAGCCACTGGCCAGCTGCTGC  
CCCAGCAAAGGGCAGGACACCTCTGAGGAGCTGCTGAGGTGGAGCACTGTGCCTGTGCCTCCC  
CTAGAGCCTGCTAGGCCAACGCCACCCAGAGTCCTGTAGGCCAGTGAAGATGGACCCCTC  
AACAGCAGGCCATCTCCCCCTGGAGATATGAGTTGGACAGAGACTTGAACCGGCTCCCCAG  
GACCTGTACCACGCCGTTGCCGTGCCCCGACTGCGTCAGCCTACAGACAGGCTCCCACATG  
GACCCCCGGGCAACTCGGAGCTGCTTACACACAACCAGACTGTCTTACAGGCCGATGC  
CATGGCGAGAAGGGCACCAAGGGCTACTGCCCTGGAGCGCAGGTGTACCGTGTTCCTTA  
GCTTGTGTGTGTGCGGCCCGTGTGATGGGCTTAGCCGGACCTGCTGGAGGCTGGTCCCTT  
TTGGGAAACCTGGAGGCCAGGTGTACAACCCTGCCATGAAGGGCAGGATGCCAGATGCTT  
GGCCCTGTGAAGTGTGCTGGAGCAGCAGCAGGATCCGGACAGGATGGGGCTTGGGAA  
AACCTGCACCTCTGCACATTGAAAAGAGCAGCTGCTGCTTAGGCCGCCAGCTGGTGT  
CCTGTCATTTCTCTCAGGAAAGGTTCAAAGTTCTGCCATTCTGGAGGCCACCACTCCT  
GTCTCTTCTCTTCCATCCCTGCTACCTGGCCAGCACAGGCACCTTCTAGATATTTC  
CCCCTGCTGGAGAAGAAAGAGGCCCTGGTTTATTGTTACTCATCACTCAGTGAGC  
ATCTACTTTGGGTGCATTCTAGTGTAGTTACTAGTCTTTGACATGGATGATTCTGAGGAGGA  
AGCTGTTATTGAATGTATAGAGATTATCAAATAATCTTATTAAAAATGAAAAA

156/168

## **FIGURE 156**

MRERPRLGEDSSLISLFLQVVAFLAMVMGTHTYSHWPSCCPKGQDTSEELLRWSTVPVPPLE  
PARPNRHPESCRASEDGPLNSRAISPWRYELDRDLNRLPQDLYHARCLCPHCVSLQTGSHMDP  
RGNSELLYHNQTVFYRRPCHGEKGTHKGYCLERRLYRVSLACVCVRPRVMG

**Important features of the protein:**

**Signal peptide:**

amino acids 1-32

**N-glycosylation site.**

amino acids 136-140

**Tyrosine kinase phosphorylation site.**

amino acids 127-135

**N-myristoylation sites.**

amino acids 44-50, 150-156

**FIGURE 157**

CCGGCGATGTCGCTCGTGTGCTAAGCCTGGCCGCCTGTGCAGGAGCGCCGTACCCCGAGAG  
CCGACCGTCAATGTGGCTCTGAAACTGGGCCATCTCCAGAGTGGATGCTACAACATGATCTA  
ATCCCCGGAGACTTGAGGGACCTCCGAGTAGAACCTGTTACAACACTAGTGTGCAACAGGGAC  
TATTCAATTTGATGAATGTAAGCTGGTACTCCGGCAGATGCCAGCATCCGTTGTAAG  
GCCACCAAGATTGTGTGACGGGAAAAGCAACTTCCAGTCCTACAGCTGTGAGGTGCAAT  
TACACAGAGGCCTCCAGACTCAGACCAGACCCCTGGTGTAAATGGACATTTCTACATC  
GGCTTCCCTGTAGAGCTGAACACAGTCTATTCTATTGGGCCATAATATTCTAATGCAAAT  
ATGAATGAAGATGGCCCTTCATGTGTGAATTTCACCTCACCAGGCTGCCTAGACCACATA  
ATGAAATATAAAAAAAAGTGTGTCAAGGCCGGAAAGCCTGTGGATCGAACATCACTGCTTGT  
AAGAAGAATGAGGAGACAGTAGAAGTGAACCTCACACCACCTCCCTGGAAACAGATACTG  
GCTCTTATCCAACACAGCACTATCATCGGTTTCTCAGGTGTTGAGCCACACCAGAAGAAA  
CAAACGCGAGCTTCAGTGGTATTCCAGTGACTGGGATAGTGAAGGTGCTACGGTGCAGCTG  
ACTCCATATTCCTACTTGTGGCAGCGACTGCATCCGACATAAGGAACAGTTGTGCTCTGC  
CCACAAACAGGCGTCCCTTCCCTGGATAACAAACAAAAGCAAGCCGGAGGCTGGCTGCCT  
CTCCTCCTGCTGTCTGCTGGCCACATGGGTGCTGGCAGGGATCTATCTAATGTGG  
AGGCACGAAAGGATCAAGAAGACTCCTTTCTACCACACACTACTGCCCTTCTAAGGTT  
CTTGTGGTTACCCATCTGAAATATGTTCCATCACACAATTGTTACTTCAGTGAATTCTT  
CAAAACCATTGCAGAAGTGGTCATCCTGAAAAGTGGCAGAAAAGAAAATAGCAGAGATG  
GGTCCAGTGCAGTGGCTGCCACTCAAAAGAAGGCAGCAGACAAAGTCGTCTCCTTCTTCC  
AATGACGTCAACAGTGTGTGGATGGTACCTGTGGCAAGAGCAGGGCAGTCCCAGTGAGAAC  
TCTCAAGACCTTCCCCCTGCCTTAACCTTCTGCAGTGTCAAGAAGCCAGATTCT  
CTGCACAAATACGTGGTGGTACTTAGAGAGATTGATAAAAAGACGATTACAATGCTCTC  
AGTGTCTGCCCAAGTACCACCTCATGAAGGATGCCACTGCTTCTGTGCAGAACTTCTCCAT  
GTCAAGCAGCAGGTGTCAGCAGGAAAAAGATCACAGCCTGCCACGATGGCTGCTCCTTG  
**TAG**

158/168

## **FIGURE 158**

MSLVLLSLAALCRSAVPREPTVQCGSETGPSPEWMLQHDLIPGDLRDLRVEPVTSVATGDYS  
ILMNVSWVLRADASIRLLKATKICVTGKSNFQSYSCVRCNYTEAFQTQTRPSGGKWTFSYIGF  
PVELNTVYFIGAHNIPNANMNEGPSMSVNFTSPGCLDHIMKYKKKCVKAGSLWDPNITACKK  
NEETVEVNFTTPLGNRYMALIQHSTIIGFSQVFEPHQKKQTRASVVIPVTGDSEGATVQLTP  
YFPTCGSDCIRHKGTVVLCPQTGVFPILDNNKSKPGGWLPLLLLSLLVATWVLVAGIYLMWRH  
ERIKKTSFSTTLLPPIKVLVVYPSEICFHHTICYFTEFLQNHCRSEVILEKWQKKKIAEMGP  
VQWLATQKKAADKVVFLNSNDVNSVCDGTCGKSEGSPSENSQDLFPLAFNLFCSDLRSQIHLH  
KYVVVYFREIDTKDDYNALSVCVKYHLMKDATAFCAELLHVKKQQVSAGKRSQACHDGCCSL

**Important features of the protein:**

**Signal peptide:**

amino acids 1-14

**Transmembrane domain:**

amino acids 290-309

**N-glycosylation sites.**

amino acids 67 - 71, 103 - 107, 156 - 160, 183 - 187, 197 - 201  
and 283 - 287

**cAMP- and cGMP-dependent protein kinase phosphorylation sites.**

amino acids 228 - 232 and 319 - 323

**Casein kinase II phosphorylation sites.**

amino acids 178 - 182, 402 - 406, 414 - 418 and 453 - 457

**N-myristoylation site.**

amino acids 116-122

**Amidation site.**

amino acids 488-452

159/168

**FIGURE 159**

AGCCACCAGCGAACATGA~~C~~AGTGAAGACCC~~T~~GCATGGCCCAGCCATGGTCAAGTACTTGCTG  
CTGTCGATATTGGGGCTTGCCTTCTGAGTGAGGC~~G~~GGCAGCTCGAAAATCCCCAAAGTAGGA  
CATACTTTTCCAAAAGCCTGAGAGTTGCCGC~~T~~GTGCCAGGAGGTAGTATGAAGCTTGAC  
ATTGGCATCATCAATGAAAACCAGCGCGTTCCATGTACGTAACATCGAGAGGCCGCTCCACC  
TCCCCCTGGAATTACACTGTCACTTGGGACCCCAACCGGTACCCCTCGGAAGTTGTACAGGCC  
CAGTGTAGGA~~A~~CTTGGGCTGCATCAATGCTCAAGGAAAGGAAGACATCTCCATGAATTCCGTT  
CCCATCCAGCAAGAGACCC~~T~~GGTC~~G~~CCGGAGGAAGCACCAAGGCTGCTGT~~T~~TTCTTCCAG  
TTGGAGAAGGTGCTGGT~~G~~ACTGTTGGCTGCACCTGCGTCACCC~~T~~GTCATCCACC~~T~~GTGCAG  
TAAGAGGTGCATATCCACTCAGCTGAAGAAG

160/168

## **FIGURE 160**

MTVKTLHGPAMVKYLLSILGLAFLSEAAARKIPKVGHTFFQKPESCPPVPGGSMKLDIGIIN  
ENQRVSMSRNIESRSTSPWNYTWTDPNYPSEVVQAQCRLGCINAQGKEDISMNSVPIQQE  
TLVVRRKHQGCSVSFQLEKVLVTVGCTCVTPVIHHVQ

**Signal sequence:**

amino acids 1-30

**N-glycosylation site.**

amino acids 83-87

**N-myristoylation sites.**

amino acids 106-111, 136-141

161/168

## FIGURE 161

ACACTGGCAAACAAAAACGAAAGCACTCCGTGCTGGAAGTAGGAGGGAGTCAGGACTCCCA  
GGACAGAGAGTGCACAAACTACCCAGCACAGCCCCCTCCGCCCTCTGGAGGCTGAAGAGGG  
ATTCCAGCCCCCTGCCACCCACAGACACGGGCTGACTGGGGTGTCTGCCCTTCTGGGGGGGG  
CAGCACAGGGCCTCAGGCCTGGGTGCCACCTGGCACCTAGAAGATGCCTGTGCCCTGGTTCTT  
GCTGTCCTGGCACTGGCCAAGCCCAGTGGTCTCTGGAGAGGCTGTGGGGCCTA  
GGACGCTACCCACTGCTCTCCGGGCTCTCCTGCCCTCTGGGACAGTGACATACTGCCT  
GCCCTGGGACATCGCCTGCTCCGGGCCCCGTGCTGGCGCTACGCACCTGCAGACAGAGCT  
GGTGTGAGGTGCCAGAAGGAGACCGACTGTGACCTCTGTCTGCGTGTGGCTGTCCACTGGC  
CGTGCATGGGCACTGGGAAGAGCCTGAAGATGAGGAAAAGTTGGAGGAGCAGCTGACTCAGG  
GGTGGAGGAGCCTAGGAATGCCCTCTCCAGGCCAAGTCGTGCTCTCCAGGCCAACCC  
TAATGCCCGCTGCGCCTGCTGGAGGTGCAAGTGCCTGCTGCCCTGTGCAGTTGGTCAGTC  
TGTGGGCTCTGTGGTATATGACTGCTTCGAGGCTGCCCTAGGGAGTGAGGTACGAATCTGGTC  
CTATACTCAGCCCAGGTACGAGAACGAACTCAACCACACAGCAGCTGCCCTGCCCTG  
GCTCAACGTGTCAGCAGATGGTACAACGTGACATCTGGTTCTGAATGTCTGAGGAGCAGCA  
CTTCGGCCCTCCCTGTACTGGAATCAGGTCCAGGGCCCCAAACCCGGTGGCACAAAAAA  
CCTGACTGGACCGCAGATCATTACCTGAACCACACAGACCTGGTCCCTGCCCTGTATTCA  
GGTGTGGCCTCTGGAACCTGACTCCGTTAGGACGAACATCTGCCCTCAGGGAGGACCCCG  
CGCACACCCAGAACCTCTGGCAAGCCGCCGACTGCGACTGCTGACCCCTGCAGAGCTGGCTGCT  
GGACGCACCGTGCTCGCTGCCGCAGAACGGCACTGTGCTGGCGGGCTCCGGTGGGACCC  
CTGCCAGCCACTGGTCCCACCGCTTCTGGAGAACGTCACTGTGGACAAGGTTCTGAGTT  
CCCATTGCTGAAAGGCCACCTAACCTCTGTGTTAGGTGAAACAGCTCGGAGAACGCTGCAGCT  
GCAGGAGTGCTTGTGGCTGACTCCCTGGGCCTCTCAAAGACGATGTGCTACTGTTGGAGAC  
ACGAGGCCAGGACAACAGATCCCTCTGTGCCCTGGAACCCAGTGGCTGTACTTCACCTACC  
CAGCAAAGCCTCCACGAGGGCAGCTGCCCTGGAGAGTACTTACTACAAGACCTGCAGTCAGG  
CCAGTGTCTGCAGCTATGGGACGATGACTTGGGAGCGCTATGGGCCTGCCCATGGACAAATA  
CATCCACAAGCGCTGGCCCTCGTGGCTGGCTGCCCTACTCTTGCCGCTGCGCTTCCCT  
CATCCTCCTCTCAAAAGGATCACCGAAAGGGTGGCTGAGGCTCTGAAACAGGACGTCCG  
CTCGGGGGCGGCCAGGGCCGCGCTCGTCCCTGTGCTCCTACTCAGCCGATGACTCGGGTT  
CGAGCGCCTGGTGGCGCCCTGGCGTGGCCCTGTGCCAGCTGCCGCTGCGGTGGCGTAGA  
CCTGTGGAGCCGTCGTGAACTGAGCGCGAGGGGCCGTGGCTTACCGCGCAGCG  
CCAGACCTGCAGGAGGGCGCGTGGTGTCTGCTCTCTCCGGTGGCGCTGTG  
CAGCGAGTGGCTACAGGATGGGTGTCGGGCCGGCGCACGGCCGCACGACGCCCTCCG  
CGCCTCGCTCAGCTCGTGTGCCGACTTCTGCAAGGGCCGGCGCAGCTACGTGG  
GGCCTGCTCGACAGGCTGCTCCACCCGACGCCGTACCGCCCTTTCCGCACCGTGCCGT  
CTTCACACTGCCCTCCCAACTGCCAGACTTCTGGGGCCCTGAGCAGCCTCGGCCCGCG  
TTCCGGCGGCTCCAAGAGAGAGCGGAGCAAGTGTCCCGGGCCCTCAGCCAGCCCTGGATAG  
CTACTTCCATCCCCGGGACTCCCGCGCCGGACGCGGGTGGACCAGGGCGGGACCTGG  
GGCGGGGGACGGGACTTAAATAAAGGCAGACGCTGTTTCTAAAAAA

162/168

## **FIGURE 162**

MPVPWFLLSLALGRSPVVL\$LERLVGPQDATHCSPGLSCLRWDSDILCLPGDIVPAPGPVLAP  
THLQTELVLRQCQKETDCDLCLRVAVHLAVHGHWEEPEDEEKFGGAADSGVEEPRNASLQAQVV  
LSFQAYPTARCVLLEVQVPAALVQFGQSVGSVYDCFEAALGSEVRIWSYTQPRYEKELNHTQ  
QLPALPWLNVSADGDNVHLVLNVSEEQHFGLSLYWNQVQGPPKPRWHKNLTGPQIITLNHTDL  
VPCLCIQVWPLEPDHSVRTNICPFREDPRAHQNLWQAARLRLLTQSWLLDAPCSLPAAEALCW  
RAPGGDPCQPLVPPLSWENVTVDKVLEFPLLKGHPNLCVQNSSEKLQLQECLWADSLGPLKD  
DVLLLETRGQPQDNRSLCALEPSGCTSLPSKASTRAARLGEYLLQDLQSGQCLQLWDDDLGALW  
ACPMDKYIHKRWALVWLACLLFAAALSLLLKKDHAKGWLRLLKQDVRSGAAARGRAALLLY  
SADDSGFERLVGALASALCQLPLRVAVDLWSRRELSAQGPVAWFHAQRQTLQEGGVVVLLFS  
PGAVALCSEWLQDGVSGPGAHGPHDAFRASLSCVLPDFLQGRAPGSYVGACFDRLLHPDAVPA  
LFRTVPVFTLPSQLPDFLGALQQPRAPRSGRLQERAEQVSRALQPALDSYFHPPGTPAPGRGV  
GPGAGPGAGDGT

**Signal sequence:**

amino acids 1-20

**Transmembrane domain.**

amino acids 453-475

**N-glycosylation sites.**

amino acids 118-121, 186-189, 198-201, 211-214, 238-241, 248-251,  
334-337, 357-360, 391-394

**Glycosaminoglycan attachment site.**

amino acids 583-586

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 552-555

**N-myristoylation sites.**

amino acids 107-112, 152-157, 319-324, 438-443, 516-521, 612-617,  
692-697, 696-701, 700-705

## FIGURE 163

GGGAGGGCTCTGCCAGCCCCG**ATG**AGGACGCTGCTGACCATCTGACTGTGGGATCCCTGG  
CTGCTCACGCCCTGAGGACCCCTCGATCTGCTCCAGCACGTGAAATTCCAGTCCAGCAACT  
TTGAAAACATCCTGACGTGGGACAGCGGCCAGAGGGCACCCCAGACACGGTCTACAGCATCG  
AGTATAAGACGTACGGAGAGAGGGACTGGGTGCAAAGAAGGGCTGTCAGCGGATCACCCGGA  
AGTCCTGCAACCTGACGGTGGAGACGGCAACCTCACGGAGCTACTATGCCAGGGTACCGCT  
GTCAGTGCAGGGAGGCCGGTCAGCCACCAAGATGACTGACAGGTTAGCTCTGCAGCACACT  
ACCCCTCAAGCCACCTGATGTGACCTGATCTCAAAGTGAGATCGATTAGATGATTGTCAT  
CCTACCCCCACGCCAATCCGTGCAGGGATGGCCACCGGCTAACCCCTGGAAGACATCTCCAT  
GACCTGTTCTACCACTTAGAGCTCCAGGTCAACCGCACCTACCAAATGCACCTTGGAGGGAAAG  
CAGAGAGAATATGAGTTCTCGGCCCTGACACAGAGTTCTTGGCACCATCATGATT  
TGCCTTCCCACCTGGCCAAGGAGAGTGCCTTACATGTCAGTGAAGACACTGCCAGAC  
CGGACATGGACCTACTCCTCTCCGGAGCCTCTGTTCTCATGGCTTCCTCGTCAGTA  
CTCTGCTACCTGAGCTACAGATATGTCACCAAGCCGCTGCACCTCCAACTCCCTGAACGTC  
CAGCGAGTCCCTGACTTCCAGCCGCTGCCTCATCCAGGAGCACGTCTGATCCCTGCTTT  
GACCTCAGCGGCCAGCAGTCTGGCCAGCCTGTCAGTACTCCAGATCAGGGTGTCTGGA  
CCCAGGGAGCCCGAGGAGCTCACAGCGGATAGCCTGTCAGGAGATCACCTACTTAGGGCAG  
CCAGACATCTCCATCCTCCAGCCCTCCAACGTGCCACCTCCCCAGATCCTCTCCCCACTGTCC  
TATGCCCAAACGCTGCCCTGAGGTCGGGCCCCCATCCTATGCACCTCAGGTGACCCCCGAA  
GCTCAATTCCCATTCTACGCCAACAGGCCATCTCTAAGGTCCAGCCTCCCTATGCCCT  
CAAGCCACTCCGGACAGCTGGCCTCCCTATGGGTATGCATGGAAGGTCTGGCAAAGAC  
TCCCCCAGTGGACACTTCTAGCTAAACACCTTAGGCCTAAAGGTCAAGCTCAGAAAGAG  
CCACCAGCTGGAAGCTGCATGTTAGGTGGCCTTCTCTGCAGGAGGTGACCTCCTGGCTATG  
GAGGAATCCAAGAAGCAAATCATTGACCCAGGCTGGGATTGACAGACAGAACATCT  
GACCCAAATGTGCTACACAGTGGGAGGAAGGGACACCACAGTACCTAAAGGGCAGCTCCCC  
CTCCTCTCCTCAGTCAGATCGAGGGCCACCCATGTCCTCCCTTGCAACCTCCTCCGGT  
CCATGTTCCCCCTCGGACCAAGGTCCAAGTCCCTGGGCTGCTGGAGTCCCTGTGTGTC  
AAGGATGAAGCCAAGAGCCCAGCCCTGAGACCTCAGACCTGGAGCAGCCCACAGAACTGGAT  
TCTCTTTCAGAGGCCTGGCCTGACTGTGCACTGGAGTCC**TG**AGGGAAATGGGAAAGGCTT  
GGTCTTCCCTCCCTGTCCTACCCAGTGTCACTCCTGGCTGTCATCCATGCCCTGCCCAT  
GCCACACACTCTGCGATCTGGCCTCAGACGGGTGCCCTGAGAGAAGCAGAGGGAGTGGCATG  
CAGGGCCCTGCCATGGTGCGCTCTCACCGAACAAAGCAGCATGATAAGGACTGCAGCGG  
GGGAGCTCTGGGAGCAGTTGTAGACAAGCGCGTGCCTGAGCCCTGCAAGGCAGAAA  
TGACAGTGCAGGGAGGAATGCAGGGAAACTCCCAGGTCCAGAGCCCCACCTCTAACACCA  
TGGATTCAAAGTGTCAGGGAAATTGCTCTCCCTGGCCATTCTGGCCAGTTCAAAATCT  
AGTCGACAGAGCATGAGGCCCTGCCTCTTGTCAATTGTCAGGTGGGAAGAGAGCCTG  
GAAAAGAACCGGCCCTGGAAAAGAACAGAACAGAGGAGCTGGCAGAACACCAGAACAC  
TCTGCCAAGGCCAGGGCAGCAGGACGGCAGGACTCTAGGGAGGGTGTGGCTGCAGCTCAT  
TCCCAGCCAGGGCAACTGCCCTGACGTTGCACGATTCAGCTCATTCTGTATAGAACAAAG  
CGAAATGCAGGTCCACCAGGGAGGAACACACAAGCCTTTCTGCAGGAGGAGTTCAAGAC  
CCTATCCTGAGAATGGGGTTGAAAGGAAGGTGAGGGCTGTGGCCCTGGACGGGTACAATAA  
CACACTGTACTGATGTCACAACCTTGCAAGCTCTGCCCTGGGTTCAGCCCACGGCTCAA  
TTCCAGCCTCACCACCTACAAGCTGTGACTTCAAACAAATGAAATCAGTGCCAGAACCTC  
GGTTCCATCTGTAATGTGGGATCATAACACCTACCTCATGGAGTTGTGGTAAGATGAA  
ATGAAGTCATGTCTTAAAGTGTAAATAGTGCCTGGTACATGGCAGTGCCAATAAACGGT  
AGCTATTAAAAAAAAAAAAAA

164/168

## **FIGURE 164**

MRTLLTILTVGSLAAHAPEDPSDLLQHVKFQSSNFENILTWSGPETPDTVYSIEYKTYGER  
DWVAKKGCQRITRKSCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDV  
TCISKVRSIQMIVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFF  
GLTPDTEFLGTIMICVPTWAKESAPYMCRVKTLPDRTWTYSFGAFLFSMGFLVAVCYLSYR  
YVTKPPAPPNSLNQRVLTQPLRFIQEHVLIPVFDLSPGSSLAQPVQYSQIRVSGPREPAGA  
PQRHSLSEITYLGQPDISILQPSNVPPPQILSPLSYAPNAAPEVGPPSYAPQVTPEAQFPFYA  
PQAISKVQPSYAPQATPDSWPPSYGVCMEGSGKDSPTGTLSSPKHLRPKGQLKEPPAGSCM  
LGGISLQEVTSLAMEESQEAKSLHQPLGICTDRSDPNVLHSGEEGTPQYLKGQLPLLSSVQI  
EGHPMSLPLQPPSGPCSPSDQGPSPWGLLESLVCPKDEAKSPAETS DLEQPTELDSLFRGLA  
LTVQWES

**Signal sequence.**

amino acids 1-17

**Transmembrane domain.**

amino acids 233-250

**N-glycosylation sites.**

amino acids 80-83, 87-90, 172-175

**N-myristoylation sites.**

amino acids 11-16, 47-52, 102-107, 531-536, 565-570

165/168

**FIGURE 165**

TGGCCTACTGGAAAAAAAAAAAAAGTCACCCGGGCCGCGGTGGCCACAACAT  
GGCTGCGGCGCCGGGCTGCTCTTCTGGCTGTTCGTGTGGGGCGCTCTGGTGGGTCCCGGG  
CCAGTCGGATCTCAGCCACGGACGGCGTTCTCGGACCTCAAAGTGTGCGGGGACGAAGAGTG  
CAGCATGTTAATGTACCGTGGAAAGCTCTGAAGAGACTTCACGGGCCCTGATTGTCGTTTGT  
GAATTTAAAAAGGTGACGATGTATATGTCTACTACAAACTGGCAGGGGATCCCTGAAC  
TTGGGCTGGAAGTGTGAACACAGTTGGATATTTCAAAAGATTGATCAAGGTACTTCA  
TAAATACACGGAAGAAGAGCTACATATTCCAGCAGATGAGACAGACTTGTCTGCTTGAAGG  
AGGAAGAGATGATTTAATAGTTATAATGTAGAACAGAGCTTTAGGATCTTGGAACTGGAGGA  
CTCTGTACCTGAAGAGTCGAAGAAAGCTGAAGAACAGTTCTCAGCACAGAGAGAAATCTCCTGA  
GGAGTCTCGGGGGCGTGAACCTGACCCCTGTGCCTGAGCCCAGGCATTAGAGCTGATTCA  
GGATGGAGAAGGTGCTTCTCAGAGAGCACCGAGGGCTGCAGGGACAGCCCTCAGCTCAGGA  
GAGCCACCCTCACACCAGCGGTCTCGGGCTAACGCTCAGGGAGTGCAGTCTCGTTGGACAC  
TTTGAAAGAAATTCTGCACGATAAATTGAAAGTGCAGGGAAAGCGAAAGCAGAACTGGCAATAG  
TTCTCCTGCCTCGGTGGAGCGGGAGAAGACAGATGCTTACAAAGTCTGAAACAGAAATGAG  
TCAGAGAGGAAGTGGACAGTGCCTTATTCAAGCAAAGGATTCTGGCATCAAATCT  
AAGTTGTTTACAAAGATTGTTTTAGACTAAGCTGCCTGGCAGTTGCATTTGAGCC  
AAACAAAAATATATTATTTCCCTCTAAGTAAAAAAA

166/168

## **FIGURE 166**

MAAAPGLLFWLFVLGALWWVPGQSDLSHGRRFSDLKVC GDEEC SMLMYRGKALEDFTGPDCRF  
VNFKKGDDVYVYYKLAGGSLELWAGSVEHSFGYFPKDLIKVLHKYTEEELHIPADETDFVCFE  
GGRDDFNSYNVEELLGSLEEDSVPEESKKAAEVSQHREKSPEESRGRELDPVPEPEAFRADS  
EDGE GAFSESTEGLQGQPSAQESH PHTSGPAANAQGVQSSLDTFEEILHDKLKVPGSESRTGN  
SSPASVEREKT DAYKVLKTEMSQRGSGQCVIHYSKGFRWHQNLSLFYKDCF

**Important features of the protein:**

**Signal peptide:**

amino acids 1-22

**N-glycosylation site.**

amino acids 294-298

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 30-34

**Tyrosine kinase phosphorylation site.**

amino acids 67-76

**N-myristoylation sites.**

amino acids 205-211, 225-231, 277-283

**Amidation site.**

amino acids 28-32

## **FIGURE 167**

CCAGGACCAGGGCGCACGGCTCAGCCTCTACTTGTCAAGGCCGGGAAGAGAAGCAAAGC  
GCAACGGTGTGGCCAAGCCGGGCTCTGCCTCGCCTCTAGGACATACACGGGACCCCCCTAA  
CTTCAGTCCCCAAACGCGCACCCCTCGAAGTCTTGACTCCAGCCCCGACATCCACGCGCG  
CACAGGGCGGCAGGCGCAGGTCCGGCGAAGGCGATGCGCCAGGGGGTGGCAGCTGG  
GCTCGGGCGGGAGTAGGGGCCCGCAGGGAGGCAGGGAGGCTGCATATTAGAGTCGCGGG  
CTGCGCCCTGGGAGAGGCCGCCCCTCGCTCACGCAACACCTGCTGCTGCCACCGCGCCGCA  
**TGAGCCCGTGGCTCGCTGCTGGCGCCGCTGCTGCGGCCACGGAGCCTCTGCC**  
GCCGCGTGGTCAGCGGCAAAAGGTGTGTTGCTGACTTCAAGCATCCCTGCTACAAAATGG  
CCTACTTCCATGAACCTGTCAGCCAGTGAGCTTCAGGAGGCACGCCCTGGCTGAGAGTG  
AGGGAGGAGTCCTCAGCCTGAGAATGAAGCAGAACAGAAGTTAATAGAGAGCATGTTGC  
AAAACCTGACAAAACCGGGACAGGGATTCGTATGGTATTCTGGATAGGGCTTGGAGGA  
ATGGAGATGGGCAAACATCTGGTGCCTGCCAGATCTTACCAAGTGGTCTGATGGAAGCAATT  
CCCAGTACCGAAACTGGTACACAGATGAACCTCCTGCCAGTGGAAAGTGGAAAGTGTGATGT  
ATCACCAACCAACTGCCAATCTGGCCTTGGGGTCCCTACCTTACCAAGTGGAAATGATGACA  
GGTGTAAACATGAAGCACAATTATTTGCAAGTATGAAACCAGAGATTAACTCAACAGCCCCCTG  
TAGAAAAGCCTATCTACAAATCAACCAGGAGACACCCATCAGAATGTGGTGTACTGAAG  
CAGGTATAATTCCAATCTAATTATGTTTACCAACAAATACCCCTGCTTACTGATAC  
TGGTTGCTTTGGAACCTGTTCCAGATGCTGCATAAAAGTAAGGAAGAACAAAAACTA  
GTCCAAACCAGTCTACACTGTGGATTCAAAAGTACCAAGAAAGTGGCATGGAAGTAT  
**AATAACTCATTGACTTGGTCCAGAATTGTAATTCTGGATCTGTATAAGGAATGGCATCAG**  
AACAAATAGCTTGBAATGGCTTGAATCACAAAGGATCTGCAAGATGAACGTGTAAGCTCCCCCT  
TGAGGCAAATATTAAAGTAATTATGCTATTATTCATTTAAAGAATATGCTGTGCTA  
ATAATGGAGTGGACATGCTTATTGCTAAAGGATGCCACCAAACCTCAAGCAAA  
TGAAATGGACAATGCAGATAAAGTGTATCACACACGTCGGGAGTATGTGTGTTAGAAGCAAT  
TCTTTATTCTTCACCTTCATAAGTGTATCTAGTCAATGTAATGTATATTGTATTGA  
AATTTACAGTGTGCAAAAGTATTACCTTGCATAAGTGTGATAAAAGTAACGTGTTCTA  
ATATTATTATTATGGCATCTCATTTCAATACATGCTTTGATTAAAGAAACTTATTAC  
TGTGTCAACTGAATTCACACACACAAATATAGTACCATAGAAAAAGTTGTTCTCGAA  
ATAATTCACTTCACTGCTCTGCTTTGGTCAATGTCTAGGAAATCTCTCAGAAATAAGA  
AGCTATTCACTTAAGTGTGATATAAACCTCCTCAACACATTACTTAGAGGCAAGGATTGTCT  
AATTTCAATTGTGCAAGACATGTGCCCTATAATTATTAGCTAAACAAACAGATTGTT  
TAATAATGTAACCTTGTAAATAGGTGCATAAACACTAATGCAGTCATTGAAACAAAGAAGT  
GACATACACAATATAATCATATGCTTCACACGTTGCCCTATAATGAGAAGCAGCTCTG  
AGGGTTCTGAAATCAATGTGGTCCCTCTCTGCCACTAAACAAAGATGGTGTGCGGGTT  
GGGATTGACACTGGAGGCAGATAGTTGCAAAGTTAGTCTAAGGTTCCCTAGCTGTATTAGC  
CTCTGACTATTAGTATACAAAGAGGTCACTGTTGAGACCAAGGTGAATAGTCACATCAG  
TGTGGAGACAAGCACAGCACAGACATTAGGAAGGAAAGGAACATCGAAATCGTGTGAA  
ATGGGTTGGAACCCATCAGTGATCGCATATTGATGAGGGTTGCTTGAGATAGAAATG  
GTGGCTCCTTCTGTCTTACCTGCTTCAATGCTTACGCCCTGTTCTCAAGAGA  
AAGTTGTAACCTCTGGTCTTCATATGCCCCGTGCTCTTAAACAAATAAGAGTTCTG  
TTCTGGGGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

168/168

## **FIGURE 168**

MSRVVSLLLGAALLCGHGFCCR VVSGQKVC FADF KHP CYK MAYF H E LSS RVS F QEAR LACES  
EGGVLLSLENEAEQKLIESMLQNLTKPGTG ISDGDFWIGLWRNGDQTSGACPDLYQWSDGSN  
SQYRNWTDEPSCGSEKCVVMYHQPTANPGLGGPYLYQWNDDRCNMKHNYICKYEPEINPTAP.  
VEKPYLTNQPGDTHQNVVVTEAGIIPNLIYVVIPTIPLLLLILVAFGTCCFQMLHKSKGRTKT  
SPNQSTLWISKSTRKESGM EV

**Important features of the protein:**

**Signal peptide:**

amino acids 1-21

**Transmembrane domain:**

amino acids 214-235

**N-glycosylation sites.**

amino acids 86-89, 255-258

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 266-269

**N-myristoylation sites.**

amino acids 27-32, 66-71, 91-96, 93-98, 102-107, 109-114, 140-145, 212-217

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**(19) World Intellectual Property Organization  
International Bureau**



**(43) International Publication Date  
8 March 2001 (08.03.2001)**

PCT

(10) International Publication Number  
**WO 01/16318 A3**

<b>(51) International Patent Classification<sup>7</sup>:</b>		<b>C12N 15/12.</b>	PCT/US00/04414	
C07K 14/47, 14/705, G01N 33/53, C12N 15/62, C07K 16/18			22 February 2000 (22.02.2000)	US
		PCT/US00/05601	1 March 2000 (01.03.2000)	US
		60/187.202	3 March 2000 (03.03.2000)	US
		60/191.007	21 March 2000 (21.03.2000)	US
<b>(21) International Application Number:</b>		PCT/US00/23328	PCT/US00/08439	30 March 2000 (30.03.2000)
<b>(22) International Filing Date:</b>		24 August 2000 (24.08.2000)	60/199.397	25 April 2000 (25.04.2000)
<b>(25) Filing Language:</b>		English	PCT/US00/14042	22 May 2000 (22.05.2000)
<b>(26) Publication Language:</b>		English	60/209.832	5 June 2000 (05.06.2000)
<b>(30) Priority Data:</b>			<b>(71) Applicant (for all designated States except US):</b> GENEN-TECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).	
PCT/US99/20111			<b>(72) Inventors; and</b>	
PCT/US99/21090		1 September 1999 (01.09.1999)	<b>(75) Inventors/Applicants (for US only):</b> EATON, Dan, L. [US/US]; 75 Knight Drive, San Rafael, CA 94901 (US). FILVAROFF, Ellen [US/US]; 538 18th Avenue, San Francisco, CA 94121 (US). GERRITSEN, Mary, E. [CA/US]; 541 Parrott Drive, San Mateo, CA 94402 (US). GODDARD, Audrey [CA/US]; 110 Congo Street, San Francisco, CA 94131 (US). GODOWSKI, Paul, J. [US/US]; 2627 Easton Drive, Burlingame, CA 94010 (US). GRIMALDI, Christopher, J. [US/US]; 1434 36th	
60/169,495		15 September 1999 (15.09.1999)		
60/170,262		7 December 1999 (07.12.1999)		
60/175,481		9 December 1999 (09.12.1999)		
PCT/US00/04341		11 January 2000 (11.01.2000)		
PCT/US00/04342		18 February 2000 (18.02.2000)		
		18 February 2000 (18.02.2000)		

[Continued on next page]

**(54) Title:** SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME

<subunit 1 of 1, 266 aa, 1 stop  
<MW: 29766, pI: 8.39, NX(S/T): 0  
MWWFQQGLSFLPSALVIWTSAAFIFSYITAVTLHHIDPALPYISDTGTVAPEKCLFGAMLNIA  
AVLCIATIYVRYKQVHALSPEENVIIKLNKAGLVLGILSCLGLSIVANFQKTTLFAAHVSGAV  
LTFGMGSLYMFVQTILSYQMOPKIHKGQFWIRLLVIWCGVSALSMLTCSSVLHSGNFGTDL  
EQKLHWNPEDKGYVLHMITTAAEWSMSFSFFGFLTYIRDQKISLRVEANLHGTLYDTAPC  
PINNERTRLLSRDI

### Important features:

#### Type II transmembrane domain:

amino acids 13-33

#### **Other Transmembrane domains:**

amino acids 54-73, 94-113, 160-180, 122-141

#### N-myristoylation sites.

amino acids 57-63, 95-101, 99-105, 124-130, 183-189

(57) **Abstract:** The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

WO 01/16318 A3



Avenue, San Francisco, CA 94122 (US). **GURNEY, Austin, L.** [US/US]; 1 Debbie Lane, Belmont, CA 94002 (US). **WATANABE, Colin, K.** [US/US]; 128 Corliss Drive, Moraga, CA 94556 (US). **WOOD, William, I.** [US/US]; 35 Southdown Court, Hillsborough, CA 94010 (US).

(74) **Agents:** **KRESNAK, Mark, T.** et al.; Genentech, Inc., MS49, 1 DNA Way, South San Francisco, CA 94080-4990 (US).

(81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report*
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description*

(88) **Date of publication of the international search report:**

29 November 2001

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 00/23328

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 7	C12N15/12	C07K14/47	C07K14/705	G01N33/53	C12N15/62
	C07K16/18				

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12N C07K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 25825 A (BOUGUELERET LYDIE ;GENSET SA (FR); DUCLERT AYMERIC (FR); DUMAS MIL) 27 May 1999 (1999-05-27) the whole document ---	1-20
X	WO 99 24836 A (ENDRESS GREGORY A ;HUMAN GENOME SCIENCES INC (US); FENG PING (US);) 20 May 1999 (1999-05-20) the whole document ---	1-20
A	EP 0 834 563 A (SMITHKLINE BEECHAM CORP) 8 April 1998 (1998-04-08) the whole document ---	
A	WO 97 07198 A (GENETICS INST) 27 February 1997 (1997-02-27) the whole document ---	
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "8" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

24 January 2001

23.04.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

# INTERNATIONAL SEARCH REPORT

International Application No  
 PCT/US 00/23328

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>YOKOYAMA-KOBAYASHI M ET AL: "A signal sequence detection system using secreted protease activity as an indicator"          GENE, NL, ELSEVIER BIOMEDICAL PRESS.          AMSTERDAM,          vol. 163, no. 2,          3 October 1995 (1995-10-03), pages          193-196, XP004041983          ISSN: 0378-1119          the whole document</p> <p>---</p> <p>KLEIN R D ET AL: "SELECTION FOR GENES ENCODING SECRETED PROTEINS AND RECEPTORS"          PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, US, NATIONAL ACADEMY OF SCIENCE. WASHINGTON,          vol. 93, no. 14, 9 July 1996 (1996-07-09),          pages 7108-7113, XP002061411          ISSN: 0027-8424          the whole document</p> <p>---</p> <p>WO 99 63088 A (BAKER KEVIN ;CHEN JIAN (US); GENENTECH INC (US); YUAN JEAN (US);          G) 9 December 1999 (1999-12-09)          L: priority.          the whole document</p> <p>---</p> <p>WO 99 46287 A (GENETICS INST)          16 September 1999 (1999-09-16)          the whole document</p> <p>---</p> <p>WO 00 73454 A (GENENTECH INC)          7 December 2000 (2000-12-07)          the whole document</p> <p>-----</p>	
P,X, L		1-20
P,X		1-20
E,L		1-20

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 00/23328

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  

Although claims 35-38, in as far as they pertain to in vivo methods, are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  

see FURTHER INFORMATION sheet PCT/ISA/210

3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  

Claims 1-20 (all partially).

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 21-38 relate to a polypeptide, designated F or PRO1, which is not characterized in the description. This gives rise to a lack of clarity within the meaning of Article 6 PCT to such an extent as to render a meaningful search of the claims in respect of said protein impossible. Consequently, the search has been limited to the remaining parts of the claims.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: Invention 1: 1-20, all partially

PRO180: nucleic acid with seq.ID.1, encoding a polypeptide comprising the amino acid sequence as represented in seq.ID.2 or a nucleic acid having at least 80% homology thereto, vector comprising said nucleic acid, host cell comprising said vector, process for producing the protein of seq.ID.2 using said host, the isolated protein or one having at least 80% homology thereto, a chimeric protein of said peptide fused to a heterologous sequence, isolated extracellular domain of said protein or said protein lacking its signal peptide, and an antibody against said polypeptide.

2. Claims: Inventions 2-76: claims 1-20, all partially

Subject matter as defined for invention 1, but related to the respective nucleic acid/polypeptide sequences of:

2. PRO218, represented by seq.ID.s 3 and 4,
3. PRO263, represented by seq.ID.s 5 and 6,
4. PRO295, as represented by seq.ID's 7 and 8,
5. PRO874, as represented by seq.ID's 9 and 10,
6. PRO300, as represented by seq.ID's 11 and 12,
7. PRO1864, as represented by seq.ID's 13 and 14,
8. PRO1282, as represented by seq.ID's 15 and 16,
9. PRO1063, as represented by seq.ID's 17 and 18,
10. PRO1773, as represented by seq.ID's 19 and 20,
11. PRO1013, as represented by seq.ID's 21 and 22,
12. PRO937, as represented by seq.ID's 23 and 24,
13. PRO842, as represented by seq.ID's 25 and 26,
14. PRO1180, as represented by seq.ID's 27 and 28,
15. PRO831, as represented by seq.ID's 29 and 30,
16. PRO1115, as represented by seq.ID's 31 and 32,
17. PRO1277, as represented by seq.ID's 33 and 34,
18. PRO1074, as represented by seq.ID's 35 and 36,
19. PRO1344, as represented by seq.ID's 37 and 38,
20. PRO1136, as represented by seq.ID's 39 and 40,
21. PRO1109, as represented by seq.ID's 41 and 42,
22. PRO1003, as represented by seq.ID's 43 and 44,
23. PRO1138, as represented by seq.ID's 45 and 46,
24. PRO994, as represented by seq.ID's 47 and 48,
25. PRO1069, as represented by seq.ID's 49 and 50,
26. PRO1411, as represented by seq.ID's 51 and 52,
27. PRO1129, as represented by seq.ID's 53 and 54,
28. PRO1027, as represented by seq.ID's 55 and 56,
29. PRO1106, as represented by seq.ID's 57 and 58,
30. PRO1291, as represented by seq.ID's 59 and 60,
31. PRO3573, as represented by seq.ID's 61 and 62,
32. PRO3566, as represented by seq.ID's 63 and 64,
33. PRO1098, as represented by seq.ID's 65 and 66,
34. PRO1158, as represented by seq.ID's 67 and 68,
35. PRO1124, as represented by seq.ID's 69 and 70,

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

36.PR01278, as represented by seq.ID's 71 and 72,  
37.PR01335, as represented by seq.ID's 73 and 74,  
38.PR01315, as represented by seq.ID's 75 and 76,  
39.PR01357, as represented by seq.ID's 77 and 78,  
40.PR01356, as represented by seq.ID's 79 and 80,  
41.PR01557, as represented by seq.ID's 81 and 82,  
42.PR01347, as represented by seq.ID's 83 and 84,  
43.PR01302, as represented by seq.ID's 85 and 86,  
44.PR01270, as represented by seq.ID's 87 and 88,

3. Claim : Invention

45.PR01268, as represented by seq.ID's 89 and 90,  
46.PR01327, as represented by seq.ID's 91 and 92,  
47.PR01328, as represented by seq.ID's 93 and 94,  
48.PR01329, represented by seq.ID.s 95 and 96,  
49.PR01340, as represented by seq.ID's 97 and 98,  
50.PR01342, as represented by seq.ID's 99 and 100,  
51.PR03579, as represented by seq.ID's 101 and 102,  
52.PR01472, as represented by seq.ID's 103 and 104,  
53.PR01461, as represented by seq.ID's 105 and 106,  
54.PR01568, as represented by seq.ID's 107 and 108,  
55.PR01753, as represented by seq.ID's 109 and 110,  
56.PR01570, as represented by seq.ID's 111 and 112,  
57.PR01446, as represented by seq.ID's 113 and 114,  
58.PR01565, as represented by seq.ID's 115 and 116,  
59.PR01572, as represented by seq.ID's 117 and 118,  
60.PR01573, as represented by seq.ID's 119 and 120,  
61.PR01550, as represented by seq.ID's 121 and 122,  
62.PR01693, as represented by seq.ID's 123 and 124,  
63.PR01566, as represented by seq.ID's 125 and 126,  
64.PR01774, as represented by seq.ID's 127 and 128,  
65.PR01928, as represented by seq.ID's 129 and 130,  
66.PR01865, as represented by seq.ID's 131 and 132,  
67.PR01925, as represented by seq.ID's 133 and 134,  
68.PR01926, as represented by seq.ID's 135 and 136,  
69.PR01801, as represented by seq.ID's 137 and 138,  
70.PR04405, as represented by seq.ID's 139 and 140,  
71.PR03435, as represented by seq.ID's 141 and 142,  
72.PR03543, as represented by seq.ID's 143 and 144,  
73.PR03443, as represented by seq.ID's 145 and 146,  
74.PR03442, as represented by seq.ID's 147 and 148,  
75.PR05990, as represented by seq.ID's 149 and 150, and  
76.PR04342, as represented by seq.ID's 151 and 152.

For the sake of conciseness, the first subject matter is explicitly defined, the subject matter of inventions 2-76 are defined by analogy thereto.

4. Claims: Invention 77: claims 1-3,5-12,14-38, all partially

PRO10272: nucleic acid with seq.ID.155, encoding a polypeptide comprising the amino acid sequence as

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

represented in seq.ID.156 or a nucleic acid having at least 80% homology thereto, vector comprising said nucleic acid, host cell comprising said vector, process for producing the protein of seq.ID.156 using said host, the isolated protein or one having at least 80% homology thereto, a chimeric protein of said peptide fused to a heterologous sequence, isolated extracellular domain of said protein or said protein lacking its signal peptide, and an antibody against said polypeptide. Also a method of detecting PRO10272 using its interaction with PRO5801 (seq.ID.158), method for linking a bioactive molecule to a cell expressing PRO10272 through the use of PRO5801, and method of modulating at least one activity of said cell thereby.

5. Claims: Invention 78: claims 1-3,5-12,14-38, all partially

PRO20110: nucleic acid with seq.ID.159, encoding a polypeptide comprising the amino acid sequence as represented in seq.ID.160 or a nucleic acid having at least 80% homology thereto, vector comprising said nucleic acid, host cell comprising said vector, process for producing the protein of seq.ID.160 using said host, the isolated protein or one having at least 80% homology thereto, a chimeric protein of said peptide fused to a heterologous sequence, isolated extracellular domain of said protein or said protein lacking its signal peptide, and an antibody against said polypeptide. Also a method of detecting PRO20110 using its interaction with PRO20040 (seq.ID.162), method for linking a bioactive molecule to a cell expressing PRO20110 through the use of PRO20040, and method of modulating at least one activity of said cell thereby.

6. Claims: Invention 79: claims 1-3,5-12,14-38, all partially

PRO10096: nucleic acid with seq.ID.153, encoding a polypeptide comprising the amino acid sequence as represented in seq.ID.154 or a nucleic acid having at least 80% homology thereto, vector comprising said nucleic acid, host cell comprising said vector, process for producing the protein of seq.ID.154 using said host, the isolated protein or one having at least 80% homology thereto, a chimeric protein of said peptide fused to a heterologous sequence, isolated extracellular domain of said protein or said protein lacking its signal peptide, and an antibody against said polypeptide. Also a method of detecting PRO10096 using its interaction with PRO20233 (seq.ID.164), method for linking a bioactive molecule to a cell expressing PRO10096 through the use of PRO20233, and method of modulating at least one activity of said cell thereby.

7. Claims: Invention 80: claims 1-3,5-12,14-38, all partially

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

PRO19670: nucleic acid with seq.ID.165, encoding a polypeptide comprising the amino acid sequence as represented in seq.ID.166 or a nucleic acid having at least 80% homology thereto, vector comprising said nucleic acid, host cell comprising said vector, process for producing the protein of seq.ID.166 using said host, the isolated protein or one having at least 80% homology thereto, a chimeric protein of said peptide fused to a heterologous sequence, isolated extracellular domain of said protein or said protein lacking its signal peptide, and an antibody against said polypeptide. Also a method of detecting PRO19670 using its interaction with PRO1890 (seq.ID.168), method for linking a bioactive molecule to a cell expressing PRO19670 through the use of PRO1890, and method of modulating at least one activity of said cell thereby.

## 8. Claims: Invention 81: claims 1-3,5-12,14-38, all partially

PRO5801: nucleic acid with seq.ID.157, encoding a polypeptide comprising the amino acid sequence as represented in seq.ID.158 or a nucleic acid having at least 80% homology thereto, vector comprising said nucleic acid, host cell comprising said vector, process for producing the protein of seq.ID.158 using said host, the isolated protein or one having at least 80% homology thereto, a chimeric protein of said peptide fused to a heterologous sequence, isolated extracellular domain of said protein or said protein lacking its signal peptide, and an antibody against said polypeptide. Also a method of detecting PRO5801 using its interaction with PRO10272 (seq.ID.156), method for linking a bioactive molecule to a cell expressing PRO5801 through the use of PRO10272, and method of modulating at least one activity of said cell thereby.

## 9. Claims: Invention 82: claims 1-3,5-12,14-38, all partially

PRO20040: nucleic acid with seq.ID.161, encoding a polypeptide comprising the amino acid sequence as represented in seq.ID.162 or a nucleic acid having at least 80% homology thereto, vector comprising said nucleic acid, host cell comprising said vector, process for producing the protein of seq.ID.162 using said host, the isolated protein or one having at least 80% homology thereto, a chimeric protein of said peptide fused to a heterologous sequence, isolated extracellular domain of said protein or said protein lacking its signal peptide, and an antibody against said polypeptide. Also a method of detecting PRO20040 using its interaction with PRO20110 (seq.ID.160), method for linking a bioactive molecule to a cell expressing PRO20040 through the use of PRO20110, and method of modulating at least one activity of said cell thereby.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

10. Claims: Invention 83: claims 1-3,5-12,14-38, all partially

PRO20233: nucleic acid with seq.ID.163, encoding a polypeptide comprising the amino acid sequence as represented in seq.ID.164 or a nucleic acid having at least 80% homology thereto, vector comprising said nucleic acid, host cell comprising said vector, process for producing the protein of seq.ID.164 using said host, the isolated protein or one having at least 80% homology thereto, a chimeric protein of said peptide fused to a heterologous sequence, isolated extracellular domain of said protein or said protein lacking its signal peptide, and an antibody against said polypeptide. Also a method of detecting PRO20233 using its interaction with PRO10096 (seq.ID.154), method for linking a bioactive molecule to a cell expressing PRO20233 through the use of PRO10096, and method of modulating at least one activity of said cell thereby.

11. Claims: Invention 84: claims 1-3,5-12,14-38, all partially

PRO1890: nucleic acid with seq.ID.167, encoding a polypeptide comprising the amino acid sequence as represented in seq.ID.168 or a nucleic acid having at least 80% homology thereto, vector comprising said nucleic acid, host cell comprising said vector, process for producing the protein of seq.ID.168 using said host, the isolated protein or one having at least 80% homology thereto, a chimeric protein of said peptide fused to a heterologous sequence, isolated extracellular domain of said protein or said protein lacking its signal peptide, and an antibody against said polypeptide. Also a method of detecting PRO1890 using its interaction with PRO19679 (seq.ID.166), method for linking a bioactive molecule to a cell expressing PRO1890 through the use of PRO19679, and method of modulating at least one activity of said cell thereby.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 00/23328

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9925825	A	27-05-1999	AU 1049199 A EP 1029045 A AU 1503099 A EP 1037977 A WO 9931236 A AU 2294499 A EP 1053318 A WO 9940189 A	07-06-1999 23-08-2000 05-07-1999 27-09-2000 24-06-1999 23-08-1999 22-11-2000 12-08-1999
WO 9924836	A	20-05-1999	AU 1303799 A EP 1032838 A AU 1303199 A	31-05-1999 06-09-2000 31-05-1999
EP 0834563	A	08-04-1998	JP 10179178 A US 5824504 A	07-07-1998 20-10-1998
WO 9707198	A	27-02-1997	US 5707829 A AU 727480 B AU 6712396 A AU 727489 B AU 6768596 A CA 2227220 A CA 2229208 A EP 0839196 A EP 0851875 A JP 11510045 T US 6043344 A WO 9704097 A US 6074849 A US 5969093 A	13-01-1998 14-12-2000 18-02-1997 14-12-2000 12-03-1997 06-02-1997 27-02-1997 06-05-1998 08-07-1998 07-09-1999 28-03-2000 06-02-1997 13-06-2000 19-10-1999
WO 9963088	A	09-12-1999	AU 4328699 A AU 2212299 A WO 9935170 A	20-12-1999 26-07-1999 15-07-1999
WO 9946287	A	16-09-1999	AU 2997299 A EP 1062233 A	27-09-1999 27-12-2000
WO 0073454	A	07-12-2000	AU 1748200 A AU 1932000 A AU 2192800 A AU 2495200 A AU 2600800 A AU 3381600 A AU 3514400 A AU 4328699 A WO 0053753 A WO 0053755 A WO 0075327 A WO 0053757 A WO 0053758 A WO 0073445 A WO 0073348 A WO 0073452 A WO 0032221 A WO 0036102 A WO 0037640 A WO 0075316 A	19-06-2000 03-07-2000 12-07-2000 28-09-2000 28-09-2000 28-09-2000 28-09-2000 20-12-1999 14-09-2000 14-09-2000 14-12-2000 14-09-2000 14-09-2000 07-12-2000 07-12-2000 07-12-2000 08-06-2000 22-06-2000 29-06-2000 14-12-2000

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/23328

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0073454 A		AU 2883600 A	28-09-2000
		WO 0053756 A	14-09-2000
		WO 0078961 A	28-12-2000
		WO 0104311 A	18-01-2001
		AU 1749800 A	04-10-2000
		AU 1749900 A	12-07-2000
		AU 2399300 A	28-09-2000
		AU 3107000 A	19-06-2000
		WO 0105972 A	25-01-2001
		WO 0032778 A	08-06-2000
		WO 0055319 A	21-09-2000
		WO 0037638 A	29-06-2000
		WO 0105836 A	25-01-2001
		WO 0053751 A	14-09-2000
		WO 0077037 A	21-12-2000
		WO 0109327 A	08-02-2001
		WO 0075317 A	14-12-2000
		AU 5922999 A	03-04-2000
		WO 0118210 A	15-03-2001
		WO 0116318 A	08-03-2001
		WO 0119987 A	22-03-2001
		AU 6498499 A	03-04-2000
		WO 0119991 A	22-03-2001
		AU 2224800 A	28-09-2000
		AU 2596700 A	28-09-2000
		AU 3107700 A	28-09-2000
		WO 0053754 A	14-09-2000
		WO 0053750 A	14-09-2000
		AU 2474700 A	19-06-2000